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Abstract 
Colorectal cancer (CRC) arises from pre-malignant polyps, a process effectively interrupted 
by colonoscopic polypectomy (CP).  Incomplete or poor-quality CP attenuates this effect. 
Large sessile colorectal polyps (≥20mm) [laterally spreading lesions – LSL] harbour a greater 
risk of malignancy versus smaller polyps but the majority can be safely and effectively 
removed in a single session by CP. 
This thesis contains four themes all relating to colonoscopic polypectomy.  Theme 1 is entitled 
quality and safety in colonoscopic polypectomy.  Within this theme Chapter 2 describes a 
published prospective imaging study of 141 sessile serrated polyps (SSP).  The study concluded 
that the accuracy of a standardised protocol for endoscopic assessment of dysplasia within SSP 
was 95.0% as compared to the gold standard of blinded specialist gastrointestinal pathologists. 
This may be an important important tool for reducing rates of interval cancer after colonoscopy 
via the recognition and complete resection of dysplastic SSP.  Chapter 3 contains a published 
pilot study of 41 SSP successfully removed using piecemeal cold snare polypectomy.  There 
was no incidence of delayed bleeding or perforation.  If confirmed in larger studies, this finding 
could reduce the burden of removing SSPs on patients and healthcare systems, particularly by 
the avoidance of clinically significant post-endoscopic bleeding.  Chapter 4 contains a 
published study demonstrating that a simple score to determine the complexity of polypectomy 
(the SMSA score) could predict robust outcomes after polypectomy of large colorectal polyps.  
Lower SMSA scores (SMSA 2 versus 4) predicted a greater likelihood of EMR success (OR 
13.34 [95% confidence interval {95% CI} 1.85-96.27]) and a lesser likelihood of adverse 
events including delayed bleeding (OR 0.36 [95% CI 0.22-0.58]), adenoma recurrence (OR 
0.19 [95% CI 0.09-0.41]) and need for surgery at 2 weeks (OR 0.53 [95% CI 0.4-0.71]) (SMSA 
3 versus 4).  This information is highly relevant for patient consent since it can be determined 
by simple criteria known prior to the procedure, often present in referring endoscopy report.  
In addition, this data lends itself to the establishment of polyp-specific key performance metrics 
for those performing endoscopic resection.  It can also be applied to time and resource 
management at an endoscopy unit level, for example to determine the estimated procedure 
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length for a particular polyp or the suitability of a particular polyp for training purposes.  
Chapter 5 contains an unpublished study of the responses of 707 endoscopists in 7 countries 
to an online survey indicating that cold snare polypectomy is underutilised for diminutive and 
small polypectomy, submucosal invasive cancer is underappreciated by endoscopists and 
benign large colorectal polyps are routinely referred for surgery.   
Theme 2 is entitled refining the management of complex large colonic laterally spreading 
lesions (LSL).    Within this theme Chapter 7 contains a published study of two-stage 
endoscopic mucosal resection.  This describes a technique where, if a resection cannot be 
completed in a single session, the LSL may be removed at a second session within 2-3 months, 
with 81.8% of cases avoiding surgery to long-term follow up.  Chapter 8 contains a published 
study on cold-forceps avulsion and adjuvant snare-tip soft coagulation (CAST).  This is a 
simple cost-effective technique to resect non-lifting adenoma, a situation which often results 
in failed or incomplete resection of LSL. Of lesions completely resected using this technique, 
99% eligible for surveillance avoided surgery to long-term follow up.  Chapter 9 contains a 
published prospective study of LSL at the appendiceal orifice (AO).  These LSL are 
traditionally described as difficult to resect endoscopically and are often an indication for 
surgery.  The study demonstrated that if the distal margin of an LSL can be visualised within 
the AO and there is no endoscopic imaging evidence of submucosal invasive cancer that 91% 
of patients undergoing surveillance avoided surgery to a median of 18 months. 
Theme 3 is entitled mitigating recurrence after endoscopic resection of large colonic 
laterally spreading lesions.  Within this theme Chapter 10 contains a published randomised 
controlled study of 400 lesions demonstrating that the technique of thermal ablation of the post 
EMR defect resection margin reduces the risk of polyp recurrence by four times.  Chapter 11 
contains a published study demonstrating that the temporal pattern of adenoma recurrence after 
EMR more likely if the LSL is ≥40mm in maximum dimension,  contains high grade dysplasia 
or there was bleeding during the procedure requiring endoscopic control methods. 
Finally theme 4 is entitled future tools and methods for collaborative research in clinical 
endoscopic practice.   Within this theme Chapter 12 contains details of a next-generation 
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validated data collector for endoscopic resection procedures which in the future may allow 
greater collaboration between centres undertaking endoscopic resection, quality of data 
captured, correlation of endoscopic imaging, histologic and procedural data and the co-
ordination of high quality observational and randomised studies. 
This thesis therefore contains 8 published studies that iterate the effectiveness of colonoscopic 
polypectomy.  The future of the management of early neoplastic colonic lesions is endoscopic 
via an evidence-based patient and polyp specific approach. 
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Chapter 1 - Introduction and Map of Thesis 
Introduction to polypectomy 
The discovery of the adenoma to carcinoma sequence in colorectal cancer (CRC) 9,10 was 
pivotal to our understanding of the molecular basis of cancer.  It suggested that it is possible to 
interrupt the process, preventing the development of cancer by the detection and removal of 
benign precursors of the disease.   
Recent data provides the clinical corroboration of this theory.  Colonoscopy and polypectomy 
(removal of benign precursors of colorectal cancer, particularly tubular and tubulo-villous 
adenomas but also including sessile serrated adenoma) has been shown to prevent colorectal 
cancer 11 and deaths from colorectal cancer 12.  The key to this effect is the detection and 
resection of pre-malignant colonic polyps.  Colonoscopy and polypectomy has been shown to 
be inversely related to interval cancer and death from interval cancer 13.  For this reason, 
organised programmes of screening colonoscopy have become a priority for governments 
worldwide. 
Despite these gains a prevalence of cancer after a prior colonoscopy (interval cancer) is 
persistently reported in multiple population based series at rates from 2.6-9%14.  Contributing 
factors are likely to include failure of adenoma detection (multifactorial and beyond the scope 
of this thesis) and the quality of polypectomy.  For colonoscopy and polypectomy to reach a 
desired standard that no patient should present with colorectal cancer within 5 years of a 
colonoscopy both of the above need to be addressed. 
Polypectomy is a general term applied to the removal of precursors of malignancy in the 
gastrointestinal tract.  Multiple techniques are available and the optimal technique (considering 
safety and efficacy) depends of the size of the polyp under discussion.  Diminutive (up to 
5mm), small (up to 10mm), intermediate (10-19mm) and large (over 19mm in diameter) 
categories are generally recognised.  The complexity of performing polypectomy increases 
with the size of the polyp as does the risk of associated adverse events.  Large colorectal polyps 
are generally termed laterally spreading lesions (LSL) and have traditionally been managed 
with surgical resection.  Mounting evidence indicates that they may be safely and effectively 
removed by endoscopic resection techniques15,16, often as a day-case procedure, without the 
morbidity and mortality of surgery. 
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This thesis is split into 4 themes which link the associated publications and chapters (Figure 
1).  The rationale and background are discussed in the introductory comments to each theme. 
Figure 1 – Graphical Representation of the Thesis Content. LSL – large colorectal laterally spreading lesion ≥ 20𝑚𝑚, 
EMR – endoscopic mucosal resection, CAST – cold avulsion with adjuvant snare tip soft coagulation, SERT – Sydney EMR 
recurrence tool. 
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Theme 1 - QUALITY AND SAFETY IN COLONOSCOPIC 
POLYPECTOMY 
Introduction 
Quality in colonoscopy has progressed immeasurably over the last decade.  Structured training 
programmes using assessment based on key performance indicators 17 have been introduced in 
many developed countries with certification often required to practise the technique 
independently.   
In contrast, focussed key performance indicators for colorectal polypectomy are in their 
infancy.  Specific training programmes for polypectomy do not exist for endoscopy trainees in 
the majority of developed countries.  There has been a rapid expansion of the literature on 
polypectomy over the last decade with a clear evidence-base emerging for the correct technique 
to use for a particular polyp encountered18,19.  The individual non-expert endoscopist is 
therefore likely to be practising techniques their trainer(s) used and these may now be outdated. 
From the recent literature three themes emerge that have altered our understanding of best 
practice in polypectomy.   
• Endoscopic Imaging. 
o Colonoscopic image quality has dramatically improved and this has been 
brought to bear on classification of polyps prior to resection, particularly with 
regard to the risk of the polyp containing submucosal invasive cancer (SMIC).  
Various classification systems (Kudo20, Sano, NICE21) have been developed to 
determine the risk of SMIC within polyps, with the latter developed specifically 
for this purpose.  If there is no evidence of SMIC the polyp can be safely 
removed with simple endoscopic techniques.  However, evidence of SMIC 
increases the significance of the polyp in the individual patient dramatically and 
an en-bloc resection with clear histologic margins (R0) is desirable.  more 
complex endoscopic techniques or surgery may be required to remove these 
polyps.  Therefore, an understanding of colonoscopic imaging is essential for 
the modern endoscopist but is poorly taught, and limited materials are readily 
available for its understanding. 
o Chapter 2 addresses the imaging of a specific group of colorectal polyps known 
as sessile serrated polyps (SSP).  The significance of SSP as precursors of CRC 
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has recently become clear.  They are subtle lesions, easily missed 
endoscopically and have a preponderance for the right colon.  They are thought 
to be partly responsible for fact that interval cancer is more likely to be situated 
in the right colon 22.  Dysplasia within SSP has recently been described23, and 
appears as a conventional adenomatous pit pattern within serrated tissue.  This 
has the potential to be incompletely resected by endoscopists not familiar with 
these lesions via recognition and resection only of the conventional 
adenomatous component.  In the described study1 expert endoscopists were 
shown to be able to determine the presence of dysplasia within SSP with high 
accuracy using a standardised imaging protocol.  If validated and rolled out to 
the wider population of endoscopists this could be an important tool for 
reducing rates of interval cancer after colonoscopy. 
• Avoidance of diathermy 
o Emerging evidence suggests that the use of electrical energy converted to heat 
(diathermy) during polypectomy results in unpredictable small but definite risks 
to patients including delayed bleeding 24 and post-polypectomy syndrome 25.  
Therefore, diathermy should be avoided if an alternative technique exists to 
remove a polyp with a similar efficacy profile but that does not require 
diathermy.   
o Cold snare polypectomy has emerged as an effective alternative to polypectomy 
techniques involving diathermy.  It has been shown to be similarly effective to 
snare polypectomy involving diathermy 26,27 with excellent rates of en-bloc 
resection 28.   
o In the majority of published studies cold snare polypectomy has been applied to 
diminutive or small (<10mm) colorectal polyps.  Chapter 3 describes a study2 
using cold snare polypectomy to remove larger polyps (in this case SSP) up to 
35mm in maximum dimension.  SSP were chosen as a target lesion due to their 
low mucosal profile and known lower recurrence rate after endoscopic resection 
as versus conventional adenomas29.  The potential benefits of cold snare 
polypectomy in this scenario involve the avoidance of delayed bleeding – rates 
of 10-12% were described in the above study using diathermy – and perforation.  
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In the described pilot study 2there was no incidence of delayed bleeding or 
perforation amongst the 41 SSP treated with the technique. 
• Recognition that certain types of large lesion are suitable for endoscopic resection
and can avoid surgery
o Evidence from large, prospective observational studies30 indicates that
endoscopic resection for laterally spreading colonic lesions/polyps (LSL) is a
safe, cost-effective31,32 and efficacious alternative to traditional surgical
resection in over 90% of cases33.  Endoscopic mucosal resection (EMR) is a
procedure using sequential injection and subsequent snare resection that can be
used to remove even very large LSL.  It is commonly performed as a day case
procedure with a significantly lesser adverse event profile as compared to
surgery 34-36.
o Of some concern, recent published data37 indicates that rates of surgery for
predicted-benign colonic polyps is increasing.  Given the extensive literature
describing the superior safety and similar efficacy of endoscopic resection as
versus surgery this is difficult to understand.  Reasons may include
unavailability of individual endoscopic skills or local referral pathways for
endoscopic resection but may also include ignorance of the published literature.
The authors of this study could not identify a specific reason for this trend but
speculated.
o Chapter 5 aimed to investigate the attitudes of an international cohort of
endoscopists responding to an online survey on this topic (see below).
• Recognition that specific consent is required for the endoscopic resection of larger
lesions
o Whilst it has become clear that the adverse event profile of endoscopic
techniques for the resection of LSL is favourable compared to surgical
resection, it is also recognised that as the complexity of LSL increases so does
the risk of adverse events.  Reporting of adverse events after endoscopic
resection is hampered by a lack of standardised key performance indicators and
poor collection and linkage of data on outcomes of endoscopic resection outside
tertiary endoscopy centres.
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o How then can we, as practitioners of endoscopic resection consent our patients 
to the specific risks of surgical versus endoscopic management of their polyp at 
our own centre without personal and unit level outcome data, and without a 
metric to compare this to in the medical literature for their particular polyp.  This 
may be particularly troublesome due to the fact that surgical outcome data is 
robust in most developed countries, over unit, personal and national levels. 
o Chapter 4 is a study3 that attempts to provide an evidence-based, polyp-specific 
estimate of the likelihood of success and adverse events after endoscopic 
mucosal resection of a specific large colorectal polyp.  A scoring system 
(SMSA) developed in the United Kingdom using expert consensus 38 to grade 
the difficulty of polypectomy was applied retrospectively to a large cohort of 
lesions removed by EMR.  Likelihood of EMR success, and risks of clinically 
relevant adverse events including delayed bleeding, surgery and recurrence of 
adenoma were determined for each level of the SMSA score.  This information 
is highly relevant for patient consent since it can be determined by criteria 
known prior to the procedure.  In addition, this data lends itself to the 
establishment of polyp-specific key performance metrics for those performing 
endoscopic resection and can be applied to time and resource management at an 
endoscopy unit level. 
In the long term the drive against interval colorectal cancer will only be won through high rates 
of polyp detection and complete resection.  Current attitudes of individual practitioners to 
polypectomy have been investigated previously39 but not internationally and not in the last 
decade where major advances in our understanding have occurred.  Therefore, little data exists 
on the practice of polypectomy outside academic institutions that publish their data.  So-called 
‘real-world’ outcomes may be expected to be inferior to those at academic institutions, but this 
is unknown. 
Chapter 5 (unpublished currently) contains a study which aimed to provide data on the practice 
of colonoscopic polypectomy in 7 developed countries through the use of an online survey.  
Primarily through the use of questions associated with images of typical colorectal polyps, 
responses of 707 current endoscopic practitioners were compared to the evidence-based 
guidelines set out in the 2017 European Society of Gastrointestinal Endoscopy Colorectal 
Polypectomy Guideline19.  The questions were designed to assess attitudes of endoscopic 
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practitioners of polypectomy to the evidence presented in this theme.  In particular, participants 
were asked to indicate how they would manage specific polyps in their everyday practice.   
Results of the survey indicated that cold snare polypectomy is underutilised for diminutive and 
small polypectomy, SMIC is underappreciated by endoscopists and benign large colorectal 
polyps are routinely referred for surgery.  These results will be useful to international societies 
who aim to improve polypectomy practice. 
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Chapter 2 - A standardized imaging protocol for the endoscopic prediction 
of dysplasia within sessile serrated polyps. 
Introduction 
The study associated with this chapter 1 addresses the imaging of a specific group of colorectal 
polyps known as sessile serrated polyps (SSP).   
The significance of SSP as precursors of CRC has recently become clear.  They are subtle 
lesions, easily missed endoscopically and have a preponderance for the right colon.  They are 
thought to be partly responsible for fact that interval cancer is more likely to be situated in the 
right colon 22.   
Dysplasia within SSP has recently been described23, and appears as a conventional 
adenomatous pit pattern within serrated tissue.  This has the potential to be incompletely 
resected by endoscopists not familiar with these lesions via recognition and resection only of 
the conventional adenomatous component.   
The described study aimed to determine whether, in a single academic tertiary endoscopy 
centre, endoscopists could accurately determine the presence of dysplasia within SSP. 
ORIGINAL ARTICLE: Clinical Endoscopy222A standardized imaging protocol for the endoscopic prediction
of dysplasia within sessile serrated polyps (with video)GASTDavid J. Tate, MA(Cantab), MBBS, MRCP(UK),1,2 Mahesh Jayanna, MBBS, FRACP,1 Halim Awadie, MD,1
Lobke Desomer, MD,1 Ralph Lee, MD, MMed(Dist), FRCPC,1 Steven J. Heitman, MD, MSc, FRCPC,1
Mayenaaz Sidhu, MBBS,1 Kathleen Goodrick, RN,1 Nicholas G. Burgess, MBChB, BSc, FRACP,1,2
Hema Mahajan, MBBS, PhD, FRCPA,3 Duncan McLeod, MBBS, FRCPA,3 Michael J. Bourke, MBBS, FRACP1,2
Sydney, New South Wales, AustraliaBackground and Aims: Dysplasiawithin sessile serratedpolyps (SSPs) is difﬁcult todetect andmaybemistaken for an
adenoma, risking incomplete resection of the background serrated tissue, and is strongly implicated in interval cancer
after colonoscopy. The use of endoscopic imaging to detect dysplasia within SSPs has not been systematically studied.
Methods: Consecutively detected SSPs 8 mm in size were evaluated by using a standardized imaging protocol
at a tertiary-care endoscopy center over 3 years. Lesions suspected as SSPs were analyzed with high-deﬁnition
white light then narrow-band imaging. A demarcated area with a neoplastic pit pattern (Kudo type III/IV, NICE
type II) was sought among the serrated tissue. If this was detected, the lesion was labeled dysplastic (sessile
serrated polyp with dysplasia); if not, it was labeled non-dysplastic (sessile serrated polyp without dysplasia). His-
topathology was reviewed by 2 blinded specialist GI pathologists.
Results: A total of 141 SSPs were assessed in 83 patients. Median lesion size was 15.0 mm (interquartile range 10-
20), and 54.6% were in the right side of the colon. Endoscopic evidence of dysplasia was detected in 36 of 141
(25.5%) SSPs; of these, 5 of 36 (13.9%) lacked dysplasia at histopathology. Two of 105 (1.9%) endoscopically
designated non-dysplastic SSPs had dysplasia at histopathology. Endoscopic imaging, therefore, had an accuracy
of 95.0% (95% conﬁdence interval [CI], 90.1%-97.6%) and a negative predictive value of 98.1% (95% CI, 92.6%-
99.7%) for detection of dysplasia within SSPs.
Conclusions: Dysplasia within SSPs can be detected accurately by using a simple, broadly applicable endoscopic
imaging protocol that allows complete resection. Independent validation of this protocol and its dissemination to
the wider endoscopic community may have a signiﬁcant impact on rates of interval cancer. (Clinical trial registra-
tion number: NCT03100552.) (Gastrointest Endosc 2018;87:222-31.)(footnotes appear on last page of article)CURRENT KNOWLEDGE
Sessile serrated polyps (SSPs) without dysplasia (SSP-
ND) account for about 8% of colorectal polyps. They may
take many years to develop dysplasia and can be managed
effectively by complete endoscopic resection. SSPs with
dysplasia (SSP-D), conversely, are high-risk lesions. Recent
evidence suggests that they may progress rapidly toThis video can be viewed directly
from the GIE website or by using
the QR code and your mobile de-
vice. Download a free QR code
scanner by searching “QR Scanner”
in your mobile device’s app store.
ROINTESTINAL ENDOSCOPY Volume 87, No. 1 : 2018colorectal cancer (CRC), particularly because they occur
in people aged similar to people with serrated pathway
CRC. The dysplastic areas on the surface of SSP-D may
mimic conventional adenomas, risking incomplete resec-
tion by an endoscopist who does not appreciate the back-
ground serrated tissue. Incomplete endoscopic resection
of SSP-D leaves a high-risk lesion in situ with the molecular
changes to rapidly progress to interval cancer. A reliableUse your mobile device to scan this
QR code and watch the author in-
terview. Download a free QR code
scanner by searching “QR Scanner”
in your mobile device’s app store.
www.giejournal.org
Tate et al Endoscopic detection of dysplasia in sessile serrated polypsand accurate method to characterize dysplasia within SSPs
by using endoscopic imaging has not been demonstrated
previously in a large series.
New study ﬁndings
In 141 SSPs, a standardized endoscopic imaging proto-
col for dysplasia was accurate in 95.0% (95% conﬁdence in-
terval [CI], 90.1%-97.6%), with a negative predictive value
of 98.1% (95% CI, 92.6%-99.7%) against the criterion stan-
dard of blinded GI specialist pathologists. The protocol is
simple to use and broadly applicable to any endoscopist
working in a unit with high-deﬁnition endoscopes. If inde-
pendently validated, and with widespread dissemination to
the endoscopic community, this protocol may help reduce
rates of interval cancer via reliable identiﬁcation and com-
plete resection of SSP-D.THE NATURE OF SSPs
SSPs account for up to 8% of colorectal polyps in a
screening population.1-3 They have a preponderance for
the right side of the colon, are difﬁcult to detect, and are
commonly incompletely resected.4 They are more
common than adenomas, potentially because of a lack of
appreciation of the boundaries of the lesion. Recent
evidence suggests that they have a long dwell time (in the
order of 17 years) before the development of dysplasia. In
support of this, SSP-D are found in signiﬁcantly older pa-
tients, with the age of patients with SSP-D closely matching
the age of individuals with serrated pathway CRC. This pro-
vides strong evidence for SSP-D as a high-risk lesion with
the potential for rapid progression to cancer.5 Serrated
pathway CRC accounts for up to 30% of CRCs6 and is
over-represented in the interval cancer subgroup.7
The majority of SSPs do not contain dysplasia (SSP-ND)8
and can be managed effectively by a meticulous withdrawal
technique for endoscopic detection, accurate lesion
characterization, delineation of the lesion boundaries, and
complete endoscopic resection. SSP-D presents a unique
challenge. It is established that adenomas are more easily
detected than SSPs,9,10 predominantly because of their
more conspicuous surface structure. SSP-D has the poten-
tial to masquerade as adenomas. Therefore if only the
dysplastic portion is appreciated and resected, then a poten-
tially rapidly progressive residual is left in situ, and CRC may
ensue. In this context, the ability to accurately recognize
and characterize SSP-D to achieve complete endoscopic
resection is a critical component of interventions to prevent
serrated pathway CRC and potentially interval cancer.
Case reports11,12 and a retrospective series13 have
described the feasibility of using endoscopic imaging to
detect dysplasia within SSPs, but no systematic study exists.
In this study, we prospectively evaluated the utility of a
simple, widely applicable endoscopic imaging protocol to
detect dysplasia within SSPs compared with histopathology.www.giejournal.orgMETHODS
Format of the study
Over 41 months to January 2017, sequential
SSPs 8 mm detected within the endoscopic resection
practice of a single tertiary-care referral center were
analyzed according to a standardized imaging protocol.
Detailed patient, procedural, and lesion characteristics
were recorded. Split-dose bowel preparation was used.
Olympus high-deﬁnition colonoscopes were used
throughout (Olympus 180/190 series, Olympus, Tokyo,
Japan). Lesion size was determined with reference to an
open snare of known diameter, as was any dysplastic
area if present. The right side of the colon was deﬁned
as proximal to, and including, the hepatic ﬂexure. For
the purposes of this study, SSP-D describes the endoscopic
determination of dysplasia within SSPs, and SSP-ND de-
scribes the endoscopic determination of no dysplasia
within SSPs. Sessile serrated adenoma with dysplasia
(SSA-D) and sessile serrated adenoma without dysplasia
(SSA-ND) were used to describe the histologic determina-
tion of dysplasia within sessile serrated adenomas (SSA).
All procedures were performed by endoscopists with
extensive experience in endoscopic resection or by an
advanced endoscopy fellow under their direct supervi-
sion. There were 8 endoscopists in total. All patients pro-
vided written informed consent. Institutional review
board approval was obtained. All authors had access to
the study data and reviewed and approved the ﬁnal
manuscript.Standardized imaging protocol
We created a standardized imaging protocol supported
by our description of endoscopic features of dysplasia
within SSPs11 and our previous analysis of large SSP-D.14
Lesions were considered as SSPs when 1 or more of the
following features were identiﬁed: mucous cap, cloud-like
or ﬁnely nodular surface, indistinct border, irregular shape,
and lesion paler than the surrounding mucosa (under
narrow-band imaging)15 (Fig. 1). Once a lesion suspected
to be an SSP was detected, the endoscopist completed a
structured datasheet with the study coordinator. A
detailed analysis of the surface of the lesion was made by
using high-resolution endoscopic imaging with high-
deﬁnition white-light (HDWL) and narrow-band imaging
(NBI) (Olympus). In keeping with our previous experi-
ence,11,14 magniﬁcation was not used nor was chromoendo-
scopy. A careful search was made for any demarcated area
with an adenomatous (Kudo III/IV, NICE II) pit pattern
among the serrated tissue. If detected, the lesion was
described as SSP-D, and the features of this area were
described in detail. The size and number of demarcated
areas was recorded. Within demarcated areas, hyper-
vascularity (in comparison to the background features of
the overall lesion under NBI) and Kudo pattern wereVolume 87, No. 1 : 2018 GASTROINTESTINAL ENDOSCOPY 223
Figure 1. Surface characteristics of sessile serrated polyps (SSP). A,Multiple SSPs in a patient with serrated polyposis all covered with a mucus cap. B, SSP
with relatively distinct border and a ﬁnely nodular, cloud-like surface. C, Barely perceptible SSP with an indistinct border. D, Same lesion seen under
narrow-band imaging, paler than the surrounding mucosa. E, Same lesion after chromo-gelofusine injection, clearly demarcating the border. F, The ﬁnal
piecemeal EMR defect demonstrating the extent of the lesion.
Endoscopic detection of dysplasia in sessile serrated polyps Tate et aldescribed (Fig. 2, Video 1, available online at www.
giejournal.org). If a demarcated area was not detected,
the lesion was labeled SSP-ND. The endoscopist was then
asked to provide conﬁdence that (1) the lesion represented
an SSP and (2) the lesion did or did not contain dysplasia.
Lesion resection
All lesions were resected endoscopically. Our common
practice is to perform en bloc cold snare polypectomy
for SSPs up to 10 mm. Larger lesions predicted as SSP-
ND are resected by using piecemeal cold snare polypec-
tomy or EMR. If there is evidence of dysplasia (SSP-D),
we prefer EMR, resect the suspected dysplastic area en
bloc, and submit it separately for histopathologic analysis.
Histopathologic analysis
Resected lesions were diagnosed as SSAs based on es-
tablished criteria.16 Hematoxylin-eosin–stained sections
were available and were retrieved in all cases. All
specimens were reviewed by 2 independent specialist GI
pathologists blinded to the endoscopic diagnosis. The
type of adenoma and the presence and grade of any
cytologic dysplasia were recorded. Serrated dysplasia was
not considered cytologic dysplasia as per current expert
opinion.17 For the initial analysis, histopathology was
treated as the criterion standard.
For cases in which the histopathologic and endoscopic
determination of dysplasia within an SSP were incon-
gruent, a structured discussion between endoscopists
and specialist pathologists was undertaken. A determination
of the most likely correct diagnosis (SSA-ND or SSA-D) was
decided by mutual agreement.224 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 1 : 2018Statistical analysis
Statistical analysis was done by using SPSS version 23
(IBM, Armonk, NY) with a 2-tailed t test used for para-
metric continuous variables, Mann-Whitney U test for
nonparametric continuous data, and the chi-square test
for categorical variables. Only the largest demarcated area
within an SSP-D was described if there was more than 1.
Agreement between endoscopy and histopathologic
analysis was determined by using 2  2 tables. For these
analyses, histopathology was regarded as the criterion stan-
dard, before and after the structured discussion between
specialist pathologists and endoscopists. The signiﬁcance
of P was regarded at <.05.RESULTS
Population characteristics
Over the study period, 144 SSPs were detected in 86 pa-
tients. Three SSPs in 3 patients were excluded
(Supplementary Fig. 1, available online at www.
giejournal.org). The mean age of patients was 64.0 years
(standard deviation 15.4) and 57 of 83 (68.7%) patients
were female. Forty-four of 83 (53.0%) patients had 1 SSP,
24 had 2 SSPs, 12 had 3 SSPs, 2 had 4 SSPs, and 1 had 5
SSPs included in the analysis.
Endoscopic features of SSPs
The median size of SSPs was 15 mm (interquartile range
[IQR] 10-20). SSPs (1) were located in the right side of the
colon in 77 of 141 cases (54.6%), (2) were most often Paris
classiﬁcation 0-IIa (119/141, 84.4%), (3) had a mucous capwww.giejournal.org
Figure 2. Examples of the use of a standardized imaging protocol to determine dysplasia within sessile serrated polyps (SSPs). A, A well-demarcated
25-mm SSP with dysplasia (SSP-D) in the transverse colon. B, C, Narrow-band imaging (NBI) reveals a 3-mm demarcated area (dotted white line) with a
Kudo type IIIs pit pattern. D, E, Twelve-millimeter SSP-D in the ascending colon, with a 5-mm demarcated area best appreciated by using NBI (dotted
white line). F, A detail of the demarcated area reveals a Kudo type IV pit pattern. G-I, Twenty-millimeter SSP-D with an indistinct border in the trans-
verse colon and a subtle hypervascular area (dotted white line) with a borderline type III Kudo pit pattern. J-L, Twenty-millimeter SSP with indistinct
border in the ascending colon, containing a demarcated area with a type IIIs Kudo pit pattern (dotted white line). All the depicted lesions were diag-
nosed as sessile serrated adenomas with dysplasia, as determined histologically by histopathology. SSA, sessile serrated adenoma (histologic determi-
nation); SSPs, sessile serrated polyps (endoscopic determination).
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TABLE 1. Characteristics of the lesions in the study including methods of resection split by endoscopic features of dysplasia by using the
standardized imaging protocol
SSP-ND
n [ 105
SSP-D
n [ 36 P value
Patient
Age ( SD), y 60.2 (18.3) 68.9 (12.8) .010
Sex, female, no. (%) 79 (75.2) 25 (69.4) .495
Endoscopic features
Size, median (IQR) 15.0 (10-20) 20 (15-30) < .001
Left side of colon location* 50 (47.6) 14 (38.9) .364
Paris classification, no. (%)
0-Is 1 (1.0) 0 (0) .027
0-IIa 91 (86.7) 28 (77.8)
0-IIb 13 (12.4) 5 (13.9)
0-IIa/Is 0 (0) 3 (8.3)
Finely nodular, cloud-like surface, no. (%) 58 (55.2) 26 (72.2) .080
Mucous cap, no. (%) 86 (81.9) 29 (80.6) .857
Indistinct border, no. (%) 73 (69.5) 22 (61.1) .353
Paler than surrounding mucosa,y no. (%) 100 (95.2) 28 (77.8) .004
Resection features
Type of resection, no. (%)
CSP 48 (45.7) 8 (22.2) .042
pCSP 13 (12.4) 5 (13.9)
EMR, en bloc 10 (9.5) 8 (22.2)
EMR, piecemeal 34 (32.4) 15 (41.7)
Intra-procedural bleeding, no. (%) 7 (6.7) 4 (11.1) .472
Deep mural injury, no. (%) 2 (1.9) 1 (2.8) 1
Complete resection, no. (%) 105 (100) 36 (100) 1
Degree of dysplasia, no. (%)z
Low grade  26 (92.9) 
High grade  2 (7.1)
SSP-ND, Sessile serrated polyp without dysplasia as determined endoscopically; SSP-D, sessile serrated polyp with dysplasia as determined endoscopically; SD, standard
deviation; IQR, interquartile range; CSP, cold snare polypectomy, pCSP, piecemeal cold snare polypectomy; x, not applicable.
*Distal to the hepatic flexure.
yUsing narrow-band imaging.
zNote this comparison /28 SSP diagnosed as SSA-ND at initial histopathologic analysis.
Endoscopic detection of dysplasia in sessile serrated polyps Tate et al(115/141, 81.6%), (4) had a ﬁnely nodular surface (84/141,
59.6%), had an indistinct border (95/141, 67.4%), and (5)
were paler than the surrounding mucosa in the majority
of cases (128/141, 90.8%). Endoscopic prediction that a
lesion was an SSP was accurate in 141 of 141 cases
(100%) compared with histopathology.
One hundred ﬁve of 141 lesions were predicted as SSP-
ND by using the standardized imaging protocol, and 36 of
141 (25.5%) were predicted as SSP-D. SSP-ND were
smaller than SSP-D (15 mm, IQR 10-20 vs 20 mm, IQR
15-30; P < .001) and were more likely to be paler than
the surrounding mucosa under NBI compared with SSP-D
(100/105, 95.2% vs 28/36, 77.8%; P Z .004). SSP-D were
more likely to contain a dominant Is component than
SSP-ND (3/36, 8.3% vs 0/105, 0%; P Z .027). Other endo-226 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 1 : 2018scopic features of SSPs were similar between the groups
(Table 1).
Endoscopic prediction of dysplasia
Of the 36 of 141 (25.5%) SSPs predicted as SSP-D by
using the standardized imaging protocol, 27 of 36
(75%) were predicted with high conﬁdence
(Supplementary Table 1, available online at www.
giejournal.org). Larger demarcated areas within SSPs
were more likely to be predicted with high conﬁdence
(median 4 mm, IQR 2-5 vs 2 mm, IQR 1.5-3; P Z .010).
Features of the demarcated area were described as
hyper-vascular in 31 of 36 (86.1%), Kudo III pit pattern in
24 of 36 (66.7%), and Kudo IV pattern in the remaining
12 of 36 (33.3%).www.giejournal.org
Figure 3. Examples of cases with incongruent endoscopic imaging and initial histopathologic analysis. Area of interest ringed in white. A, B,
A 30-mm sessile serrated polyp with dysplasia (SSP-D) with a 3-mm hypervascular demarcated area. Thinner tissue sections revealed a small 2-
mm focus of dysplasia. Final diagnosis was sessile serrated adenoma with dysplasia as determined histologically (SSA-D). C, D, A 30-mm SSP-D
with a 3-mm demarcated area, type IIIs Kudo pit pattern. No dysplasia was detected despite further tissue sections, so failure to retrieve the cor-
rect specimen was suspected because the endoscopic appearances were convincing. Final diagnosis was SSA-D. E, F, A 15-mm sessile serrated
polyp without dysplasia (SSP-ND). Histopathology revealed a focus of dysplasia. On further inspection of the images, a demarcated area was visible
and was likely under-appreciated by the endoscopist because of over-distension of the colon. Final diagnosis was SSA-D. G, H, A 20-mm SSP-ND.
Histopathology revealed small, multifocal areas of dysplasia. Lack of a clear transition zone from dysplastic to nondysplastic sessile serrated polyp
(SSP) was judged responsible for this error. Final diagnosis was SSA-D. I, J, A 15-mm sessile serrated polyp with dysplasia (SSP-D). Histopathology
revealed no evidence of dysplasia despite further tissue sections. A borderline type II-O/IIIs Kudo pit pattern was judged to be responsible for this
error. Final diagnosis was sessile serrated adenoma without dysplasia as determined histologically (SSA-ND). K, L, A 35-mm SSP-D. A small focus of
traditional serrated adenoma within the SSP was detected at histopathology review, likely corresponding to the demarcated area (photomicro-
graph in Fig. 4C). Final diagnosis was SSA-ND (no conventional dysplasia17). M, N, A 25-mm SSP-D. No dysplasia was detected at histopathology
despite additional sections, however a 1.5-mm perineurioma was detected. It was judged likely that this pathology elevated and stretched the
lesion surface, creating the appearance of a demarcated area (Fig. 4D). Final diagnosis was SSA-ND. O, P, A 25-mm SSP-D at the appendiceal
oriﬁce. No dysplasia was detected at histopathology review. The appearance of a demarcated area created by the colon contour was judged to
be responsible for this error. Final diagnosis was SSA-ND.
Tate et al Endoscopic detection of dysplasia in sessile serrated polypsAfter initial histopathologic analysis, the standardized
imaging protocol had a sensitivity of 92.9% (95% CI,
75.0%-98.7%), a speciﬁcity of 91.2% (95% CI, 83.9%-
95.4%), and a negative predictive value of 98.1% (95% CI,
92.6%-99.7%). The accuracy was 91.4% (95% CI, 85.7%-
95.1%).www.giejournal.orgCases with disagreement between histologic
and endoscopic determination of dysplasia
within SSP
In 12 of 141 cases (8.5%), there was disagreement be-
tween endoscopic and histopathologic determination of
dysplasia within speciﬁc SSPs. In each case, endoscopicVolume 87, No. 1 : 2018 GASTROINTESTINAL ENDOSCOPY 227
Figure 4. Examples of cases in which histopathologic features other than dysplasia created a demarcation zone, causing the endoscopist to predict
dysplasia when none was present. A, Typical sessile serrated polyp with dysplasia (SSP-D) with a transition zone from dysplastic mucosa (D) to nondys-
plastic serrated tissue (ND) marked by the arrow (H&E, orig. mag. 2). B, A higher magniﬁcation of A (H&E, orig. mag. 4). C, Endoscopically predicted
SSP-D (corresponding to Fig. 3K and L). A small focus of traditional serrated adenoma was detected at histopathology (arrow), likely corresponding to the
demarcated area in the endoscopic image. Final diagnosis was sessile serrated adenoma without dysplasia as determined histologically (SSA-ND) (H&E,
orig. mag. 4). D, Endoscopically predicted SSP-D (corresponding to Fig. 3M and N) (H&E, orig. mag. 5). The photomicrograph shows a focal
perineurioma (arrow) measuring 1.5 mm across within the SSA-ND. This elevated and stretched a focal area of the lesion, creating the appearance of
a demarcated area. Final diagnosis was SSA-ND (H&E, orig. mag. 4). E, Magniﬁcation of area shown by arrow in D (H&E, orig. mag. 10).
Endoscopic detection of dysplasia in sessile serrated polyps Tate et aland histologic images of the procedure were retrieved, and
a structured discussion between endoscopists and the
specialist histopathologists was undertaken (Fig. 3).
In 5 of 12 cases (41.7%), a consensus was reached that
the endoscopic imaging was correct. Causes for histopath-
ologic error were not errors in retrieval and/or processing
of the specimen in 4 of 5 cases (80.0%), and a small area of
dysplasia missed between tissue slices in 1 case of 5
(20.0%).
In 7 of 12 cases (58.3%), a consensus was reached that
the histopathologic assessment was correct. Causes for
endoscopic error were a demarcation area created by an
alternative pathology in 3 of 7 cases (42.9%) (traditional
serrated adenoma in 1 of 3 and a perineurioma in 2 of 3)
(Fig. 4), colon morphology in 2 of 7 cases (28.6%), a
borderline type II-O/III Kudo pit pattern in 1 of 7 cases
(14.3%), and multifocal dysplasia with no transition point
in 1 of 7 cases (14.3%).
After the results of consensus opinion were taken into
consideration, the standardized endoscopic imaging
protocol demonstrated a sensitivity of 93.9% (95% CI,
78.4%-98.9%), speciﬁcity of 95.4% (95% CI, 89.0%-98.3%),
negative predictive value of 98.1% (95% CI, 92.6%-
99.7%), and an accuracy of 95.0% (95% CI, 90.1%-97.6%)
for the prediction of dysplasia within SSPs (Table 2).228 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 1 : 2018Endoscopic resection
En bloc cold snare polypectomy was the most common
form of resection for SSPs (56/141, 39.7%). Piecemeal
cold snare polypectomy (18/141, 12.8%) was principally
used for large, nondysplastic SSPs. EMR was preferred
for SSP-D (20/28, 71.4% vs 47/113, 41.6%; P Z .005).
Endoscopic resection was judged to be complete in all
cases.DISCUSSION
Recent data show that SSA-ND has a long dwell time
before the development of dysplasia and progression to
CRC.5 Standardized description of their endoscopic
features15 has enabled their reliable detection, and they
can be managed effectively by complete endoscopic
resection. Conversely, SSA-D are high-risk lesions. Once
they have acquired speciﬁc molecular changes (commonly
hyper-methylation of MLH118), the available evidence
suggests they progress rapidly to CRC.5,7 It is established
that SSPs often are incompletely resected.4 Although this
may be of little consequence for SSP-ND, incomplete
resection of SSP-D may be responsible for a signiﬁcant pro-
portion of interval CRC, perhaps primarily because of awww.giejournal.org
TABLE 2. Accuracy of the endoscopic assessment of dysplasia within serrated lesions ≥8 mm before and after discussion with the specialist
histopathologists
Before discussion Histopathologic assessment
Endoscopic assessment SSA-ND (113) SSA-D (28)
SSP-ND (105) 103 (98.1%) 2 (1.9%)
SSP-D (36) 10 (27.8%) 26 (72.2%)
Accuracy of endoscopic assessment of dysplasia (before discussion)
Sensitivity 92.9% (95 CI, 75.0%-98.7%)
Specificity 91.2% (95% CI, 83.9%-95.4%)
Negative predictive value 98.1% (95% CI, 92.6%-99.7%)
Accuracy 91.4% (95% CI, 85.7%-95.1%)
After discussion Histopathologic assessment
Endoscopic assessment SSA-ND (108) SSA-D (33)
SSP-ND (105) 103 (98.1%) 2 (1.9%)
SSP-D (36) 5 (13.9%) 31 (86.1%)
Accuracy of endoscopic assessment of dysplasia (after discussion)
Sensitivity 93.9% (95% CI, 78.4%-98.9%)
Specificity 95.4% (95% CI, 89.0%-98.3%)
Negative predictive value 98.1% (95% CI, 92.6%-99.7%)
Accuracy 95.0% (95% CI, 90.1%-97.6%)
SSA-ND, Sessile serrated adenoma without dysplasia as determined histologically; SSA-D, sessile serrated adenoma with dysplasia as determined histologically or by structured
discussion; SSP-ND, sessile serrated polyp without dysplasia as determined endoscopically; SSP-D, sessile serrated polyp with dysplasia as determined endoscopically;
CI, confidence interval.
Tate et al Endoscopic detection of dysplasia in sessile serrated polypsfailure to appreciate the nature or extent of the lesion. For
example, SSP-D may be mistaken for adenomas with the
endoscopist not appreciating the surrounding serrated
component, which may then be left in situ. In this study
we have demonstrated that a simple, broadly applicable,
endoscopic imaging protocol can accurately determine
the presence of dysplasia within SSPs in a large prospective
cohort. This protocol therefore allows the suitably trained
endoscopist to reliably recognize SSP-D, precisely delin-
eate its extent, and ensure its complete endoscopic
resection.
Contemporary colonoscopists with high adenoma
detection rates report serrated lesion detection rates of
approximately 8%,8 and the serrated lesion detection rate
is emerging as an important quality measure for
colonoscopists. This success has, in large part, been
because of studies deﬁning19,20 and standardizing the
endoscopic features of SSPs. A recent international
consensus15 suggests an accuracy of 0.93 (95% CI, 0.87-
0.98) in discriminating SSPs from non-SSPs after training.
Among the cohort of tertiary-care center endoscopists in
this study, SSPs were correctly identiﬁed in all cases. We
conﬁrmed that the features of SSPs in the WASP classiﬁca-
tion15 were common and can be used readily to identify
SSPs, particularly a clouded or ﬁnely nodular surface,
indistinct border, and a lesion paler than the surrounding
mucosa by using NBI.www.giejournal.orgModern endoscopic imaging allows reliable visualization
to the level of the individual colon mucosal gland, permit-
ting differentiation of so-called neoplastic pit patterns from
non-neoplastic patterns.21 The detection of a demarcated
area of disordered pit pattern within a regular neoplastic
pattern has emerged as a predictor of submucosal
invasive cancer.22 Multiple case reports have described
the feasibility of using endoscopic imaging11 or
chromoendoscopy12 to describe demarcated areas of
dysplasia within SSPs. A recent Japanese still-image–based
study13 conducted retrospectively among 41 SSP-D derived
a set of endoscopic lesion characteristics (reddishness,
double elevation, and central depression), which predicted
dysplasia or serrated cancer. The inclusion of serrated can-
cer, use of still images, and derivation of highly subjective
predictors limits the widespread applicability of this
method of determining SSP-D.
We used features derived from our previous
studies11,14 in addition to our anecdotal observations to
develop a standardized imaging protocol to determine
dysplasia within SSP. Dysplasia commonly appears as a
transition from type II open pits typical of SSP to type
III or type IV pits typical of tubular or tubulovillous
adenoma. The transition stands out to the observer
and creates a demarcated area, particularly under NBI.
This area often is hypervascular or dark (under NBI)
compared with the surrounding serrated tissue. WhenVolume 87, No. 1 : 2018 GASTROINTESTINAL ENDOSCOPY 229
Endoscopic detection of dysplasia in sessile serrated polyps Tate et althe imaging protocol was applied prospectively to the 141
lesions in this study, the accuracy of determining
dysplasia was very high (95%) as was the negative predic-
tive value (98%).
Incomplete resection of a rapidly progressive high-risk
lesion such as SSP-D is likely responsible for a proportion
of interval cancers after colonoscopy. In this scenario, the
endoscopist, distracted by the adenomatous pit pattern of
an SSP-D, resects only the dysplastic portion, leaving part
of a lesion with the mutations, allowing rapid progression
to CRC in situ. The ability to determine accurately, by us-
ing endoscopic imaging, whether a given colon lesion is an
SSP-D allows real-time appreciation of its high-risk nature
as well as the full extent of the lesion, guarding against
incomplete resection. It also allows selection of a safe
method of endoscopic resection. Dysplastic lesions should
be resected by established techniques, that is, EMR. In
particular, the dysplastic focus should be removed en
bloc and submitted separately for histopathology to avoid
missing a focus of submucosal invasive cancer. At our cen-
ter, we routinely perform piecemeal cold snare polypec-
tomy for large SSPs without endoscopic evidence of
dysplasia, aiming to avoid the risks of electrocautery, espe-
cially delayed bleeding from the right side of the colon.
Prospective randomized studies (compared with EMR)
are required to determine the safety and utility of this
technique. The 5 patients who underwent piecemeal
cold snare polypectomy for SSP-D in this study were
elderly, and therefore avoidance of electrocautery risk
was prioritized.
Another potential beneﬁt of an accurate endoscopic im-
aging protocol to detect and characterize SSP-D concerns
patients with multiple SSPs (including those meeting
criteria for serrated polyposis syndrome), requiring several
colonoscopic sessions to clear the colon. The majority of
these lesions may take many years to develop the molecu-
lar changes required to become CRC. Endoscopic determi-
nation of dysplasia allows the endoscopist to prioritize
high-risk lesions for resection.
Real-time analysis notwithstanding, histopathology re-
mains an imperfect criterion standard in the study of
dysplastic areas within SSPs. Dysplastic foci often are small
(median 3 mm diameter in this study). These small foci
may not be retrieved or may be destroyed during tissue
processing. They may lie undiscovered between tissue sec-
tions, which can be as wide as 3 to 5 mm.
The majority of endoscopic errors in determining
SSP-D were due to an alternative lesion mimicking the
appearance of a demarcated area or the colon contour
hiding the presence of a nodule. Overall, 10 of 12 cases
(83.3%) with a discrepancy between endoscopic and his-
tologic ﬁndings were endoscopically predicted as SSP-D,
whereas histology determined SSA-ND. Although 5 of 10
such cases (50%) were later determined to be histologic
error, the clinical relevance of these discrepancies
should be played down because it is the ability to230 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 1 : 2018endoscopically determine a lack of dysplasia that matters
clinically.
Given the accuracy of the standardized imaging proto-
col in predicting SSP-D among a group of expert endoscop-
ists, independent validation of these ﬁndings is necessary
before dissemination of learning materials to the wider
endoscopic community. Complementary efforts should
include dissemination of validated criteria to accurately
identify SSPs. The support of international societies will
be vital in this endeavor.
The strengths of this study include a large, previously
unstudied cohort of patients with SSP, which were sys-
tematically described and prospectively collected.
Involvement of multiple endoscopists and review of all
specimens by 2 blinded specialist histopathologists mini-
mized bias in analysis of the protocol and the histopatho-
logic analysis. The standardized imaging protocol is
simple and can be generalized widely because the major-
ity of endoscopy units will have the equipment required
to implement it.
The drawbacks of the study include the collection of
cases from a single center. In addition, SSPs were detected
within a tertiary-care resection cohort, potentially biasing
the type of lesion seen in the everyday practice of a
screening endoscopist. In particular, the mean size of
SSPs in a screening populations is about 10 mm, according
to a recent study,8 as compared with the median size in
this study of 15 mm. The experience described here with
larger SSPs may be a stepping stone to understanding
the problem and elucidating the imaging signs of dysplasia
in smaller lesions. In addition, not only is SSP-D rare
in screening populations (0.6% of all polyps in 1 study8),
but if an SSP is small, the endoscopist is more likely to
appreciate the lesion as a whole rather than be drawn to
the dysplastic focus as such.
In conclusion, we have demonstrated that dysplasia
within SSPs can be predicted accurately by using a stan-
dardized endoscopic imaging protocol. This simple pro-
tocol allows the appropriately trained endoscopist to
characterize SSP-D fully–particularly the extent of the
lesion–with a view to achieving complete resection.
Given that SSP-Ds are strongly implicated in interval
cancers after colonoscopy, independent validation of
this protocol and its dissemination to the wider endo-
scopic community may have profound clinical
consequences.REFERENCES
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Referred for ER of SSP or
SSP ≥ 8mm detected
n=144
86 patients 
Image analysis
with HDWL and
NBI
SSP-ND
median size 15mm
(IQR 10-20)
n=105
SSP-D
median size 20mm
(IQR 15-30)
n=36
Histologic
confirmation
103/105 (98.1%)
Histologic
confirmation
26/36 (72.2%)
Consensus
SSA-ND
103/105 (98.1%)
Consensus
SSA-D
31/36 (86.1%)
EXcluded (3 lesions, 3 patients )
1 specimen not retrieved
1 not resected (cancer suspected)
1 image capture failure therefore no
possibility to undertake structured
discussion
Resection method
CSP 56 (39.7%)
pCSP 18 (12.8%)
en bloc EMR 18 (12.8%)
piecemeal EMR 49 (34.8%)
Structured discussion
between Endoscopists
and Histopathologists
in cases of
disagreement
Supplementary Figure 1. Recruitment and ﬂow through the study. ER, endoscopic resection; SSP, sessile serrated polyp; HDWL, high-deﬁnition white
light; NBI, narrow-band imaging; SSP-ND, nondysplastic SSP as determined endoscopically; SSP-D, dysplastic SSP as determined endoscopically; CSP, cold
snare polypectomy; pCSP, piecemeal cold snare polypectomy; SSA-ND, sessile serrated adenoma without dysplasia as determined histologically; SSA-D,
sessile serrated adenoma with dysplasia as determined histologically.
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SUPPLEMENTARY TABLE 1. Characteristics of dysplastic demarcated areas within 36 sessile serrated polyps with dysplasia detected within the
study period, split by the endoscopist’s confidence in the presence of dysplasia
Total
n [ 36
Low confidence
n [ 9
High confidence
n [ 27 P value
Endoscopic features of demarcated area
Size (median, IQR), mm 3 (2-5) 2 (1.5-3) 4 (2-5) .010
Hypervascular, no. (%) 31 (86.1) 8 (88.9) 23 (85.2) 1.000
Highest Kudo, no. (%)
III 24 (66.7) 6 (66.7) 18 (66.7) 1.000
IV 12 (33.3) 3 (33.3) 9 (33.3)
Histologic outcome
SSA-D before discussion, no. (%) 26 (72.2) 4 (44.4) 22 (81.5) .627
SSA-D after discussion, no. (%) 31 (86.1) 6 (66.7) 25 (92.6) .088
IQR, Interquartile range; SSA-D, sessile serrated adenoma with dysplasia as determined histologically Before and after discussion refer to the discussion of cases between the
endoscopist and the specialist pathologists.
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Synopsis and Significance 
In this prospective study of 141 SSP the accuracy of a standardised protocol for endoscopic 
assessment of dysplasia within SSP was 95.0% as compared to the gold standard of blinded 
specialist gastrointestinal pathologists.  When a discussion with the pathologists was 
undertaken the agreed accuracy of endoscopic determination of dysplasia within SSP was 
98.1%.   
If validated and subsequently rolled out to the wider population of endoscopists, this 
standardised imaging protocol could be an important tool for reducing rates of interval cancer 
after colonoscopy via the recognition and complete resection of dysplastic SSP. 
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Chapter 3 - Wide-field piecemeal cold snare polypectomy of large sessile 
serrated polyps without a submucosal injection is safe. 
Introduction 
Cold snare polypectomy has emerged as an effective alternative to polypectomy techniques 
involving diathermy.  It has been shown to be similarly effective to snare polypectomy 
involving diathermy 26,27 with excellent rates of en-bloc resection 28.  In the majority of 
published studies to date cold snare polypectomy has been applied to diminutive or small 
(<10mm) colorectal polyps.   
This chapter describes a study2 using cold snare polypectomy to remove larger polyps (in this 
case SSP) up to 35mm in maximum dimension.  SSP were chosen as a target lesion due to their 
low mucosal profile and known lower recurrence rate after endoscopic resection as versus 
conventional adenomas29.  The potential benefits of cold snare polypectomy in this scenario 
involve the avoidance of delayed bleeding, since rates of 10-12% were described in the above 
study using endoscopic mucosal resection. 
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1.  Abstract 
     
Large series suggest endoscopic mucosal resection is safe and effective for the removal of 
large sessile serrated polyps ≥10mm (large SSP) but it exposes the patient to the risks of 
electrocautery including delayed bleeding. We examined the feasibility and safety of 
piecemeal cold snare polypectomy (pCSP) for the resection of large SSP. 
1.2.  Methods 
Over 12 months sequential large SSP (10-35mm) without endoscopic evidence of dysplasia 
referred to a tertiary endoscopy centre were considered for pCSP.  A thin-wire snare was 
used in all cases. Submucosal injection was not performed. High definition imaging of the 
defect margin was used to ensure the absence of residual serrated tissue. Adverse events 
were assessed at 2 weeks and surveillance was planned between 6 and 12 months. 
1.3.  Results 
41 SSP were completely removed by pCSP in 34 patients.  The median size of SSP was 
15mm (IQR 14.5-20), range 10-35mm. The median duration of procedures was 4.5 
minutes (IQR 1.4-6.3). There was no evidence of perforation or significant intra-procedural 
bleeding.  There were no significant adverse events at 2 week follow up including delayed 
bleeding and post polypectomy syndrome. 15/41 lesions underwent first follow up at 
median 6 months with no evidence of recurrence.  
1.1. Background and Aims
  Chapter 3 Manuscript  |  Page 3 
1.4.  Conclusions 
There is potential for pCSP to become the standard of care for non-dysplastic large SSP.  
This may reduce the burden on patients and healthcare systems of removing SSP, 
particularly by avoidance of delayed bleeding. 
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2.  Introduction 
Sessile serrated polyps (SSP) are important precursor lesions for colorectal cancer [1]. They 
may remain indolent for many years but once they develop dysplasia they are high-risk 
lesions for transformation to colorectal cancer [2]. 
Endoscopic mucosal resection (EMR) offers a safe and effective method to resect large 
(≥10mm) SSP[3] but exposes the patient to the risks of diathermy, including post EMR 
bleeding which may occur in up to 10% in the right colon and is likely due to unintended 
thermal injury of submucosal tissue and vessels.  While these risks are small and certainly 
significantly lower than the risks of surgery, they are resource intensive when they occur. 
Cold snare polypectomy (CSP) is the first line treatment for colorectal polyps ≤10mm due 
to its efficacy, precision and excellent adverse event profile[4]. Extension of this technique 
to piecemeal resection of larger lesions using a submucosal cushion has been described in 
small retrospective series[5],[6].  
Large SSP are lower risk for recurrence and dysplasia than conventional adenomas[7],[8]. 
They are therefore low risk for developing submucosal invasive cancer and potentially 
suited to a piecemeal technique with a low risk of complications.  We sought to 
systematically examine the safety of piecemeal cold snare polypectomy (pCSP) without a 
submucosal cushion for large SSP. 
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3. Methods
Over 12 months to January 2017, large SSP (≥10mm and ≤35mm) without endoscopic 
evidence of dysplasia referred to a tertiary endoscopy centre were removed using pCSP by 
seven expert endoscopists. Resection was with a stiff thin-wire snare (TeleMed 10mm 
Hexagonal, Telemed Systems Inc, MA, USA). Injection of a submucosal lifting solution prior 
to resection was not performed. Detailed patient, procedural and lesion characteristics were 
recorded prospectively. Standard peri-procedural advice regarding anticoagulation was 
given and split dose bowel preparation was used. Procedures were performed using 
Olympus 180/190 colonoscopes (Olympus, Tokyo, Japan). Written consent was obtained. 
Institutional review board approval was obtained for the study. 
The technique for pCSP was standardised (Supplementary Figure 1, Supplementary video 
1). The lesion and its margins were assessed using high definition endoscopic imaging. If 
there was evidence of dysplasia EMR was preferred. Snare resection commenced at one 
margin including a 2-3mm rim of normal tissue. Firm downward pressure and suction of 
luminal gas aided tissue capture. Subsequently the assistant closed the snare until 
resistance was felt, and then completely once the endoscopist was satisfied with the amount 
of captured tissue.  If transection did not occur within five seconds gentle traction was 
exerted on the snare catheter against the tip of the colonoscope. If transection still did not 
occur, the snare placement was revised. The mucosal defect was then expanded with a 
flushing pump (Olympus, Tokyo, Japan) containing 0.9% saline.  Further resections were 
then performed aligning the snare with the cut edge of the expanding mucosal defect. 
Once the resection was completed the mucosal defect was inspected for residual serrated 
tissue.  If residual was detected further generous snare resection was performed.  Oozing of 
blood from the resection site was common and was not actively treated (Figure 1). Intra-
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procedural bleeding described bleeding requiring endoscopic control. Complete endoscopic 
resection described the removal of all serrated tissue. 
After the procedure patients were observed for two hours and discharged on a clear liquid 
diet overnight.  Structured telephone interview was performed at two weeks.  Clinically 
significant post endoscopic bleeding (CSPEB) described bleeding requiring admission to 
hospital or re-intervention. 
Patients were followed up at 6-12 months determined by the endoscopist dependent on the 
number of synchronous lesions, presence of serrated polyposis syndrome and presence of 
dysplasia in the resection specimen.  At surveillance colonoscopy the endoscopic resection 
scar(s) (using the previously documented colonic location and prior images) was located 
and analysed using high definition white light and NBI. 
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4.  Results 
41 SSP were removed by pCSP in 34 patients. Supplementary Figure 2 shows four further 
examples. 7 patients had two lesions removed. The mean age of patients was 68.58 years 
(standard deviation 10.12 years) and 27/34 (79.4%) were female (Table 1).  The median 
size of SSP was 15mm, IQR 14.5-20, range 10-35mm and 26/41 (63.4%) were located 
proximal to the transverse colon.  Figure 2 shows recruitment to the study. 
4.1.  Procedure 
The median procedure duration was 4.5 minutes (IQR 1.4-6.3). The median number of 
pieces required to completely remove SSP was 3.0 (IQR 3-5). There was no evidence of 
deep injury to the colonic wall in any case. A cold snare protrusion was noted in 9/41 
(22.0%) cases. No intra-procedural bleeding was noted. Complete resection was achieved 
in all cases. No modality other than snare resection was used or required.  
Pathology demonstrated sessile serrated adenoma in all cases. Low grade dysplasia was 
present in 3 (7.3%) resection specimens.  Completeness of resection was not assessed 
histologically due to the piecemeal nature of resection. 
4.2.  Outcomes and Safety 
Outcomes after pCSP are summarized in Table 2.  There were no instances of CSPEB, post 
polypectomy syndrome or delayed perforation either during observation after the 
procedure or when patients were contacted at 2 weeks.  
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15/41 (36.5%) patients have so far undergone surveillance colonoscopy at median 6 
months (IQR 5-7) after the index procedure. None of the cases had evidence of recurrent 
serrated tissue at the endoscopic resection scar. 
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5. Discussion
Large sessile serrated polyps (SSP) are recognised as important precursors of colorectal 
cancer. They can be safely removed by EMR[7] but, despite a favourable risk profile 
compared to surgery[9], electrocautery exposes patients to risks including clinically 
significant post endoscopic bleeding, post-polypectomy syndrome and perforation.  Since 
SSP commonly lack high grade histology, have a long dwell time prior to developing 
dysplasia[2] and recur less frequently than conventional adenomas[7], they represent 
comparatively indolent disease and are excellent targets for piecemeal mucosal resection.  
In this study we have demonstrated the feasibility and safety of pCSP for large colonic SSP. 
Cold snare polypectomy (CSP) is safe and effective for the complete endoscopic resection of 
small colorectal polyps[10]. Multiple randomised studies have demonstrated the similar 
efficacy with significantly less adverse events of CSP versus hot snare polypectomy (HSP) 
for polyps up to 10mm in size[11-13].  
Whether these benefits extend to larger lesions is unclear.  Only retrospective studies, not 
restricted to SSP and utilizing submucosal elevation exist.  Muniraj et al. [5] reported pCSP 
of 30 sessile polyps ≥10mm using a thin-wire snare (Exacto, US Endoscopy, Ohio, USA). 
No significant adverse events occurred, although 20% of lesions recurred.  Choksi, et al. [6] 
studied 15 colonic polyps larger than 10mm removed by pCSP.  They found no significant 
complications save for a single patient with pain post-polypectomy. Long term follow up 
was not described. 
We have described the simple technique of pCSP (without submucosal injection) for large 
SSP.  A thin-wire snare is paramount, both to aid tissue capture and to create a crisp 
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resection margin which can be examined for residual serrated tissue. Progressant resections 
utilise this margin to ensure snare purchase and avoid tissue islands.  Submucosal 
protrusion is often noted within the defect e.g. Supplementary Figure 2, Series d Panel 3; 
this is composed of bunched up submucosal tissue and has been previously shown to not 
contain epithelium [14].  Minor oozing of blood is common and appears not to predict 
CSPEB in this cohort. The technique is quick to perform and we anecdotally find it much 
faster than EMR for equivalent lesions. 
We avoided resecting SSP with endoscopic evidence of dysplasia using pCSP since these 
represent high risk lesions and this was a pilot study. 3 elderly patients with endoscopic 
evidence of dysplasia underwent pCSP in this study, primarily in an attempt to minimize 
the risk of pos-EMR bleeding.  We did not use submucosal injection or a chromic dye.  
While we acknowledge its utility for delineation of serrated tissue, we found that high 
definition imaging was sufficient for this purpose and to detect residual serrated tissue at 
the resection margin.  In situations of uncertainty further resections were made expanding 
the defect without apparent adverse events. 
Adverse events associated with pCSP in this study were infrequent. In-particular there was 
no CSPEB, post polypectomy syndrome nor delayed bleeding within 2 weeks.  The lack of 
CSPEB is clinically important.  The absolute risk of CSPEB after EMR of a proximal LSL – 
the most common location for SSP - is 10-12%[15].  Care of the patient with CSPEB is 
expensive and resource intensive.  Prophylaxis of CSPEB with endoscopic clips is expensive 
and not possible with larger resections[16].   
We detected no recurrence (endoscopic or histologic) at the endoscopic resection scar in 
the patients who have undergone follow up thus far. We suggest, cautiously, that this is 
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related to the wide margin of tissue removed at the initial procedures and meticulous 
examination of the defect and margin for residual tissue.  
This study has several strengths. The technique is well characterised and was applied 
prospectively with defined data parameters collected at the time of the procedures. 
Drawbacks include the single centre series and the limited follow up to date. Future study 
should randomise large SSP to EMR – the current standard of care – or pCSP to accurately 
define outcomes and the place of the two techniques.  
In conclusion in this pilot study we have demonstrated the safety and feasibility of pCSP in 
a tertiary referral cohort of patients referred for the removal of large SSP.  There is 
potential for pCSP to become the standard of care for non-dysplastic SSP.  This may reduce 
the burden on patients and healthcare systems of removing SSP, particularly by avoidance 
of CSPEB. 
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7. Tables 
 pCSP (n=41) 
Patient   
Age, mean (standard deviation) 68.58 (10.12) 
Sex, female (%) 27 (79.4) 
Lesion  
 Size, median (IQR) 15 (14.5-20) 
Location, proximal to transverse colon 
(%) 
26 (63.4) 
Paris classification (%)  
0-IIa 40 (97.6) 
0-IIb 1 (2.4) 
Endoscopic evidence of dysplasia (%) 3 (7.3) 
Kudo, highest (%)  
II-O 41 (100) 
Procedure  
Duration, median minutes (IQR) 4.5 (1.4 to 6.3) 
Pieces, median (IQR) 3.0 (3-5) 
Protrusion within defect (%) 9 (22.0) 
Intra-procedural bleeding requiring 
intervention (%) 
0 (0) 
Histopathology, serrated adenoma (%) 41 (100) 
Low grade cytological dysplasia (%) 3 (7.3) 
Table 1 Baseline characteristics of the 34 patients and 41 SSP that underwent piecemeal 
cold snare polypectomy (pCSP).  IQR – interquartile range. 
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Outcome pCSP 
(n=41) 
Adverse events  
Clinically significant post endoscopic 
bleeding (%)  
0 (0)  
Delayed perforation (%) 0 (0) 
Post procedural pain (%) 0 (0) 
Admission to hospital for related 
complication within 2 weeks 
0 (0) 
Follow up  
Months to SC1, IQR 6 (5-7) 
Recurrence at SC1, (%), n=15 0 (0) 
Histologic recurrence at SC1, (%), n=9 0 (0) 
Table 2 Outcomes of the 41 SSP that underwent piecemeal cold snare polypectomy (pCSP).  
SC1 – first surveillance colonoscopy 
 
8. Figure Legends 
Figure 1: Piecemeal cold snare polypectomy of a 25mm SSP in the ascending colon. a-c) 
Lesion assessment is performed using narrow band imaging and high definition white light 
to assess for endoscopic evidence of dysplasia. Dysplasia is demonstrated in this example 
and is particularly well seen under narrow band imaging.  Given the patients age and 
comorbidities pCSP is preferred over EMR.  d) Multiple snare resections are used with the 
cut edge of the mucosal defect acting as a guide for the next snare placement. f) Minor 
ooze of blood from the resection defect is common, does not usually require active 
treatment and the defect can be safely expanded as needed to achieve complete excision. g) 
Completed cold snare defect after expansion with normal saline with no evidence of 
continued bleeding or deep injury. SSP - sessile serrated polyp. 
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Figure 2 : Recruitment to the study and description of all patients referred for endoscopic 
resection (ER) of a large SSP (≥10mm) during the study period.  The blue shade represents 
lesions described in this study.  The orange star represents a decision by the endoscopist to 
resect the lesion by pCSP or EMR;  this decision was primarily based on lesion size and 
presence/absence of dysplasia.  SSP – large sessile serrated polyp, EMR – endoscopic 
mucosal resection, pCSP – piecemeal cold snare polypectomy, HGD – high grade dysplasia, 
LGD – low grade dysplasia, SMIC – submucosal invasive cancer, IQR – interquartile range.  
Recurrence denotes endoscopic determination of adenoma recurrence. 
Supplementary Figure 1: Technique of piecemeal cold snare polypectomy of colonic SSP 
without mucosal elevation. a,b) a 30mm SSP is detected overlying a colonic fold. 
Endoscopic imaging does not suggest the presence of dysplasia. c) A hexagonal, stiff, thin-
wire snare is used to commence resection starting at the edge of the lesion with a 2mm rim 
of normal tissue. d) Irrigation of the mucosal defect expands the submucosal plane and e) 
allows identification of residual serrated tissue which can be subsequently resected using 
the cut edge of the defect as a guide for the snare. f,g) The completed cold snare defect is 
inspected within and at the edge for residual SSP. h) Appearances of the scar at first 
surveillance, 5 months after the original procedure. A well-formed scar is present in the six 
o’clock orientation with no evidence of residual or recurrent adenoma. SSP - sessile 
serrated polyp. 
Supplementary Figure 2: Four examples of piecemeal cold snare polypectomy for SSP. 
Vertical series a) 20mm Paris classification 0-IIa SSP in the ascending colon removed by 3-
piece cold snare excision. Minor ooze of blood at the end of the procedure was not treated 
and led to no clinical sequelae. Series b) barely perceptible 20mm Paris classification 0-IIb 
SSP in the proximal transverse colon removed by 5-piece cold snare excision. Series c) 
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barely perceptible 25mm Paris classification 0-IIb SSP in the ascending colon removed by 
cold snare excision; the centre image shows residual serrated tissue at the 9 o’clock edge of 
the defect. Series d) 25mm Paris classification 0-IIb SSP with adherent mucus at the hepatic 
flexure removed in 6 pieces by cold snare excision. SSP - sessile serrated polyp. 
Video Legend 1 : Video illustrating the assessment and resection of a large sessile serrated 
adenoma using the piecemeal cold snare technique. 
Figure 1: Piecemeal cold snare polypectomy of a 25mm SSP in the ascending colon. a-c)
Lesion assessment is performed using narrow band imaging and high definition white light
to assess for endoscopic evidence of dysplasia. Dysplasia is demonstrated in this example
and is particularly well seen under narrow band imaging. Given the patients age and
comorbidities pCSP is preferred over EMR. d) Multiple snare resections are used with the
cut edge of the mucosal defect acting as a guide for the next snare placement. f) Minor ooze
of blood from the resection defect is common, does not usually require active treatment and
the defect can be safely expanded as needed to achieve complete excision. g) Completed
cold snare defect after expansion with normal saline with no evidence of continued bleeding
or deep injury. SSP - sessile serrated polyp.
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Figure 2 : Recruitment to the study and description of all patients referred for endoscopic 
resection (ER) of a large SSP (≥10mm) during the study period. The blue shade represents 
lesions described in this study. The orange star represents a decision by the endoscopist to 
resect the lesion by pCSP or EMR; this decision was primarily based on lesion size and
presence/absence of dysplasia. SSP – large sessile serrated polyp, EMR – endoscopic 
mucosal resection, pCSP – piecemeal cold snare polypectomy, HGD – high grade dysplasia, 
LGD – low grade dysplasia, SMIC – submucosal invasive cancer, IQR – interquartile range. 
Recurrence denotes endoscopic determination of adenoma recurrence.
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Supplementary Figure 1: Technique of piecemeal cold snare polypectomy of colonic SSP 
without mucosal elevation. a,b) a 30mm SSP is detected overlying a colonic fold. 
Endoscopic imaging does not suggest the presence of dysplasia. c) A hexagonal, stiff, thin- 
wire snare is used to commence resection starting at the edge of the lesion with a 2mm rim 
of normal tissue. d) Irrigation of the mucosal defect expands the submucosal plane and e) 
allows identification of residual serrated tissue which can be subsequently resected using 
the cut edge of the defect as a guide for the snare. f,g) The completed cold snare defect is 
inspected within and at the edge for residual SSP. h) Appearances of the scar at first
surveillance, 5 months after the original procedure. A well-formed scar is present in the six 
o’clock orientation with no evidence of residual or recurrent adenoma. SSP - sessile 
serrated polyp.
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barely perceptible 25mm Paris classification 0-IIb SSP in the ascending colon removed by 
cold snare excision; the centre image shows residual serrated tissue at the 9 o’clock edge of 
the defect. Series d) 25mm Paris classification 0-IIb SSP with adherent mucus at the hepatic 
flexure removed in 6 pieces by cold snare excision. SSP - sessile serrated polyp.
Supplementary Figure 2: Four examples of piecemeal cold snare polypectomy for SSP. 
Vertical series a) 20mm Paris classification 0-IIa SSP in the ascending colon removed by 3- 
piece cold snare excision. Minor ooze of blood at the end of the procedure was not treated 
and led to no clinical sequelae. Series b) barely perceptible 20mm Paris classification 0-IIb 
SSP in the proximal transverse colon removed by 5-piece cold snare excision. Series c)
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Synopsis and Significance 
In the described pilot study 2 41 SSP were successfully removed using piecemeal cold snare 
polypectomy.  There was no incidence of delayed bleeding or perforation.  There was no 
recurrence in 15/41 lesions that had undergone first surveillance colonoscopy at the time of 
writing. 
There is potential for piecemeal cold snare polypectomy to become the standard of care for 
non-dysplastic SSP, as it is for small and diminutive colorectal polyps.  This could reduce the 
burden of removing SSPs on patients and healthcare systems, particularly by avoidance of 
clinically significant post-endoscopic bleeding.  Further, multi-centre prospective studies are 
required in this area. 
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Chapter 4 - The size, morphology, site, and access score predicts critical 
outcomes of endoscopic mucosal resection in the colon 
Introduction 
The adverse event profile of endoscopic resection for the removal of LSL is favourable 
compared to surgical resection.  It is also recognised that as the complexity of LSL increases 
so does the risk of adverse events, although outcome data stratified by type of LSL is not 
available.  Reporting of adverse events after endoscopic resection is hampered by a lack of 
standardised key performance indicators and poor collection and linkage of data on outcomes 
of endoscopic resection outside tertiary endoscopy centres.  Performance and outcome data 
related to surgical procedures is often more complete and is available for the majority of 
procedures performed.   
This chapter contains a study3 that attempts to provide an evidence-based, polyp-specific 
estimate of the likelihood of success and adverse events after endoscopic mucosal resection of 
a large colorectal polyp.  A scoring system (SMSA) developed in the United Kingdom using 
expert consensus 38 to grade the difficulty of polypectomy was applied retrospectively to a 
large cohort of lesions removed by EMR.  The SMSA score separates lesions into 4 groups 
based on their size, morphology, site within the colon and ease of access to the lesion.  
Likelihood of EMR success, and risks of clinically relevant adverse events including delayed 
bleeding, surgery and recurrence of adenoma were determined for each level of the SMSA 
score.  The aim was to establish whether this scoring system could predict the likelihood of 
these outcomes occurring. 
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Abbreviations: 
EMR Endoscopic mucosal resection 
SC1 First surveillance colonoscopy after EMR 
SC2 Second surveillance colonoscopy after EMR 
LSLs Laterally spreading lesions 
ICV Ileo-caecal valve 
CSPEB Clinically significant post endoscopic bleeding 
IPB Intra-procedural bleeding 
IQR Inter-quartile range 
DMI Deep mural injury 
CI Confidence Interval 
OR Odds ratio 
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ABSTRACT	
 
Introduction: The size, morphology, site and access (SMSA) polyp scoring system is a 
method of stratifying the difficulty of polypectomy through assessment of four domains.  
Aims & Methods: We retrospectively applied SMSA to a prospectively collected multicenter 
database of large colonic laterally spreading lesions (LSLs) ≥ 20mm referred for endoscopic 
mucosal resection (EMR). Standard inject and resect EMR procedures were performed. The 
primary endpoints were correlation of SMSA score with technical success, adverse events 
and endoscopic recurrence. 
Results: 2675 lesions in 2675 patients (52.6% male) underwent EMR. Failed single session 
EMR occurred in 124 (4.6%) LSLs and was predicted by SMSA (p<0.001). Intra-procedural 
and clinically significant post endoscopic bleeding was significantly less common for SMSA 2 
(OR – 0.36, p<0.001 & OR – 0.23, p<0.001) and SMSA 3 LSLs (OR – 0.41, p<0.001 & OR – 
0.60, p = 0.05) when compared to SMSA 4 lesions. Similarly endoscopic recurrence at first 
surveillance was less likely amongst SMSA 2 (OR – 0.19, p<0.001) and SMSA 3 (OR – 0.33, 
p<0.001) lesions in comparison to SMSA 4. This also extended to second surveillance 
amongst SMSA 4 LSLs. 
Conclusion: SMSA is a simple readily applicable clinical score that identifies a subgroup of 
patients who are at increased risk of failed EMR, experiencing adverse events and adenoma 
recurrence at surveillance colonoscopy. This information may be useful for improving 
informed consent, planning endoscopy lists and development of quality control measures 
for practitioners of EMR with potential implications for EMR benchmarking and training. 
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Background & Aims: 
Endoscopic mucosal resection (EMR) is safer, more efficient and less expensive than surgery 
and is now accepted as the standard of care for large (≥ 20mm) laterally spreading lesions 
(LSLs) in the colon [1,2,3,4].  
Although conventionally evaluated primarily on lesion size alone, procedural difficulty, 
clinical outcomes and complications after EMR of LSLs can vary significantly independent of 
lesion size [5,6]. Scoring systems predicting outcomes such as the risk of clinically significant 
post endoscopic bleeding score (CSPEB score) or the Sydney EMR recurrence tool (SERT) are 
useful but report on one-dimensional outcomes and are limited by their reliance on prior 
knowledge of the EMR procedure[7,8].  
In recent years a scoring system developed by expert consensus focusing on size, 
morphology, access and site, the ‘SMSA’ polyp score[9], has been proposed as a method of 
helping grade polyps to define their complexity and associated level of difficulty during 
resection. Its major benefit is its ability to be applied prior to the EMR procedure with 
information from the referral letter or procedure report. 
In this study we aimed to evaluate the ability of SMSA to predict critical outcomes of EMR, 
specifically technical success, adverse events and recurrence. 
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Methods: 
Consecutive patients were enrolled over a period of 106 months (June 2008-April 2017). For 
patients with multiple large LSLs referred for EMR, only the largest lesion was included in 
the analysis due to the difficulty in ascribing adverse events to a specific lesion and 
correlated observations in a single patient. 
 
Applying SMSA polyp score: 
The SMSA score was applied to a prospectively collected multi-center database (seven sites 
across Australia) of patients referred to tertiary endoscopy facilities for EMR of large LSLs. 
Large LSLs were defined as non-polypoid lesions ≥ 20mm. 
All aspects of the SMSA polyp score were collected prospectively. Data was regrouped into 
the four domains of the ‘SMSA’ score; lesion size, morphology, site and access (see Figure 1) 
retrospectively. As per the scoring system, points were allocated related to the features of 
the LSL in the mentioned domains and were graded into four ‘SMSA’ levels (1-4).  No lesions 
in this cohort were classified as SMSA 1, as to qualify as SMSA 1 the maximum total points 
for an individual lesion must be less than 6 (see supplementary table 2). As all lesions in this 
cohort were ≥ 20mm and sessile therefore, the minimum possible SMSA polyp score was 9 
(size – 5 points, morphology – 2 points, site – 1 point, access – 1 point). 
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Size and morphology were recorded as per the endoscopist performing EMR.  Lesion size 
was approximated relative to a snare of known dimensions open adjacent to the lesion. Site 
was defined as right colon if the lesion was location proximal to including splenic flexure and 
left colon if distal to the splenic flexure. Access was defined as difficult if the referring 
endoscopist had significant difficulty in positioning the scope to enable resection or 
dependent on lesion location such as peri-appendiceal, peri-diverticular or involvement of 
the ileo-caecal valve (ICV). 
 
EMR Procedure 
All EMR procedures were performed by senior endoscopists with extensive EMR experience 
or by an advanced endoscopy fellow under their direct supervision. Written informed 
consent was obtained from all patients. Split dose bowel preparation was used. Intravenous 
sedation was with a combination of fentanyl, midazolam and propofol. Insufflation of the 
colon was initially with air moving to carbon dioxide in August 2010 once the benefits were 
understood[10]. Colonoscopy was performed using Olympus 180 or 190 series high-
definition variable-stiffness colonoscopes (180/190 PCF/CF; Olympus, Tokyo, Japan). A 
standardized and previously described inject-and-resect EMR technique was used[11]. Most 
cases used a microprocessor-controlled electrosurgical generator (Endocut effect 3, VIO 
300D; ERBE Elektromedizin, Tübingen, Germany) with fractionated current. The submucosal 
injectate comprised normal saline until 2010 when it was replaced with succinylated gelatin 
(Gelofusine; B. Braun Australia Pty Ltd, Bella Vista, Australia)[12]. The fluid was dyed with 
indigo carmine blue (80 mg/ 500 mL solution) and epinephrine was added to achieve a final 
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concentration of 1:100,000. Occasionally methylene blue was used as an alternative when 
indigo carmine was not available. 
Duration of procedure was defined as the total length of the EMR procedure from first snare 
resection in minutes. Technical success was defined at the completion of the endoscopic 
procedure as complete removal of all macroscopically visible polyp tissue. 
 
Study Outcomes 
The primary outcome of the study was the ability of the SMSA score to predict technical 
success, adverse events and endoscopic recurrence during follow-up examinations.   
 
Adverse events 
All patients were contacted by the study nurse two weeks post procedure to assess for any 
adverse events related to their EMR procedure. Intra-procedural bleeding (IPB) was defined 
as significant oozing or pulsatile bleeding requiring endoscopic control and was treated with 
snare-tip soft coagulation (Soft Coagulation, 80 W Effect 4; ERBE Electromedizin, Tübingen, 
Germany)[13].  
Clinically significant post endoscopic bleeding (CSPEB) was defined as bleeding after the 
completion of EMR and discharge from the endoscopy unit resulting in presentation to the 
emergency department, hospitalization, or re-intervention within 14 days[14]. Delayed 
perforation was defined as a perforation occurring after the completion of the EMR 
procedure. Deep mural injury (DMI) was defined, as per the Sydney DMI classification[15], 
as injury to the mucosa as a visible target sign or actual hole corresponding to DMI type 
III/IV. Examples of the endoscopic appearance of adverse events are shown in Figure 2. 
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Follow up 
Follow-up data were collected from patients eligible for SC1 at a planned interval of 4 to 6 
months. Time to longest follow-up and any associated recurrence after SC1 were recorded if 
available. SC2 was performed at a planned interval of 12 months (i.e. 18 months after the 
original EMR). 
EMR scar assessment 
Recurrence was defined as the endoscopic appearance of residual or recurrent adenoma at 
an EMR scar unless otherwise stated.  A standardized imaging protocol was used to assess 
the post EMR scar for recurrence[16]. If no visible residual adenoma was detected biopsies 
were performed for histology. Any suspected recurrence was biopsied and then treated 
endoscopically. 
Statistical Analysis: 
All data was analysed using IBM SPSS Statistics Version 22.0. Categorical variables were 
described using frequencies and percentages. Mean, median and interquartile ranges were 
calculated for continuous data. Statistical significance was set at a threshold of 0.05 and 
comparison between different groups and outcomes were performed using the chi-squared, 
Fisher’s exact tests and binary logistic regression. Odds ratios with a 95% confidence interval 
were used to compare categorical outcomes of interest between the groups with reference 
to SMSA 4 LSL. 
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Results: 
A total of 2947 lesions (Figure 3) were referred for EMR. A total of 272 lesions were 
excluded; 148 – multiple lesions in same patient, 83 – non-attempted lesions suspected 
submucosal invasive cancer, 41 – technical reasons (involvement of ICV, appendix or 
difficult access).  
A total of 2675 lesions in 2675 patients underwent EMR.  The mean age of patients was 67.3 
years and 52.6% were male.  1743 (65.2%) LSL were located in the right colon. The median 
size of lesions was 35 mm (IQR, 25-45mm). Distribution of lesions as per SMSA (Table 1) was 
as follows; SMSA 2 – 175 (6.5%), SMSA 3 -1110 (41.5%) and SMSA 4 -1390 (52.0%)  
On assessment of morphology Paris 0-IIa/Is lesions were most commonly noted amongst 
SMSA 4 LSL (37.0%). SMSA 4 LSL were also significantly more likely to be granular in 
comparison to other SMSA groups (67.7%). En-bloc resection was most common amongst 
SMSA 2 LSL (44.0%). On histopathology review tubulo-villous adenomas were most common 
amongst SMSA 4 LSL (63.1%). 
For detailed analysis of patient, lesion and procedural features by SMSA score see Table 2.  
Procedure 
Technical success at EMR was achieved in 174/175 (99.4%) of SMSA 2 LSL, 1086/1110 
(97.8%) of SMSA 3 LSL and 1291/1390 (92.9%) of SMSA 4 LSL (see Table 3). Successful EMR 
was more likely amongst SMSA 2 (Odds-ratio (OR) 13.34 [95% confidence interval – 1.85-
96.27], p=0.01) and SMSA 3 (OR - 3.47 95% CI [2.20-5.46], p<0.001) LSL when compared to 
SMSA 4 LSL. Procedure duration was longest amongst SMSA 4 LSL (median time 30 mins, 
IQR 20-45 min). 
 
Intra-procedural adverse events 
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Intra-procedural bleeding was significantly less common amongst SMSA 2 (OR – 0.36 95% CI 
[0.22-0.58], p<0.001) and SMSA 3 (OR – 0.41 95% CI [0.34-0.54], p<0.001) LSL as compared 
to SMSA 4 lesions. Deep injury was observed with highest frequency in the post EMR defect 
of SMSA 4 LSL (31/1390).   
Post-EMR adverse events 
CSPEB was also significantly less likely for SMSA 2 (OR – 0.23 95% CI [0.07-0.74], p=0.01) and 
SMSA 3 (OR – 0.60 95% CI [0.42-0.86], p = 0.05) lesions as compared to SMSA 4 LSL. Referral 
for surgery at two weeks after the index procedure was also less common SMSA 3 LSL as 
compared to SMSA 4 (OR – 0.53 95% CI [0.40-0.71], p<0.001). No significant difference for 
surgical referral was noted when comparing SMSA 2 LSL against SMSA 4 lesions (OR – 1.01 
95%CI [0.61-1.65], p=0.98). 
Recurrence 
A total of 1910 (77.8%) of eligible patients underwent their first surveillance colonoscopy at 
median 5.1 months (IQR:4-6.6 months).  Recurrence at SC1 was significantly less common 
amongst SMSA 2 (OR – 0.19 95%CI [0.09-0.4], p<0.001) and SMSA 3 (OR – 0.33 95% CI [0.25-
0.44], p<0.001) LSL when compared to the SMSA 4 group. There was no significant 
difference in the rates of surgery at SC1 between the groups (p=0.08).  A total of 1019 
patients underwent a second surveillance colonoscopy at median 18 months (IQR:15-22 
months). Recurrence at SC2 was observed with highest frequency for SMSA 4 LSL (53/543). 
Similarly SMSA 3 LSL were less likely to recur at SC2 when compared to SMSA 4 (OR – 0.50 
95% CI [0.30-0.84], p=0.08), with no recurrences noted amongst SMSA 2 LSL. There were 
three referrals for surgery at SC2, which were all SMSA 4 lesions. 
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Discussion: 
Colonic LSLs are now successfully and safely treated by EMR in the vast majority of 
cases[17].  Traditionally size has been described as the main factor predicting outcomes 
after EMR [18]. However other factors including morphology, location, and lesion 
accessibility are now recognized to also be associated with a successful EMR procedure and 
subsequent outcomes[19,20&21].  For several years practitioners of EMR have had no 
evidence based scoring system to grade the difficulty of their procedures or describe lesion 
complexity. Recently several scoring systems have been developed to predict adverse 
events after EMR and recurrence[7,8]. However these scoring systems are uni-dimensional, 
pertaining to a single outcome, and have the limitation of only being assessable after the 
endoscopic resection.  
The SMSA polyp score is a simple scoring system comprised of four variables; size, 
morphology, colonic site and access to the target lesion. It was derived from expert 
consensus amongst nine experienced endoscopists from the United Kingdom using two 
focus group discussions and the Delphi method [9]. Its main aim is to identify factors 
predicting the difficulty of endoscopic polyp resection, thereby creating ‘levels of 
polypectomy’ competency. The main benefit of this scoring system is its ability to be applied 
prior to the procedure, ideally to a well-documented referral letter or procedure report.  
Our study describes the application of the SMSA polyp score to 2675 prospectively collected 
LSLs, from a multi-center cohort, referred for EMR. This cohort had a median lesion size of 
35mm. Over half the lesions were assigned the highest SMSA score of 4 and no 
pedunculated lesions were included. All procedural and short-term outcome data including 
technical success, procedure duration, bleeding (IPB and CSPEB) and deep injury was 
collected prospectively. Our cohort had a high compliance rate with over 70% undergoing a 
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follow-up examination. From this EMR specific cohort it is evident that technical success, 
duration, procedural adverse events (IPB and CSPEB), referral for surgery at 2 weeks and 
recurrence at surveillance are all correlated to the SMSA level.  
Longcroft-Wheaton et al. [22] published the first validation of the SMSA polyp score. In this 
retrospective, single-center, non-EMR specific study of 220 pedunculated and sessile polyps 
(mean size 36mm) they concluded that technical success, procedural outcomes and adverse 
events correlated significantly with the SMSA level. Of the 179 patients who had follow-up, 
endoscopic cure was strongly predicted by the SMSA polyp score.  In 2017, Sansone et al. 
[23] described a multi-center study undertaken in two high-volume tertiary centers in the 
United Kingdom and Italy attempting to validate the SMSA polyp score.  In 1668 lesions, 
primarily < 20mm in size (78.8%), which included pedunculated lesions (14.4%) where only 
the index procedure was described, technical success, advanced histology and adverse 
events correlated significantly with SMSA. 
It is noted from our data that 12 % of lesions assessed as SMSA 2 were referred for surgery 
as compared to 6.4% of SMSA 3 lesions. This is likely due to a higher proportion of SMSA 2 
lesions undergoing en-bloc resection in comparison to SMSA 3 LSL (44.0% vs 23.1%) for 
suspected submucosal invasive cancer. 
The clinical utility of this scoring system for EMR procedures is likely to impact positively on 
the interaction between the endoscopist and their patients. More detailed and precise 
informed consent for patients and their carers may ensue.  Patients can be provided with 
more reliable information on the likelihood of clinical success pertinent to their specific 
lesion in the short and long term (Figure 4).  Other patient related benefits of calculating the 
SMSA polyp score prior to the procedure may include guidance on cessation and 
recommencement of antiplatelet/anticoagulant therapy in the peri-procedural setting.  
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With the advent of widespread colorectal cancer screening programs tertiary referral for LSL 
treatment is likely to increase. Endoscopy units are likely to benefit from utilizing this 
scoring system to assist in list planning and resource allocation. Higher complexity lesions 
for example could be triaged to be performed by those with more experience or 
subspecialty training in complex EMR as suggested by European guidelines for quality 
assurance in colorectal cancer screening[24]. The need for post-procedure admissions may 
also be more precisely assessed.  
The SMSA polyp score may also be used to inform the process of training in polypectomy 
and EMR. It is feasible that the routine SMSA grading of lesions may be used for the 
development of formalized training pathways to certify trainees in advanced colonic tissue 
resection. Critical numbers of EMR procedures for LSLs of each SMSA level would be 
sequentially accumulated to allow progression through training to achieve final 
accreditation.  
The SMSA polyp score may also allow objective benchmarks to be developed for assessing 
the quality of EMR procedures by accounting for variations in case-mix. Such quality 
measures are currently lacking for EMR. Surgeons readily use well-validated scoring systems 
such as POSSUM and P-POSSUM[25,26], which inform the training process and serve as a 
metric by which performance of individual surgical units can be compared. Such systems 
have been shown to improve the process of medical audits. 
The SMSA polyp score is an objective tool applicable prior to the EMR procedure. However, 
the level of experience of the referring endoscopist may influence assessment of lesion 
access in this scoring system, if applied in this context. Lesion access may be judged as 
“difficult” depending on lesion location (peri-appendiceal, ICV) or if the endoscopist is 
unable to maintain a stable position when performing EMR. Assessment of lesion access 
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might also not be mentioned specifically by the referring endoscopist. However we found 
that procedural and short-term outcomes still correlate significantly relative to the SMSA 
level even when all lesions are marked as “easy access” (see supplementary table 1). 
Therefore this potentially subjective variable is unlikely to the impact the validity of this 
score.    
We recognize that in an EMR specific cohort, the SMSA polyp score has limitations. Factors 
such as previously attempted LSLs [27], flat/depressed LSLs[28] and LSL morphology 
(granular vs non-granular) are all recognized to increase the difficulty of EMR . These are not 
addressed by this scoring system. This therefore gives credence to the development and 
validation of a modified SMSA scoring system, more specific for EMR, integrating these 
additional factors. 
Other limitations of our study include the application of the SMSA polyp score 
retrospectively to prospectively collected data.  Whilst the SMSA polyp score was not 
devised at the commencement of data collection all of the domains of the score were 
collected prospectively in a comparable fashion.   The only subjective part of the score, 
access, but was collected using a standardized definition similar to previous studies.  By 
performing a separate analysis, whereby all lesions had ‘easy’ access and therefore scored 
1, we were still able to demonstrate the ability of the SMSA score to predict important 
outcomes after EMR. We also note that the SMSA polyp score was not derived for LSLs ≥ 
20mm; as a result our data primarily lies at the more complex end of the spectrum with no 
lesions graded as SMSA 1. Despite this, the study demonstrates the ability of this scoring 
system to predict outcomes in this complex patient cohort. 
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Conclusion: 
The SMSA polyp score is a simple readily applicable clinical score that identifies a subgroup 
of patients who are at increased risk of failed EMR, experiencing adverse events and 
adenoma recurrence at surveillance colonoscopy. This information may be useful for 
improving informed consent, planning endoscopy lists and development of quality control 
measures for practitioners of EMR. Moreover, SMSA could also have a major impact on EMR 
benchmarking and training.  
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Figure Legends 
Figure 1 – SMSA score and level 
 
Figure 2 - EMR Adverse Events; a) Type III Deep Mural Injury as per the Sydney DMI 
Classification, b) Intra-procedural bleeding – transected artery, c) Clinically significant post 
endoscopic bleeding – multifocal bleeding from the post EMR defect, d) Recurrence – 
endoscopic recurrence demonstrated by Kudo Pit Pattern III within the area of post-EMR 
scar. 
 
Figure 3 – Study design and follow-up. 
 
Figure 4 – Predicted outcomes relative to SMSA polyp score, CSPEB – clinically significant 
post endoscopic bleeding. 
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Table	1	 Size	 Morphology	 Site	 Access	
SMSA	 <10mm	 10-
19mm	
20-
29mm	
30-
39mm	
40mm	 Ped	 Sessile	 Flat	 Right	 Left	 Easy	 Difficult	
1	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	
2	 0	 0	 175	 0	 0	 0	 175	 0	 175	 0	 175	 0	
3	 0	 0	 667	 443	 0	 0	 1087	 23	 213	 897	 859	 251	
4	 0	 0	 10	 283	 1097	 0	 1329	 61	 544	 846	 702	 688	
Total	 0	 0	 852	 726	 1097	 0	 2591	 84	 932	 1743	 1736	 939	
				Table	1	–	Lesion	distribution	by	SMSA	(Size,	Morphology,	Site,	Access),	Ped	-	Pedunculated	
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Table	2	 SMSA	2	n=175	
SMSA	3	
n=1110	
SMSA	4	
n=1390	
Total	
n=2675	
p-value	
PATIENT	Mean	Age,	years	(SD)	 66.3	(11.2)	 67.0	(11.8)	 67.77	(11.9)	 .116	Sex,	n	(%)	 M	F	 99	(56.6)	76	(43.4)	 567	(51.1)	543	(48.9)	 740	(53.2)	650	(46.8)	 1406	(52.6)	1269	(47.4)	 .307	
LESION	Median	Size,	mm	(range)	 20	(20-28)	 26	(15-35)	 45	(20-180)	 <	0.001	Paris,	n	(%)	 0-Is	0-IIa0-IIa/Is	Others	(IIb,	IIc,	etc)	
64	(36.6)	69	(39.4)	28	(16.0)	14	(8.0)	
214	(19.3)	680	(61.3)	124	(11.2)	92	(8.3)	
248	(17.8)	501	(36.0)	514	(37.0)	127	(9.1)	
526	(19.7)	1250	(46.7)	666	(24.9)	233	(8.7)	 <	0.001	Morphology,	n	(%)	 Granular	Non-granular	Mixed	Unable	to	classify	
94(53.7)	59	(33.7)	6	(3.4)	12	(6.9)	
564	(51.2)	329	(29.9)	52	(4.7)	70	(6.4)	
934	(67.7)	253	(18.3)	121	(8.8)	40	(2.9)	
1592	(59.9)	641	(24.1)	179	(6.7)	122	(4.6)	 <	0.001	Location,	n	(%)		 Right	colon*		 0	 897	(80.8)	 846	(60.9)	 1743	(65.2)	En-bloc,	n	(%)	 77	(44.0)	 253	(23.1)	 37	(2.7)	 367	(13.9)	 <	0.001	Histopathology,	n	(%)	 Tubular	adenoma	Tubulo-villous	adenoma	Sessile	Serrated	Adenoma	Other	
57	(32.5)	83	(47.4)	14	(8.0)	21	(12.0)	
297	(26.8)	483	(43.5)	243	(21.9)	87	(7.8)	
270	(19.4)	877	(63.1)	110	(7.9)	133	(9.6)	
624	(23.3)	1443	(53.9)	370	(13.8)	238	(8.9)	 <	0.001	Submucosal	Invasive	Cancer,	n	(%)	 21	(12.0)	 47	(4.2)	 122	(8.8)	 190	(7.1)	 <	0.001	
Table	2	–	Demographics,	age	distribution,	lesion	size,	Paris	classification,	morphology,	location,	en-bloc	resection	rate	and	histopathology,	*right	colon	-	proximal	to	and	including	hepatic	flexure)	
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Table	3	 	
SMSA	2	
	
SMSA	3	
	
SMSA	4	
	
Total	
	
p-value	
	
SMSA	2	v	SMSA	4	
OR	(CI)	
	
p-value	
	
SMSA	3	v	SMSA	4	
OR	(CI)	
	
p-value	
Total	count,	n	(%)	 175	(6.5)	 1110	(41.5)	 1390	(52.0)	 2675	 	 	 	 	 	Technical	success	at	EMR,	n	(%)	 174	(99.4)	 1086	(97.8)	 1291	(92.9)	 2551	(95.4)	 <0.001	 13.34	(1.85-96.27)	 0.01	 3.47	(2.20-5.46)	 <0.001		 	 	 	 	 	 	 	 	 	IPB,	n	(%)	 20	(11.4)	 144	(13.0)	 368	(26.5)	 532	(19.9)	 <0.001	 0.36	(0.22-0.58)	 <0.001	 0.41	(0.34-0.54)	 <0.001	Deep	injury*,	n	(%)	 4	(2.3)	 16	(1.4)	 31	(2.2)	 51	(1.9)	 0.34	 	 	 	 		 	 	 	 	 	 	 	 	 	CSPEB,	n	(%)	 3	(1.7)	 48	(4.3)	 97	(7.0)	 148	(5.5)	 <0.001	 0.23	(0.07-0.74)	 0.01	 0.60	(0.42-0.86)	 0.05	Delayed	perforation,	n	(%)	 0	(0)	 3	(0.3)	 8	(0.6)	 11(0.4)	 0.40	 	 	 	 	Surgery	at	2w,	n	(%)	 21	(12.0)	 71	(6.4)	 157	(11.3)	 249	(9.3)	 <0.001	 1.01	(0.61-1.65)	 0.98	 0.53	(0.40-0.71)	 <0.001	
Underwent	SC1,	n	(%)**	 128/172	(74.4)	 801/1051	(76.2)	 981/1231	(79.7)	 1910/2454	(77.8)	 	 	 	 	 	Recurrence	at	SC1,	n	(%)	**	 7	(5.5)	 74	(9.2)	 231	(23.5)	 312(12.7)	 <0.001	 0.19	(0.09-0.41)	 <0.001	 0.33	(0.25-0.44)	 <0.001	Histologic	recurrence	SC1	(%)***	 2/42	(4.8)	 44/333(13.2)	 150/498	(30.1)	 196/874	(22.5)	 <0.001	 	 	 	 	Surgery	at	SC1,	n	(%)	**	 1	(0.8)	 6	(0.7)	 19	(1.9)	 26	(1.4)	 0.08	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
Underwent	SC2,	n	(%)	**	 63	(50.4)	 413		(52.9)	 543	(56.9)	 1019/1859	(54.8)	 	 	 	 	 	Recurrence	at	SC2	(%)**	 0	(0)	 21	(5.1)	 53	(9.8)	 74	(7.3)	 .002	 	 	 0.50	(0.30-0.84)	 0.08	Surgery	at	SC2,	n	(%)	**	 0	(0)	 0	(0)	 3	(0.3)	 3	(0.2)	 0.40	 	 	 	 	
	
	Table	3;	Outcomes	after	endoscopic	mucosal	resection	at	the	initial	procedure,	2	weeks	and	subsequent	surveillance	procedures.		EMR	–	endoscopic	mucosal	resection,	IPB	–	intra-procedural	bleeding,	CSPEB	–	clinically	significant	post	endoscopic	bleeding	(bleeding	after	EMR	requiring	admission	to	hospital	or	re-intervention),	2w	–	two	weeks,	SC1/2	surveillance	colonoscopy1/2,	OR	–	odds	ratio,	CI	–	95%	confidence	interval.	*	Target	sign	or	actual	hole	corresponding	to	DMI	type	III/IV	Sydney	classification,	**	percentages	refer	to	total	eligible	for	SC1/SC2***	percentages	refer	to	number	of	lesions	with	histologic	data	available.		 	
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Supplementary	Table	1	 SMSA	2	 SMSA	3	 SMSA	4	 Total	 p-value	 SMSA	2	vs	SMSA	4	
OR	(CI)	
p-value	 SMSA	3	vs	SMSA	4	
OR	(CI)	
p-valueTotal	count,	n	(%)	 230	(8.6)	 1320	(49.3)	 1125	(42.1)	 2675	Technical	success	at	EMR,	n	(%)	 227	(98.7)	 1281	(97.0)	 1043	(92.7)	 2551	(95.4)	 <.	001	 5.95	(1.86-19.00)	 0.003	 2.6	(1.75-3.81)	 <0.001	IPB,	n	(%)	 26	(11.3)	 193	(14.6)	 313	(27.8)	 532	(19.9)	 <	.001	 0.33	(0.22-0.51)	 <0.001	 0.44	(0.36-0.54)	 <0.001	Deep	injury*,	n	(%)	 5	(2.2)	 21	(1.6)	 25	(2.2)	 51	(1.9)	 .52	CSPEB,	n	(%)	 5	(2.2)	 61	(4.6)	 82	(7.3)	 148	(5.5)	 .001	 0.28	(0.11-0.71)	 0.007	 0.61	(0.44-0.87)	 0.05	Delayed	perforation,	n	(%)	 0	(0)	 4	(0.3)	 7	(0.6)	 11(0.4)	 .30	Surgery	at	2w,	n	(%)	 25	(10.9)	 94	(7.1)	 130	(11.6)	 249	(9.3)	 <	.001	 0.93	(0.59-1.47)	 0.77	 0.59(0.44-0.78)	 0.02	
Underwent	SC1,	n	(%)**	 170	 959	 781	 1910/2454	(77.8)	Recurrence	at	SC1,	n	(%)	 10	(5.9)	 101	(10.5)	 201	(25.7)	 312(16.3)	 <	.001	 0.18(0.09-0.35)	 <.001	 0.34	(0.26-0.44)	 <0.001	Histologic	recurrence	SC1,	n(%)***	 4(7.0)	 58	(14.8)	 134	(31.7)	 196	(22.5)	 <	.001	Surgery	at	SC1,	n	(%)	 2	(1.2)	 8	(0.8)	 16	(2.0)	 26	(1.4)	 .09	
Underwent	SC2	(n)**	 82	 499	 438	 1013/1859	(54.8)	Recurrence	at	SC2,	n	(%)	 1	(1.2)	 30	(6.0)	 43	(9.8)	 74	(7.3)	 .01	 0.11	(0.02-0.84)	 0.03	 0.59	(0.36-0.95)	 0.03	Surgery	at	SC2,	n	(%)	 0	(0)	 1	(0.1)	 2	(0.3)	 3	(0.2)	 .68	
Supplementary	Table	1	(Access	=	Easy)	-	Outcomes	after	endoscopic	mucosal	resection	at	the	initial	procedure,	2	weeks	and	subsequent	surveillance	procedures.		EMR	–	endoscopic	mucosal	resection,	IPB	–	intra-procedural	bleeding,	CSPEB	–	clinically	significant	post	endoscopic	bleeding	(bleeding	after	EMR	requiring	admission	to	hospital	or	re-intervention),	2w	–	two	weeks,	SC1/2	surveillance	colonoscopy1/2,	OR	–	odds	ratio,	CI	–	95%	confidence	interval.	*	Target	sign	or	actual	hole	corresponding	to	DMI	type	III/IV	Sydney	classification,	**	percentages	refer	to	total	eligible	for	SC1/SC2***	percentages	refer	to	number	of	lesions	with	histologic	data	available.	
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APPENDICES	
APPENDIX 1 
 
Table	1	 SMSA	2	n=248	
SMSA	3	
n=1050	
SMSA	4	
n=1377	 `	
p-value	
PATIENT	
Mean	Age,	years	(SD)	 66.4	(11.2)	 67.0	(11.9)	 67.78	(11.8)	 	 .114	
Sex,	n	(%)	
M	
F	
	
138	(55.6)	
110	(44.4)	
	
528	(50.3)	
522	(49.7)	
	
734	(53.3)	
643	(46.7)	
	
1400	(52.3)	
1275	(47.6)	
	
.159	
LESION	
Median	Size,	mm	(range)	 20	(20-28)	 25	(15-35)	 45	(20-180)	 	 <	0.001	
Paris,	n	(%)	
0-Is	
0-IIa	
0-IIa/Is	
Others	(IIb,	IIc,	etc)	
	
78	(31.5)	
119	(48.0)	
31	(12.5)	
20	(8.1)	
	
200	(19.0)	
630	(60.0)	
121	(11.5)	
99	(9.4)	
	
248	(18.0)	
501	(36.4)	
513	(37.3)	
115	(8.4)	
	
526	(19.7)	
1250	(46.7)	
665	(24.9)		
234	(8.7)	
	
	
<	0.001	
Morphology,	n	(%)		
Granular	
Non-granular	
Mixed	
Unable	to	classify	
	
118(47.6)	
90	(36.3)	
9	(3.6)	
31	(12.5)	
	
540	(51.4)	
310	(29.5)	
49	(4.7)	
151	(14.4)	
	
933	(67.8)	
241	(17.5)	
121	(8.8)	
82	(6.0)	
	
1591	(59.5)	
641	(24.0)	
179	(7.0)	
264	(9.9)	
	
	
<	0.001	
Location,	n	(%)		
Right	colon*		
	
0	
	
742	(70.7)	
	
701	(50.9)	
	
1443	(53.9)	
	
En-bloc,	n	(%)	 102	(41.1)	 229	(21.8)	 36	(2.6)	 367	(13.7)	 <	0.001	
Histopathology,	n	(%)	
Tubular	adenoma	
Tubulo-villous	adenoma	
Sessile	Serrated	Adenoma	
Other	
	
85	(34.3)	
104	(42.0)	
36	(14.5)	
23	(9.3)	
	
279	(26.6)	
463	(44.1)	
227	(21.7)	
81	(7.7)	
	
263	(19.1)	
876	(63.6)	
107(7.8)	
131	(9.5)	
	
627	(23.4)	
1443	(53.9)	
370	(13.8)	
235	(8.8)	
	
	
<	0.001	
Submucosal	Invasive	Cancer,	n	(%)	 24	(9.7)	 43	(4.1)	 123	(8.9)	 190	(7.1)	 <	0.001	
	
Table	1	–	Demographics,	age	distribution,	lesion	size,	Paris	classification,	morphology,	location,	en-bloc	resection	rate	and	histopathology,	*right	colon	-	proximal	to	and	including	hepatic	
flexure)	
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APPENDIX 2 
Table	2	 	
SMSA	2	
	
SMSA	3	
	
SMSA	4	
	
Total	
	
p-value	
	
SMSA	2	v	SMSA	4	
OR	(CI)	
	
p-value	
	
SMSA	3	v	SMSA	4	
OR	(CI)	
	
p-value	
Total	count,	n	(%)	 248	(9.3)	 1050	(39.3)	 1377	(51.5)	 2675	 	 	 	 	 	
Technical	success	at	EMR,	n	
(%)	
244	(98.4)	 1029	(98.0)	 1278	(92.8)	 2551	(95.4)	 <0.001	 4.73	(1.72-
12.96)	
0.003	 3.80	(2.35-6.12)	 <0.001	
	 	 	 	 	 	 	 	 	 	
IPB,	n	(%)	 25	(10.1)	 142	(13.5)	 365	(26.5)	 532	(19.9)	 <0.001	 0.31	(0.20-0.48)	 <0.001	 0.43	(0.35-0.54)	 <0.001	
Deep	injury*,	n	(%)	 5	(2.0)	 17	(1.6)	 29	(2.1)	 51	(1.9)	 .643	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
CSPEB,	n	(%)	 5	(2.0)	 47	(4.5)	 96	(7.0)	 148	(5.5)	 .001	 0.28	(0.11-0.68)	 0.05	 0.63	(0.44-0.90)	 0.01	
Delayed	perforation,	n	(%)	 0	(0)	 3	(0.3)	 8	(0.6)	 11(0.4)	 .431	 	 	 	 	
Surgery	at	2w,	n	(%)	 27	(10.9)	 65	(6.2)	 157	(11.4)	 249	(9.3)	 <0.001	 0.94	(0.62-1.46)	 0.81	 0.51	(0.38-0.69)	 <0.001	
Underwent	SC1,	n	(%)**	 177	(73.1)	 761	(76.6)	 972	(79.8)	 1910/2454	
(77.8)	
	 	 	 	 	
Recurrence	at	SC1,	n	(%)		 8	(4.5)	 76	(10.0)	 228	(23.4)	 312(16.3)	 <0.001	 0.14	(0.04-0.45)	 0.001	 0.35	(0.24-0.51)	 <0.001	
Histologic	recurrence	SC1	
(%)***	
3/58	(5.2)	 39/323(12.1)	 139/493	(28.2)	 181/874	
(20.7)	
<0.001	 	 	 	 	
Surgery	at	SC1,	n	(%)		 1	(0.6)	 7	(0.9)	 18	(1.9)	 26	(1.1)	 .208	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
Underwent	SC2,	n	(%)	**	 89	(51.4)	 381	(54.0)	 524	(58.7)	 994/1770	
(56.1)	
	 	 	 	 	
Recurrence	at	SC2	(%)	 0	(0)	 22	(5.8)	 52	(9.9)	 74	(7.4)	 .001	 	 	 0.54	(0.32-0.91)	 0.02	
Surgery	at	SC2,	n	(%)		 0	(0)	 1	(0.2)	 3	(0.4)	 4	(0.2)	 .764	 	 	 	 	
	
Table	2;	Outcomes	after	endoscopic	mucosal	resection	at	the	initial	procedure,	2	weeks	and	subsequent	surveillance	procedures.		EMR	–	endoscopic	
mucosal	resection,	IPB	–	intra-procedural	bleeding,	CSPEB	–	clinically	significant	post	endoscopic	bleeding	(bleeding	after	EMR	requiring	admission	to	
hospital	or	re-intervention),	2w	–	two	weeks,	SC1/2	surveillance	colonoscopy1/2,	OR	–	odds	ratio,	CI	–	95%	confidence	interval.	*	Target	sign	or	actual	
hole	corresponding	to	DMI	type	III/IV	Sydney	classification,	**	percentages	refer	to	total	eligible	for	SC1/SC2***	percentages	refer	to	number	of	lesions	
with	histologic	data	available.	
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APPENDIX 3 
	
	
Table	3	 Size	 Morphology	 Location	 Access	
SMSA	 <10mm	 10-
19mm	
20-
29mm	
30-
39mm	
40mm	 Ped	 Sessile	 Flat	 Right	 Left	 Easy	 Difficult	
1	 0		 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	
2	 0	 0	 248	 0	 0	 0	 248	 0	 248	 0	 248	 0	
3	 0	 0	 596	 454	 0	 0	 1014	 36	 308	 742	 798	 252	
4	 0	 0	 8	 273	 1096	 0	 1329	 48	 676	 701	 690	 687	
Total	 0	 0	 852	 727	 1096	 0	 2591	 84	 1232	 1443	 1736	 939	
	
Table	3	–	Lesion	distribution	by	SMSA	(Size,	Morphology,	Site,	Access),	Ped	–	Pedunculated	
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APPENDIX 4 
	
Supplementary	Table	
1	
SMSA	2	 SMSA	3	 SMSA	4	 Total	 p-value	 SMSA	2	vs	SMSA	4	
OR	(CI)	
p-value	 SMSA	3	vs	SMSA	4	
OR	(CI)	
p-
value	
Total	count,	n	(%)	 322	(12.0)	 1240	(46.4)	 1113	(41.6)	 2675	 	 	 	 	 	
Technical	success	at	
EMR,	n	(%)	
316/322	
(98.1)	
1204	(97.1)	 1031/1112	
(92.7)	
2551	(95.3)	 <.	001	 7.6	(2.38-24.51)	 0.001	 2.4	(1.55-3.66)	 <0.001	
	 	 	 	 	 	 	 	 	 	
IPB,	n	(%)	 33	(10.2)	 189	(15.2)	 310	(27.9)	 532	(19.9)	 <	.001	 0.33	(0.21-0.51)	 <0.001	 0.41	(0.32-0.53)	 <0.001	
Deep	injury*,	n	(%)	 6	(1.9)	 22	(1.8)	 23	(2.1)	 51	(1.9)	 .872	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
CSPEB,	n	(%)	 7	(2.2)	 60	(4.8)	 81	(7.3)	 148	(5.5)	 .001	 0.23	(0.09-0.57)	 0.002	 0.73	(0.50-1.1.06)	 0.09	
Delayed	perforation,	n	
(%)	
0	(0)	 4	(0.3)	 7	(0.6)	 11(0.4)	 .316	 	 	 	 	
Surgery	at	2w,	n	(%)	 34	(10.6)	 86	(6.9)	 129	(11.6)	 249	(9.3)	 <	.001	 0.91	(0.60-1.39)	 0.67	 0.61(0.45-0.83)	 0.02	
	 	 	 	 	 	 	 	 	 	
Underwent	SC1,	n	
(%)**	
231	 907	 772	 1910/2454	(77.8)	 	 	 	 	 	
Recurrence	at	SC1,	n	
(%)		
12	(5.2)	 102	(11.2)	 198	(25.6)	 312(16.3)	 <	.001	 0.15	(0.05-0.42)	 0.001	 0.40	(0.27-0.58)	 <0.001	
Histologic	recurrence	
SC1,	n(%)***	
4(5.4)	 53	(13.8)	 124	(29.7)	 181(20.7)	 <	.001	 	 	 	 	
Surgery	at	SC1,	n	(%)		 2	(0.9)	 9	(1.0)	 15	(1.9)	 26	(1.1)	 .211	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
Underwent	SC2	(n)**	 117	 461	 421	 1013/1770	(56.1)	 	 	 	 	 	
Recurrence	at	SC2,	n	
(%)		
2	(1.8)	 30	(6.5)	 42	(10.0)	 75	(7.4)	 .008	 0.16(0.04-0.67)	 0.01	 0.66	(0.40-1.06)	 0.09	
Surgery	at	SC2,	n	(%)		 1	(0.5)	 1	(0.1)	 2	(0.3)	 4	(0.2)	 .337	 	 	 	 	
	
Supplementary	Table	1	(Access	=	Easy)	-	Outcomes	after	endoscopic	mucosal	resection	at	the	initial	procedure,	2	weeks	and	subsequent	surveillance	procedures.		EMR	–	
endoscopic	mucosal	resection,	IPB	–	intra-procedural	bleeding,	CSPEB	–	clinically	significant	post	endoscopic	bleeding	(bleeding	after	EMR	requiring	admission	to	
hospital	or	re-intervention),	2w	–	two	weeks,	SC1/2	surveillance	colonoscopy1/2,	OR	–	odds	ratio,	CI	–	95%	confidence	interval.	*	Target	sign	or	actual	hole	
corresponding	to	DMI	type	III/IV	Sydney	classification,	**	percentages	refer	to	total	eligible	for	SC1/SC2***	percentages	refer	to	number	of	lesions	with	histologic	data	
available.	
! " #$%&’  (  ) #* +, - ’ .$% / 0#1& 22
Figure 2 - EMR Adverse Events; a) Type III Deep Mural Injury as per the Sydney DMI Classification, b) Intra-procedural bleeding – transected artery, 
c) Clinically significant post endoscopic bleeding – multifocal bleeding from the post EMR defect, d) Recurrence – endoscopic recurrence 
demonstrated by Kudo Pit PaHern III within the area of post-EMR scar.
 
 
 
 
 
     ! " #$%&’ ( ) #* +, - ’ .$%/ 0#1&2(
Figure 3 – Study design and follow-up. EMR - endoscopic mucosal resection, SMSA - site morphology size and access score, SC1 - first surveillance 
colonoscopy, SC2 - second surveillance colonoscopy
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Synopsis and Significance 
A lower SMSA score (SMSA 2 versus 4) predicted greater likelihood of EMR success (OR 
13.34 [95% confidence interval {95% CI} 1.85-96.27]) and lesser likelihood of adverse events 
including delayed bleeding (OR 0.36 [95% CI 0.22-0.58]), adenoma recurrence (OR 0.19 [95% 
CI 0.09-0.41]) and surgery at 2 weeks (OR 0.53 [95% CI 0.4-0.71]) (SMSA 3 versus 4).   
This information is highly relevant for patient consent since it can be determined by simple 
criteria known prior to the procedure, often present in referring endoscopy report.  In addition, 
this data lends itself to the establishment of polyp-specific key performance metrics for those 
performing endoscopic resection.  It can also be applied to time and resource management at 
an endoscopy unit level, for example to determine the estimated procedure length for a 
particular polyp or the suitability of a particular polyp for training purposes. 
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Chapter 5 - An International Survey of Polypectomy Practice 
Demonstrates Encouraging Adherence To Published Guidance and 
Demonstrates Priorities For Change 
This article is unpublished currently.  It is included as a chapter in its own right.  The 
introduction of the manuscript below should be read in conjunction with the comments in the 
introduction to Theme 1.   
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Clinical implications of Decision Making 
in Colorectal Polypectomy – results of an 
International Survey suggest priorities for 
change
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Current knowledge 
• Colonoscopy prevents deaths from colorectal cancer via the detection and resection of 
pre-malignant polyps.   
• This effect may be attenuated by variations in polypectomy practice, with multiple 
techniques available and a wide range of experience amongst practising endoscopists.   
 
New findings from this study 
• Results from a survey of 707 endoscopists performing colorectal polypectomy in 7 
Western countries indicate that: 
o Cold snare polypectomy (CSP) is underutilised for small polyp resection despite 
its proven favourable safety and efficacy profile. 
o Benign large colorectal polyps are commonly referred for surgery. 
o Endoscopically overt submucosal invasive cancer is underappreciated. 
 
• These results should be viewed in the context that the respondents are likely to be a 
self-selected group of endoscopists interested in colorectal polypectomy. 
 
• Highlighting and addressing these issues may reduce diathermy-related adverse events, 
obviate the need for surgery or unnecessary colonoscopic procedures for patients and 
potentially reduce rates of post colonoscopy colorectal cancer. 
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Abstract 
Introduction: Colonoscopy prevents colorectal cancer via the detection and resection of pre-
malignant polyps.  This effect may be attenuated by variations in polypectomy, with multiple 
techniques available and a wide range of experience amongst endoscopists.  We assessed 
current practice against the best-available contemporary evidence. 
Methods: An online survey was distributed to members of the gastroenterological and 
surgical societies of 7 countries during July 2017.  Images of colorectal polyps were presented 
and respondents requested to provide the polypectomy technique they would employ in their 
daily practice.  R esponses were compared to the evidence-based techniques in the 2017 ESGE 
Colorectal Polypectomy Guideline. 
Results: 707 endoscopists (627 physicians, 71 surgeons, 9 nurse endoscopists, median 
practice duration 18 years) completed the survey.  3.1% selected hot biopsy forceps and 5.2% 
hot snare polypectomy (without submucosal lifting) to remove a 3mm ascending colon polyp.  
Only 43.3% selected cold snare polypectomy (CSP) to remove an 8mm ascending colon polyp. 
16.7% selected surgical referral for a 45mm transverse colon polyp without endoscopic 
evidence of submucosal invasive cancer (SMIC). 12.0% selected endoscopic resection for an 
80mm sigmoid polyp with imaging consistent with deep SMIC, and a further 26.4% selected 
tertiary endoscopist referral, suggesting they had not appreciated it was endoscopically 
unresectable. 
Conclusion: CSP is underutilised for small polyp resection despite its favourable safety and 
efficacy.  Benign polyps are commonly referred for surgery and overt SMIC is 
underappreciated using endoscopic imaging.  Addressing these issues may reduce diathermy-
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related adverse events, surgery and unnecessary colonoscopic procedures for patients and 
reduce rates of post colonoscopy colorectal cancer. 
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Introduction 
Colonoscopy has been shown to prevent colorectal cancer[1] and deaths from colorectal 
cancer[2].  The key to this effect is the detection and resection of pre-malignant polyps.  
Colonoscopy and polypectomy has been shown to be inversely related to post colonoscopy 
colorectal cancer (PCCRC) and death from PCCRC[3].  This effect is likely to be smaller than 
is potentially achievable since polypectomy has been shown to be commonly incomplete, 
particularly depending on the operator and the size and type of polyp [4]. 
The effectiveness of polypectomy is limited by several factors. Training in polypectomy is 
not standardised nor a focus in many countries.  Many practitioners work in relatively isolated 
environments and receive little feedback on their technique or the occurrence of adverse events 
including PCCRC following their procedures.  Importantly, until recently there was no 
evidence based guideline upon which to base decisions about the most effective polypectomy 
technique to be used in specific situations.  
Moreover, recent advances have led to key principles in polypectomy practice.  Avoidance 
of diathermy-related adverse events for resection of small and diminutive (< 10mm) polyps 
through the use of cold snare polypectomy (CSP) is well established[5-10].  There is also strong 
evidence for the superiority of endoscopic resection versus surgery for predicted-benign large 
colorectal neoplasia [11-14].  There is no published evidence as to whether these messages 
have reached the wider international community of endoscopists. 
The European Society of Gastrointestinal Endoscopy (ESGE) has recently released a 
thoroughly researched position statement[11] with evidence based guidelines for the optimal 
polypectomy technique based on size of polyp. The recommendations are summarised in 
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Figure 1.  The aim of this study was to compare the stated practice of endoscopists in 7 
countries with this synthesis of the best available contemporary evidence. 
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Methods 
Definitions 
Throughout this manuscript ‘the guideline’ refers to the ESGE Colorectal Polypectomy 
Guideline 2017[11]. Participant refers to a single endoscopist taking the survey. 
Demographic information was collected from participants.  Definitions can be found in the 
legend for Figure 2. 
Cold biopsy forceps polypectomy (CBF) refers to the use of a biopsy forceps to remove a 
polyp in one or more bites. CSP refers to the use of any endoscopic snare to mechanically 
resect a polyp without the use of diathermy. Hot snare polypectomy (HSP) refers to the use of 
any endoscopic resection snare to resect a polyp using diathermy without injection of a 
submucosal lifting solution.  HSP with a prior submucosal lift is referred to as endoscopic 
mucosal resection (EMR).  Endoscopic submucosal dissection (ESD) describes the use of an 
electrosurgical knife to circumferentially incise the mucosa and then dissect the polyp en-bloc.  
Right colon location was defined as proximal to and including the hepatic flexure. 
Polyp size categories were <10mm, 10-19mm and ³ 20mm.  Correct management for each 
category was assigned according to the technique(s) recommended in the guideline (Figure 1), 
as a surrogate for the best available contemporary evidence with which colonoscopic 
practitioners would be expected to be up-to-date.   Pedunculated polyps were intentionally 
excluded from the images and the discussion. 
Survey design 
Survey questions were based on the standards set forth in the guideline.  All authors were 
required to answer all questions in the first draft of the survey.  The final survey reflected 
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refinement based on their responses and suggestions.  All authors reviewed and agreed the final 
version of the survey. 
Participating countries were Australia, Belgium, Canada, Israel, New Zealand, the United 
Kingdom and the United States of America.  The only differences between survey versions 
sent to endoscopists in different countries were in the questions regarding demographics.  
Institutional review board approval for the survey design was obtained from Western Sydney 
Local Health District Human Research Ethics Committee and individual countries as required. 
The survey contained 3 sections - participant demographics, images of specific polyps and 
questions regarding correct polypectomy techniques and questions regarding the nuances of 
polypectomy.  The full survey (Australian version) is available in Appendix 1.   
The section presenting 9 still images of specific polyps (Figure 2) constituted the majority 
of the survey. Participants were asked to specify the technique they would use in their daily 
practice to resect the displayed polyp.  The images were chosen and agreed by the investigators 
as typical examples of the polyp size categories presented in the guideline.  All techniques were 
presented as possibilities for every polyp.   
 
Dissemination 
Gastrointestinal endoscopy societies of the countries involved were contacted by the 
investigators and invited to participate in the survey.  Participating societies sent an email to 
members of their mailing lists.  The USA version of the survey was disseminated using a 
marketing mailing list (Supplementary Table 1).  The online survey tool (SurveyMonkey, 
San Mateo, CA, USA) recorded the IP address of each respondent.  Each participant was asked 
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to enter a random unique identifier at the end of the survey to protect against multiple responses 
from an individual.   
Emails were sent in all countries within July 2017. Two weeks later a reminder email was 
sent. After 4 weeks the survey was closed and the responses analysed.  
 
Analysis 
The study data was analysed using SPSS statistics 23 (IBM, Armonk, NY).  Incomplete 
responses were not analysed.  Categorical variables were correlated using the chi square test. 
Continuous variables were analysed using either student t test (two-tailed) or Mann Whitney 
U test.  If categorised, continuous data described using the median value.  All authors had 
access to the study data and reviewed the final manuscript.  
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Results 
19,467 endoscopists in 7 countries received the survey.  772 (4.0%) responded and 707 
(91.7%) completed the survey.   
Demographic data (Supplementary Table 2) 
162/707 respondents identified their location of practice as Australia, 102 Belgium, 60 
Canada, 52 Israel, 45 New Zealand, 131 the United Kingdom and 155 the USA.  Supplementary 
Table 2 shows per country responses.  627/707 (88.7%) were gastroenterologists, 71 (10.0%) 
were surgeons and 9 (1.3%) were nurse endoscopists.  63 (8.9%) were trainees.  312 (44.1%) 
identified their practice as academic. 
Respondents had performed endoscopy for a median of 18 years (IQR 10 – 27) and most 
commonly performed >20 colonoscopies per week (25.9%).  327 (46.3%) had undertaken a 
specific endoscopy training attachment of ≥6 months and 243 (34.4%) received tertiary 
referrals for polypectomy.   
 
Polyp analysis and resection (Figure 2, Table 1, Figure 2 and 3) 
All polyps presented in the survey and the responses regarding their management in the 
daily practice of respondents are displayed in Figure 2.  Subgroup analyses of these responses 
by demographic are presented in Figure 3 (practitioner type), Table 1 (practitioner type, trainee 
status, undertaking of a specific endoscopy attachment, referral endoscopist, performing 11+ 
or 20+ colonoscopies per week, academic location of practice, performing 17+ EMRs per year 
and 18+ years of total practice),  and Suppl. Figure 1 (country of practice).  Correctness of 
responses was assessed using the flow reported in Figure 1. 
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Small (<10mm) Polyps  
302 (42.7%) participants correctly identified management for both small polyps.  152 
(21.5%) indicated they would remove a 3mm ascending colon polyp (Figure 2a) using CBF 
and 22 (3.1%) hot biopsy forceps (HBF).  206 (29.1%) indicated they would remove an 8mm 
ascending colon polyp (Figure 2b) using HSP and 176 (24.9%) using EMR.   
Surgeons were more likely to remove the 3mm polyp using HBF (12.7% versus 2.1%, P<) 
and less likely to use CSP (36.6% versus 69.1%), P<.001 (Figure 3).  Overall practitioners 
performing >11 colonoscopies/week (46.3% versus 35.9%, P=.008) and academic practitioners 
(49.0% versus 37.7%, P=.003) were more likely to identify correct management and surgeons 
less likely than physicians (26.8% versus 44.2%, P=.005) (Table 1).   
 
Intermediate (10-19mm) Polyps  
433 (61.2%) study participants correctly managed both intermediate sized polyps.  169 
(23.9%) indicated they would remove a 10mm polyp in the ascending colon (Figure 2c) using 
CSP and 105 (14.9%) using HSP.  88 (12.4%) would have removed a 15mm ascending colon 
polyp (Figure 2d) using CSP and 36 (5.1%) using HSP.  Surgeons were more likely to remove 
the 10mm polyp using HSP (29.6% versus 13.4%, P=.006) (Figure 3).   
 
Large ≥ (20mm) Polyps  
416 (58.8%) participants correctly identified management for all large polyps.  26 (3.7%) 
would remove a 20mm transverse colon polyp (Figure 2e) using HSP and 10 (1.4%) using 
ESD.  125 (17.7%) would have referred this polyp to another endoscopist for resection and 8 
(1.1%) to a surgeon.  283 (40.0%) would have performed piecemeal EMR on a 45mm mid-
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rectal polyp (Figure 2f) whilst 265 (37.5%) would have referred it to a tertiary endoscopist.  30 
(4.2%) would have performed ESD themselves whilst 10 (1.4%) would have attempted HSP.  
91 (12.9%) would have referred it to a surgeon for resection.  A minority of respondents would 
have elected to remove a 45mm transverse colon polyp (Figure 2g) using EMR themselves 
(180, 25.5%), with the majority 336 (47.5%) preferring to refer this polyp to a tertiary 
endoscopist.  118 (16.7%) would have referred this polyp to a surgeon for resection. 
Surgeons were significantly less likely to make correct decisions regarding large polyps (19, 
26.8% versus 277, 44.2%, P < .001).  In particular, for the 2 largest polyps, surgeons were more 
likely to refer for surgical resection than physicians (33.8% versus 10.2%, P < .001 and 22.5% 
versus 16.1%, P < .001 respectively) (Figure 3).   
 
Specifics of Large (≥20mm) polyp resection or referral 
Those who indicated they would resect the 45mm transverse polyp themselves (28%) were 
asked if they would biopsy the polyp before resection (15.1% would) and whether they would 
remove the polyp in the same session it was detected (28.1% would) (Figure 4).  The majority 
(71.9%) indicated they would perform the procedure at a later date, 41.2% due to a perceived 
need for specific consent for this procedure.   
Of those who elected to refer (64%) the polyp, 47.1% indicated they would refer to a tertiary 
endoscopist and 16.7% a surgeon.  When referring to a surgeon 88.1% would have biopsied 
the polyp and 95.8% would have marked the position with carbon particle suspension (tattoo).  
When referring to a tertiary endoscopist 35.4% would have biopsied the polyp and 59.2% 
marked the position with tattoo. 
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8% of respondents suggested other management strategies, mainly calling for multi-
disciplinary discussion prior to a decision or biopsy prior to a decision on final management. 
 
Polyp with endoscopic evidence of submucosal invasive cancer (SMIC)  
360 (50.9%) participants correctly identified that the 80mm polyp in the sigmoid colon 
contained an endoscopically demarcated area consistent with SMIC and suggested surgical 
referral (Figure 2h).  187 (26.4%) suggested referral to a tertiary endoscopist.  95 (13.4%) 
would attempt to remove the polyp themselves, 12.0% using EMR and 1.4% ESD. 
Surgeons were more likely to directly refer this polyp to surgery (69.0% versus 48.8%, P < 
.001) (Figure 3).  Academic practice (P=.025), more than 20 colonoscopies performed per week 
(P= .049), more than 17 EMRs per year (P<.001) and 18+ years total independent practice 
(P=.046) identified practitioners significantly less likely to identify correct management of this 
polyp (Table 1). 
 
Specific polypectomy techniques  
508/675 (75.3%) respondents routinely use carbon dioxide insufflation during colonoscopy 
and polypectomy (Table 2).  423/694 (61.0%) use a thin wire snare (diameter < 0.4mm) for 
CSP. 
516/692 (74.6%) routinely take measures to prevent bleeding from the stalks of 
pedunculated polyps with stalk diameter >10mm (most often clip placement over the polyp 
stalk 216/516 [41.9%]). 
The commonest snare diameter reported for EMR was 15mm in the right colon [237/645, 
36.7%] and 20mm in the left colon [223/644, 34.5%].  The commonest injection solution was 
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saline (352/660, 53.3%).  Adrenaline/epinephrine was added to the injectate by 407/681 
(59.8%).  A chromic dye was added to the injectate by 501/686 (73.0%) and was most often 
methylene blue (295, 43.0%). 
77/674 (11.4%) of respondents reported performing ESD in the rectum and 44/673 (6.2%) 
in the rest of the colon. 
 
Variation in polyp analysis and resection techniques between countries  
Australian endoscopists were most likely to identify the correct management of small polyps 
(77.8%) and Belgians were the least likely (16.7%), P < .001 (Supplementary Figure 1).  For 
intermediate polyps Australian endoscopists identified correct management least often (35.8%) 
versus Canadians who had the highest rates (76.7%, P < .001).  Large polyp management was 
most often correctly identified by Australian endoscopists (74.7%) and least often by those 
from the United States (34.2%, P < .001).  Belgian endoscopists most often correctly suggested 
management for the polyp with SMIC (84.3%).  
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Discussion 
Colorectal cancer may be prevented by high-quality colonoscopy and complete 
polypectomy.  It is increasingly recognised that the safety and completeness of polypectomy 
depend upon the technique used.  We analysed the responses of 707 endoscopists in 7 countries 
to a survey designed to assess their practice against a contemporary synthesis of the available 
evidence in  colorectal polypectomy[11].  The results demonstrate areas for focussed 
interventions to improve polypectomy practice and therefore patient outcomes.   
The 2017 ESGE Colorectal Polypectomy Guideline offers an excellent synthesis of the 
contemporary evidence for technique choice in polypectomy, stratified by polyp size and is 
freely available from the organisation’s website.  The standards set forth in the guideline had 
been clear from important publications in peer-reviewed journals on the subject [12,13] and 
the accumulating publications on the safety and efficacy of CSP[14,15], the risks of HBF[16] 
[17] and the efficacy and superior safety profile of endoscopic resection versus surgery[18-21] 
over the prior decade.  It is incumbent upon all medical practitioners to remain up-to-date with 
the evidence in their field of practice.  Therefore we used the guideline as a benchmark against 
which to assess the polypectomy practice of individual endoscopists against the best 
contemporary evidence at the time of the survey. 
The lowest rates of adherence to the guideline were regarding resection of the smallest 
polyps (<10mm).  CSP is the preferred technique here (CBF considered a second-line option 
for polyps ≥ 3mm where CSP is ‘technically difficult’).  Recent data reinforce the safety [7], 
and efficacy of CSP in achieving en-bloc resection and adenoma clearance in addition to its 
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comparative efficacy versus HSP[5,6].  The small polyps presented were located in the right 
colon where the risk profile of diathermy is highest.   
Whilst encouraging numbers of respondents indicated they would perform CSP or CBF for 
the 3mm ascending colon polyp, for an 8mm polyp in the same location >50% of respondents 
indicated they would perform EMR or, more concerningly, HSP [without a submucosal lift] in 
their daily practice.  This suggests unnecessary exposure of patients to the small yet definite 
risks of diathermy, namely delayed bleeding[22] and post-polypectomy syndrome [15].  A 
particular focus for the promotion of CSP should be non-academic practitioners performing 
smaller numbers of colonoscopies since these groups demonstrated lower adherence in this 
category. 
A small number of respondents stated that they would perform HBF to resect the 3mm 
ascending colon polyp.  Animal[16] and clinical[17] studies suggest HBF should be avoided 
due to the possibility of full thickness colonic injury and poor rates of complete resection.  
Surgeons were significantly more likely to suggest HBF as a response.  The message that HBF 
should be avoided must be further promoted in this context. 
Higher rates of adherence to the guideline were recorded regarding intermediate (10-19mm) 
polyps.  HSP [without submucosal injection] or EMR are recommended here but deep thermal 
injury is a potential risk with HSP and submucosal injection is strongly recommended.  
Respondents expressed a preference for EMR over HSP in the majority of cases regarding both 
polyps.  Only 15% indicated they would remove the 10mm polyp and 5% the 15mm right colon 
polyp with HSP; those responding in this way were more commonly surgeons.  Therefore, 
although the guideline suggests HSP is acceptable, it is clearly not the practice of the majority 
of study respondents or that of the authors, particularly in the right colon.   
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Correct management of all large polyps was identified by 60% of respondents overall.  
Polyps ≥ 20mm in size (>90%) can be safely and effectively resected in a single session using 
EMR[20,23] without resorting to surgery with its higher risk of morbidity and mortality13,15.  
Therefore patients have much to gain from correct responses in this category.  
The majority of respondents suggested endoscopic management for a 20mm polyp in the 
transverse colon and felt comfortable undertaking this themselves.  Conversely, only 40% 
suggested they would attempt a 45mm rectal polyp themselves and 26% a 45mm transverse 
colon polyp.   Given the cohort bias, this suggests the majority of endoscopists prefer to refer 
large laterally spreading polyps to a tertiary endoscopist.  Of significant concern, 13% 
suggested they would refer the rectal polyp for surgery and 17% the transverse colon polyp.  
This is supported by recent US data indicating the rate of surgery for non-malignant colorectal 
polyps is high (9.4/100,000 adults) and has increased over the past 14 years[24].  Surgeons and 
non-academic endoscopists were more likely to refer benign disease for surgery.  This finding 
suggests that the establishment of review pathways for endoscopic images of large colorectal 
polyps by expert endoscopists prior to surgical referral is necessary. 
Almost all respondents indicated they would biopsy and mark a polyp being referred for 
surgery with tattoo.  The authors agree with this practice.  If referring to a tertiary endoscopist 
only 1/3 would biopsy the polyp (even with ‘hindsight’) and 2/3 would mark the polyp with 
tattoo.  Anecdotal evidence suggests that both practices are associated with fibrosis at 
endoscopic resection so the authors take a common-sense approach of marking subtle polyps 
at least 2cm distally and biopsying only superficially and if there is concern for SMIC. 
A third of respondents indicated they would remove the 45mm transverse polyp (if detected 
on a screening list) at the session it was detected without specific consent.  Presuming the 
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patient is sedated, the authors would recommend specific consent be obtained prior to 
endoscopic resection of such a polyp.  Reasons include the higher rates of delayed bleeding, 
hospital admission, adenoma recurrence and need for further surgery than polypectomy of 
smaller polyps. Patients should also be informed of the available alternative management 
options including observation, alternative endoscopic techniques or surgery. 
1 in 4 respondents did not recognise that an 80mm sigmoid polyp contained overt evidence 
of SMIC and suggested endoscopic resection was appropriate.  Interestingly those with a longer 
practice duration and academic practice were less likely to answer correctly.  Consideration 
should be given to the development of training schemes incorporating endoscopic imaging for 
practicing endoscopists to avoid unnecessary repeat procedures for patients (either after tertiary 
endoscopist referral of an endoscopically unresectable polyp, or due to a failed endoscopic 
resection attempt of the same).  
The technical polypectomy data from the survey provide interesting insights into real-world 
polypectomy practice when compared to the best available evidence.  In particular, 11% of 
respondents reported performing ESD in the rectum and 6% in the remainder of the colon.  This 
demonstrates the expertise bias within the survey cohort but taking this into consideration, also 
demonstrates that ESD is not performed by the vast majority of endoscopists in the countries 
surveyed. 
This study has some limitations.  The response rate to the study was low.  In addition the use 
of a marketing mailing list for dissemination of the survey in the USA may also have biased 
the results.  Prior to use of a marketing list we approached the largest endoscopy organisation 
in that country, but it declined to participate.   
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Studies with similar methodology had response rates from 13-45% [25-29] [30], but 
significantly lower response pools (maximum 5,030 versus 19,467 in this study) and therefore 
significantly less respondents [excepting the US only study[28]].  Such a large study on 
polypectomy with >700 complete responses and contribution from 7 Western countries has not 
previously been described.  Due to the low response rate there is a significant risk of non-
response bias.  To mitigate this as far as possible multiple, focussed questions to address 
potentially confounding demographics were included in the survey.  The responses to these 
suggested the respondents are a self-selected group with extensive experience and with an 
interest in endoscopy.   The results should be interpreted in this context.  Indeed, while this 
cannot be proven, the practice of non-respondents could reasonably be expected to be less 
adherent than that of respondents.   
Still single images were used for the questions regarding polyp management.  Whilst not a 
substitute for in-vivo polyp assessment similar judgements must often be made from previously 
acquired images (often single and of low quality) provided for referral purposes.  All authors 
confirmed the polyp images as representative prior to circulation of the survey.  The power of 
individual, anonymous reporting of images to judge current practice should not be 
underestimated.  Rigid classifications were used to judge adherence to guidelines of participant 
responses.  We acknowledge that individual cases must be judged using clinical acumen and 
guidelines are not a substitute for this.   
 The number of surgeons and trainees in this study was small compared to the overall cohort.  
Despite this statistical significance was demonstrated, however we accept the possibility of 
bias within the small group of individuals recruited.   
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Conclusions 
Responses of over 700 colonoscopists in 7 countries suggest that CSP is underutilised for 
diminutive polypectomy despite its favourable safety and similar efficacy profile as compared 
to alternative techniques requiring diathermy.  Benign colorectal neoplasia is routinely referred 
for surgery.  Overt SMIC is underappreciated using endoscopic imaging amongst a self-
selected group of interested endoscopic practitioners.  Addressing these issues via focussed 
interventions by international endoscopy societies may reduce burdens of diathermy-related 
adverse events, surgery and unnecessary colonoscopic procedures on patients, in addition to 
potentially reducing rates of PCCRC. 
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Table 1 – Correct decision making regarding colorectal polypectomy stratified by demographic cohort factors as compared to the 
standards in the ESGE polypectomy guideline.    Polyp size criteria (small, intermediate, large) are defined in the methods and Figure 1.  
Predicated SMIC refers to the 80mm sigmoid polyp with endoscopic evidence of submucosal invasive cancer (SMIC).  Phys – physician, surg – 
surgeon, cons – consultant or independent practitioner, trainee – not consultant or independent practitioner.  Specific endoscopy attachment - 
undertaken a specific endoscopy training attachment/fellowship for a period of greater than, or including, 6 months.  Referral – practitioner reports 
Polyp 
type 
n (%) 
[95% CI] 
Practitioner type* Trainee Specific Endoscopy Attachment Referral 11+ colons 
 Phys Surg P Cons Trainee P Yes No P Yes No P Yes No P 
Small 277 (44.2) [40.3-48.1] 
19 (26.8) 
[17.9-38.1] .005 
278 (43.2) 
[39.4-47.0] 
24 (38.1) 
[27.1-50.5] .437 
133 (40.7) 
[35.5-46.1] 
169 (44.5) 
[39.6-49.5] .308 
92 (37.9) 
[32.0-44.1] 
210 (45.3) 
[40.8-49.8] .059 
214 (46.3) 
[41.8-50.9] 
88 (35.9) 
[30.2-42.1] .008 
Intermediate 386 (61.6) [57.7-65.3] 
45 (63.4) 
[51.8-73.6] .765 
398 (61.8) 
[58.0-65.5] 
35 (55.6) 
[43.3-67.2] .331 
213 (65.1) 
[59.8-70.1] 
220 (57.9) 
[52.9-62.8] .049 
164 (67.5) 
[63.4-73.1] 
269 (58.0) 
[53.4-62.4] .014 
292 (63.2) 
[58.7-67.5] 
141 (57.6) 
[51.3-63.6] .142 
Large 391 (62.4) [58.5-66.1] 
21 (29.6) 
[20.2-41.0] <.001 
378 (58.7) 
[54.9-62.4] 
38 (60.3) 
[48.0-71.5] .803 
175 (53.5) 
[48.1-58.9] 
241 (63.4) 
[58.5-68.1] .008 
146 (60.1) 
[53.8-66.0] 
270 (58.2) 
[53.7-62.6] .627 
266 (57.6) 
[53.0-62.0] 
150 (61.2) 
[55.0-67.1] .348 
Predicted 
SMIC 
484 (77.2) 
[73.8-80.3] 
55 (77.5) 
[66.5-85.6] .959 
490 (76.1) 
[72.7-79.2] 
57 (90.5) 
[80.7-95.6] .009 
240 (73.4) 
[68.4-77.9] 
307 (80.8) 
[76.5-84.4] .019 
132 (54.3) 
[48.0-60.5] 
415 (89.4) 
[86.3-92.0] <.001 
357 (77.3) 
[73.2-80.9] 
190 (77.6) 
[71.9-82.3] .933 
Total per 
subgroup 627 71  644 63  327 380  243 464  462 245  
 
 20+ colons Academic 17+ EMRs 18+ years practice Overall 
 Yes No P Yes No P Yes No P Yes No P  
Small 87 (47.5) [40.4-54.8] 
215 (41.0) 
[36.9-45.3] .125 
153 (49.0) 
[43.5-54.6] 
149 (37.7) 
[33.1-42.6] .003 
80 (31.5) 
[26.1-37.5] 
222 (49.0) 
[44.4-53.6] <.001 
140 (39.7) 
[34.7-44.9] 
162 (45.8) 
[40.6-51.0] .101 302 (42.7) 
Intermediate 105 (57.4) [50.1-64.3] 
328 (62.6) 
[58.4-66.6] .212 
185 (59.3) 
[53.8-64.6] 
248 (62.8) 
[57.9-67.4] .344 
189 (74.4) 
[68.7-79.4] 
244 (53.9) 
[49.3-58.4] <.001 
220 (62.3) 
[57.2-67.2] 
213 (60.2) 
[55.0-65.1] .557 433 (61.2) 
Large 103 (56.3) [49.0-63.3] 
313 (59.7) 
[55.5-63.8] .414 
198 (63.5) 
[58.0-68.6] 
218 (55.2) 
[50.3-60.0] .026 
145 (57.1) 
[50.9-63.0] 
271 (59.8) 
[55.2-64.2] .478 
198 (56.1) 
[50.9-61.2] 
218 (61.6) 
[56.4-66.5] .138 416 (58.8) 
Predicted 
SMIC 
132 (72.1) 
[65.2-78.1] 
415 (79.2) 
[75.5-82.5] .049 
229 (73.4) 
[68.2-78.0] 
229 (80.5) 
[53.1-62.7] .025 
 168 (66.1) 
[60.1-71.7] 
379 (83.7) 
[80.0-86.8] <.001 
262 (74.2) 
[69.4-78.5] 
285 (80.5) 
[76.1-84.3] .046 547 (77.4) 
Total per 
subgroup 183 524  312 395  254 453  353 354  707 
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receiving referrals for colonoscopic polypectomy.  11+ colons – practitioner reports performing 11 or more colonoscopies per week, 20+ colons – 
practitioner reports performing 20 or more colonoscopies per week, academic – practitioner reports at least part of their practice in an academic 
institution, 17+ EMRs – practitioner reports performing 17 or more endoscopic mucosal resection procedures of polyps ≥ 20mm per year, 18+ 
years practice – practitioner reports 18 or more years of continuous practice as a consultant or independent practitioner.  95% CI – 95% confidence 
interval of the proportion above.  P values in bold typeface indicate significance at the .05 level.  *Denominator 698 after removing nurse 
endoscopists n=9. 
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 Respondents 
Cold Snare Polypectomy   
What type of snare do you use for cold 
snare polypectomy? 
Thin wire snare (snare wire diameter < 0.4mm) 423 (61.0%) 
Thick wire snare (snare wire diameter ≥ 0.4mm) 106 (15.3%) 
Don't know 165 (23.8%) 
Total 694  
Pedunculated Polypectomy   
Do you take routine measures to pre-
vent bleeding from pedunculated 
polyps with stalk diameter greater than 
10mm? 
Yes 516 (74.6%) 
No 176 (25.4%) 
Total 692  
General Polypectomy   
Do you routinely use carbon dioxide 
insufflation during colonoscopy and 
polypectomy? 
Yes 508 (75.3%) 
No 166 (24.6%) 
Don't know 1 (0.1%) 
Total 675  
Do you routinely (or frequently) use 
dye spraying (chromo-endoscopy) to 
evaluate colon polyps? 
Yes 82 (12.2%) 
No 592 (87.8%) 
Total 674  
Do you routinely (or frequently) use 
optical or digital image enhancement 
Yes 497 (73.7%) 
No 177 (26.3%) 
Other (please specify) 0 (0.0%) 
  Chapter 5 Manuscript – Page 33 
   
(NBI, FICE etc.) to evaluate colon 
polyps? 
Total 674  
  
Do you perform endoscopic submuco-
sal dissection (ESD) in the rectum? 
Yes 77 (11.4%) 
No 597 (88.6%) 
Total 674 
  
Do you perform ESD in the remainder 
of the colon? 
Yes 44 (6.2%) 
No 629 (89.0%) 
Total 673 (100.0%) 
  
 
Submucosal Lift Polypectomy – (endoscopic mucosal resection – EMR)  
What size snare do you most com-
monly use for a standard submucosal 
lift polypectomy (EMR) in the right 
colon? (proximal and including the he-
patic flexure) 
10mm 110 (17.1%) 
15mm 237 (36.7%) 
20mm 172 (26.7%) 
Other Snare Size 51 (7.9%) 
Don't know 75 (11.6%) 
Total 645  
What size snare do you most com-
monly use for a standard submucosal 
lift polypectomy (endoscopic mucosal 
resection (EMR) in the left colon? 
(Distal to the hepatic flexure) 
10mm 79 (12.2%) 
15mm 218 (33.7%) 
20mm 223 (34.5%) 
Other Snare Size 52 (8.0%) 
Don't know 74 (11.5%) 
Total 646  
Saline 352 (53.3%) 
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If you perform submucosal injection 
prior to snare resection or EMR what 
do you use as the injection solution? 
Succinylated Gelatin (e.g. Gelofusine) 4 (0.6%) 
Starch (e.g. Voluven) 235 (36.1%) 
Hyaluronic Acid 54 (8.2%) 
Other 12 (1.8%) 
Total 660 
Do you routinely add adrenaline/epi-
nephrine to your injection solution for 
submucosal lift polypectomy (endo-
scopic mucosal resection [EMR]) 
Yes 274 (40.2%) 
No 407 (59.8%) 
Total 681  
Do you routinely add a chromic dye to 
your injection solution for submucosal 
lift polypectomy? (endoscopic mucosal 
resection [EMR]) 
Yes, indigo carmine 193 (28.1%) 
Yes, methylene blue 295 (43.0%) 
No 185 (27.0%) 
Other dye  13 (1.9%) 
Total 686  
 
 
Table 2 – Specific polypectomy techniques identified by respondents.    Number of respondents to each question identified separately since 
not all participants answered all  questions, and unlike responses to the questions regarding specific polyps, this did not disqualify their data from 
analysis. 
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Figure Legends 
Figure 1 – Overview of recommendations from the guideline.  Evidence-based recommendations from the ESGE Colorectal Polypectomy 
Guideline 2017 [11] represented graphically.  This flow diagram was used to assess adherence of participant responses in the study.  CSP – cold 
snare polypectomy, CBF – cold biopsy forceps polypectomy, EMR – endoscopic mucosal resection or hot snare polypectomy with a submucosal 
lift, HSP – hot snare polypectomy without submucosal lifting, ESD – endoscopic submucosal dissection, SMIC – submucosal invasive cancer. * 
- consider ESD correct only if rectal and morphology suggests higher risk for submucosal invasive cancer. ** - outside of the rectum or 
endoscopic imaging evidence of deep submucosal invasive cancer. 
Figure 2 – Images of polyps presented to study participants stratified by size with resection technique or decision to refer.  The text 
beneath the polyp image represents the exact text presented to the survey participants.  Green typeface indicates a correct response when 
compared with the ESGE Colorectal Polypectomy Guideline.  Cold snare – cold snare polypectomy, cold biopsy – cold biopsy forceps 
polypectomy, hot snare – hot snare polypectomy without submucosal lifting, EMR – endoscopic mucosal resection (hot snare polypectomy with 
prior submucosal lifting), hot biopsy – hot biopsy forceps polypectomy, correct – indicates percentage of respondents who chose a correct 
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response as defined by the ESGE colorectal polypectomy guideline.  A small minority of respondents chose responses not included on this figure 
and so percentages do not necessarily add up to 100%. 
 
 
Figure 3 - Images of polyps presented to study participants stratified by size with resection technique or decision to refer further 
stratified by type of practitioner.  The text beneath the polyp image represents the exact text presented to the survey participants.  Green 
typeface indicates a correct response when compared with the ESGE Colorectal Polypectomy Guideline.  Phys – physician, Surg – surgeon, 
Cold snare – cold snare polypectomy, cold biopsy – cold biopsy forceps polypectomy, hot snare – hot snare polypectomy without submucosal 
lifting, EMR – endoscopic mucosal resection (hot snare polypectomy with prior submucosal lifting), hot biopsy – hot biopsy forceps 
polypectomy, correct – indicates percentage of respondents who chose a correct response as defined by the ESGE colorectal polypectomy 
guideline.  Nurse endoscopists are excluded from this figure, total n=698.  A small minority of respondents chose responses not included on this 
figure and so percentages do not necessarily add up to 100%. 
 
Figure 4 – Management of a large 45mm laterally spreading polyp in the transverse colon after detection in routine practice.  
Respondents were shown the image in the top left of the figure and given the management options listed in the table below the image.  If they 
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selected to resect the polyp they were asked biopsy and consent related questions (a).  If they selected to refer to another practitioner 
(endoscopist or surgeon) they were asked questions regarding biopsy and carbon particle suspension (Spot) marking (b).  Respondents who 
selected other were invited to comment but were not given the opportunity to answer a or b.  A selection of their comments are presented.  EMR 
– endoscopic mucosal resection, ESD – endoscopic submucosal dissection, MDT – multi-disciplinary team. 
 
Supplementary Figure 1 – Graph of correct responses for different sizes of polyp stratified by country of practice of respondent.  * a 
correct response was defined as compared to the standards set out in the ESGE polypectomy guideline.  See the green text in figure 1 for 
accepted correct responses per polyp and per polyp size group.  A correct response was recorded per participant if a correct technique was 
chosen for all polyps in that size category. 
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Participating 
Organisations 
Complete 
Responses 
Received 
Survey 
Response Rate 
Cohort weight 
(recipients) 
Cohort weight 
(responses) 
Australia GESA 162 1,030 15.7% 5.3% 22.9% 
Belgium VVGE, BSGIE, SRBE 102 664 15.4% 3.4% 14.4% 
Canada CAG, CAGS 60 1,366 4.4% 7.0% 8.5% 
Israel IGA 52 460 11.3% 2.4% 7.4% 
New Zealand NZSG 45 109 41.3% 0.6% 6.4% 
UK BSG 131 3,214 4.1% 16.5% 18.5% 
USA D+R Lathian* 155 12,624 1.2% 64.8% 21.9% 
       
Totals  707 19,467 3.6%   
 
Supplementary Table 1 – Organisations participating in the survey and the response rates from their members.  GESA – Gastrointestinal 
Sociaty of Australia, VVGE – Vlaamse Vereniging voor Gastro-Enterologie (Flemish Association of Gastroenterology), SRBE – Société Royal 
Belge de Gastro-Entérologie, BSGIE – Belgian Society of Gastrointestinal Endoscopy, CAG – Canadian Society of Gastroenterologists, CAGS – 
Canadian Society of General Surgeons, IGA – Israeli Gastroenterology Association, NZSG – New Zealand Society of Gastroenterology, BSG – 
British Society of Gastroenterology,   *D+R Lathian is a medical marketing company that provided an email list of practicing gastroenterologists 
in the United States of America free of charge to DKR as a service to research.  The American Society of Gastrointestinal Endoscopy was 
approached first but declined to participate in the study. 
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 Country  
Demographic Australia Belgium Canada Israel New Zealand UK USA Total P 
          
Complete Responses (n) 162 102 60 52 45 131 155 707  
          
Practitioner Type          
Physician 152 (93.8) 102 (100.0) 42 (70.0) 52 (100.0) 37 (82.2) 121 (92.4) 121 (78.1) 627 (88.7) < .001 
Surgeon 9 (5.6) 0 18 (30.0) 0 (0) 5 (11.1) 6 (4.6) 33 (21.3) 71 (10.0)  
Nurse Endoscopist 1 (0.6) 0 0 (0) 0 (0) 3 (6.7) 4 (3.1) 1 (0.6) 9 (1.3)  
          
In academic practice, n (%) 85 (52.5) 26 (25.5) 35 (58.3) 39 (75.0) 24 (53.3) 63 (48.1) 40 (25.8) 312 (44.1) < . 001 
          
Trainee, n (%) 10 (6.2) 30 (29.4) 2 (3.3) 8 (15.4) 7 (15.6) 4 (3.1) 2 (1.3) 63 (8.9) < . 001 
          
Time as independent practitioner, 
years, median (IQR) 16 (8-30) 17 (6-25) 12 (7-20) 15 (7-21) 16 (8-25) 20 (12-25) 25 (15-31) 18 (10-27) < . 001 
          
Number of colonoscopies per 
week, n (%)          
0 0 0 1 (1.7) 0 (0) 1 (2.2) 0 (0) 2 (1.3) 4 (0.6) < . 001 
1-5 16 (9.9) 2 (2.0) 6 (10.0) 3 (5.8) 5 (11.1) 25 (19.1) 7 (4.5) 64 (9.1)  
6-10 31 (19.1) 24 (23.5) 12 (20.0) 5 (9.6) 20 (44.4) 63 (48.1) 22 (14.2) 177 (25.0)  
11-15 42 (25.9) 35 (34.3) 13 (21.7) 12 (23.1) 10 (22.2) 21 (16.0) 20 (12.9) 153 (21.6)  
16-20 19 (11.7) 30 (29.4) 18 (30.0) 5 (9.6) 4 (8.9) 11 (8.4) 39 (25.2) 126 (17.8)  
>20 54 (33.3) 11 (10.8) 10 (16.7) 27 (51.9) 5 (11.1) 11 (8.4) 65 (41.9) 183 (25.9)  
          
Has undertaken a specific 
Advanced Endoscopy Fellowship 
of ³ 6 months, n (%) 
59 (36.4) 50 (49.0) 27 (45.0) 19 (36.5) 11 (24.4) 39 (29.8) 122 (78.7) 327 (46.3) < . 001 
          
Identifies as a referral 
endoscopist, n (%) 43 (26.5) 22 (21.6) 21 (35.0) 30 (57.7) 16 (35.6) 60 (45.8) 51 (32.9) 243 (34.4) < . 001 
          
Number of polyps ³ 20mm in last 
year? median (IQR) 1 (0-6) 5 (15-30) 15 (5-50) 14 (3-37) 20 (10-30) 20 (6-40) 15 (1-33) 17 (5-35)  
  Chapter 5 Manuscript – Page 41 
   
Supplementary Table 2 - Demographics of the study participants split by primary country of practice.  EMR – endoscopic mucosal resection, IQR – 
interquartile range 
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Figure  2 — I mag es of  polyps  pr esent ed to  study  part icipa nts  str at if ied  by  size w ith  resection  technique  or  
decis ion  to  re fer.  The  te x t  beneath  the  po lyp image  represe nts  the  exact  te x t  pr esented  to  the survey  
pa r t icipants.  Green  typef ace indicat es a corr ect  response  when compar ed w ith  the  ESGE Color ectal
Polypectomy  Guide line.  Cold  snare  — cold  snare  po lyp ectomy,  cold  b iopsy  — cold  b iopsy  forceps
polypectom y,  hot  snare  — hot  snare  po lypectomy  w ithout  submuc osal  lift ing,  EMR — endoscopic  mucosal
resect ion  (hot  sna re polypecto my  with  prior  submu cosal  lift ing),  hot  b iopsy  — hot  biopsy  forc eps
polypectom y,  correct  — indicates  perce ntage  of  respo ndents  who  chose  a corr ect  respo nse as defined  by  the  
ESGE co lorectal  polyp ectomy  gu ideline.  A small  minority  of  respondents  chose  respo nses not  inc luded  on  
this  f igu re and  so perc entag es do  not  necessa r ily  add  up  to  100%.
     
             
               
             
              
    
              
              
            
               
             
                
          
             
               
             
              
              
              
            
               
             
                
     
Figure 3 - Images of polyps presented to study participants stratified by size with resection technique or
decision to refer further stratified by type of practitioner. The text beneath the polyp image represents the 
exact text presented to the survey participants. Green typeface indicates a correct response when
compared with the ESGE Colorectal Polypectomy Guideline. Phys – physician, Surg – surgeon, Cold snare –
cold snare polypectomy, cold biopsy – cold biopsy forceps polypectomy, hot snare – hot snare polypectomy 
without submucosal lifting, EMR – endoscopic mucosal resection (hot snare polypectomy with prior
submucosal lifting), hot biopsy – hot biopsy forceps polypectomy, correct – indicates percentage of
respondents who chose a correct response as defined by the ESGE colorectal polypectomy guideline. 
Nurse endoscopists are excluded from this figure, total n=698. A small minority of respondents chose 
responses not included on this figure and so percentages do not necessarily add up to 100%.
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Figure 3 – Management of a large 45mm laterally spreading polyp in the transverse colon after detection in 
routine practice. Respondents were shown the image in the top left of the figure and given the
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i  4 —    l   l t ll  r  l  i  t  t r   ft  t ion  i  
r ine  t i .  s ts  r   t  i  i  t  t  l f   t  f i r   i  t
m anag ement  opt ions  listed in  the  tab le below  the  image.  If  they  selected  to  resect  the polyp  they  were
asked  biopsy  and  consent  related  questions  (a).  If  they  select ed to  re fer  to another  practitioner
(endoscopist  or  surgeon)  they  were  ask ed questions  reg ard ing biopsy  and  carbon  partic le susp ens ion  (Spot)  
m arking  (b).  Respond ents  who  selected  other  were  inv ited to  comm ent  but  were  not  g iven the  opport un ity  
to  answer  a or  b.  A select ion  of  their  comm ents  are  prese nted.  EMR — endosc op ic mucos al resection,  ESD — 
end oscop ic submucos al d issect ion,  MDT — mult i-disci p linary  te am.
     
                  
                 
    
    
                
                
Chapter 5 Manuscript | Page 46
                  
                 
    
                
                Supp lement ary  Figure  1 — Graph  of  corr ect  responses  for  d iffe rent  sizes  of  polyp  stratified  by  country  of
pr act ice of  respo ndent.  *  a corr ect  response  was de f ined as compared  to  the standards  set  out  in  the  ESGE 
polypectomy  guidel ine.  See the  gr een  text  in figure  1 for  accepted  correct  respons es per  po lyp and per
polyp  size gro up.  A correct  respo nse was  reco rded  per  part icipa nt  if  a correct  technique  was chos en for  all  
polyps  in  that  size  categor y.
Thank you for agreeing to take this survey led by Professor Michael Bourke at Westmead Hospital in
Sydney, Australia.
 
The survey contains 36-39 (depending on choices) quick, multiple choice questions regarding your
polypectomy practice as a Gastroenterologist or Surgeon, Consultant or trainee.
We recognise your time is valuable and you receive many such surveys.  The purpose of this is to
inform current international practice and adherence to published guidelines.  We intend to publish the
results of this survey.  By completing the survey you imply your consent for the data to be used for this
purpose. 
1. Thank you
International Survey of Polypectomy Practice
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 2. Your practice (4 questions)
International Survey of Polypectomy Practice
1. In which country do you practice?
Australia
Israel
New Zealand
Great Britain
Canada
United States
Belgium
Other (please specify)
2. Which best describes your practice?
Public Academic Hospital
Public Non Academic Hospital
Private Hospital
Ambulatory Endoscopy Centre
Other (please specify)
3. Please enter the state/county/administrative area in which you work?
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4. Do you consider yourself a
Physician
Surgeon
Nurse endoscopist
Other (please specify)
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3. Your practice (9 questions)
International Survey of Polypectomy Practice
5. How many years have you performed endoscopy for?
0 40
6. Are you a consultant or have you completed your training AND are undertaking independent
practice?
Yes
No
7. If you are a consultant / have completed your training in what year did you start independent
practice?
              
   
No
Yes
9. If so, were you offered training in endoscopic mucosal resection (EMR) during your
attachment/fellowship?
No
Yes
10. Were you offered training in endoscopic submucosal dissection (ESD) during your
attachment/fellowship?
No
Yes
4
! " # $%& ’ ( )  ) * +&, -$. &* $ / 0&12321 &* +/ 1( 0’  -,$2* 2* 4 $--$156 &* -73&88( 9 / 520 3( ,  $ 0&,2( + ( 3 
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11. How many colonoscopies do you perform yourself per week?
0
1-5
6-10
11-15
16-20
>20
12. Do you receive referrals from other endoscopists for polypectomy procedures? (i.e. are you a
tertiary interventional endoscopist)
No
Yes
13. How many endoscopic mucosal resection (EMR) procedures for lesions >=20mm did you
perform in the last year?
0
1-10
11-50
51-100
>101
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Please provide the technique you would most commonly use in your
daily practice to remove the displayed lesions
4. Specific polyps and polypectomy technique (5 questions)
International Survey of Polypectomy Practice
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14. 3mm polyp in the ascending colon
Cold standard sized biopsy forceps (CBF)
Cold jumbo sized biopsy forceps (CJBF)
Hot biopsy forceps (HBF)
Cold snare polypectomy (CSP)
Piecemeal Cold snare polypectomy (pCSP) with
submucosal lifting
Piecemeal Cold snare polypectomy (pCSP) without
submucosal lifting
Hot snare polypectomy (HSP) without submucosal
lifting
Piecemeal or en bloc hot snare polypectomy (HSP)
with submucosal lifting (Endoscopic Mucosal
Resection [EMR])
Endoscopic Submucosal Dissection (ESD)
Would not attempt to remove myself - refer to a tertiary
endoscopist
Would not attempt to remove myself - refer to a
surgeon
Other (please specify)
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15. 8mm polyp in the ascending colon
Cold standard sized biopsy forceps (CBF)
Cold jumbo sized biopsy forceps (CJBF)
Hot biopsy forceps (HBF)
Cold snare polypectomy (CSP)
Piecemeal Cold snare polypectomy (pCSP) with
submucosal lifting
Piecemeal Cold snare polypectomy (pCSP) without
submucosal lifting
Hot snare polypectomy (HSP) without submucosal
lifting
Piecemeal or en bloc hot snare polypectomy (HSP)
with submucosal lifting (Endoscopic Mucosal
Resection [EMR])
Endoscopic Submucosal Dissection (ESD)
Would not attempt to remove myself - refer to a tertiary
endoscopist
Would not attempt to remove myself - refer to a
surgeon
Other (please specify)
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16. 10mm polyp in the ascending colon
Cold standard sized biopsy forceps (CBF)
Cold jumbo sized biopsy forceps (CJBF)
Hot biopsy forceps (HBF)
Cold snare polypectomy (CSP)
Piecemeal Cold snare polypectomy (pCSP) with
submucosal lifting
Piecemeal Cold snare polypectomy (pCSP) without
submucosal lifting
Hot snare polypectomy (HSP) without submucosal
lifting
Piecemeal or en bloc hot snare polypectomy (HSP)
with submucosal lifting (Endoscopic Mucosal
Resection [EMR])
Endoscopic Submucosal Dissection (ESD)
Would not attempt to remove myself - refer to a tertiary
endoscopist
Would not attempt to remove myself - refer to a
surgeon
Other (please specify)
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17. 15mm polyp in the ascending colon
Cold standard sized biopsy forceps (CBF)
Cold jumbo sized biopsy forceps (CJBF)
Hot biopsy forceps (HBF)
Cold snare polypectomy (CSP)
Piecemeal Cold snare polypectomy (pCSP) with
submucosal lifting
Piecemeal Cold snare polypectomy (pCSP) without
submucosal lifting
Hot snare polypectomy (HSP) without submucosal
lifting
Piecemeal or en bloc hot snare polypectomy (HSP)
with submucosal lifting (Endoscopic Mucosal
Resection [EMR])
Endoscopic Submucosal Dissection (ESD)
Would not attempt to remove myself - refer to a tertiary
endoscopist
Would not attempt to remove myself - refer to a
surgeon
Other (please specify)
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18. 20mm polyp in the transverse colon
Cold standard sized biopsy forceps (CBF)
Cold jumbo sized biopsy forceps (CJBF)
Hot biopsy forceps (HBF)
Cold snare polypectomy (CSP)
Piecemeal Cold snare polypectomy (pCSP) with
submucosal lifting
Piecemeal Cold snare polypectomy (pCSP) without
submucosal lifting
Hot snare polypectomy (HSP) without submucosal
lifting
Piecemeal or en bloc hot snare polypectomy (HSP)
with submucosal lifting (Endoscopic Mucosal
Resection [EMR])
Endoscopic Submucosal Dissection (ESD)
Would not attempt to remove myself - refer to a tertiary
endoscopist
Would not attempt to remove myself - refer to a
surgeon
Other (please specify)
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Please describe the action you would take for the following lesions in
your daily practice.
5. More complex lesions (1 question)
International Survey of Polypectomy Practice
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19. 45mm polyp in the transverse colon*
Cold standard sized biopsy forceps (CBF)
Cold jumbo sized biopsy forceps (CJBF)
Hot biopsy forceps (HBF)
Cold snare polypectomy (CSP)
Piecemeal Cold snare polypectomy (pCSP) with
submucosal lifting
Piecemeal Cold snare polypectomy (pCSP) without
submucosal lifting
Hot snare polypectomy (HSP) without submucosal
lifting
Piecemeal or en bloc hot snare polypectomy (HSP)
with submucosal lifting (Endoscopic Mucosal
Resection [EMR])
Endoscopic Submucosal Dissection (ESD)
Would not attempt to remove myself - refer to a tertiary
endoscopist
Would not attempt to remove myself - refer to a
surgeon
Other (please specify)
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6. Regarding referral of the polyp in the last question (2 questions)
International Survey of Polypectomy Practice
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You indicated that you would refer this lesion either to a tertiary
endoscopist or surgeon.  Please answer the two questions below.
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20. Would you biopsy this lesion prior to referral?
No
Yes
21. Would you mark this lesion with carbon particle suspension (e.g. Spot) prior to referral?*
No
Yes
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7. Regarding resection of the polyp in the last question (2 questions)
International Survey of Polypectomy Practice
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You indicated that you would attempt to resect this lesion in your
practice.  Please answer the two questions below.
19
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22. Would you biopsy this lesion prior to attempting resection to accurately discern histology or
rule out invasive disease?
No
Yes
23. Assuming you detected this lesion on a screening list, would you remove this lesion in the
same procedure you detected it or attempt removal during a later procedure after discussion with
the patient regarding risks and benefits?
*
Same procedure, I consent all of my patients for removal of such lesions
Same procedure, consent implied in the original discussion with the patient
Later procedure, primarily to obtain consent
Later procedure, primarily due to time constraints
Other rationale (please justify)
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8. More complex lesions (2 questions)
International Survey of Polypectomy Practice
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24. 45mm polyp in the rectum
Cold standard sized biopsy forceps (CBF)
Cold jumbo sized biopsy forceps (CJBF)
Hot biopsy forceps (HBF)
Cold snare polypectomy (CSP)
Piecemeal Cold snare polypectomy (pCSP) with
submucosal lifting
Piecemeal Cold snare polypectomy (pCSP) without
submucosal lifting
Hot snare polypectomy (HSP) without submucosal
lifting
Piecemeal or en bloc hot snare polypectomy (HSP)
with submucosal lifting (Endoscopic Mucosal
Resection [EMR])
Endoscopic Submucosal Dissection (ESD)
Would not attempt to remove myself - refer to a tertiary
endoscopist
Would not attempt to remove myself - refer to a
surgeon
Other (please specify)
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25. 80mm polyp in the sigmoid colon
Cold standard sized biopsy forceps (CBF)
Cold jumbo sized biopsy forceps (CJBF)
Hot biopsy forceps (HBF)
Cold snare polypectomy (CSP)
Piecemeal Cold snare polypectomy (pCSP) with
submucosal lifting
Piecemeal Cold snare polypectomy (pCSP) without
submucosal lifting
Hot snare polypectomy (HSP) without submucosal
lifting
Piecemeal or en bloc hot snare polypectomy (HSP)
with submucosal lifting (Endoscopic Mucosal
Resection [EMR])
Endoscopic Submucosal Dissection (ESD)
Would not attempt to remove myself - refer to a tertiary
endoscopist
Would not attempt to remove myself - refer to a
surgeon
Other (please specify)
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Again please answer the following questions with reference to your standard daily polypectomy practice
9. Instruments of choice for polypectomy (8 questions)
International Survey of Polypectomy Practice
26. What type of snare do you use for cold snare polypectomy?
Thin wire snare (snare wire diameter < 0.4mm)
Thick wire snare (snare wire diameter > 0.4mm)
Don't know
27. What size snare do you most commonly use for a standard submucosal lift polypectomy
(endoscopic mucosal resection [EMR]) in the right colon? (proximal and including the hepatic
flexure)
10mm
15mm
20mm
Don't know
I don't perform submucosal lift polypectomy / EMR
Other (please specify)
28. What size snare do you most commonly use for a standard submucosal lift polypectomy
(endoscopic mucosal resection [EMR]) in the left colon? (Distal to the hepatic flexure)
10mm
15mm
20mm
Don't know
I don't perform submucosal lift polypectomy / EMR
Other (please specify)
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29. If you perform submucosal injection prior to snare resection or EMR what do you use as the
injection solution?
Saline
Hyaluronic acid
Succinylated Gelatin / Gelofusine
Starch / Voluven
Do not use submucosal injection
Other (please specify)
30. Do you routinely add adrenaline/epinephrine to your injection solution for submucosal lift
polypectomy (endoscopic mucosal resection [EMR])
Yes
No
31. Do you routinely add a chromic dye to your injection solution for submucosal lift
polypectomy? (endoscopic mucosal resection [EMR])
No
Yes, indigo carmine
Yes, methylene blue
Other dye (please specify)
32. Do you take routine measures to prevent bleeding from pedunculated polyps with stalk
diameter greater than 10mm?
Yes
No
33. If yes which particular measures do you use? tick all that apply
Adrenaline (epinephrine) injection alone
Clip placement alone
Adrenaline and clip placement
Nylon loop application (endoloop)
Other (please specify)
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10. Electrosurgery and more complex tissue resection (7 questions)
International Survey of Polypectomy Practice
34. What electrosurgical settings would you use for a routine submucosal lift polypectomy
(endoscopic mucosal resection [EMR]).  Please be as specific as possible.  If unsure please give
as much detail as possible e.g. ERBE VIO 300D EndoCut Q, Olympus ESG 100 PulseCut Slow, ConMed Beamer
CE600 BlendCut...etc
35. What electrosurgical settings would you use for resection of a pedunculated polyp with a
7mm stalk? Please be as specific as possible. If unsure please give as much detail as possible
e.g. ERBE VIO 300D EndoCut Q, Olympus ESG 100 PulseCut Slow, ConMed Beamer CE600 BlendCut...etc
36. Do you routinely use carbon dioxide insufflation during colonoscopy and polypectomy?
Yes
No
Don't know
37. Do you routinely (or frequently) use dye spraying (chromendoscopy) to evaluate colon
polyps?
Yes
No
38. Do you routinely (or frequently) use optical or digital image enhancement (NBI, FICE etc) to
evaluate colon polyps?
Yes
No
Other (please specify)
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39. Do you perform endoscopic submucosal dissection (ESD) in the rectum?
Yes
No
40. Do you perform ESD in the remainder of the colon?
Yes
No
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 11. Thank you for participating
International Survey of Polypectomy Practice
41. Please enter your email if you wish to receive updates
42. Please enter a random word/number combination that is unique to you.  (This could be anything
but an example might be first two numbers in your date of birth and last two letters of your surname e.g. 10te)
*
Small print; your email will only be used to distribute results.  The unique word will only be used to detect and identify
duplicate responses.  Your personal data will not be used for any other purpose.
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Theme 2 - REFINING THE MANAGEMENT OF COMPLEX LARGE 
COLONIC LATERALLY SPREADING LESIONS (LSL) 
Introduction 
The introduction to Themes 2 and 3 is provided in the introductory comments to Chapter 6 . 
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Chapter 6 - Advanced Colorectal Polyps and Early Cancer Resection.  A 
literature review. 
Introduction 
This chapter serves as an introduction to the second theme of the thesis entitled ‘Refining the 
management of complex large colonic laterally spreading lesions (LSL)’.  It contains a 
literature review for a book chapter 4 originally produced in early 2016 and published in early 
2018.  The review focusses on advanced colorectal polyps, defined as any polyp larger than 
20mm in size.  For the remainder of the discussion advanced colorectal polyps are considered 
equivalent to laterally spreading lesions (LSL) and laterally spreading tumours (LST).   
LSL are more difficult to resect than the more commonly encountered, smaller colorectal 
polyps and are more likely to contain advanced histology.  They have traditionally been 
referred for surgical resection.  However, the majority of LSL are non-invasive and limited to 
the colonic mucosa.  Over the last decade evidence from large, prospective observational 
studies30 indicates that endoscopic resection for laterally spreading colonic lesions/polyps 
(LSL) is a safe, cost-effective31,32 and efficacious alternative to traditional surgical resection in 
over 90% of cases33.  Endoscopic mucosal resection (EMR) is a procedure using sequential 
injection and subsequent snare resection that can be used to remove even very large LSL.  It is 
commonly performed as a day case procedure with a significantly lesser adverse event profile 
as compared to surgery 34-36. 
The chapter below presents a comprehensive overview of endoscopic resection for LSL.  
Patient preparation, LSL assessment using high definition imaging, technical aspects of the 
procedure, dealing with complications and how to prevent recurrence at subsequent follow up 
are discussed.  
Several important publications that support the data in the chapter have emerged since it was 
written, and these are included below with the numbered section of the chapter and a discussion 
that should be read in the context of that chapter.  In addition, the reader will note that the 
publications included throughout the rest of Theme 2 and Theme 3 enhance our understanding 
of topics discussed in this chapter.  These will be specifically discussed prior to each individual 
chapter.   
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• 36.3 Lesion Assessment 
o An important publication 40 regarding the risk of submucosal invasive cancer 
(SMIC) in LSL has emerged since the chapter was written.  The authors 
excluded lesions with ‘overt’ evidence of SMIC (i.e. an area of endoscopically 
visible demarcation with disordered pit pattern).   They then stratified the risk 
of SMIC in remaining LSL by Paris classification, LSL location and LSL 
morphology.  They showed that non-granular distal colon IIa/Is or Is LSL had 
a risk of SMIC of up to 21.4% whereas proximal, granular IIa LSL had a risk 
of around 1%.   
o This is very important in terms of lesion selection for endoscopic resection.  If 
a lesion has a very low risk of SMIC then a piecemeal, safe and effective 
technique may be employed such as EMR.  If there is a high risk of SMIC then 
the endoscopic practitioner should consider a technique which will achieve en-
bloc resection such as endoscopic submucosal dissection (ESD) or full 
thickness resection.  If this is not available surgery should be considered.  It is 
important to note that the main benefit of en-bloc resection here is the 
acquisition of accurate histological assessment rather than endoscopic cure (see 
below). 
o The authors noted that this classification could not differentiate between LSL 
that contained deep submucosal invasion (SM2/3 disease) and superficial 
submucosal invasion (SM1 disease) that may be amenable to endoscopic cure.  
Further research is needed in this area.  For now, practitioners of endoscopic 
resection should risk stratify LSL based on imaging and morphology and refer 
suspicious LSL to another practitioner or surgery as appropriate. 
• 36.5.5 EMR of Peri-appendiceal LSL 
o Covered in detail in Chapter 9.   
• 36.5.6 EMR of Multiply Recurrent LSL 
o Covered in detail in Chapter 8. 
• 36.5.7 Sessile serrated lesions 
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o Chapter 2 contains a study, published since this chapter was written, that 
demonstrates that dysplasia within SSP can be characterised accurately using a 
standardised imaging protocol. 
o Data has emerged on the characteristics of large sessile serrated polyps that do 
not fulfil the criteria for serrated polyposis syndrome41.  Previously 
uncharacterised, it seems that patients with a solitary large SSP a lower risk of 
synchronous polyps, including advanced adenomas than patients with SPS.  In 
addition, the authors identified a group of patients with more than one large SSP 
but who did not fulfil the criteria for serrated polyposis syndrome; since these 
patients had a similar risk of advanced adenomas and synchronous polyps as 
patients with SPS they concluded that they should be offered a similar 
programme of intensive surveillance. 
o In addition to the statement in this chapter that ‘care should be taken to 
recognise the patients who fulfil criteria for serrated polyposis syndrome’. 
• 36.7.3 Deep Injury 
o The Sydney Classification of Deep Mural Injury42 was subsequently published. 
• 36.8.2 Techniques at the Initial EMR to Prevent Recurrence 
o The SCAR study mentioned in the text of this section is the subject of Chapter 
10 . 
• 36.8.3 Triaging Patients to Follow Up Based on Risk of Recurrence 
o The evidence base to personalise follow up intervals for patients after 
endoscopic resection of LSL has progressed since this section was written. 
o Chapter 11 contains the first description of a clinical score designed to stratify 
the risk of adenoma recurrence at follow up examinations. 
o The score described in Chapter 11 has recently been validated in an independent 
cohort of patients 43 demonstrating the ability of the score to discriminate rates 
of adenoma recurrence during follow up.  Perhaps due to a lack of power the 
results were not statistically significant. 
• 36.8.4 Accurate Assessment of the Post-EMR scar 
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o The scar assessment protocol described in this section has since been 
published44. 
o This important study demonstrates that the negative predictive value for the 
endoscopic assessment of recurrence at an EMR scar is 98.6% with a tight 95% 
confidence interval of 95.1% - 99.8%.  This is extremely important since, at 
least in a single expert centre, routine biopsies of an EMR scar would appear 
unnecessary.  This needs to be understood in the context of non-targeted scar 
biopsy being an imperfect gold standard. 
• 36.8.5 Endoscopic Treatment of post EMR recurrence (ETOR) 
o A comprehensive description of the characteristics of post EMR recurrence and 
the methods used for its treatment coupled with long term outcomes was 
recently presented in abstract form at Digestive disease week, Washington DC, 
June 2018 45.   
o In this study recurrence at the EMR scar was commonly ≤ 5mm in size (64%), 
uni-focal (75%) and within the scar.  The commonest modality used to resect 
recurrence was hot snare with adjuvant snare tip soft coagulation (35%). Cold 
avulsion with adjuvant snare tip soft coagulation (CAST – see Chapter 8 for a 
description of the technique) was used in 30% and was also used in combination 
with hot snare (9%).  Prior injection was performed in a minority of cases 
(16%). In 124/143 (86.7%) cases where tissue was retrieved, there was 
histologic confirmation of recurrence. 
o ETOR achieved clearance of recurrent adenoma in 94.7% of cases at first 
surveillance colonoscopy with 8 (5.3%) referred for surgery primarily due to an 
inability to resect recurrence. For LSLs that underwent further surveillance, 
89% (1 further surveillance), 86.5% (2 further surveillances) and 89.5% (3 
further surveillances) respectively showed no evidence of recurrence. 
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Summary 
Advanced colorectal polyps and early cancer resection.  Endoscopic resection (ER) of 
advanced colorectal polyps (ACPs) of the colon is a durable, safer and more cost effective 
treatment than surgery.  2% of colorectal lesions are flat, 20mm or larger and termed laterally 
spreading lesions (LSLs).  Even very large LSLs limited to the mucosa are resectable 
endoscopically due to the lack of lymphatic drainage from this area.  Over the last decade high 
quality prospective studies have emerged that provide an evidence base for the technique and 
safety of ER for ACPs.  Two techniques exist; endoscopic mucosal resection (EMR) and 
endoscopic submucosal dissection (ESD).  The main benefit of ESD is en bloc resection 
providing accurate histopathological assessment of submucosal invasive cancer (SMIC), but 
this is at the expense of significantly greater complications.  EMR is the main technique used 
in Western centres to resect large LSLs in the colon.  Complications of EMR are infrequent 
and in the vast majority of cases are controlled endoscopically; these include intra-procedural 
bleeding (11.3%), clinically significant post endoscopic bleeding (CSPEB, 6%) and perforation 
(1.3%).  Adenoma recurrence rates of 10-20% are reported in high volume centres but this is 
easily resected endoscopically at surveillance procedures.  Novel techniques promise to reduce 
the rate of recurrent adenoma and further and predict those lesions which will recur. Novel 
techniques in ER are promising but require validation in prospective, multicenter randomised 
trials. 
Keywords 
Colonoscopy 
Colorectal cancer 
Adenoma 
Advanced colorectal polyp 
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1 Introduction 
The incidence and mortality1 of colorectal cancer can be significantly decreased by 
colonoscopy and polypectomy2.  Most colorectal polyps are small (<10mm) and can be easily 
treated by endoscopists with the relevant degree of training using cold snare polypectomy3,4 or 
conventional electrosurgical polypectomy where necessary. 
 
Advanced colorectal polyps (ACP) are generally considered as those ≥20mm and these larger 
lesions have a much greater frequency of advanced histology and invasive cancer, are more 
challenging and hazardous to completely remove endoscopically and require special techniques 
to safely achieve this.  Some smaller lesions also fall into this group due to morphological 
features suggesting advanced histology (e.g. depressed component). 
 
Approximately 2% of colorectal lesions are flat, ≥20mm and often termed laterally spreading 
tumors or lesions (LSLs)5.  These may grow to an enormous size, yet remain confined to the 
mucosa and since this layer has no lymphatic drainage, these lesions do not metastasize and 
are a target for endoscopic resection (ER).   
 
LSLs were traditionally managed surgically, but a growing body of evidence supports the 
similar efficacy6 and durability7 of ER versus surgery and more recently the superior cost 
effectiveness8 and safety profiles of ER, particularly in dedicated tertiary centres.  Once 
submucosal invasive cancer (SMIC) has developed there is still a possibility for ER if certain 
criteria are met, although this is more controversial.  Box 1 lists the indications for endoscopic 
therapy of advanced colorectal polyps.   
 Chapter 6 Manuscript  |  Page 5 
 
 
 
 
 
 
  
Box 1 
Indications for endoscopic therapy of advanced colorectal polyps (ACP) 
o LSLs with no features suggestive of deep SMIC (e.g. those with Kudo II-O/III/IV, Sano 
II, NICE type 2 morphology) 
o Large pedunculated lesions arising from the mucosa  
o Previously attempted LSLs or LSLs in difficult locations (e.g. peri-appendiceal, 
ileocaecal valve, ano-rectal junction) 
Indications for surgery for ACPs 
o LSLs with features of deep SMIC (Kudo Vi/n, SANO IIIb vascular pattern, NICE type 
3, non-lifting, Paris 0-IIa+c or Paris 0-III morphology) 
o Potentially LSLs with previously failed endoscopic resection at a specialised tertiary 
center 
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2 Technical aspects and preparation 
ER of colonic ACPs requires training, adequate case volume to maintain skills, tertiary level 
radiology and surgical support and a histopathologist with a dedicated interest in colorectal 
neoplasia.   
 
2.1 Patient preparations 
Outcomes are optimized when patients are managed within an advanced tissue resection 
network.  Research infrastructure is also highly desirable as many important clinical questions 
remain unanswered.  Prospective monitoring of procedural and clinical outcomes with 
benchmarking against accepted standards is a minimum requirement9.  Regular clinical 
meetings between stakeholders with discussion of interesting and challenging cases facilitates 
best patient care. 
 
Seamless referral pathways that facilitate rapid and accurate transfer of data are preferable.  
This should include detailed imaging, a description of the lesion and comorbidities of the 
patient including any anticoagulant medications and the indication for their use (see Baron, 
201410 for a contemporary review).  Biopsy prior to the referral of a colonic LSL is not 
necessary unless invasive cancer is strongly suspected; extensive photo-documentation 
provides more useful information.  Biopsy commonly results in submucosal fibrosis, increasing 
the complexity of ER.  Endoscopic tattoo placed on the opposite wall to the lesion for ER is 
encouraged to mark lesions that may be difficult to locate later. 
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Informed consent is vital.  Complications of endoscopic mucosal resection (EMR) include deep 
injury to the colonic wall (deep mural injury, DMI), bleeding, post-procedural pain, serositis 
and recurrent or residual adenoma (RRA).  For EMR of large colonic LSLs rates of 1.3%11 for 
colonic perforation, and up to 7% for post-EMR bleeding are quoted. Pain after EMR is 
uncommon and usually self limiting, but must be reported.  Patients are given contact details 
such that timely advice may be given should complications occur once they have left the 
endoscopy unit. 
 
2.2 Techniques of Endoscopic Resection 
Two established techniques exist for the ER of large LSLs; endoscopic mucosal resection 
(EMR) and endoscopic submucosal dissection (ESD).  EMR has been refined extensively since 
its inception in 197712.  The technique involves expansion of the submucosal layer with a 
chromo-injectate, and placement of a snare over the target lesion.  Closure of the snare with 
the addition of microprocessor controlled fractionated current transects the tissue and the 
submucosal cushion provides a heatsink and safety barrier against ensnaring and damaging 
deeper structures.  Lesions up to 20mm in size can be removed en bloc, with larger lesions 
usually requiring piecemeal resection.  
 
ESD was initially developed in Japan for the en bloc excision of early gastric cancer, avoiding 
the morbidity associated with surgery.  The technique involves expansion of the submucosal 
plane with chromo-injectate, use of an endoscopic ‘knife’ to incise the margin of the lesion 
(incision phase) and then separation of the lesion from the deeper structures in the submucosal 
plane (dissection phase) using various types of electrosurgical current and the endoscopic 
knife.   
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The main advantages afforded by ESD over EMR are derived from en bloc resection of the 
target lesion.  This results in reduced recurrence in short and medium term follow up, possible 
cure in low risk submucosal invasive cancer and a superior specimen for histological 
assessment.  Long term follow up studies of EMR for LSL >20mm however show that if the 
initial EMR was technically successful then after two follow up procedures at intervals of 4 
and 12 months more than 98% of patients are free of recurrence and considered cured. 
 
ESD can be used to treat LSLs with potential superficial SMIC to achieve cure. However, in 
large Japanese series the number of such patients is approximately 10% and thus a universal 
ESD strategy does not offer a true benefit to the majority13.  Moreover this benefit only applies 
if both patient and physician decide and agree that surgery is not necessary despite there being 
submucosal invasive cancer. 
 
These benefits come at a cost.  ESD is technically challenging, significantly more time 
consuming and is associated with a significantly higher rate of complications in comparison to 
EMR; even in expert Japanese centres perforation rates are higher (5.7% versus 1.4%) and 
mean procedure durations significantly longer (65.9-108 minutes versus 29-30 minutes)14.   In 
addition multi-night hospital stay is mandated for all lesions removed by ESD whereas it is 
required for <5%11 of those removed by EMR.  However, the strongest argument against a 
universal ESD approach for all LSLs is that it does not decrease the rate of additional surgery 
after ER.  In Japanese centres, an ESD only approach was associated with a significantly higher 
rate of surgery (9.9% versus 5.8%) than EMR14.  
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2.3 Equipment required 
2.3.1 Submucosal injectate 
Historically the submucosal injectate for EMR was normal saline (NS), however it results in a 
non-sustained mucosal lift and does not delineate the lesion margin. The optimal submucosal 
injectate contains three constituents:  
1) A colloid solution, e.g. succinylated gelatin (e.g. Gelofusine®; B. Braun, Sempach, 
Switzerland) has been shown to be superior to NS in a double blind randomised trial15, 
resulting in significantly fewer injections and resections and a halving of the procedure 
time.  Other solutions have also been described including hyaluronic acid, dextrose 
solution and hydroxyethyl starch.  
2) The addition of an inert dye to the injectate (chromo-injectate) allows for accurate 
delineation of the lesion margin; this is particularly useful for lesions with serrated or 
non-granular morphology to ensure complete resection.  It also shows the extent of the 
submucosal cushion, the safe zone for EMR. Methylene Blue and Indigo Carmine (e.g. 
80 mg of indigo carmine or 20 mg of methylene blue in a 500-mL solution) are in 
commonplace use.  They are avid for the submucosal areolar tissue and create a 
relatively homogeneous ‘blue mat’ appearance when resection is within the submucosal 
plane (Fig. 1).  
3) Dilute adrenaline (1:100,000 solution) added to the injectate reduces intra-procedural 
bleeding maintaining a clean EMR field and delays the dispersion of the submucosal 
injectate.  It may also reduce the rate of clinically significant post-endoscopic bleeding 
(CSPEB)16. 
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2.3.2 Electrosurgical generators     
The use of a microprocessor controlled electrosurgical generator capable of delivering 
fractionated current in short cutting bursts interspersed with longer coagulation pulses is 
essential for safe ER.  These are now commonplace in tertiary endoscopy units and include e.g. 
ERBE VIO 300 (ERBE, Tübingen, Germany) or Olympus ESG 100 (Olympus, Tokyo, Japan).  
The return electrode senses tissue impedance and modifies current delivery to achieve the 
desired result. 
 
2.3.3 Insufflation of carbon dioxide 
The superiority of carbon dioxide insufflation over air during GI endoscopy is firmly 
established, particularly with regards to decreased post-procedural pain, flatus and bowel 
distension17.  During EMR for large LSLs, carbon dioxide insufflation resulted in significantly 
less post procedural admissions for pain in a large prospective series18. 
 
 
2.3.4 Snares for endoscopic resection 
A complete suite of snares of various sizes, shapes, stiffness and wire diameters is necessary. 
Snares with a thinner wire diameter provide greater current density and owing to this and their 
narrower caliber, more swiftly transect the target tissue. The workhorse for EMR of LSLs is 
the 20mm “spiral” snare (0.48mm wire diameter). This snare has a series of serrations covering 
the wire and facilitates the capture of normal tissue at the lesion margin. Increasingly there are 
a range of alternatives available and there is renewed interest in the performance characteristics 
of various snares for particular indications.  Commonly in the right colon we use a 15mm 
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braided snare; the smaller size is possibly safer.  Different wire stiffness, snare shape (oval, 
hexagonal) and performance characteristics can facilitate removal of a variety of potentially 
refractory lesions. Stiff thin wire snares (0.3mm) can allow tissue capture of residual adenoma 
at resection margins or previously attempted adenoma associated with significant submucosal 
fibrosis (Fig. 2).  Larger snares may be required for pedunculated or bulky exophytic lesions. 
 
3 Lesion assessment 
Techniques to interrogate LSLs in real-time prior to ER and determine the presence and degree 
of SMIC have been developed in recent years.   
 
Overview assessment of the lesion is performed using high definition white light (HD-WL).  
Lesion morphology should be described using the Paris classification19.  This describes a flat 
lesion with ≤2.5mm elevation above the surrounding mucosa as 0-IIa, with a central depression 
as 0-IIc and a completely flat lesion as 0-IIb.  0-Is lesions are broad based but elevated >2.5mm 
above the surrounding mucosa.  Combinations of these terms exist, (Fig. 3).  0-Ip and 0-Isp 
lesions are polypoid and semi-polypoid respectively and classified separately.  Sessile lesions 
are also labelled based on their surface morphology as granular (G) or non granular (NG) (Fig. 
4). 
 
Focal interrogation of the lesion is then performed with HD-WL and image enhancement 
techniques such as narrow-band imaging (NBI) (Olympus) or FICE (Fujifilm Medical, 
Saitama, Japan).  The intention is to assess the pit pattern and vascular pattern of the lesion.  
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Areas suspicious for SMIC, which are commonly demarcated, are identified and interrogated 
in turn, possibly with the addition of magnification.   
 
Three systems exist for such assessment (Table 1).  Kudo20 described 5 types of pit pattern; 
types III and IV indicate non-invasive disease and are suitable for ER.  Experts suggest that the 
combination of chromic dye and magnification is required to assess the Kudo pit pattern.  The 
Sano classification21 is based on the capillary pattern as observed under NBI.  Three types are 
recognized. Sano type II, a regular brown mesh network is seen with pit pattern types III and 
IV and indicates non-invasive disease suitable for ER.  Recently, the NBI International 
Colorectal Endoscopic (NICE)22 criteria have been described. These are based on a 
combination of colour, vessel and surface pattern.  The score has been reported to have  a 
sensitivity of 94.9% and negative predictive value of 95.9% when any one of the three criteria 
demonstrate evidence of submucosal invasion, with substantial inter-observer agreement 
(Kappa value 0.70).   
 
Combining Paris classification, surface morphology and lesion location is very useful for 
stratifying the risk of SMIC.  Distal colonic lesions in general have a higher risk of SMIC.  In 
large Japanese and Western6 23 studies 90% of lesions ≥20mm presenting for endoscopic 
resection are granular and >75% are Paris 0-IIa class.  In the absence of Kudo V pit pattern or 
a depressed ‘c’ component, both strong predictors of invasive disease, the risk of SMIC varies 
with LSL morphology24 (Fig. 6).  In granular lesions the risk is 0.9% for 0-IIa, 2.9% for 0-Is 
and 7.1% for 0-IIa/Is lesions, with a greater risk in the distal colon.  Non granular lesions are 
at higher risk for SMIC with a 4.0% risk for 0-IIa NG lesions, 12.8% for 0-IIa+Is NG and 
16.7% for 0-Is NG.  Again there is generally a greater risk in the distal colon.   This information 
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can inform a targeted approach to ER, employing en bloc excision in the case of those lesions 
with a predicted high risk for SMIC. 
 
4 Resection technique 
4.1 EMR 
4.1.1 Injection technique 
An adequate submucosal cushion is required for safe EMR, and is used to improve access to 
the lesion.  A deficient cushion risks deep injury to the colonic wall; an excessive cushion 
creates tension and can impede snare capture and visibility during the resection. 
 
The technique for injection is as follows; 
• Position the lesion at 6 o’clock in the colonoscopic view 
• Place the tip of the catheter at 30 to 45 degrees tangential to the lesion  
• Ask the assistant to extend the needle  
• Ask the assistant to commence injection while simultaneously stabbing the mucosa 
with the needle tip.  Confirmation that the submucosal plane has been entered is with 
immediate and swift elevation of the lesion.  
• Dynamic movement of the catheter during injection can be used to elevate the lesion to 
the required orientation with the needle tip anchored in the submucosal cushion.  The 
most inaccessible portion of the lesion can often be exposed in this manner 
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If the lesion does not lift, consider the following: 
• Extra-mural needle placement; gentle pulling back on the injection catheter will 
usually locate the submucosal plane. 
• Needle tip remaining within the colonic lumen; recognised by visualisation of 
chromo-injectate spilling into the lumen. 
• Non-lifting lesion; this can be caused by submucosal fibrosis from a previous resection 
attempt, previous biopsy or lesion biology (SMIC).  The appearances of canyoning 
(lifting of the surrounding normal mucosa without lifting of the lesion) and the ‘jet 
sign’ (rapid ejection of the chromo-injectate from the lesion) are confirmatory signs 
associated with non-lifting. 
Intra-mucosal injection is another type of failed injection. This can be recognised by 
immediate bleb-like elevation of the mucosa with no simultaneous lifting of the lesion.  The 
bleb can be punctured with the needle tip and the injection repeated. 
 
4.1.2 Resection technique (Fig. 8 and accessory video 13.1) 
One injection is suggested per 1-3 resections.  The principles of snare placement and resection 
are detailed below: 
• The lesion is sited at 6 o’clock.  The snare is opened fully above the lesion and then 
aligned with the margin of the lesion, taking care to capture a 2-3mm margin of normal 
mucosa, the remainder being adenoma.   
• Firm pressure is applied with the snare onto the lesion with the up-down control and 
suction of luminal gas is performed to tent the lesion into the snare.   
• The assistant closes the snare slightly until the target tissue is seen to ‘seat’ within the 
snare.  Once visually confirmed the snare is then closed until resistance is felt.   
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• The assistant passes the snare to the endoscopist who uses tactile feedback to sense the 
amount of tissue captured.  The snare can be opened slightly under direct vision to 
release a portion of the captured tissue if required. 
• The snare is closed tight to within 1cm to ensure swift tissue transection at the time of 
snare excision which preserves the endoscopic delineation within and between the 
tissue planes and resection margins. With this approach the layered anatomical 
structures of the colonic wall are easily identified. 
• The mobility of the captured tissue with relation to the colonic wall is checked by 
rapidly moving the snare catheter back and forth within the working channel. 
• The endoscopist applies one to three pulses of fractionated current with alternating 
cutting and coagulating cycles (e.g. EndoCut mode Q, effect 3, cut duration 1, cut 
interval 6; ERBE, Tübingen, Germany), to transect the tissue.  This phase should be 
quick and there should be immediate evidence that the snare has ‘bedded in’ with each 
pulse.  There are occasions when longer application of fractionated current may be 
required including lesions with significant submucosal fibrosis and resections 
involving adipose tissue e.g. around the ileo-caecal valve. 
• The resected specimen is pushed aside with the snare catheter. 
• Water-jet irrigation expands the mucosal defect, tamponades bleeding and allows 
assessment of the plane of resection. 
• For subsequent resections the free edge of the snare is aligned precisely with the edge 
of the mucosal/lesion incision to minimise the possibility residual adenoma islands. 
 
 
 Chapter 6 Manuscript  |  Page 16 
4.2 ESD 
The technique of endoscopic submucosal dissection involves the creation of a submucosal 
cushion, incision of the lesion margin with an endoscopic knife and dissection beneath the 
lesion in the submucosal plane leading to an en bloc resection.  The injectate is similar to that 
used for EMR with a colloid solution plus an inert dye.  Most Japanese centres use 0.4% 
hyaluronic acid (MucoUp, Johnson and Johnson, Tokyo, Japan) as the basis of the injectate25, 
due to its superior retention in the submucosal space, particularly in the colon.  Use in Western 
centres is limited by availability and cost. 
 
Different knives are available for ESD and have different properties.  The dual knife (Olympus, 
Tokyo, Japan) allows for precise dissection but requires exchange of knife and injection 
catheters, whereas the hybrid knife (ERBE, Tübingen, Germany) requires no such exchange, 
speeding up the ESD procedure26,27, greatly improving the ease of further submucosal 
injections and potentially increasing safety28, perhaps at the expense of precise dissection due 
to the larger size of the cutting tip.  Other knives are available29.  In the future even more 
tapered and precise knives with the ability to inject without device exchange have the potential 
to greatly speed up the technique of ESD. 
 
The technique for ESD is as follows; 
• A transparent cap is applied to the endoscope to aid separation of the mucosal and 
submucosal layers and to exert traction on the lesion. 
• The lesion is marked with the knife tip.  This is often unnecessary in the colon but of 
paramount importance in the stomach and oesophagus as lesions can be subtly 
demarcated. 
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• Chromic solution is injected to lift the lesion 
• The lesion is isolated from the surrounding mucosa with the knife using cutting current 
e.g. ERBE Dry Cut (30 Watts, effect 2).  Ultimately a circumferential mucosal incision 
is required, although the timing to fully complete this depends on anatomical and lesion 
factors.   
• The lesion is dissected in the submucosal plane using cutting current e.g. ERBE DryCut 
(30 Watts, effect 2). Diathermy power settings can be adjusted to achieve the desired 
result. The division of tissue in the submucosal plane must be precisely controlled to 
avoid inadvertent muscle layer injury. 
• Bleeding within the defect is controlled using either Swift Coagulation (e.g. ERBE 
effect 3, 30W) or soft coagulation (e.g. ERBE effect 4, maximum 80W) with the knife 
tip. More substantial bleeding can be controlled with haemostatic forceps using soft 
coagulation. 
• Prophylactic coagulation of large blood vessels in the ESD defect is common practice30. 
• Consideration is made to the direction of gravity as the dissection progresses such that 
the lesion falls in a direction that aids the procedure, and patient position is changed as 
necessary to achieve this (Fig. 8). 
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5 Unique situations 
5.1 EMR of LSLs at the anorectal junction (ARJ) 
LSLs that extend to or involve the ARJ are challenging to remove endoscopically and have 
traditionally been managed surgically.  The ARJ has unique anatomic and physiologic 
characteristics which necessitate modifications to the standard EMR technique31: 
• Endoscopic access may be difficult and visualisation impaired.  This can be 
improved by the use of a gastroscope or paediatric colonoscope and a short 4mm 
transparent cap. 
• The area has rich somatic nervous innervation and therefore ER is often painful. 
A long acting local anaesthetic is added to the submucosal injectate.  We use 
ropivacaine final concentration 0.5% to a maximum dose of 40mg with 
electrocardiographic monitoring.  This provides local anaesthesia for 4 hours and 
analgesia for up to 12 hours. 
• In contrast to the more proximal colo-rectum the lymphatic and venous drainage of 
the ARJ and distal 5cms of rectum enters directly into the systemic circulation 
bypassing the filtering function of the reticulo-endothelial system/portal-venous 
circulation and thus there is a risk of significant systemic bacteraemia with repeated 
submucosal injection and extensive resection.  Broad spectrum antibiotics are given to 
all patients undergoing ER at the ARJ. 
• EMR over the haemorrhoidal plexus is considered potentially hazardous. In 
practice these thick-walled vascular columns are resistant to entrapment via the snare. 
Tangential injection of dye solution in the forward view into the submucosal plane 
elevates the mucosa away from the haemorrhoidal columns and creates a cushion over 
which snare resection can commence. 
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Post procedure the patient should be advised to maintain soft stools for 1-2 weeks and use 
simple analgesia e.g. paracetemol 1g every 6 hours. 
 
5.2 EMR of LSLs at the ileocaecal valve (ICV) 
Involvement of the ICV has been identified as an independent risk factor for failure of 
EMR11,32.  This is often due to challenging endoscopic access and complete visualization of 
the extent of the lesion. .  A transparent endoscope cap can be invaluable in this context, 
enabling fold deflection and visualisation of LSLs extending into the ileum.  Small stiff thin 
wire snares may optimize tissue capture in tight spaces and angles.  ICV LSLs are at greater 
risk of recurrence than lesions elsewhere in the colon (17.5% vs 11.5%)33, but in a prospective 
series surgery was ultimately avoided in 43/53 (81.1%) of cases attempted.  Risk factors for 
failure were identified as ileal infiltration and involvement of both lips of the ICV. 
 
5.3 EMR of circumferential LSLs 
LSLs involving the full circumference of the colonic wall can be removed by EMR (Fig. 9).  
These lesions are uncommon and have previously been a relative contraindication to ER.  A 
recent case series indicates that resection of such lesions is safe and, particularly in the rectum, 
prevents exposure of the patient to the significant morbidity risk and the potential poor long 
term functional outcome of surgery34.  
 
Normal bowel function is demonstrated after resection of such extensive lesions. Transient 
luminal stenosis may arise and steroid enemas with pre-emptive balloon dilatation at intervals 
of 1-2 weeks for the first 6 weeks may be necessary. 
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5.4 EMR of lumen filling lesions  
LSLs with very large Is components occur and can fill the entire colonic lumen extending over 
multiple folds.  These lesions are highly vascular and are often difficult to approach 
endoscopically due to their bulk and the potential invagination of the colonic wall into the 
lumen which risks deep mural injury with snare resection. 
• Commence the resection at the anal end of the lesion involving a 2-3mm rim of normal 
mucosa to enter the submucosal plane. 
• Continue inject and resect EMR, expanding the submucosal plane, carefully following 
the resected edge of the lesion and the plane of the colonic wall for each subsequent 
snare placement, “up and over” the Is component. This approach aims to avoid cutting 
across folds and deep mural injury.  
• Tactile feedback prior to each snare resection is essential to avoid capture of excessive 
tissue or deeper structures within the snare.  
 
5.5 EMR of peri-appendiceal LSLs (PA-LSLs) 
LSLs involving the appendiceal orifice (or within 5mm thereof) pose unique challenges. A 
single series of lesions removed by underwater EMR has been described35.  These lesions can 
be safely resected by conventional EMR provided that they do not extend deeply (beyond 
endoscopic vision) into the appendiceal orifice and in general do not involve more than 50% 
of the circumference of the appendiceal orifice.  They often have substantial submucosal 
fibrosis and are best approached with small stiff thin wire snares (Fig. 10). By contrast patients 
who have undergone prior appendectomy can often safely have fully circumferential lesions 
involving the prior appendiceal orifice carefully resected endoscopically.   
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5.6 EMR of multiply recurrent LSLs 
LSLs with a previous resection attempt present particular challenges since there is often 
significant submucosal fibrosis beneath the lesion.  Some modifications to the standard EMR 
technique are often required: 
• It is often difficult to obtain adequate lifting of the target lesion due to submucosal 
fibrosis. Start the injection/resection in the non-fibrotic area, even outside the lesion if 
necessary. Areas which lift should be resected first with the goal of isolating the fibrotic 
area. This frees up the lateral attachments of the fibrotic area and creates a “step” 
adjacent to it to allow seating of the snare for tissue capture.  Again small stiff, thin-
wire snares are preferred.   
• Areas that cannot be resected by snare can be treated by hot or cold avulsion36.  We use 
the CAST technique (Cold Avulsion and adjuvant Snare Tip soft coagulation).  A cold 
serrated cup biopsy forceps is used to systematically avulse the residual tissue which 
now only has it’s deep attachment.  Such tissue often ‘peels off’ easily.  This is repeated 
until no further adenomatous tissue remains. 
• The area that was resected by cold avulsion is then treated with snare tip soft 
coagulation (STSC – e.g. ERBE Effect 4, maximum 80W) to residual micro-adenoma. 
 
5.7 Sessile serrated lesions  
The serrated neoplasia pathway accounts for 20-30% of sporadic colon cancers.  Sessile 
serrated adenomas/polyps (SSA/P) are difficult to detect endoscopically37 and often 
incompletely resected (Fig. 11)38.  Approximately 30% of SSA/P ≥ 20mm contain a dysplastic 
focus (which endoscopically and histologically resembles adenoma).  If this dysplastic focus 
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is large or conspicuous it can distract the endoscopist from a larger underlying serrated lesion39.  
Failure to recognize the full extent of the lesion may predispose to incomplete resection40.  
Chromo-injection can be used to better delineate the lesion margin.  Care should be taken to 
recognise those patients that fulfil criteria for serrated polyposis syndrome41 They require 
regular colonoscopic surveillance and familial screening42.  Recent large studies suggest that 
in tertiary centers SSA/P can be treated by EMR with equivalent outcomes and rates of 
recurrence to conventional adenomas43,44. 
 
5.8 Endoscopic resection of large pedunculated lesions 
Pedunculated lesions represent < 1/3 of all polyps in the colon and those <20mm in diameter 
with stalks <5mm in diameter are safe to resect with hot snare polypectomy.  Larger 
pedunculated adenomas with broad stalks (≥5mm) can be safely resected, but often have large 
feeding blood vessels in their stalk which, if not prophylactically treated, may lead to post-
procedural bleeding and thus mechanical haemostasis of the stalk with either clip or 
detacahable loop is recommended45. Prophylactic placement of a detatchable nylon loop 
(Endoloop (Ethicon), Polyloop (Olympus)) has been shown to reduce post-polypectomy 
bleeding in pedunculated lesions ≥20mm with stalks ≥5mm from 15.1% (control group) to 
2.7%46.  Adrenaline injection into the stalk reduced bleeding to 2.9% in the same study. 
 
Lipomas and other submucosal lesions can also herniate into the lumen resembling a 
pedunculated polyp or adenoma; the clue to the nature of the lesion is the normal overlying 
mucosa.  While such lesions can be safely resected if symptomatic, extreme care should be 
taken due to the possibility of invaginating muscularis propria (MP) and the large amount of 
current required to transect the fatty tissue due to the poor conduction of electrosurgical energy. 
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Detachable nylon loop ligation of the stalk mitigates against the risk of perforation in cases 
where the MP may be invaginated47. 
 
Resection of these lesions should employ the ‘snare traction’ technique, particularly where 
there is a loop at the base of the stalk, whereby the snare is placed over the lesion and the snare 
catheter pulled back into the endoscope to exert traction on the stalk.  This allows direct 
visualisation of the exact point of snare closure on the proximal side of the lesion, which 
generally should be mid stalk, to ensure that neither the loop or surrounding tissue is captured 
(see accessory video 13.2). 
 
6 Endoscopy vs Surgery 
The emergence of ER as a safe alternative to surgery for colonic LSLs over the last decade has 
stimulated comparative modeling of mortality, morbidity and cost.  For lesions limited to the 
mucosa there is no doubt that ER is safe, effective and durable with a low rate of complications 
in large prospective series6,48.  A large prospective multicentre study of 1050 patinets with LSL 
≥ 20mm comparing actual EMR outcomes against predicted surgical outcomes using two 
independent and well validated surgical scoring systems49 showed that there was 0% mortality 
for EMR8, versus a predicted surgical mortality of 3.3% (p < .0001). The number needed to 
treat (NNT) to prevent one death was 30.  Furthermore endoscopic management has recently 
been shown to be significantly more cost effective than surgery with a mean cost saving per 
patient treated of US$7602 (p < .001) and a saving of 2.81 nights of hospital inpatient stay per 
patient50.  A US centre has recently reported similar cost-saving51.  Given the ease of treatment 
of recurrent or residual adenoma (RRA) (94.5% in one recent study48) at surveillance 
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endoscopy there would appear to be little benefit of surgery over EMR for colonic LSLs limited 
to the mucosa. 
 
Lesions which have invaded the submucosa (SMIC, the hallmark of colorectal cancer) are at 
risk for lymph node metastasis (LNM) at a rate of approximately 6-12%52,53.  Such lesions are 
T1 cancers and are divided into low and high risk for LNM: Low risk lesions invade < 1mm 
into the submucosa, do not demonstrate lymphovascular invasion (LVI), are well differentiated 
in grade and do not demonstrate tumour budding at histological assessment.  Such lesions can 
be considered for curative endoscopic therapy by en bloc excision.  Therefore, particularly 
when in vivo real-time imaging suggests the presence of high risk for SMIC (see section 3 
and box 1), consideration of either en bloc endoscopic resection for accurate histological 
assessment or surgery should be made.  With LSLs larger than 20-25mm en bloc ER is often 
only achievable endoscopically with ESD. There are no cost or mortality studies comparing 
ESD with surgery;  however, at least in Western centres, the technique is not readily available. 
Even in Japanese centres, where ESD is performed routinely, the majority of patients do not 
have SMIC.  Of the minority that do (10%), only 50% with superficial SMIC (SM1) are 
theoretically cured by ESD13.  When high risk histological features for LNM are present in 
the resection specimen then surgically fit patients should be referred for consideration of 
surgical resection.  
 
7 Complications 
Bleeding occurs in 7 to 9% of ER for colonic LSLs removed by EMR and ESD respectively13,54 
and can be divided into intra-procedural bleeding (IPB) or clinically significant post 
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endoscopic bleeding (CSPEB).  CSPEB is defined as bleeding after completion of endoscopic 
resection which necessitates presentation to the emergency department or re-intervention. 
 
7.1 Intra-procedural bleeding (IPB) 
IPB is to be expected during ER as submucosal vessels are exposed which may be injured and 
bleed.  In a large prospective study the rate of IPB during EMR was 11.3%16.  Independent 
predictors of bleeding included increasing lesion size, Paris 0-IIa+Is morphology and 
tubulovillous or villous histology.  In addition, IPB was associated with an increased risk of 
RRA at surveillance colonoscopy.  All episodes of IPB in this cohort were controlled 
endoscopically. 
 
Control of IPB is easily achieved with snare tip soft coagulation (STSC) using the tip (1-2mm 
extended) of the snare with short pulses of soft coagulation (e.g. ERBE Effect 4, maximum 
80W).  It is a light touch technique.  This is convenient, inexpensive and efficient as device 
exchange is not required.  In a prospective study of EMR for LSL ≥ 20mm haemostasis was 
achieved in 91% of IPB cases55.  As the tissue is dessicated the resistance to current flow rises 
exponentially limiting deep injury and ensuring safety.  With brisk bleeding , vessels > 2mm 
in caliber or if STSC fails to control bleeding after 3-4 applications haemostatic forceps should 
be used, generally with the same settings  The causative vessel is grasped and cessation of 
bleeding confirms correct placement; the tissue is then tented slightly and soft coagulation 
applied.  Endoscopic clips can also be used to treat IPB but are often ineffective and impair 
further tissue resection. 
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7.2 Clinically Significant Post Endoscopic Bleeding (CSPEB) 
CSPEB occurs in 6% of patients after EMR, and 2/3 of cases occur within 48 hours54.  Fig. 12 
demonstrates techniques for the treatment of CSPEB.  Risk factors for CSPEB are right colon 
EMR, IPB and use of a non-microprocessor controlled current for resection16.  Use of 
anticoagulant medication according to guidelines was not significant at multivariable analysis.  
A study from the same group showed that 55% of cases of CSPEB settled spontaneously56. 
Factors associated with the need for intervention were hourly or more frequent haematochezia, 
higher ASA grade, features of shock at presentation and transfusion requirement.   
 
Prophylactic coagulation of visible vessels within the EMR defect did not reduce the rate of 
CSPEB in a large multicenter randomized control trial57.  Clip closure of the EMR defect 
showed a trend towards significance in a retrospective study58, however lesions in difficult to 
access locations were not clipped; it is also difficult to close defects > 40mm in our experience 
thus potentially confounding these results. Techniques to improve clip closure require further 
study.  In any event the ideal solution to CSPEB is not defined and patients should be aware of 
who to contact should it occur. 
   
7.3 Deep injury 
The safety of endoscopic resection in the colon in part rests upon the ability to detect resection 
that is deeper than the submucosal layer and apply endoscopic closure techniques.  Inspection 
of the post-EMR defect is a critical component of the procedure. Generally, one should see a 
relatively homogeneous blue mat of intersecting submucosal connective tissue fibres. 
Resection deeper than the submucosa is termed deep mural injury (DMI) and has recently been 
graded in the Sydney classification (Fig. 13). 
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• Type 1 Visible muscularis propria (MP) injury but no visible mechanical injury 
• Type 2 Focal or generalized loss of the submucosal plane raising concern for 
MP injury or rendering the MP defect uninterpretable. 
• Type 3 MP injured, specimen target sign59 (STS) or defect target sign (DTS) 
identified 
• Type 4 Actual hole within a white cautery ring, no observed contamination 
• Type 5 Actual hole within a white cautery ring, observed contamination 
 
Type 1 injuries do not require closure, types 3-5 mandate closure of the injury to the MP. It is 
generally not necessary to close the whole mucosal defect. Closure of the focal area of concern, 
i.e. the area of SM fibrosis may be wise in type 2 injuries (Fig. 14). In a large multicenter  
prospective series of EMR for LSL >20mm the rate of frank perforation was 1.3%6.  After 
endoscopic closure and if the patient is stable the resection can often be continued.  A repeat 
procedure at a later date for two stage resection is also possible.  If there is uncertainty 
regarding deep injury, irrigation of chromic dye into the submucosa with the injection catheter 
without using the needle (topical submucosal chromendoscopy (TSC) 60) can identify areas of 
non-staining. The loose areolar tissue of the SM is avid for the dye unlike the MP and so 
unstained areas within the defect may be injured MP. 
 
7.4 Post-procedural pain 
Pain is uncommon after EMR. When it does occur it does not necessarily represent deep mural 
injury to the colonic wall.  Other causes include deep thermal injury, excessive transmural 
chromoinjection and serositis.  We suggest the following algorithm for managing patients post 
EMR (Fig. 15). 
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A two stage recovery process is in place at our centre with patients remaining in first stage 
recovery for 1-2 hours until they are ambulant.  Once in the second stage recovery, the 
endoscopist should discuss the outcome of the case with the patient and reinforce the guidance 
to maintain a clear fluid diet until the next morning, symptoms to watch for requiring medical 
assistance and the follow up plan. 
 
8 Residual and recurrent disease 
8.1 Recurrence and EMR 
A recent meta-analysis including 6442 patients from 50 studies demonstrated a rate of 
endoscopic recurrence of 13.8% at first surveillance endoscopy after piecemeal ER of colonic 
LSLs, 95% CI 12.9 to 14.7%61.  If the EMR scar is clear at 3-6 months, the likelihood of late 
recurrence is low (4.0%)48.  Such high rates of early recurrence have led to international 
guidance recommending surveillance procedures 4-6 months, then 18 months post ER for 
colonic LSLs62.  This is a significant burden on patients and healthcare systems alike and there 
is thus a drive to define techniques that may reduce this rate, improve the endoscopic detection 
and treatment of adenoma recurrence and triage patients who are unlikely to experience 
adenoma recurrence to later follow up.  
 
8.2 Techniques at the initial EMR to prevent recurrence 
Care to resect a border of normal mucosa (2-3mm) at the edge of an LSL undergoing EMR and 
inspection of the post EMR defect for residual adenoma is paramount to prevent adenoma 
recurrence.  Argon Plasma Coagulation (APC) ablation systematically applied to the the edge 
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or base of a polypectomy site in lesions >15mm was shown to reduce adenoma recurrence 
(1/10 recurrences APC group, 7/11 non APC group p=0.02) in an older small study63.  Snare 
tip soft coagulation applied systematically to the margin of EMR defects of lesions ≥20mm is 
the subject of a current Australian randomised controlled trial (SCAR trial) which is due to 
report shortly; interim results are promising.  
 
8.3 Triaging patients to follow up based on risk of recurrence 
Size of LSL ≥ 40mm, intra-procedural bleeding requiring endoscopic control and use of APC 
to complete initial ER were identified as predictors of recurrence at first surveillance 
colonoscopy48.  The future of EMR will likely involve evidence based staged surveillance 
procedures depending on individual risk factors identified at the time of the initial EMR. 
 
8.4 Accurate assessment of the post-EMR scar 
EMR scars are identified by a pale area of colonic mucosa with disruption of the normal 
vascular pattern, sometimes with puckering of the mucosa at the edges of the scar (Fig. 16).  
We suggest a standard scar assessment protocol to maximise the sensitivity and specificity of 
endoscopic analysis of the post-EMR scar: 
• Interrogate the edges of the scar using HD-WL, followed by the centre of the scar. 
• The same routine is performed using NBI.  
• Careful inspection of the scar includes the search for a transition point, where a non-
neoplastic pit or vascular pattern (Kudo I or II) becomes a neoplastic pit pattern (Kudo 
III or IV).  Examples of RRA within post-EMR scars are shown in Fig. 17. 
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Areas of concern are always treated endoscopically as follows, even if not particularly 
suspicious to avoid the need to repeat the examination based on histology. 
 
8.5 Endoscopic treatment of post-EMR recurrence 
Post-EMR RRA is easily and successfully treated endoscopically in the vast-majority of cases, 
90.3% in a recent meta-analysis61 and 94.5% in a large prospective multi-centre Australian 
series48.  
 
Chromo-injection of RRA is not performed since injection often leads to a canyon effect with 
marked elevation of  the normal non-fibrotic mucosa around the target area making it harder 
to resect64.  Instead a small, stiff, thin-wire snare is used to resect RRA with a coagulating 
current (e.g. Forced coagulation ERBE effect 2, 30W).  Difficult to ensnare areas of RRA can 
be removed with biopsy forceps and cold avulsion.  The area of RRA is then treated liberally 
with STSC (CAST, described in section 5.6).  Fig. 18 shows the endoscopic treatment of RRA 
within a post EMR scar.  RRA is retrieved and sent for histopathological assessment.  Recently 
the phenomenon of clip artifact has been described65,66; this describes nodular mucosa around 
endoscopic clips that were used in the initial ER (Fig. 18); this mucosa can be differentiated 
reliably with endoscopic imaging from recurrence by its normal vascular pattern, but if there 
is doubt the scar should be treated. 
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9 Future Direction of ER 
Endoscope imaging and post-processing techniques are evolving rapidly and now enable high-
quality assessment of lesions pre-resection and EMR scars for RRA.  These techniques will 
likely make biopsies of lesions pre-resection obsolete.  Standardising the interpretation of such 
imaging will allow more accurate prediction of SMIC with less inter-observer variability.   
 
Multiple modifications to the technique of EMR have been proposed. Underwater EMR67 
involves full immersion of the colonic lumen with water and dispenses with the need for 
submucosal chromo-injection. This is based on the EUS observation that water distension 
allows the mucosa to float on the submucosa during EMR.  One problem with the technique is 
the lack of a chromic dye to interpret the submucosal defect.  Good success rates have been 
reported but the technique needs standardisation and validation in prospective multicentre 
studies.  
  
Full thickness resection techniques for removal of invasive disease and submucosal lesions 
exist but are in their infancy, and are mainly limited by unreliable defect closure techniques68.  
Further prospective randomised studies comparing these techniques with surgery and ESD for 
the treatment of T1 cancers are required. 
 
Much is now known about the molecular basis of colorectal cancer.  Association studies 
between patients with AMN and normal controls may allow screening of at risk patients, and 
knowledge of the molecular profile of resected lesions may lead to personalised surveillance 
intervals. 
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11 Figure legends 
Fig. 1; Uncomplicated appearances of the mucosal defect after endoscopic mucosal 
resection.  a) Large herniating veins (arrow).  b) Large veins and non stained submucosa 
(arrow).  c) Large branching veins.  d) Artery (arrow).  Herniating vessels within the post-EMR 
defect do not require endoscopic treatment. 
 
Fig. 2; Types of snare available for EMR.  a) Serrated 20mm snare (right) and braided 15mm 
snares (left), both thick (.48mm) wire, are the commonest snares used for EMR.  b) Thin 
(.30mm) wire monofilament snares of different shapes are used in specific situations, see text 
for details. 
 
Fig. 3; Common Paris morphologies of laterally spreading colonic lesions referred for 
endoscopic resection. m, mucosa.  After Paris consortium22. 
 
Fig. 4; Lesion morphology. a), b) Granular laterally spreading lesions (LSLs) in the rectum a) 
Paris 0-IIa/Is lesion with dominant nodule, b) Paris 0-Iia lesion, both with tubulovillous 
architecture.  c) d) Non-granular LSLs in the transverse colon.  None of these lesions have 
suspicious features for submucosal invasive cancer, and can be stratified for such risk by the 
scheme in figure 6. 
 
Fig. 5; High definition imaging and prediction of submucosal invasive cancer (SMIC). a) 
50mm granular laterally spreading lesion (LSL) in the sigmoid colon with a central demarcated 
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area (white dash line) suggestive of focal submucosal invasive cancer. b) White light 
magnification of the central area. c) Narrow band imaging (NBI) demonstrating NICE III and 
SANO IIIb vascular pattern within the demarcated area. D) Non-granular LSL in the mid-
transverse colon with central depression. e) NBI imaging suggesting a demarcated area 
concerning for submucosal invasive cancer. f) Magnification demonstrating SANO IIIb 
vascular, NICE III and Kudo Vn pit pattern.  Histopathology confirmed SMIC in both cases. 
 
Fig. 6; Combining lesion morphology and granularity can predict risk of submucosal 
invasive cancer (SMIC).  Granular (G, red colour) lesions are lower risk for SMIC than non-
granular (NG, green colour) lesions [data from the ACE cohort]*.  Triangular  penetration into 
the submucosa (sm) is the likeliest site of SMIC in lesions with a dominant nodule26.  *(Data 
presented is in the absence of a depressed component or a Kudo type V pit pattern within the 
target lesion).  
 
Fig. 7; Stages of EMR.  a) 50mm Paris 0-IIa/Is granular laterally spreading lesion (LSL) in 
the proximal rectum with a dominant nodule. b) Snare placement (20mm, serrated) after 
chromogelofusine injection.  c) Uncomplicated bland blue mat defect after completed EMR. 
d) 40mm Paris-IIa non-granular LSL in the mid-transverse colon. e) Injection of 
chromogelofusine.  f) Hemi-circumferential uncomplicated mucosal defect with adipose tissue 
(arrow). 
 
Fig. 8; ESD of a 35mm rectal 0-IIa+Is LSL a) with amorphous surface pattern and areas of 
disrupted vessels suggesting en bloc endoscopic excision would be preferable.  b) The lesion 
is isolated from the surrounding normal mucosa.  c) During the dissection significant bleeding 
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is encountered and controlled with the hemostatic forceps d). e) The specimen is retrieved en 
bloc for histopathological analysis.  f) A clip is placed over an area of muscularis propria (MP) 
injury within the defect. 
 
Fig. 9; EMR of a fully circumferential granular 100mm Paris 0-IIa/Is granular laterally 
spreading lesion (LSL) in the proximal rectum.  b) Completed uncomplicated mucosal defect.  
c) Surveillance procedure at 2 months; uncomplicated EMR scar which was passable by the 
paediatric colonoscope after balloon dilatation.  d) 90mm Paris 0-IIa/Is granular fully 
circumferential LSL in the proximal rectum.  e) Progressant EMR procedure.  f) Completed 
uncomplicated mucosal defect. 
 
Fig. 10; EMR of a previously attempted peri-appendiceal laterally spreading lesion 
(LSL).  A small (10mm) thin wire snare is used for optimal resection.  c) Significant fibrosis 
associated with the previous resection preventing complete snare excision.  d) Cold avulsion 
of remaining adenoma that is subsequently treated with adjuvant snare tip soft coagulation 
(CAST).  f) Completed resection defect. 
 
Fig. 11; a), d) Typical appearances of a sessile serrated adenoma (SSA/P).  a) The lesion is 
barely visible under high definition white light.  Under close inspection there is often adherent 
mucus and stool debris, lacy capillary structure and a cloud like appearance.  Colonic vessels 
cannot be followed into the lesion.  b) The same lesion seen under narrow band imaging (NBI) 
demonstrating superior delineation.  c) Lesions up to 15mm in size can be safely removed by 
cold snare polypectomy, in a piecemeal fashion, avoiding the risks of EMR.  e,f) Larger lesions 
should be removed by EMR; the chromic dye sharply delineates the lesion margins. 
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 Fig. 12; Control of clinically significant post-endoscopic bleeding (CSPEB).  a) A partially 
clipped EMR defect is seen with a clot overlying the responsible vessel.  Hemostatic forceps 
are applied to the vessel (b) with obliteration of the target vessel (c).  d) Significant bleeding 
from a vessel within an EMR defect; the apex of the bleeding indicates the site of the vessel.  
e) The vessel has been grasped with hemostatic forceps; confirmation of the correct target is 
by cessation of bleeding f) completed defect with no further bleeding. 
 
 
Fig. 13; The Sydney Classification of Deep Mural Injury (DMI) after EMR.  Schematic 
showing the depth of injury to the colonic wall with each type of DMI.  Representative 
endoscopic images are presented above the schematic. See text for descriptions of the types of 
DMI (Section 7.3).  Types iii to v require definitive endoscopic closure.  Closure is suggested 
for type ii injury, which represents loss of the submucosal plane, often due to fibrosis from 
previous resection or lesion biology.  m – mucosa, sm – submucosa, mp – muscularis propria, 
s- serosa. 
 
Fig. 14; Endoscopic closure of deep mural injury (DMI) type IV at EMR.  a) Full thickness 
perforation is identified at the site of EMR.  This is mirrored by a specimen showing a target 
sign.  b) Initial clip placement to close the defect.  c-e) Further clips are placed to fully close 
the defect.  The lesion was successfully resected endoscopically by EMR at a subsequent 
procedure. 
 
 Chapter 6 Manuscript  |  Page 43 
Fig. 15; Management of pain post EMR and the suggested recovery procedure. NBM – nil 
by mouth. 
 
Fig. 16; Interpretation of the post EMR scar.  Images of normal post-EMR scars are shown 
under high definition white light (HD-WL) and narrow band imaging (NBI).  A standard scar 
assessment protocol allows for accurate endoscopic prediction of presence of recurrent or 
residual adenoma (RRA), see text, section 8.4. 
 
 Fig. 17; Interpretation of recurrence within the post EMR scar. a,b) Recurrence at the site 
of previous EMR within a scar.  c,d) Nodular mucosa with normal pit pattern (Kudo II) 
suggesting clip artifact which can be mistaken for recurrence. 
 
Fig. 18; Treatment of large multifocal recurrent adenoma after EMR of a 100mm 90% 
circumferential proximal rectal lesion. This patient presented late for surveillance at 12 months 
post EMR.  a) Multifocal recurrent adenoma in the EMR scar under high definition white light.  
b) First snare excision of recurrent adenoma with a thin wire snare.  c) Result of snare tip soft 
coagulation applied to the scar. 
 
Box 1; Indications for endoscopic therapy of advanced colorectal polyps (ACP) 
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12 Tables 
 Image enhancement HD-WL/NBI/chromendoscopy NBI NBI 
 
Management Kudo Sano NICE examples 
Normal I        
Endoscopic resection not required 
(hyperplastic) 
nb SSA/P fits this classification but 
requires endoscopic resection, see 
section 5.7 
II - stellar or open pits I - invisible capillary 
pattern 
Type I - Lighter than background, no visible 
vessels 
 
Endoscopic  
Resection advised 
  
IIIs/IIIL - tubular short or long pits 
IV - gyriform pits 
II - structured 
capillary pattern 
Type II - Brown relative to background, colour 
arising from vessels.  Vessels surround white, 
regular structures 
 
Likely SMIC; consider surgery or en 
bloc endoscopic resection for staging 
  
Vi - disordered pit pattern with some 
maintained structure 
Vn - completely disordered pit pattern 
III - disordered or 
absent capillary 
pattern 
Type III - Dark brown relative to background.  
Areas of absent vessels and amorphous surface 
pattern 
 
Table 1; Significant features of Kudo, Sano and NICE classifications of colorectal lesions and their relationship to endoscopic resectability.  
SMIC – submucosal invasive cancer, SSA/P - sessile serrated adenoma/polyp, NBI -  narrow band imaging, NICE - NBI International Colorectal 
Endoscopic Criteria 
a) b)
c) d)
                      
         
          
resection. a) Large herniating veins (arrow). b) Large veins and non stained submucosa 
(arrow). c) Large branching veins. d) Artery (arrow). Herniating vessels within the post-EMR 
defect do not require endoscopic treatment.
Fig. 1; Uncomplicated appearances of the mucosal defect after endoscopic mucosal
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a) b)
Fig. 2; Types of snare available for EMR. a) Serrated 20mm snare (right) and braided 15mm 
snares (left), both thick (.48mm) wire, are the commonest snares used for EMR. b) Thin 
(.30mm) wire monofilament snares of different shapes are used in specific situations, see text 
for details.
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Fig. 3; Common Paris morphologies of laterally spreading colonic lesions referred for 
endoscopic resection. m, mucosa. After Paris consortium22.
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a) b)
c) d)
Fig. 4; Lesion morphology. a), b) Granular laterally spreading lesions (LSLs) in the rectum a) 
Paris 0-IIa/Is lesion with dominant nodule, b) Paris 0-Iia lesion, both with tubulovillous
architecture. c) d) Non-granular LSLs in the transverse colon. None of these lesions have 
suspicious features for submucosal invasive cancer, and can be stratified for such risk by the 
scheme in figure 6.      Chapter 6 Manuscript | Page48
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area (white dash line) suggestive of focal submucosal invasive cancer. b) White light 
magnification of the central area. c) Narrow band imaging (NBI) demonstrating NICE III and 
SANO IIIb vascular pattern within the demarcated area. D) Non-granular LSL in the mid- 
transverse colon with central depression. e) NBI imaging suggesting a demarcated area 
concerning for submucosal invasive cancer. f) Magnification demonstrating SANO IIIb 
vascular, NICE III and Kudo Vn pit pattern. Histopathology confirmed SMIC in both cases.
a)
a) b)
a) b) c)
d) e) f)
50mm granular laterally spreading lesion (LSL) in the sigmoid colon with a central demarcated
Fig. 5; High definition imaging and prediction of submucosal invasive cancer  (SM IC). a)
Granular lesions Non-granular lesions
     
            
               
             
                
                  
 
                     
                         
                             
Fig. 6; Combining lesion morphology and granularity can predict risk of submucosal invasive cancer (SMIC). Granular (G, red colour) lesions are
lower risk for SMIC than non- granular (NG, green colour) lesions [data from the ACE cohort]*. Triangular penetration into the submucosa (sm) is the likeliest
site of SMIC in lesions with a dominant nodule26. *(Data presented is in the absence of a depressed component or a Kudo type V pit pattern within the target 
lesion). Chapter 6 Manuscript | Page 50
a)
d)
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Fig. 7; Stages of EMR. a) 50mm Paris 0-IIa/Is granular laterally spreading lesion (LSL) in 
the proximal rectum with a dominant nodule. b) Snare placement (20mm, serrated) after 
chromogelofusine injection. c) Uncomplicated bland blue mat defect after completed EMR. 
d) 40mm Paris-IIa non-granular LSL in the mid-transverse colon. e) Injection of 
chromogelofusine. f) Hemi-circumferential uncomplicated mucosal defect with adipose tissue 
(arrow).
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Fig. 8; ESD of a 35mm rectal 0-II a+Is LSL  a) with amorphous surface pattern and areas of 
disrupted vessels suggesting en bloc endoscopic excision would be preferable. b) The lesion 
is isolated from the surrounding normal mucosa. c) During the dissection significant bleeding
is encountered and controlled with the hemostatic forceps d). e) The specimen is retrieved en 
bloc for histopathological analysis. f) A clip is placed over an area of muscularis propria (MP) 
injury within the defect.
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Fig. 9; EMR of a fully circumferential granular 100mm Par is 0-II a/Is granular laterally 
spreading lesion (LSL ) in the proximal rectum. b) Completed uncomplicated mucosal defect. 
c) Surveillance procedure at 2 months; uncomplicated EMR scar which was passable by the 
paediatric colonoscope after balloon dilatation. d) 90mm Paris 0-IIa/Is granular fully 
circumferential LSL in the proximal rectum. e) Progressant EMR procedure. f) Completed 
uncomplicated mucosal defect.
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Fig. 10; EMR of a previously attempted per i-appendiceal laterally spreading lesion 
(LSL ). A small (10mm) thin wire snare is used for optimal resection. c) Significant fibrosis 
associated with the previous resection preventing complete snare excision. d) Cold avulsion 
of remaining adenoma that is subsequently treated with adjuvant snare tip soft coagulation 
(CAST). f) Completed resection defect.
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Fig. 11; a), d) Typical appearances of a sessile ser rated adenoma (SSA/P). a) The lesion is 
barely visible under high definition white light. Under close inspection there is often adherent 
mucus and stool debris, lacy capillary structure and a cloud like appearance. Colonic vessels 
cannot be followed into the lesion. b) The same lesion seen under narrow band imaging (NBI) 
demonstrating superior delineation. c) Lesions up to 15mm in size can be safely removed by 
cold snare polypectomy, in a piecemeal fashion, avoiding the risks of EMR. e,f) Larger lesions 
should be removed by EMR; the chromic dye sharply delineates the lesion margins.
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clipped EMR defect is seen with a clot overlying the responsible vessel. Hemostatic forceps 
are applied to the vessel (b) with obliteration of the target vessel (c). d) Significant bleeding 
from a vessel within an EMR defect; the apex of the bleeding indicates the site of the vessel. 
e) The vessel has been grasped with hemostatic forceps; confirmation of the correct target is 
by cessation of bleeding f) completed defect with no further bleeding.
Fig. 12; Control of clinically significant post-endoscopic bleeding (CSPEB). a) A partially
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showing the depth of injury to the colonic wall with each type of DMI. Representative endoscopic images are presented above the schematic. See text for 
descriptions of the types of DMI (Section 7.3). Types iii to v require definitive endoscopic closure. Closure is suggested for type ii injury, which represents loss 
of the submucosal plane, often due to fibrosis from previous resection or lesion biology. m — mucosa, sm — submucosa, mp — muscularis propria, s- serosa.
Fig. 13; The Sydney Classification of Deep Mural Injury (DM I ) after  EMR. Schematic
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EMR performed
First stage recovery
No pain, patient 
ambulant
Second stage 
recovery
Clear fluids after 2 
hours; discharge with 
appropriate advice 
and contact details of 
department
Pain
Simple analgesia, 
encourage passing 
wind, bladder 
emptying
Pain resolves
Persistent pain or 
evolving clinical signs 
of peritonism
Computed 
tomography scan of 
abdomen
Conservative 
management, admit, 
IV antibiotics, NBM, 
monitor
SurgeryNo finding
Evidence of 
perforation
Pain does not settle, 
or clinical signs 
evolve
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Fig. 15; Management of pain post EMR and the suggested recovery procedure. NBM — nil 
by mouth.
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Fig. 16; Interpretation of the post EMR scar. Images of normal post-EMR scars are shown 
under high definition white light (HD-WL) and narrow band imaging (NBI). A standard scar 
assessment protocol allows for accurate endoscopic prediction of presence of recurrent or 
residual adenoma (RRA), see text, section 8.4.
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of previous EMR within a scar. c,d) Nodular mucosa with normal pit pattern (Kudo II) 
suggesting clip artifact which can be mistaken for recurrence.
Fig. 17; Interpretation of recurrence within the post EMR scar . a,b) Recurrence at the site
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circumferential proximal rectal lesion. This patient presented late for surveillance at 12 months 
post EMR. a) Multifocal recurrent adenoma in the EMR scar under high definition white light. 
b) First snare excision of recurrent adenoma with a thin wire snare. c) Result of snare tip soft 
coagulation applied to the scar.
Fig. 18; Treatment of large multifocal recur rent adenoma after  EMR of a 100mm 90%
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Chapter 7 - Two-stage endoscopic mucosal resection is a safe and effective 
salvage therapy after a failed single-session approach. 
Introduction 
Endoscopic mucosal resection (EMR) can be successfully used to resect LSL in >90% of 
cases33,46.  Commonly it is performed as a day case procedure and completed in a single session.  
The patient is then discharged and reviewed with a further surveillance colonoscopy at 4-6 
months after the index procedure.   
In a minority of cases it may not be possible to complete the LSL resection in a single session.  
Reasons for this include non-lifting LSL (due to prior biopsy, resection or carbon particle 
suspension marking), difficult endoscopic access, patient tolerance of the procedure and 
adverse events.  After failure of this procedure, and particularly if the resection was performed 
in a tertiary endoscopy centre, LSL were traditionally referred for surgical resection. 
The study described in this chapter5 investigated whether, instead of surgical resection, 
acceptable patient outcomes could be obtained by a second attempt (two stage EMR, tsEMR) 
at endoscopic resection within 2-3 months. 
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ABSTRACT 
BACKGROUND AND STUDY AIMS 
Endoscopic mucosal resection (EMR) of laterally spreading colonic lesions ≥ 20mm (LSL) is 
ideally performed in a single session(ssEMR) and avoids surgery in >90% of patients.  We 
investigated whether a second attempt is safe or useful when ssEMR fails at a tertiary 
centre. 
PATIENTS AND METHODS  
Amongst a multicentre prospective observational study of patients with LSL treated by EMR 
at 4 tertiary centres over 8 years, incompletely resected LSL were referred for surgery or 
underwent two stage EMR(tsEMR).  At tsEMR the scar was located and all visible residual 
tissue removed by snare with thermal treatment permitted thereafter. Scheduled surveillance 
was performed at 5 months (SC1) and 18 months (SC2). The primary outcome was 
avoidance of surgery. 
RESULTS 
1944 LSL (median size 35 mm) underwent EMR with 127 failing ssEMR.  43 LSL underwent 
tsEMR with success in 36 (83.7%).  Compared to ssEMR, tsEMR lesions were larger 
(median size 50mm vs 30mm, p<.001), exhibited more submucosal fibrosis (p<.001) and 
histology was more often tubular adenoma and less often serrated (p=.005).  Lesions mainly 
required tsEMR due to non-lifting (41.9%) or poor endoscopic access (37.2%).  Failure of 
tsEMR was predicted by larger LSL (p =.032).  Safety was comparable to ssEMR.  Of the 33 
LSL that underwent tsEMR for benign disease and completed first surveillance, 81.8% 
avoided surgery to long term follow up. 
CONCLUSIONS 
tsEMR shows promise as a salvage therapy for LSL that cannot be resected in a single 
session where other options such as surgery are not preferred or not possible. 
Clinicaltrials.gov NCT01368289. 
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INTRODUCTION 
Wide field endoscopic mucosal resection (EMR) has become the primary treatment of large 
laterally spreading lesions ≥20mm (LSL) in the colon.  As a day case procedure it has 
cost(1) and morbidity benefits over surgery, and modelling indicates that it is safer(2).   
EMR is commonly performed in a single session (ssEMR) with complete snare resection of 
adenoma achieved in the majority of cases at tertiary endoscopy centres (3).  Failure of 
ssEMR is often due to non-lifting of the target LSL(4), difficult endoscopic positioning or 
challenging colonic location including the ileo-caecal valve (5), appendiceal orifice (6) or the 
anorectal junction (7).  Failure of ssEMR commonly results in referral of the patient for 
surgical resection.    
When ssEMR has failed, there may be benefit to repeating the procedure at an interval, 
allowing the mucosal defect to heal, highlighting the residual adenoma and allowing 
purchase with the snare or more successful use of adjunctive techniques.  We aimed to 
investigate the safety and efficacy of two-stage EMR (tsEMR) in situations where ssEMR 
failed at a tertiary endoscopy centre. 
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MATERIALS AND METHODS 
EMR PROCEDURE 
Data were collected within a multicentre prospective observational study of patients referred 
for EMR of colonic LSL performed at four Australian academic tertiary referral centres from 
9/2008 until 06/2016 (The Australian Colonic EMR Resection Study (ACE) (3), 
Clinicaltrials.gov NCT01368289).  There were no exclusions to enrolment.  Institutional 
review board approval was obtained at each centre.   
EMR procedures were performed by senior endoscopists with extensive EMR experience or 
by a senior endoscopy fellow under their direct supervision.  Written informed consent was 
obtained from all patients.  LSL were described as previously attempted if an attempt at 
resection had been made at the referring institution or naïve if no previous attempt had been 
made.  Split dose bowel preparation was used.  Intravenous sedation was with a 
combination of fentanyl, midazolam and propofol.  Insufflation of the colon was initially with 
air moving to carbon dioxide in August 2010 (8).  
Colonoscopy was performed using Olympus 180 or 190 series high-definition variable-
stiffness colonoscopes (180/190 PCF/CF;Olympus, Tokyo, Japan).  Lesion assessment was 
performed with high definition white light and narrow band imaging.  Size of lesion was 
determined with reference to an open snare of known diameter.  A standardized and 
previously described inject-and-resect EMR technique (9) was used in an attempt to achieve 
complete adenoma clearance by snare in a single session (ssEMR). 
Most cases used a microprocessor-controlled electrosurgical generator (ERBE VIO300D; 
ERBE Elektromedizin, Tübingen, Germany) (10) with fractionated current.  The submucosal 
injectate comprised normal saline until 2010 when succinylated gelatin (Gelofusine; B.Braun 
Australia Pty Ltd, Bella Vista, Australia) was adopted (11).  The fluid was dyed with indigo 
carmine blue (80mg/500mL solution) and adrenaline was added to achieve a solution of 
1:100,000.  Methylene blue was occasionally used when indigo carmine blue was not 
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available.  Intra-procedural bleeding was treated with snare tip soft coagulation [ERBE Effect 
4, 80W] and was recorded as present if endoscopic control was required.  Intra-procedural 
perforation was described as the presence of a target sign (12) or actual hole in the colonic 
wall.   
If complete snare excision could not be achieved in a single session at the tertiary centre the 
patient was either referred for surgery or a repeat resection attempt (tsEMR) was scheduled.  
This decision was completely at the discretion of the individual operator based on the reason 
for ssEMR failure and the predicted complexity of a future resection.  tsEMR always referred 
to a second procedure at the tertiary centre, whether or not the lesion had been previously 
attempted by the referrer. 
If the patient was booked for tsEMR this was scheduled for 1-2 months after the index 
procedure.  At tsEMR the EMR scar was located and the residual was then resected by 
snare using standard EMR technique if possible.  If there was extensive residual adenoma 
injection was performed away from the scarred area using resection of normal tissue to 
isolate the non-lifting area and create a step to allow purchase with the snare.  Tangential 
snare positioning over the residual with firm downward pressure aided tissue capture.  
Adjuvant thermal therapy with argon plasma coagulation (APC) or snare tip soft coagulation 
(after 2012) was used to ablate remaining residual adenoma if complete snare excision was 
not possible.  Fig. 1 + 2 demonstrate two examples of the tsEMR technique.  Technical 
success was recorded where there was complete removal/destruction of adenomatous 
tissue. 
After EMR patients were observed for 4 hours and discharged home if well.  A clear fluid diet 
was advised until the next morning.  Specialist gastrointestinal pathologists at the individual 
centres reviewed all histological specimens.  
Post-procedural data including delayed adverse events and results of follow-up were 
collected by structured telephone interview at 14 days following the index procedure and at 
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the time of each surveillance colonoscopy.  Clinically significant post EMR bleeding was 
defined as bleeding after EMR that required hospital admission or re-intervention (13).  All 
authors had access to the study data and reviewed and approved the final manuscript. 
FOLLOW UP 
Follow up data was collected from patients eligible for first surveillance colonoscopy (SC1) at 
a desired interval of 4-6 months after ssEMR or tsEMR.  Time to longest follow-up and any 
associated endoscopic and histologic residual or recurrent adenoma (RRA) after SC1 was 
recorded if available.  Analysis was performed on a per patient basis with only the largest 
lesion from each patient included.  
All EMR scars were evaluated endoscopically at SC1 and at subsequent follow up.  The 
primary endpoint of the study was avoidance of surgery.  Secondary endpoints included 
endoscopically determined recurrence (RRA) and safety.  RRA was defined as the presence 
of tissue suspicious for adenoma under high definition white light and/or narrow band 
imaging.  When there was any doubt as to the presence of RRA, biopsies of the EMR scar 
were taken to document the presence or absence of histological recurrence.  Detected RRA, 
once sampled, was excised by snare or if this was not possible removed by cold forceps 
avulsion followed by snare tip soft coagulation.   
STATISTICAL ANALYSIS  
Statistical analysis was performed using SPSS version 22 (Armonk, New York, USA) with 2-
tailed t-test used for normally distributed continuous variables, Mann Whitney U Test for 
skewed continuous data and chi-squared test or Fisher’s exact test for categorical variables.  
Significance of P was regarded at p<.05. Comparisons were made between tsEMR, naïve 
LSL completed in a single session and previously attempted LSL completed in a single 
session. 
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RESULTS 
PATIENT POPULATION 
Over 8 years to June 2016, 2254 lesions in 2035 patients were referred for EMR at four 
academic Australian Tertiary referral centres.  91 lesions (4.0%) were not attempted due to 
either concern for submucosal invasive cancer (61) or technical difficulties (30) and were 
referred directly for surgery.  EMR was attempted in 1944 (95.5%) cases of which 222 
(11.4%) had been previously attempted.  Successful ssEMR was accomplished in 
1817/1944 (93.5%) lesions.  Of the 127 lesions which were not completely resected at the 
initial EMR procedure, 78 (61.4%) were referred for surgery and 49 (38.6%) for tsEMR.  26 
(20.5%) LSL referred for surgery were previously attempted as were 14/49 (28.6%) cases 
referred for tsEMR.  6 lesions referred for tsEMR actually underwent surgery, 2 for 
submucosal invasive cancer in the initial resection specimen and 4 due to patient choice.  
Detailed recruitment and exclusions are shown in Fig. 3. 
CHARACTERISTICS OF LESIONS UNDERGOING TSEMR 
43 lesions underwent tsEMR at median 2 months (interquartile range (IQR) 1-2) after the 
index procedure. Reasons cited by the endoscopist at the initial EMR for the lesion requiring 
tsEMR were non-lifting of the target lesion in 18/43 (41.9%) cases; in 9/18 cases (50.0%) 
there had been a previous resection attempt and 7 (38.9%) further cases had undergone 
previous biopsy.  Difficult endoscopic access was cited in 16/43 (37.2%) cases; these 
locations included the ileo-caecal valve (8/16, 50.0%), the hepatic or splenic flexures (3, 
18.8%) and around the base of the caecum or the appendiceal orifice (3, 18.8%).  Other 
reasons given for a lesion requiring tsEMR were concern for submucosal invasive cancer in 
4/43 cases (9.3%), concern for intra-procedural perforation in 2 (4.7%), lesion extent in 2 
(4.7%) and problems with patient sedation in 1 (2.3%). 
Baseline lesion characteristics and treatment outcomes are summarised in table 1. 
Compared to naïve LSL completed at ssEMR, LSL undergoing tsEMR were larger (median 
 Chapter 7 Manuscript  | Page 9 
size 50mm (IQR 35-60) versus 30mm (IQR 25-45), p<.001), exhibited a greater degree of 
submucosal fibrosis (58.1% vs 18.6%, p <.001) and were more often tubular adenomas (19 
(44.2%) versus 385 (24.6%)) and less often serrated adenomas (2 (4.7%) versus 271 
(17.3%)), p=.005.  Surgical referral prior to surveillance colonoscopy was made in 7 (16.3%) 
cases and was more common in lesions undergoing tsEMR (7 (16.3%) versus 81 (5.0%), p 
=.006). 
Compared to LSL referred directly for surgery after ssEMR, LSL referred for tsEMR were 
found in older patients (mean age 70.4 years (standard deviation (STD) 9.5) versus 66 years 
(STD 11.7), p=.049), were less likely to involve a dominant Is component (7/49 (14.6%) 
versus 21/78 (26.9%), p=.008) and were less likely to contain high-grade dysplasia (41/78 
(54.7%) versus 14/78 (28.6%), p=.010) (table 2). 
Technical success at tsEMR was achieved in 36/43 lesions (83.7%) versus 1621/1708 
(94.9%) naïve lesions undergoing ssEMR, p=.007.  Primary procedural techniques used to 
achieve complete clearance of adenoma at tsEMR were repeat snare excision in 33/43 
(76.7%), cold forceps avulsion with adjunctive thermal therapy in 8 (18.6%) and argon 
plasma coagulation to visible adenoma in 2 (4.7%).  Additional thermal therapy was applied 
to the margin of the EMR defect or over the scarred mucosa in 12/33 (36.4%) of cases 
where repeat snare excision was used.  Additional techniques used to clear adenoma at 
tsEMR included use of a short transparent endoscope cap for LSL located at the ileo-caecal 
valve (4/43, 9.3%), scarred retraction of adenoma at the ileo-caecal valve allowing snare 
resection (3, 7.0%) and use of a gastroscope allowing retroflexion and improved 
visualisation at the splenic flexure in 1 case.  Complete clearance of residual adenoma was 
achieved in 14/16 (87.5%) cases where poor access required tsEMR and 16/18 (88.9%) 
cases where non-lifting adenoma was the primary reason for tsEMR.   
Complications at tsEMR were intra-procedural bleeding in 10/43 (23.8%) with 2 (4.7%) 
cases of intra-procedural perforation which were treated with endoscopic clips in both cases 
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with no clinical sequelae.  These rates were not significantly different to the rates at ssEMR 
(table 1).  A single patient had uncontrollable bleeding from a tsEMR site; thermal therapy 
with snare tip soft coagulation and coagulation forceps failed to control the bleeding and 
endoscopic clip placement was not possible due to extensive fibrosis from the previous 
resection.  After blood transfusion, emergent angio-embolisation resolved the bleeding with 
no negative consequences for the patient. 
Failure of tsEMR requiring surgery occurred in 7 lesions.  It was not more common with 
previously attempted lesions, p=.652 (Fig. 4).  LSL where tsEMR failed were larger (50mm 
(IQR 50-120mm) versus 40mm (IQR 35-60mm), p=.032) lesions than those in which tsEMR 
was successful, with size range 40-120mm in the failed group.  No other procedural or lesion 
factor was significantly different.  Reasons given by the endoscopist as to why tsEMR was 
abandoned were persistent non-lifting in 3 (42.9%), difficult endoscopic access in 2 (28.6%), 
deep ileal infiltration in 1 (14.3%), and suspicion of submucosal invasive cancer in 1 further 
(14.3%).  Suppl. Table 1 presents all lesions that were directly referred for surgery after 
failed tsEMR.  All surgical specimens contained residual adenoma, none contained invasive 
malignancy. 
FOLLOW UP 
Median time to SC1 for lesions successfully resected by tsEMR was 6.7 months (IQR 5.9-
9.9) and was undertaken in 33 patients (Table 3, Suppl. Fig 1).  3 patients were not due 
SC1 at the time of writing.  RRA at SC1 was detected in 13/33 patients (39.4%).  Histologic 
data was available in 8 cases where endoscopic recurrence was present and was positive in 
8/8 cases (100%).  Other histology was not retrieved or did not survive processing.  After 
ssEMR of naïve LSL, RRA was detected in 166/1224 (13.6%, p<.001) cases.  Histologic 
data was available in 573 cases and was positive in 114 (19.9%).  RRA was detected in 
28/158 (17.7%, p=.157) cases after ssEMR of previously attempted LSL.  Two patients 
(6.1%) undergoing SC1 after tsEMR were referred for surgery (p=.064), one due to inability 
to resect RRA (attributed to extensive fibrosis and non-lifting) and another due to a proximal 
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metachronous malignancy detected at the surveillance procedure; in the latter case, while 
technically possible, no attempt was made to resect the residual adenoma at the EMR scar 
as it was to be included in the surgical specimen.  
4 patients did not undergo second surveillance colonoscopy (SC2) due to age and/or 
comorbidity, 2 were deceased, 1 was missing follow up data (moved abroad) and 1 was not 
due.  SC2 was performed on 23 lesions at median 14 months, IQR 11.4-22.5, and 6/23 
(26.1%) lesions demonstrated RRA of which 2/23 (8.7%) were referred for surgery.  In 
comparison SC2 was performed on 691 lesions that underwent ssEMR of naïve LSL with 
RRA in 31/592 (5.2%), p=.001, and 2 (0.3%) of which were referred for surgery, p=.008.   
SC3 or later was performed on 12 of the 21 eligible tsEMR patients at median 40.1 months 
(IQR 33.7-48).  3 patients did not undergo surveillance due to comorbidities, 2 were 
deceased, 1 refused and 3 were not due.  RRA was detected in 2/12 (16.7%), with both 
patients referred for surgery due to non-lifting adenoma.  At ssEMR of naïve LSL 5/152 
(3.5%, p=.094) patients had RRA and 1/142 (0.7%, p=.016) patients were referred for 
surgery.  Suppl. Table 2 presents all lesions that were referred for surgery during follow up.  
Overall, if a patient underwent successful tsEMR and completed their first follow up 
procedure, 27/33 (81.8%) avoided surgery to longest follow up.   
COMPARISON BETWEEN NAÏVE LSL AND PREVIOUSLY ATTEMPTED LSL 
236 LSL (12.1%) undergoing EMR had been previously attempted.  Their morphology was 
more likely to be non-granular than naïve LSL (33.7% versus 20.9%, p=.023) and they were 
less commonly resected en bloc (9.2% versus 17.8%).  They often exhibited submucosal 
fibrosis (63.3% of cases versus 18.6%) and were more commonly tubular adenoma (p=.034) 
(Table 1).  They were significantly less likely to be resected successfully in a single session 
than naïve LSL (83.1% versus 94.9%, p < .001), but did not recur or undergo surgery more 
frequently than naïve LSL during long term follow up (Table 3). 
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COMPARISON BETWEEN FIRST AND SECOND HALF OF THE COHORT 
The cohort was divided temporally directly in half between 9/2008 and 6/2016.  ssEMR was 
a more likely outcome of an attempt at EMR in the second half of the cohort (1006/1047, 
96.1%) than in the first half of the cohort (811/897, 90.4%, p=.001) and consequently both 
tsEMR and surgery were less frequently required.  When comparing the fate of lesions 
which failed ssEMR, tsEMR and surgery were of equal likelihood in the first (tsEMR 35/86, 
40.7%) and second (tsEMR 14/41, 34.1%, p=.478) half of the cohort (Table 4). 
 
DISCUSSION 
ssEMR is the gold standard and preferred approach for the treatment of large LSL(14).  It is 
inexpensive, safe, effective and avoids surgery in >90% of patients referred in a tertiary 
setting.  However, for a variety of reasons it does not always succeed and at the present 
time the general default position is to refer the patient to surgery.  In this study we 
demonstrate that amongst 43 LSL which could not be resected in a single session by EMR 
at a tertiary referral centre, 36 (83.7%) could be resected at a second EMR procedure 
(tsEMR) at an interval of 1-2 months thereby avoiding surgery.  We have compared the 
outcomes of tsEMR with ssEMR of naïve LSL to inform discussion, however tsEMR should 
be seen as a salvage therapy where ssEMR has failed.  
Other authors have recognised the skill of the endoscopist as a risk factor for incompete 
polypectomy (15) and it is likely that this effect is more pronounced for complex endoscopic 
resection.  In this study EMR procedures failed at the referring centre could be completed in 
83.1% of cases in a single session, although this was lower than the rate for naïve LSL 
(94.9%).  In addition, once fully resected, previously attempted LSL did not recur more 
frequently than naïve LSL resected in a single session, whereas lesions requiring tsEMR 
did.  Taken together these observations indicate that a second stage procedure at a tertiary 
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endoscopy centre is not equivalent to complete resection of a previously attempted LSL in a 
single session and validates the study description of tsEMR as a specific situation within the 
referral pathway of LSL.  
The majority of failures of ssEMR and consequent need for tsEMR were due to non-lifting 
adenoma, a sign commonly associated with previously attempted LSL resection or lesion 
biopsy but also associated with submucosal invasive cancer or increasingly recognised to be 
part of the biology of certain LSL subtypes such as non-granular lesions.  Non-lifting may be 
overcome by other published techniques including hot avulsion (16,17), forced argon plasma 
coagulation using a saline cushion (18) and needle knife incision of the LSL margin (19) 
prior to snare resection.   However, these techniques are limited to case series and tertiary 
institutions and in our experience patients with non-lifting LSL are often referred for surgery.  
tsEMR may offer an alternative to treat non-lifting adenoma since 16/18 such lesions were 
resected successfully.  
Other reasons for failure of ssEMR and need for tsEMR are without a clear single session 
solution.  Access to the lesion was the second commonest reason for cases requiring 
tsEMR.  In 14/16 of these cases complete excision of residual adenoma was achieved.  This 
highlights a potential benefit of tsEMR - retraction of the mucosal defect via scarring and 
exposure of residual adenoma.  In addition, with the knowledge of particular complexities of 
the previous procedure, one can of course employ an alternative approach to optimize 
access; different endoscope, a short transparent cap, patient position etc.   
Younger patients, lesions with high-grade dysplasia and lesions with large Is components 
were more likely to be referred for surgery rather than tsEMR when ssEMR failed.  These 
factors highlight the benefits of tsEMR and the situations in which it is most useful.  The 
disadvantages of surgery versus EMR (2) are magnified with advancing age and 
comorbidity.  If the patient, their family and the physician agree that resection of the LSL is 
appropriate, tsEMR may offer an attractive solution.   Large Is components may be a marker 
 Chapter 7 Manuscript  | Page 14 
for particularly difficult EMR procedures and the endoscopist must consider the patient and 
their future trajectory – i.e. if a lesion is complex to resect and these difficulties will likely be 
encountered again at the tsEMR procedure in a surgically fit patient then surgery is likely the 
better option. High-grade dysplasia in the histology of the first EMR may be a marker for 
more serious unresected pathology or propagation of adenoma in between procedures and 
these lesions should not wait for definitive treatment.   
The commonest techniques employed to resect residual adenoma at tsEMR were further 
snare resection with or without additional thermal therapy in almost 80% and cold forceps 
avulsion with adjuvant snare tip soft coagulation after its introduction in mid-2012.  The 
ability to ensnare adenoma that was previously inaccessible was mainly due to the retraction 
effect of scarring discussed above.  Failure of tsEMR was predicted only by increasing 
lesion size and this group contained some very large lesions (maximum diameter 120mm).  
There is a large body of evidence for the safety and efficacy of ssEMR (20),(21),(22); due to 
its superior safety profile compared to surgery and simplicity compared to endoscopic 
submucosal dissection it has become the primary technique for the treatment of LSL.  Since 
the tsEMR technique is analogous to ssEMR one would expect a similar complication profile.   
In this series a single adverse event involving uncontrolled bleeding was resolved with 
angio-embolisation and was attributed to the scarred area from the initial EMR being fibrotic 
and therefore difficult to close with endoscopic clips.  There were no episodes of delayed 
perforation or delayed bleeding at tsEMR. 
Rates of RRA after tsEMR were significantly higher than those seen after ssEMR of naïve 
and previously attempted LSL.  In addition rates of surgery at SC2 and SC3 were 
significantly higher than lesions that underwent ssEMR of naïve LSL and need for surgery 
was related to an inability to resect the RRA endoscopically in all but one case.  Overall, 
however, LSL which underwent first follow up examination after successful tsEMR for benign 
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disease avoided surgery in >80% of cases to longest follow up and there was no evidence 
that propagation of residual adenoma between procedures led to invasive malignancy. 
Several important considerations flow from the high rates of RRA and surgery after tsEMR.  
Firstly meticulous follow up is required with careful attention to the EMR scar (23).  This 
should be performed at the tertiary centre that undertook the resection, particularly for SC1, 
and if there is any doubt biopsies should be taken from the EMR scar.  RRA should be 
treated using standard techniques (24).  Secondly comprehensive information must be 
communicated to the patient, with agreement from both parties, prior to embarking upon a 
tsEMR strategy.  Particularly they must understand that more procedures will be required to 
achieve adenoma clearance with tsEMR than ssEMR and this may translate into lost 
workdays or morbidity related to the procedure or bowel preparation.  They must also 
understand that compliance with follow up examinations is mandatory.  The metachronous 
cancer detected in a patient at SC1 serves as a reminder to practitioners of the need to 
inspect the whole colonic mucosal surface when undertaking surveillance procedures after 
EMR of LSL (25). 
tsEMR may be viewed by some authorities as a means to complete procedures that the 
endoscopist should not have initially attempted as they were too complex for their skillset.  
Indeed, splitting our cohort into two shows that the rate of ssEMR in lesions attempted 
increased over the second four-year period.  This is almost certainly due to the technical skill 
and increased understanding of the study endoscopists.  However, while the need for tsEMR 
decreased, the proportion of lesions referred for tsEMR versus surgery did not change and 
this suggests a role for the procedure independent of the skill of the endoscopist.   In support 
of this the proportion of patients requiring tsEMR for non-lifting adenoma and access to the 
lesion did not change between the two periods.   
The strengths of this study include the involvement of four academic tertiary referral centres, 
the consecutively described lesions over eight years collected in a prospective fashion, and 
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the meticulously described outcomes of all the lesions described in the study.  However, the 
small number of patients and retrospective description of their outcomes means that this can 
be at best described as a pilot study.  There was also insufficient data available for 
histological analysis of the EMR scar later than SC1 for meaningful analysis.  There was a 
high rate of drop out between SC1 and later examinations, particularly due to patients not 
attending for surveillance due to age and or comorbidity.  Of course this has much to do with 
the cohort who benefit the most from tsEMR, but also describes the nature of medicine in 
rural Australia where attendance at a tertiary centre many miles from the patient’s home is 
often not practical.  
In conclusion, this study demonstrates the feasibility of the previously unreported technique 
of completing an EMR procedure at a separate session. tsEMR is a safe and effective 
technique which, whilst it cannot be recommended as a first line therapy, can be a useful 
salvage therapy when ssEMR fails at a tertiary endoscopy centre, particularly when surgery 
is not preferred or not possible.  Such lesions may be expected to be encountered more 
frequently as EMR becomes the primary technique for resection of LSL. Compliance with 
high quality endoscopic surveillance is mandatory since RRA is commonplace.   
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TABLES 
 tsEMR p ssEMR p 
   Naïve LSL Previously 
attempted 
LSL 
 
Total number of LSL 43  1621 196  
      
Patient      
Age, mean (STD) 70.0 
(9.75) 
.117 67.2 (11.9) 69.2 
(10.2) 
.022 
Sex, male (%) 23 (53.5) .786 833 (51.4) 109 (55.6) .264 
Time of case within cohort (first 
half, %) 
30 (69.8) .001 714 (44.0) 97 (49.5) .148 
      
Lesion      
Size, median (IQR) 50 (35-60) <.001 30 (25-45) 30 (25-40) .075 
Paris (%)      
0-Is 5 (11.9) .749 278 (17.2) 37 (19.0) .316 
0-IIa 21 (50.0) 818 (50.7) 106 (54.4) 
0-IIa/Is 12 (28.6) 396 (24.5) 36 (18.5) 
Others (IIb, IIa+c, etc) 4 (9.5) 123 (7.6) 16 (8.2) 
Morphology (%)      
Granular 28 (65.1) .688 949 (58.5) 100 (51.0) .023 
Non granular 9 (20.9) 399 (24.6) 66 (33.7) 
Unable to classify 6 (14.0) 273 (16.8) 30 (15.3) 
      
Location (%)      
Left colon 19 (44.2) .691 766 (47.3) 104 (53.1) .124 
Right colon 24 (55.8) 855 (52.7) 92 (46.9) 
En bloc (%) 0 (0) .002 288 (17.8) 18 (9.2) .002 
Resection attempt prior to EMR 
(%) 
12 (27.9) <.001 0 (0) 196 (100) <.001 
      
Procedure      
Submucosal fibrosis (%) 25 (58.1) <.001 301 (18.6) 124 (63.3) <.001 
Intra-procedural bleeding (%) 10 (23.8) .285 276 (17.0) 26 (13.3) .182 
Intra-procedural perforation (%) 2 (4.7) .705 69 (4.3) 14 (7.1) .068 
Histopathology (%)      
Tubular adenoma 19 (44.2) .005 385 (24.6) 59 (30.3) .034 
Tubulovillous adenoma 22 (51.2) 907 (58.0) 110 (56.4) 
Serrated adenoma 2 (4.7) 271 (17.3) 21 (10.8) 
Technical success (%)* 36/43 
(83.7) 
.007 1621/1708 
(94.9) 
196/236 
(83.1) 
<.001 
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Complication      
Clinically significant post 
endoscopic bleeding (%) 
0 (0) .258 74 (4.6) 8 (4.1) .758 
Delayed perforation (%) 0 (0) 1.000 3 (0.2) 1 (0.5) .367 
      
Surgical referral prior to first 
surveillance 
7 (16.3) .006 81 (5.0) 18 (9.2) .015 
 
Table 1; Patient and lesion characteristics split by whether or not the procedure was 
completed in a single session (ssEMR) [further divided by whether a previous 
attempt was made at the referring institution or not (naïve LSL)] or completion was 
delayed for a two stage procedure (tsEMR).  Procedural and complication 
characteristics for tsEMR relate to the second stage procedure, lesion factors to the 
first stage.  tsEMR - two stage endoscopic mucosal resection, STD - standard 
deviation, IQR – interquartile range.  Not all data points were available for all lesions. 
*note the different denominator for technical success since this includes all 
attempted lesions.  P values indicate comparison to naïve LSL. 
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Failed ssEMR Surgery tsEMR 
planned 
p 
Total number of lesions 78 49  
    
Patient    
Age, mean (STD) 66.0 (11.7) 70.4 (9.5) .049 
Sex, male (%) 43 (55.1) 24 (49.0) .499 
    
    
Lesion    
Size, median (IQR) 40 (30-60) 50 (35-60)  .303 
Paris (%)    
0-Is 21 (26.9) 7 (14.6) .008 
0-IIa 18 (23.1) 22 (45.8)  
0-IIa/Is 17 (21.8) 14 (29.2)  
Others (IIb, IIa+c, etc) 22 (28.2) 5 (10.4)  
Morphology (%)    
Granular 38 (48.7) 30 (61.2) .317 
Non granular 25 (32.1) 10 (20.4)  
Unable to classify 15 (19.2) 9 (18.4)  
    
Location (%)    
Left colon 35 (44.9) 22 (44.9) .998 
Right colon 43 (55.1) 27 (55.1)  
    
Submucosal fibrosis (%) 33 (42.3) 26 (53.1) .237 
Intra-procedural bleeding (%) 9 (15.5) 11 (22.9) .332 
Intra-procedural perforation (%) 5 (6.4) 2 (4.1) .706 
Histopathology (%)    
Tubular adenoma 21 (30.0) 20 (40.8) .118 
Tubulovillous adenoma 48 (68.6) 26 (53.1)  
Serrated adenoma 1 (1.4) 3 (6.1)  
Dysplasia    
None 3 (4.0) 2 (4.1) .010 
Low grade 31 (41.3) 33 (67.3)  
High grade 41 (54.7) 14 (28.6)  
 
Table 2; Patient and lesion characteristics after failed ssEMR split by whether or not 
the lesion was referred for surgery or booked for tsEMR.  ssEMR - single session 
endoscopic mucosal resection, tsEMR – two stage endoscopic mucosal resection, 
STD – standard deviation, IQR – interquartile range. Not all data points were 
available for all lesions 
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Follow up tsEMR p ssEMR p 
   
Naïve LSL 
Previously 
attempted 
LSL 
 
      
Months to SC1, 
median(IQR) 
6.7 
(5.9-9.9) <.001 
5.1 
(4.0-6.7) 
4.8 
(3.8-6.4) .119 
RRA at SC1 (%) 13/33 (39.4) <.001 
166/1224 
(13.6) 
28/158 
(17.7) .157 
      
Surgery at SC1 (%) 2/33 (6.1) .064 
14/1224 
(1.1) 
1/158 
(0.6) 1.000 
      
Months to SC2,  
median(IQR) 
14 
(11.4-22.5) .098 
17.7 
(14.7-22.0) 
17.8 
(14.0-21.3) .728 
RRA at SC2 (%) 6/23 (26.1) .001 
31/592 
(5.2) 
8/99 
(8.1) .256 
Surgery at SC2 (%) 2/23 (8.7) .008 
2/592 
(0.3) 
2/99 
(2.0) .100 
      
Months to SC3, 
median(IQR) 
40.1 
(33.7-48.0) .104 
33.3 
(25.4-42.9) 
29.6 
(24.3-42.8) .389 
RRA at SC3 (%) 2/12 (16.7) .094 
5/142 
(3.5) 
5/22 
(22.7) .004 
Surgery at SC3 (%) 2/12 (16.7) .016 
1/142 
(0.7) 
1/22 
(4.5) .251 
 
Table 3; Follow up data from the cohort with rates of RRA to specific follow up 
intervals. The number of patients undergoing each stage of follow up is included as 
the denominator in each case. RRA – residual or recurrent adenoma, tsEMR – two 
stage endoscopic mucosal resection, ssEMR – single session endoscopic mucosal 
resection, SC1,2,3 – surveillance colonoscopy 1,2,3, IQR – interquartile range.  P 
values indicate comparison to naïve LSL. 
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 First Half of 
Cohort 
Second Half of 
Cohort 
 
 
Lesion outcomes 
 
n = 897 
 
n = 1047  
ssEMR 811 (90.4%) 1006 (96.1%) 
.001 tsEMR 35 (3.9%) 14 (1.3%) 
Surgery 51 (5.7%) 27 (2.6%) 
 
After failed ssEMR 
 
n = 86 
 
n = 41  
tsEMR 35 (40.7%) 14 (34.1%) .478 Surgery 51 (59.3%) 27 (65.9%) 
    
Reason for tsEMR n = 30 n = 13  
Non-lifting 12 (40.0%) 6 (46.2%) 
.833 Access 12 (40.0%) 4 (30.8%) 
Other 6 (20.0%) 3 (23.1%) 
    
Failure of tsEMR    
Need for surgery 5 (16.7%) 2 (15.4%) 1.0 
 
Table 4; Fate of lesions split by temporal location within the lesion cohort (9/2008 
until 6/2016) and details of their resection. n= delineates number of eligible lesions 
for the described proportion. tsEMR – two stage endoscopic mucosal resection, 
ssEMR – single session endoscopic mucosal resection. 
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Patient 
Age 
Size 
of 
LSL 
Location Paris Mo
rph
olo
gy 
Histo
logy 
Dysplasia Time Reason for surgery Surgical outcome 
83 50 C, ICV IIa/Is G TVA HGD 1 Deep ileal infiltration Residual adenoma, LGD 
82 100 R > 5cm anus IIa/Is G TVA LGD 1 NL Residual adenoma, LGD 
69 50 Ascending IIa G S LGD 1 NL Residual serrated tissue, LGD 
59 120 Descending IIa G TA LGD 1 Access, stenosis Residual adenoma, HGD 
71 120 Hepatic 
flexure 
IIa/Is G TVA HGD 1 Suspect SMIC Residual adenoma, HGD 
63 50 C, ICV IIa/Is G TVA HGD 2 Access Residual adenoma, HGD 
72 40 Ascending IIa NG TA HGD 2 NL Residual adenoma, HGD 
 
Supplementary Table 1; Detailed characteristics of lesions that underwent surgery having failed tsEMR.  tsEMR – two stage endoscopic 
mucosal resection, LSL - laterally spreading lesion, C – caecum, ICV – ileo-caecal valve, R – rectum, G – granular, NG – non-granular, TVA – 
tubulovillous adenoma, S – serrated lesion, TA – tubular adenoma, time – timing within the lesion cohort (1 – first half, 2- second half), LGD – low 
grade dysplasia, HGD – high grade dysplasia, NL – non-lifting, SMIC – submucosal invasive cancer 
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Age Size of 
LSL 
Location Paris Morp
holog
y 
Histolog
y 
Dysplasia Surgery 
Stage 
Prior 
surveill
ance 
Half 
of 
coh
ort 
Reason for surgery Surgical outcome 
79 35 C, ICV  IIa/Is G TA LGD SC1 na 1 Fibrosis and NL Referred, did not 
undergo due to 
age and 
comorbidity 
78 35 Sigmoid IIa G TVA LGD SC1 na 1 Metachronous 
lesion 
TVA, LGD in 
area of sigmoid 
LSL 
73 40 Transverse IIa NG TA HGD SC2 - 2 Fibrosis and NL TA, HGD 
83 30 Transverse IIa NG TA HGD SC2 + 1 Fibrosis and NL TA, HGD 
69 60 C, ICV  IIa G TVA LGD SC3 - 1 Fibrosis and NL TVA, HGD 
59 40 C, ICV IIa G TA LGD SC3 - 1 Fibrosis and NL TA, HGD 
Supplementary table 2; Detailed characteristics of lesions that underwent surgery during follow up due to recurrence after successful tsEMR.  tsEMR – 
two stage endoscopic mucosal resection, LSL - laterally spreading lesion, C – caecum, ICV – ileo-caecal valve, G – granular, NG – non-granular, 
TVA – tubulovillous adenoma, TA – tubular adenoma, LGD – low grade dysplasia, HGD – high grade dysplasia, SC 1,2,3 – surveillance 
colonoscopy 1,2,3, NL – non-lifting, LSL – laterally spreading lesion 
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1 FIGURE LEGENDS 
Figure 1; Two stage endoscopic mucosal resection.  a) a large 35mm resection-naive non-granular LSL is shown in the ascending colon, b) standard inject 
and resect EMR is used to isolate a non-lifting central component, c) a stiff thin-wire snare is used to attempt resection of the central non-lifting component, d) 
ultimately the non-lifting component cannot be fully resected by snare and the patient is booked for a second stage procedure.  e) Appearance of the EMR 
scar at 1.5 months after the initial EMR; scarring can be seen to highlight the residual adenoma, f) after injection a thin wire snare is used to resect the 
residual adenoma and, g) argon plasma coagulation is applied to the resection bed and surrounding scar tissue. h) Appearances of the EMR scar at SC1 with 
no evidence of recurrence. LSL – laterally spreading lesion, EMR – endoscopic mucosal resection, SC1 – surveillance colonoscopy 1 
 
Figure 2; Two stage endoscopic mucosal resection of a previously attempted LSL.  a) 50% circumferential previously attempted granular LSL in the distal 
rectum extending to the anal verge is shown, b+c) standard inject and resect EMR is used to isolate a non-lifting central component that cannot be resected 
by the end of the initial procedure.  The patient is booked for tsEMR.  d) Appearance of the EMR scar at 1 month after the initial EMR demonstrating an area 
of central residual adenoma, e) multiple snare excision with coagulation current is used to resect the non-lifting adenoma and, f) snare tip soft coagulation is 
applied to the resection bed and surrounding scar tissue. g,h) Appearances of the EMR scar under high definition white light and narrow band imaging at SC1 
with no evidence of recurrence.  LSL – laterally spreading lesion, EMR – endoscopic mucosal resection, SC1 – surveillance colonoscopy 1. 
 
Figure 3; Recruitment to the study from 4 academic tertiary referral centres is shown.  EMR – endoscopic mucosal resection, ssEMR – single session EMR, 
SC1 first surveillance colonoscopy, IQR – interquartile range. 
 
 
Figure 4; Description of the outcomes of the 236 previously attempted lesions included in the cohort compared with naïve lesions.  EMR – endoscopic 
mucosal resection, tsEMR – two stage EMR.  Technical success denotes a complete removal/destruction of adenomatous tissue. 
 
Supplementary Figure 1; Outcomes of the 43 lesions that underwent a two stage procedure (tsEMR). RRA – residual or recurrent adenoma. SC1 first 
surveillance colonoscopy, SC2 second surveillance colonoscopy, SC3+ later surveillance, IQR – interquartile range. 
 
Figure 1; Two stage endoscopic mucosal resection. a) a large 35mm resection-naive non-granular LSL is shown in the ascending colon, b) standard inject 
and resect EMR is used to isolate a non-lifting central component, c) a stiff thin-wire snare is used to attempt resection of the central non-lifting component, d) 
ultimately the non-lifting component cannot be fully resected by snare and the patient is booked for a second stage procedure. e) Appearance of the EMR 
scar at 1.5 months after the initial EMR; scarring can be seen to highlight the residual adenoma, f) after injection a thin wire snare is used to resect the 
residual adenoma and, g) argon plasma coagulation is applied to the resection bed and surrounding scar tissue. h) Appearances of the EMR scar at SC1 with 
no evidence of recurrence. LSL — laterally spreading lesion, EMR — endoscopic mucosal resection, SC1 — surveillance colonoscopy 1
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Figure 2; Two stage endoscopic mucosal resection of a previously attempted LSL. a) 50% circumferential previously attempted granular LSL in the distal 
rectum extending to the anal verge is shown, b+c) standard inject and resect EMR is used to isolate a non-lifting central component that cannot be resected 
by the end of the initial procedure. The patient is booked for tsEMR. d) Appearance of the EMR scar at 1 month after the initial EMR demonstrating an area 
of central residual adenoma, e) multiple snare excision with coagulation current is used to resect the non-lifting adenoma and, f) snare tip soft coagulation is 
applied to the resection bed and surrounding scar tissue. g,h) Appearances of the EMR scar under high definition white light and narrow band imaging at SC1 
with no evidence of recurrence. LSL — laterally spreading lesion, EMR — endoscopic mucosal resection, SC1 — surveillance colonoscopy 1.
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Figure 3; Recruitment to the study from 4 academic tertiary referral centres is shown. EMR — endoscopic mucosal resection, ssEMR — single session EMR, 
SC1 first surveillance colonoscopy, IQR — interquartile range.
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Figure 4; Description of the outcomes of the 236 previously attempted lesions included in the cohort compared with na  ve lesions. 
mucosal resection, tsEMR — two stage EMR. Technical success denotes a complete removal/destruction of adenomatous tissue.
EMR — endoscopic
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Supplementary Figure 1; Outcomes of the 43 lesions that underwent a two stage procedure (tsEMR). RRA — residual or recurrent adenoma. SC1 first 
surveillance colonoscopy, SC2 second surveillance colonoscopy, SC3+ later surveillance, IQR — interquartile range.
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Synopsis and Significance 
When lesions undergoing tsEMR were compared with those which were completed in a single 
session (ssEMR) there was no difference in terms of safety.  81.8% of LSL that underwent 
tsEMR for benign disease avoided surgery to long term follow up.  Amongst a population of 
lesions that would otherwise have been referred for surgery these are excellent outcomes.  
tsEMR therefore shows promise as a salvage therapy for LSL that cannot be resected in a single 
session, or for patients in whom other resection options such as surgery are not preferred or not 
possible. 
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Chapter 8 - Cold-forceps avulsion with adjuvant snare-tip soft coagulation 
(CAST) is an effective and safe strategy for the management of non-lifting 
large laterally spreading colonic lesions. 
Introduction 
Non-lifting LSL are commonly encountered in tertiary endoscopic resection practice.  Non-
lifting describes the situation during endoscopic resection where the target tissue does not 
elevate after adequate submucosal injection due to fibrosis within the submucosal layer.  
Causes of submucosal fibrosis are numerous but the commonest are previous biopsy, previous 
attempt at endoscopic resection or previous injection of carbon particle suspension.  Invasive 
malignancy can also cause submucosal fibrosis. 
Following from the previous chapter, this chapter describes a study6 investigating the use of a 
novel technique to remove non-lifting LSL.  The technique, known as cold avulsion with 
adjuvant snare tip soft coagulation (CAST), uses a readily available biopsy forceps and the 
same snare that has been used for the endoscopic mucosal resection.  The key to the success of 
the technique is the resection of lifting tissue to isolate an area of non-lifting adenoma.  This 
can then be gently avulsed from the underlying submucosa using a biopsy forceps with soft 
coagulation current applied to the avulsion bed using a light-touch technique.  The technique 
is demonstrated in the video associated with the chapter.   
The aim of the study was to demonstrate that CAST was a safe and effective technique to treat 
non-lifting LSL. 
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Abbreviations 
EMR Endoscopic mucosal resection 
SC1 First surveillance colonoscopy after EMR 
SC2 Second surveillance colonscopy after EMR 
LSL Laterally spreading lesion 
NBI Narrow band imaging 
Recurrence Adenoma or suspicion thereof at an EMR scar 
  
CAST Cold forceps avulsion and adjuvant snare tip soft coagulation 
L-LSL Lifting laterally spreading lesion having undergone complete snare excision 
NL Non-lifting 
NL-LSL Non-lifting laterally spreading lesion 
NNL-LSL Naïve non-lifting laterally spreading lesion 
PANL Previously attempted non-lifting laterally spreading lesion 
  
STSC Snare tip soft coagulation 
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Cold forceps avulsion with adjuvant snare tip soft coagulation (CAST) is 
an effective and safe strategy for the management of non-lifting large 
laterally spreading colonic lesions (NL-LSL) 
Abstract 
BACKGROUND AND AIMS: Non-lifting (NL) large laterally spreading colorectal lesions 
(NL-LSL) are challenging to resect endoscopically and often necessitate surgery. A safe, 
simple technique to treat NL-LSL endoscopically with robust long term outcomes has not 
been described. 
METHODS: Amongst a single-centre prospective observational study of consecutive patients 
referred for endoscopic mucosal resection (EMR) of laterally spreading colonic lesions ≥ 
20mm, LSL not completely resectable by snare due to NL had standardised completion of 
resection with cold forceps avulsion and adjuvant snare tip soft coagulation (CAST). 
Scheduled surveillance colonoscopy was performed at 4-6 (SC1) and 18 months. Primary 
outcomes were endoscopic evidence of adenoma clearance and avoidance of surgery. The 
secondary outcome was safety. 
RESULTS: From January 2012 to October 2016, 540 (82.2%) lifting LSL (L-LSL) underwent 
complete snare excision at EMR. 101 (17.8%) NL-LSL (63 naive, non-lifting LSL (NNL, 
62.7%) and 38 previously attempted non-lifting LSL (PANL, 37.3%)) required CAST for 
complete removal. PANL were smaller (p<.001) and more likely non-granular (p=.001) 
than L-LSL. NNL were of similar size (p=.773) and morphology (p=.101) to L-LSL. CAST 
was successful in all cases and adverse events were comparable to L-LSL resected by 
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complete snare excision.  Recurrence at SC1 was comparable for PANL (15.2%) and L-LSL 
(15.3%, p=.985), whereas NNL recurred more frequently (27.5%, p=.049), however 
surgery was no more common for either type of NL-LSL than L-LSL. 
CONCLUSION: CAST is a safe, effective and surgery sparing therapy for the majority of NL-
LSL. It is easy to use, inexpensive and does not require additional equipment.  
Clinicaltrials.gov (NCT 2000141). 
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Impact statement 
Current knowledge 
• Non-lifting large and laterally spreading lesions (NL-LSL) of the colo-rectum are 
challenging to remove endoscopically and often necessitate surgery. 
• NL-LSL may be caused by a previous resection attempt (PANL), prior biopsy 
sampling or SPOT marking, or lesion biology (NNL) 
• Techniques to remove NL-LSL have been described in small, single centre expert 
studies but all suffer from either increasing the complexity of the procedure, limited 
case experience and follow up or lack of availability 
This study adds 
• Cold avulsion and adjuvant snare tip soft coagulation (CAST) is a simple technique 
that can be mastered by any endoscopist.  It is safe and avoided surgery in 99% of 
patients eligible for first follow up who would otherwise have required surgery for 
NL-LSL 
• PANL treated by CAST recur at the same frequency as lifting LSL with complete 
snare excision whereas NNL recur more frequently.  
• Efforts should be directed to matching lesion complexity with 
endoscopist/departmental skill levels and to identifying NNL and signposting them 
to tertiary endoscopy centres. 
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Introduction 
Endoscopic mucosal resection (EMR) is now the standard of care for large laterally 
spreading colorectal lesions (LSL) and a growing body of evidence demonstrates the 
efficacy and durability of endoscopic resection [1] and the superior cost and safety profile 
as versus surgery [2-4]. As increasing numbers of LSL are resected by EMR, tertiary 
endoscopy centres encounter more LSL whose resection has been previously attempted 
(PANL, previously attempted non lifting LSL), or which have been biopsied or marked with 
carbon particle suspension. All these insults are recognised to lead to non-lifting (NL) by 
inducing submucosal fibrosis with consequent obliteration of the submucosal plane and 
thereby increasing the complexity of endoscopic resection.  With the mucosa closely 
approximated or adherent to the muscularis propria, snare capture is more difficult and 
there is a higher likelihood of capturing the deep muscle layer within the ensnared tissue 
with subsequent deep mural injury or frank perforation[5]. 
Traditionally surgery was required to manage non-lifting LSL, (NL-LSL). Endoscopic 
techniques to treat NL-LSL have been described but all suffer from either increasing the 
complexity of the procedure, limited case experience and follow up or lack of availability 
[6-9]. There is a clear need for a safe, reliable, cost effective endoscopic treatment for NL-
LSL that is easy to use and leads to durable long term results. 
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Methods 
EMR Procedure 
All EMR procedures were performed by senior endoscopists with extensive EMR experience 
or by a senior endoscopy fellow under their direct supervision. Written informed consent 
was obtained from all patients. Split dose bowel preparation was used. Intravenous 
sedation was with a combination of fentanyl, midazolam and propofol.  Consensus stopping 
rules for antiplatelet and anticoagulant agents in patients undergoing high risk endoscopic 
procedures were applied [10].  Insufflation of the colon was with carbon dioxide in all 
cases.  Colonoscopy was performed using Olympus 180 or 190 series high-definition 
variable-stiffness colonoscopes (180/190 PCF/CF; Olympus, Tokyo, Japan). A standardized 
and previously described inject-and-resect EMR technique [11] was used. All cases used a 
microprocessor-controlled electrosurgical generator (Endocut effect 3, VIO 300D; ERBE 
Elektromedizin, Tübingen, Germany) with fractionated current. The submucosal injectate 
comprised succinylated gelatin (Gelofusine; B. Braun Australia Pty Ltd, Bella Vista, 
Australia). The fluid was dyed with indigo carmine blue (80 mg/ 500 mL solution) and 
epinephrine was added to achieve a final solution of 1:100,000. Occasionally methylene 
blue was used as an alternative when indigo carmine blue was not available. 
Consecutive EMR procedures during the study period were included. Patients enrolled and 
randomised to the active arm of the SCAR study (Snare Tip Soft Coagulation to Prevent 
Adenoma Recurrence Following EMR, NCT NCT01789749) were excluded. There were no 
other exclusion criteria.  Lesions at and proximal to the hepatic flexure were deemed to be 
located in the right colon. Prior to resection all lesions were carefully assessed with high 
definition white light and narrow band imaging.  Resection was predominantly with a 
15mm or 20mm snare (SnareMaster; Olympus, Tokyo, Japan). A stiff, thin wire (0.3mm 
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wire diameter [TeleMed 10mm Hexagonal, Telemed Systems Inc, MA, USA]) snare was 
used in the case of non-lifting adenoma. Complete snare excision was the goal in all cases.  
LSL with adequate lifting after submucosal injection and complete snare excision were 
labelled L-LSL. LSL which failed complete snare excision due to NL were labelled NL-LSL. 
These were divided into previously attempted non-lifting LSL (PANL) which had undergone 
a prior endoscopic resection and naïve, non-lifting LSL (NNL) Figure 1. NL-LSL had 
completion of resection using a standardised approach with cold forceps avulsion and 
adjuvant snare tip soft coagulation (CAST) Figure 2, Video 1. Prior to CAST the NL area 
was isolated by snare excision of all adjacent tissue including adenoma and/or normal 
mucosa to free the lateral margins. Systematic cold forceps (Radial Jaw Biopsy Forceps, 
Boston Scientific, Massachusetts, USA) avulsion was then performed to remove all visible 
NL adenoma. The exposed submucosa of the avulsion site and its margins were then 
treated with controlled thermal ablation using snare tip soft coagulation (STSC) (ERBE 
effect 4, 80W, VIO 300D generator; ERBE Elektromedizin, Tübingen, Germany).  The 
endomucosal defect was graded using the Sydney Classification of Deep Mural injury [12].  
Areas of endomucosal defects exhibiting type II to V deep mural injury were routinely 
closed with endoscopic clips (Instinct clip, Cook Medical, Bloomington, Indiana, United 
States).  Intra-procedural perforation was described as target sign[13] or actual hole in the 
colonic wall (Sydney deep mural injury classification III, IV and V). 
Specialist gastrointestinal pathologists at the study centre reviewed all histological 
specimens. After EMR, patients were observed for 4 hours and discharged home if well. A 
clear fluid diet was advised until the next morning. Patients were contacted by the study 
co-ordinator at two weeks and a structured telephone interview performed to assess for 
adverse events. Delayed bleeding was described as bleeding after the procedure and was 
recorded if it required readmission or endoscopic intervention.  The study was approved by 
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the Western Sydney Local Health District Human Research Ethics Committee and registered 
with ClinicalTrials.gov (NCT 2000141). 
 
Follow up 
All lesions were evaluated for endoscopic recurrence at surveillance colonoscopy 1 (SC1) 
and later if undertaken. Patients were excluded if they were referred for surgery at the time 
of the initial EMR based on lesion morphology or histopathology. Patients with missing 
data were regarded as lost to follow up. The primary endpoints of the study were 
endoscopic recurrence (unless otherwise stated ‘recurrence’ throughout this manuscript 
refers to endoscopic recurrence), defined as the presence of tissue suspicious for adenoma 
under high definition white light (HDWL) and/or NBI and avoidance of surgery. When 
there was any doubt as to the presence of recurrence endoscopically, biopsies of the EMR 
scar were taken to document the absence of histological recurrence. Late endoscopic 
recurrence was defined as recurrence occurring after a negative previous surveillance 
procedure.  Figure 3 shows an example of a PANL treated by CAST with appearances of the 
endoscopic resection scar at SC1.  Detected recurrence, once sampled, was excised by snare 
or (if this was not possible) removed by CAST. The secondary endpoints of the study were 
rates of adverse events including intra-procedural bleeding requiring endoscopic control, 
delayed bleeding and delayed perforation. 
 
Statistical analysis 
Statistical analysis was performed using SPSS version 23 (Armonk, New York, USA) with 2-
tailed t-test used for parametric continuous variables, Mann Whitney U Test for non-
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parametric continuous data and chi-squared test for categorical variables. Significance of p 
was regarded at <.05. Multiple lesions within the same patient were excluded to avoid the 
bias associated with correlated findings for a single patient; in this case the largest LSL or 
the NL-LSL (if smaller) was retained. 
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Results 
From January 2012 to October 2016, 829 patients with 929 lesions were referred for EMR 
(Figure 4). 51.0% were male and 52.7% were located in the right colon. EMR was 
attempted on 787 LSL (94.9%). 130 LSL enrolled and randomized to the active arm of the 
SCAR study were excluded. Of the 657 remaining eligible LSL, 540 (82.2%) were 
completely resected by snare and labelled L-LSL. 117 (17.8%) LSL failed complete snare 
excision due to NL and were labelled NL-LSL. Of these 16/117 (13.7%) were referred for a 
second stage procedure since there was extensive residual adenoma. The remainder 
(101/117 (86.3%)) were treated with CAST. 
Amongst NL-LSL there were 38 PANL and 63 NNL. Key comparisons between NL-LSL and 
L-LSL are presented in Table 1. PANL were smaller than L-LSL (median size 27.5mm (IQR 
20-40) versus 35mm (IQR 30-50), p<.001) and more often non-granular (NG) in 
morphology (23/38 (60.5%) versus 172/540 (31.9%), p=.001.  They invariably 
demonstrated submucosal fibrosis within the resection site (38/38, 100%) and took longer 
to resect than L-LSL (median time 35 minutes (IQR 21.3-47.5) versus 20 minutes (IQR 15-
35), p=.003). NNL were similarly sized to L-LSL (median size 40mm (IQR 30-50), p=.773) 
and were not more likely to be NG (28/63 (44.4%), p=.101). Similar to PANL they took 
longer to resect than L-LSL (median time 30 minutes (IQR 20-41.3), p=.002).  Both PANL 
(31/38, 81.6%, P<.001) and NNL (47/63, 74.6%, P=.036) were more commonly of Paris 
0-IIa morphology than L-LSL (294/540, 54.4%).  Neither type of NL-LSL was distributed 
differently throughout the colon compared to L-LSL (PANL 15/38 (39.5%) located in the 
right colon, p=.094 and NNL 34/63 (54.0%) located in the right colon, p=.946 versus 
289/540 (53.5%) for L-LSL). 
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Both PANL and NNL were biopsied more commonly than L-LSL (PANL 17/38, 44.7%, p < 
.001, NNL 19/63, 30.2%, p<.001 versus L-LSL 72/540, 13.3%) and marked with carbon 
particle suspension (PANL 9/38, 23.7%, p < .001, NNL 14/63, 22.2%, p<.001 versus L-LSL 
24/540, 4.4%). The histopathology of NL-LSL was more often tubular adenoma than L-LSL, 
but this was significant only for NNL (24/63 (38.1%)) versus L-LSL (130/540 (24.1%), 
p=.008). 
Safety 
CAST was successful at complete removal of visible NL adenoma in all 101/101 (100%) 
cases where it was performed. One patient with a previously multiply attempted and 
severely scarred lesion experienced a full thickness perforation secondary to the avulsion 
phase over NL adenoma; this was closed successfully with endoscopic clips without clinical 
sequelae. Pathology in this case showed tubulovillous adenoma with high grade dysplasia.  
Type II deep mural injury was observed more commonly in PANL treated by CAST (7/38 
[18.4%]) versus L-LSL (5/63 [7.9%], P = 0.001.  This difference was not observed for 
NNL-LSL.  There was no difference in rates of intra-procedural bleeding or perforation, 
hospital admission on the night of the procedure, delayed bleeding or delayed perforation 
between NL-LSL treated by CAST and L-LSL which were completely resected by snare 
(Table 1). 
Follow up 
Key features of the follow up of all LSL in the cohort are presented in Table 2. At 2 weeks 
after the initial procedure 1/38 PANL (2.6%, p=.715) and 3/63 NNL (4.8%, p=1.0) versus 
32/540 (5.9%) L-LSL had been referred for surgery due to submucosal invasive cancer in 
the EMR specimen.  1 of these patients with L-LSL had surgery as an inpatient due to a 
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delayed perforation.  1 NNL containing submucosal invasive cancer was managed with 
endoscopic follow up due to the age and wishes of the patient.  
33 PANL, 40 NNL and 340 L-LSL (100, 87.0 and 81.7% of eligible patients respectively) 
underwent first follow up examination (SC1) at median 5.4 months (IQR 4.6 to 6.5).  
Reasons for missing follow up data are presented in Figure 4.  Recurrence at SC1 was 
detected in the EMR scar of 5/33 (15.2%) PANL (p=.985) and 11/40 (27.5%) NNL 
(p=.049) compared with 53/347 (15.3%) L-LSL.  Histologically determined recurrence was 
no different between the groups. Amongst all NL-LSL there was no significant difference 
versus L-LSL in recurrence at SC1 (16/73 (21.9%) versus 53/347 (15.3%), p=.164). 66/69 
(95.6%) cases of recurrence were treated endoscopically at SC1. There were no surgeries in 
the PANL and NNL groups at SC1. 3 (0.9%) patients in the L-LSL group underwent surgery 
due to inability to resect recurrence. 
Data is available on 16 PANL, 24 NNL and 109 L-LSL who have undergone second follow 
up colonoscopy (SC2).  Recurrence was more common in NNL (5/24, 20.8%) than L-LSL 
(5/109, 4.6%, p=.017) whereas PANL recurred at a similar rate to L-LSL (1/16 (6.3%), 
p=.568). Surgery was required in 1 case at SC2 for malignancy within the EMR scar in a 
patient who had CAST for a 40mm NNL with focal high grade dysplasia 11.7 months 
previously. There were no surgeries in the other two groups at SC2.  After 2 follow up 
procedures 94/95 (99.0%) patients that underwent CAST and were eligible for follow up 
avoided surgery. 
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Discussion 
Non-lifting adenoma is difficult to resect endoscopically and has traditionally necessitated 
surgery. A simple, safe and effective technique to manage NL-LSL has not been described. 
In this study cold forceps avulsion and adjuvant snare tip soft coagulation was technically 
successful in the complete removal of all 101 cases of NL adenoma amongst a complex 
population of LSL referred for tertiary endoscopic resection. The adverse event profile was 
similar to that of the standard EMR outcomes for lifting lesions during the same time 
period. In addition adenoma recurrence was not significantly more common overall than 
standard EMR at first surveillance colonoscopy.  Amongst a group of LSL that would 
otherwise have required surgery, 94/95 (99%) patients eligible for follow up avoided 
surgery. 
Other endoscopic techniques to treat NL-LSL have been described but all suffer from 
increasing the complexity of the procedure, limited experience and/or follow up or lack of 
availability. Hot avulsion(8,9) is the most promising technique; first described by Haber et 
al. it is effective and, similar to CAST, can precisely target NL adenoma. Histology of the 
non-lifting area may not be reliably obtained due to electrocautery artifact. In the largest 
(retrospective) description of hot avulsion to date [14], 46 LSL with NL were treated with 
complete snare excision and subsequent hot avulsion within a parent cohort where 49% of 
LSL required methods other than complete snare excision for complete removal (17.8% in 
this study).  The recurrence rate was 10.3% in 29 patients who underwent first follow up.  
No description of later follow up was given.  There is also concern regarding the 
unpredictability of the depth of thermal injury when using hot biopsy forceps for diminutive 
polypectomy [15] and this may be an issue for the hot avulsion technique, although it is 
argued that this risk is mitigated by using cutting current.  
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Circumferential mucosal incision prior to EMR [6] allows resection of NL adenoma by 
creating a mucosal step and enhancing snare capture. The technique is limited by lesion 
size for en bloc resection and the requirement for skill in endoscopic submucosal dissection 
(ESD) techniques to create the mucosal incision. In our experience snare purchase on NL 
adenoma can be improved by using standard EMR technique to resect surrounding lifting 
tissue (both normal and adenomatous) in a similar fashion without the need for ESD 
techniques. 
ESD has been described in the context of NL-LSL in multiple small case series which have 
all found lower rates of en bloc resection with increased rates of complications as versus 
ESD for L-LSL [16] [17-19].  In a recent (retrospective) analysis by Lee et al. [20] 173 
patients with F1 (mild) or F2 (severe) submucosal fibrosis underwent ESD in a Korean 
centre; en bloc resection rates were 93.6% and 77.4% for F1 and F2 fibrosis respectively.  
In the F2 group 19.4% patients experienced a perforation, 27.4% required surgery and 
40.3% of procedures lasted longer than 90 minutes.  While we did not prospectively grade 
the degree of fibrosis in this study, all NL-LSL had submucosal fibrosis comparable to F1 or 
F2.  Considering the median procedure time for EMR with CAST of 30-35 minutes for our 
group of similar sized lesions, the significantly higher rate of complications and surgery 
associated with ESD and the higher opportunity cost of ESD, the CAST technique is 
appealing.   
Forced APC following injection of a saline cushion showed promise in a small single centre 
series [7]but does not allow for histopathological analysis and therefore there is concern 
regarding missed high grade histology within NL adenoma. Also if the submucosa is able to 
be expanded with a saline cushion then snare resection is likely to be possible.  
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We have some experience of completing complex and NL lesions at a second stage 
procedure at our centre[21].  This represents a safe and effective alternative to single 
session EMR when there is extensive residual adenoma.  The downside of this approach is 
the need for a repeat colonoscopy, morbidity, patient compliance, loss of workdays etc. The 
majority of NL-LSL have small areas of NL which are readily amenable to CAST and 
therefore the applicability of two stage EMR is to very complex lesions encountered in 
tertiary centres. 
Recently the use of a device allowing endoscopic full thickness resection in the colon has 
been described [22] in cases of non-lifting adenoma.  The acquisition of full thickness 
histology was described in 21/24 cases (87.5%) in lesions with a mean diameter of 24mm.  
However, the device is large and cumbersome, requires re-insertion of the colonoscope to 
mount and is very expensive.  Future iterations of the device are awaited and may provide 
a useful option for the treatment of PANL.  
CAST is a simple technique that can be performed by all interventional endoscopists. It 
requires no extra equipment in addition to a biopsy forceps which is ubiquitous in 
endoscopy departments worldwide. Key to the technique is the removal of normal and/or 
adenomatous tissue surrounding the NL area with snare prior to attempting CAST. After 
this, NL adenoma tears away from the underlying fibrosis easily once the lateral margins 
have been freed. Accurate targeting of the NL adenoma is possible by working 
systematically and controlling the tip with the shaft of the endoscope. Histology of the non-
lifting area is reliably obtained and this is important due to the association of NL with high 
grade dysplasia and submucosal invasion. A systematic approach should be made to ensure 
complete removal of all visible NL adenoma. STSC is applied to the avulsion bed using the 
tip of the same snare used to perform the EMR. Standard snares produce the best effect. 
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The technique is a light touch of the snare over the avulsion bed and is extremely precise 
and very safe [23] due to the properties of the soft coagulation current. 
The recently described Sydney Classification of Deep mural injury (DMI)[12] describes 5 
levels of potential injury to the colonic wall after EMR that can be identified by features of 
the post EMR defect. As may be evident from the figures, CAST can lead to type II DMI 
within the post EMR defect; this describes focal loss of the submucosal plane raising 
concern for muscularis propria injury or rendering the defect uninterpretable.  It is our 
pratice to close all defects exhibiting type II DMI with endoscopic clips.  There was no 
incidence of delayed perforation within NL-LSL treated with CAST. 
The rates of adenoma recurrence of PANL after the use of CAST are comparable to those 
after resection of L-LSL with complete snare excision, which is remarkable given the 
complexity of these lesions. Moreover, late recurrence – that which occurs after a negative 
surveillance examination – was comparatively rare in all the groups.  While it is therefore 
possible to treat PANL successfully, the optimal scenario would be their avoidance by 
complete snare excision at the first attempt. This is achievable in the vast majority with 
good technique and perhaps more attention should be paid to teaching programmes for 
advanced endoscopy and lesion selection; for example a recent scoring system shows utility 
of predicting the difficulty of EMR from a well-worded referral letter [24]. The reason for 
the higher rate of adenoma recurrence in NNL is not immediately obvious. NNL are a 
population of naïve lesions which all exhibit dense submucosal fibrosis (F1 or F2), are 
biopsied and marked with carbon particle suspension at a similar rate to PANL and do not 
display any evidence of higher rates of submucosal invasive cancer than L-LSL. Further 
study is required to unravel the details but it is possible that NNL are a specific subset of 
LSL with unique biology that makes them difficult to resect endoscopically due to extensive 
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submucosal fibrosis. An ability to predict whether a specific LSL is a NNL would be helpful 
in this context although no such red flag was identified in this study. Overall, despite a 
higher incidence, all recurrences were endoscopically treatable in the NNL group save for 
the single malignancy detected at SC2. 
The only surgery to occur during follow up of the NNL group was for a 40mm tubulovillous 
adenoma with focal high grade dysplasia in the distal transverse colon of a patient with 
serrated polyposis syndrome.  The EMR scar had been reported clear at the first 
surveillance procedure (5.7 months after the index procedure) but had not been biopsied 
and multiple other large lesions were removed during this procedure. At 12 months after 
the index procedure, when the procedure was repeated, a 10mm depressed lesion 
consistent with malignancy was detected in the transverse colon.  The patient was referred 
for surgery and the specimen showed submucosal invasive cancer, SM3, with no lymph 
nodes involved.  On retrospective review of this case it is possible that the scar was not 
correctly visualised at SC1 and the endoscopist was distracted by the multiple other lesions 
and scars. This case demonstrates the need for rigorous follow-up examinations after EMR, 
especially if ablative techniques are used, including localisation and meticulous 
interrogation of the EMR scar with a structured scar assessment [25] using high definition 
white light and narrow band imaging. 
The strengths of the study include the fully characterised, prospectively collected, large 
population of complex NL-LSL with a large comparator cohort of L-LSL, themselves 
complex, serving to highlight the difficulty of resecting NL-LSL even at expert tertiary 
centres.  Excluding 130 lesions with thermal ablation to the margin as part of a randomized 
trial (the SCAR study) allowed a fair comparison of recurrence rates between NL-LSL and 
LSL since NL-LSL were excluded from SCAR.  A limitation of this study is that it comes from 
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a single centre.  In addition further long term follow up data (particularly for the L-LSL 
cohort) is clearly required to validate these initially promising results. Moreover, a large 
multi-centre study would be beneficial to ensure the wider applicability of the technique. 
Conclusion 
In a prospective series of over 100 patients, drawn from a cohort of 829 referred for EMR, 
CAST was a safe, effective and cost-saving method to avoid surgery in patients with non-
lifting adenoma. PANL are similar to L-LSL resected by complete snare excision since once 
they are fully resected they do not recur more frequently.  Methods of matching the 
complexity of a lesion to the skillset of individual operators/departments are required to 
avoid the occurrence of PANL. NNL are a specific subset of lesions whose biology make 
them uniquely more difficult to resect endoscopically due to dense submucosal fibrosis, and 
they recur more frequently.  Further characterisation of NNL to identify and direct them to 
tertiary endoscopic centres is required. 
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Tables 
  PANL 
(n=38) 
P † NNL 
(n=63) 
P † L-LSL 
(n=540) 
Patient      
Age, mean (SD) 69.9 (9.1) .136 71.7 (10.4) .003 66.8 (12.1) 
Male (%) 19 (50.0) .912 33 (52.4) .827 275 (50.9) 
Lesion      
Size (median, IQR) 27.5 (20-40) <.001 40 (30-50) .773 35 (30-50) 
Highest Kudo Pit Pattern (%)*      
II 3 (7.9) .364 4 (6.3) .194 72 (13.5) 
III 16 (42.1)  19 (30.2)  155 (29.0) 
IV 19 (50.0)  40 (63.5)  301 (56.3) 
V 0 (0)  0 (0)  7 (1.3) 
Paris Classification (%)      
0-IIa 31 (81.6) <.001 47 (74.6) .036 294 (54.4) 
0-Is 1 (2.6)  1 (1.6)  33 (6.1) 
0-IIa+Is 1 (2.6)  12 (19.0)  170 (31.5) 
0-IIb 5 (13.2)  3 (4.8)  29 (5.4) 
other 0 (0)  0 (0)  14 (2.6) 
Morphology (%)      
Granular 10 (26.3) .001 29 (46.0) .101 283 (52.4) 
Non-granular 23 (60.5)  28 (44.4)  172 (31.9) 
Unable to classify 5 (13.2)  6 (9.5)  85 (15.7) 
Location proximal to transverse colon (%) 15 (39.5) .094 34 (54.0) .946 289 (53.5) 
Complex** location (%) 7 (18.4) .320 13 (20.6) .085 69 (12.8) 
SMF (%) 38 (100) <.001 64 (100) <.001 143 (26.5) 
Previous resection attempt (%) 38 (100) <.001 0 (0) .019 44 (8.1) 
Previous biopsy (%) 17 (44.7) <.001 19 (30.2) <.001 72 (13.3) 
Marked within carbon particle suspension within 
10mm of LSL (%) 
9 (23.7) <.001 14 (22.2) <.001 24 (4.4) 
Histopathology (%)      
TA 14 (36.8) .240 24 (38.1) .008 130 (24.1) 
TVA 21 (55.3)  35 (55.6)  304 (56.3) 
SSA 3 (7.9)  3 (4.8)  101 (18.7) 
Submucosal invasive cancer (%) 1 (2.6) .715 4 (6.3) .782 32 (5.9) 
Dysplasia (%)      
None 1 (2.6) .162 3 (4.8) .165 63 (11.7) 
LGD 31 (81.6)  44 (69.8)  374 (69.3) 
HGD 6 (15.8)  16 (25.4)  103 (19.1) 
Procedure      
Duration (min, IQR) 35 (21.3-
47.5) 
.003 30 (20-
41.3) 
.002 20 (15-35) 
IPB (%) 5 (13.2) .076 18 (28.6) .675 141 (26.1) 
Sydney Classification Type II Deep Injury (%) 7 (18.4) .001 5 (7.9) .168 20 (3.7) 
Intra-procedural perforation*** (%) 2 (5.3) .642 1 (1.6) .711 19 (3.5) 
Clip closure of endoscopic resection defect (%) 9 (23.7) .143 10 (15.9) .823 80 (14.8) 
Delayed bleeding (%) 1 (2.6) .502 5 (7.9) .795 38 (7.0) 
Delayed perforation (%) 0 (0) 1.0 0 (0) 1.0 1 (0.2) 
Overnight hospital admission on day of EMR (%) 2 (5.3) 1.0 6 (6.3) 1.0 37 (6.9) 
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Table 1 Lesions where cold forceps avulsion and snare tip soft coagulation (CAST) was 
used in the resection of PANL or NNL; † P values represent comparison to L-LSL with 
complete snare excision. LSL - Laterally spreading colonic lesion, SD - standard deviation, 
IQR - interquartile range, SC1/2 - surveillance colonoscopy 1/2, ICV - ileo-caecal valve, 
PANL - previously attempted non lifting lesion, NNL - naïve non lifting LSL, L-LSL - lifting 
LSL with complete snare excision, LGD - low grade dysplasia, HGD - high grade dysplasia, 
TA - tubular adenoma, TVA - tubulovillous adenoma, SSA - sessile serrated adenoma, SMF - 
submucosal fibrosis, IPB - intra-procedural bleeding. *data available for Kudo pit pattern in 
all NL-LSL and 535/540 LSL. **includes the appendiceal orifice, ileo-caecal valve and 
hepatic and splenic flexures.  *** Corresponds to Sydney classification III-IV deep mural 
injury.  In all cases the area of perforation was successfully closed with endoscopic clips. 
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Outcome PANL (n=38) P † NNL (n=63) P † L-LSL (n=540) 
 Surgery at week 2 (%)  1 (2.6) .715 3 (4.8) 1 32 (5.9) 
Due SC1 33  46  416 
Underwent SC1 (n, % due) 33 (100)  40 (87.0)  340 (81.7) 
Months to SC1, median (IQR) 5 (4.1-6.0) .248 5.1 (4.4-5.7) .065 5.4 (4.8-6.7) 
Recurrence at SC1 (%)  5 (15.2) .985 11 (27.5) .049 53 (15.3) 
Histologic recurrence at SC1(%)  4/26 (15.4) 1 7/37 (18.9) .735 38/228 (16.7) 
Surgery at SC1 (%)  0 (0) 1 0 (0) 1 3 (0.9) 
Due SC2 (n) 21  34  310 
Underwent SC2 (n, % due) 16 (76.2)  24 (70.5)  109 (35.2) 
Months to SC2, median (IQR) 17.5 (11.8-21.6) .850 14.7 (9-16.7) .035 17.2 (13.1-19.3) 
Recurrence at SC2 (%)  1 (6.3) .568 5 (20.8) .017 5 (4.6) 
Late recurrence at SC2 (%) 1 (6.3) .502 1 (4.2) 1 4 (3.7) 
Histologic recurrence at SC2 (%)  1/7 (14.3) .440 2/16 (12.5) .602 4/59 (6.8) 
Surgery at SC2 (%)  0 (0) 1 1 (4.2) .180 0 (0) 
Table 2 Outcomes of NL-LSL undergoing CAST to complete their resection compared with 
L-LSL. NL-LSL – non-lifting LSL, CAST - cold avulsion and adjuvant snare tip soft 
coagulation, PANL - previously attempted non-lifting laterally spreading lesion, NNL - naïve 
non lifting laterally spreading lesion, SC1/2 - first/second surveillance colonoscopy, late 
recurrence – recurrence occurring after a previously negative surveillance examination. 
Recurrence denotes endoscopic determination of adenoma recurrence at an endoscopic 
resection scar unless otherwise stated. † P values represent comparison to L-LSL. 
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Figure Legends 
Figure 1 Naive non-lifting LSL (NNL). a) NNL seen in the mid-transverse colon. b,c) After 
the commencement of EMR a central non-lifting area is isolated with significant 
submucosal fibrosis. In this case the lesion could be completely resected by snare. d) 
Endoscopic clips are applied to the centre of the defect after identification of type II DMI to 
prevent delayed perforation. The histopathology of this lesion showed tubular adenoma 
with low grade dysplasia.  EMR - endoscopic mucosal resection, DMI - deep mural injury 
[12]. 
Figure 2 a,b) 40mm Paris 0-IIa G PANL in the mid rectum, associated with a large scar 
(white arrow). c) Injection and snare excision of the lifting areas adjacent to the NL 
adenoma is performed to free the lateral margins. d) Evidence of previous injection of 
carbon particle suspension is seen within the expanding resection defect (white arrow). e) 
Further inject and resect EMR is performed at the opposite lateral margin.  f,g) Despite 
attempts at complete snare excision using a thin wire snare, a large area of non-lifting 
adenoma remains associated with scarring from the previous attempt. h,i) Cold avulsion of 
all visible adenoma is performed.  j) Soft coagulation using the snare tip is applied to the 
avulsion bed and surrounding tissue. k) The extensive submucosal fibrosis associated with 
the previous resection attempt is shown here, completely obliterating the submucosal 
plane.  l) Final resection defect.  PANL - previously attempted non lifting laterally spreading 
lesion, NL - non lifting, EMR – endoscopic mucosal resection. 
Figure 3 a) 40mm PANL in the mid-transverse colon associated with a large scar. b) Snare 
excision of the area adjacent to the NL adenoma frees the lateral margins and creates a 
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‘step’ for snare capture. c-d) Despite attempts at complete snare excision a central NL area 
remains. e-f) Cold forceps avulsion is performed of all visible NL adenoma and g) STSC is 
applied to the avulsion bed. h) Appearances of the EMR scar at first follow up colonoscopy; 
a small area of residual adenoma (white arrow) was easily treated at this examination. 
Procedure also available to view in Video 1.  PANL - previously attempted, non lifting 
laterally spreading lesion, NL - non lifting, STSC - snare tip soft coagulation, EMR - 
endoscopic mucosal resection. 
Figure 4 Design of the study and recruitment. The fate of all lesions referred for EMR 
during the study period is displayed. EMR - endoscopic mucosal resection, SMIC - 
submucosal invasive cancer, SCAR - randomised study assessing the effect of snare tip soft 
coagulation of the margin of the EMR defect on adenoma recurrence, CAST - cold forceps 
avulsion with adjuvant snare tip soft coagulation, NL-LSL - non-lifting laterally spreading 
lesion, SC1 - surveillance colonoscopy 1, late recurrence – recurrence that occurred after a 
previously negative surveillance examination.  +denotes endoscopic determination of 
recurrence.  ++denotes losses from both NL-LSL cohorts. *one patient declined surgery but 
had submucosal invasive cancer in the specimen. ** surgery was in the NNL cohort. 
             
                
           
         
             
 
 
Figure 1 Naive non-lifting LSL (NNL). a) NNL seen in the mid-transverse colon. b,c) After 
the commencement of EMR a central non-lifting area is isolated with significant 
submucosal fibrosis. In this case the lesion could be completely resected by snare. d) 
Endoscopic clips are applied to the centre of the defect after identification of type II DMI 
to prevent delayed perforation. The histopathology of this lesion showed tubular adenoma 
with low grade dysplasia. EMR - endoscopic mucosal resection, DMI - deep mural injury
[12].
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Figure 2 a,b) 40mm Paris 0-IIa G PANL in the mid rectum, associated with a large scar
(white arrow). c) Injection and snare excision of the lifting areas adjacent to the NL 
adenoma is performed to free the lateral margins. d) Evidence of previous injection of 
carbon particle suspension is seen within the expanding resection defect (white arrow). e) 
Further inject and resect EMR is performed at the opposite lateral margin. f,g) Despite 
attempts at complete snare excision using a thin wire snare, a large area of non-lifting 
adenoma remains associated with scarring from the previous attempt. h,i) Cold avulsion of 
all visible adenoma is performed. j) Soft coagulation using the snare tip is applied to the 
avulsion bed and surrounding tissue. k) The extensive submucosal fibrosis associated with 
the previous resection attempt is shown here, completely obliterating the submucosal
plane. l) Final resection defect. PANL - previously attempted non lifting laterally spreading 
lesion, NL - non lifting, EMR – endoscopic mucosal resection.
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Figure 3 a) 40mm PANL in the mid-transverse colon associated with a large scar. b) Snare 
excision of the area adjacent to the NL adenoma frees the lateral margins and creates a
               
                
                
              
              
               
  
‘step’ for snare capture. c-d) Despite attempts at complete snare excision a central NL area 
remains. e-f) Cold forceps avulsion is performed of all visible NL adenoma and g) STSC is 
applied to the avulsion bed. h) Appearances of the EMR scar at first follow up colonoscopy; 
a small area of residual adenoma (white arrow) was easily treated at this examination. 
Procedure also available to view in Video 1. PANL - previously attempted, non lifting 
laterally spreading lesion, NL - non lifting, STSC - snare tip soft coagulation, EMR - 
endoscopic mucosal resection.
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Figure 4 Design of the study and recruitment. The fate of all lesions referred for EMR 
during the study period is displayed. EMR - endoscopic mucosal resection, SMIC - 
submucosal invasive cancer, SCAR - randomised study assessing the effect of snare tip soft 
coagulation of the margin of the EMR defect on adenoma recurrence, CAST - cold forceps 
avulsion with adjuvant snare tip soft coagulation, NL-LSL - non-lifting laterally spreading 
lesion, SC1 - surveillance colonoscopy 1, late recurrence – recurrence that occurred after a 
previously negative surveillance examination. +denotes endoscopic determination of
recurrence. ++denotes losses from both NL-LSL cohorts. *one patient declined surgery but 
had submucosal invasive cancer in the specimen. ** surgery was in the NNL cohort.
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Synopsis and Significance 
Amongst 101 non-lifting lesions included in the study which could not be completely resected 
by snare excision, CAST was successful in resecting all lesions in a single session without an 
excess of adverse events over standard LSL resection.  Non-lifting lesions represented 17.8% 
of the lesions referred to the single centre during the study period.  During follow up 99% of 
patients eligible for surveillance avoided surgery.  All of these lesions would have req uired 
surgical resection if not resected using CAST.  
CAST is a simple, inexpensive technique that can be used to transform the management of 
non-lifting LSL sparing patients from unnecessary surgery.  It should be emphasised that all 
tissue resected using CAST should be retrieved for histopathology since invasive malignancy 
also causes fibrosis of the submucosal layer. 
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Chapter 9 - EMR of laterally spreading lesions around or involving the 
appendiceal orifice: technique, risk factors for failure, and outcomes of a 
tertiary referral cohort  
Introduction 
Another group of LSL that are complex to resect are those involving inaccessible areas of the 
colon.  Such areas include the anorectal junction, flexures, ileo-caecal valve and appendiceal 
orifice.  The study that forms the basis of this chapter7 investigated the outcomes of LSL at the 
appendiceal orifice. 
The appendiceal orifice (AO) is a technically challenging location for EMR due to the often 
difficult endoscopic access to the base of the caecum, the blind ended and endoscopically 
inaccessible appendiceal lumen and the thin colonic wall at this location.  LSL in this location 
are generally referred for surgery.  Surgery at the AO may often be laparoscopic and localised 
e.g. caecectomy47 and may provide a single episode solution to the lesion whereas endoscopic 
resection mandates a structured programme of surveillance colonoscopy.  For these reasons the 
risk/benefit profile for EMR at the AO is more complex than in other locations. 
In the study described below a prospective observational study of EMR at the AO was 
undertaken with particular attention paid to outcomes of patients who failed EMR and 
underwent surgery.  The aim was to define a cohort of patients who benefit from an attempt at 
EMR and those who would be best served by direct referral to a surgeon. 
  
ORIGINAL ARTICLE: Clinical EndoscopywwwEMR of laterally spreading lesions around or involving the
appendiceal oriﬁce: technique, risk factors for failure, and
outcomes of a tertiary referral cohort (with video).giejoDavid J. Tate, MBBS, MA (Cantab), MRCP,1,2 Lobke Desomer, MD,1 Halim Awadie, MD,1 Kathleen Goodrick,1
Luke Hourigan, MBBS, FRACP,3,4 Rajvinder Singh, MBBS, MRCP, MPhil, FRACP,5
Stephen J. Williams, MBBS, FRACP,1 Michael J. Bourke, MBBS, FRACP1,2
Sydney, New South Wales; Brisbane, Queensland; Adelaide, South Australia, AustraliaBackground and Aims: EMR of sessile periappendiceal laterally spreading lesions (PA-LSLs) is technically
demanding because of poor endoscopic access to the appendiceal lumen and the thin colonic wall at the base
of the cecum. We aimed to assess the feasibility and safety of EMR for PA-LSLs.
Methods: Consecutive LSLs 20 mm and PA-LSLs 10 mm detected at 3 academic endoscopy centers from
September 2008 until January 2017 were eligible. Prospective patient, procedural, and lesion data were collected.
PA-LSLs were compared with LSLs in other colonic locations.
Results: Thirty-eight PA-LSLs were compared with 1721 LSLs. Referral for surgery without an attempt at EMR was
more likely with PA-LSLs (28.9% vs 5.1%, P < .001), and those that involved a greater percentage of the appendi-
ceal oriﬁce (AO) were less likely to be attempted (PZ .038). Most PA-LSLs (10/11) were not attempted because of
deep extension into the appendiceal lumen; 2 of 11 of these surgical specimens contained invasive cancer. Once
attempted, complete clearance of visible adenoma (92.6% PA-LSLs vs 97.6% LSLs, P Z .14), adverse events, and
rates of adenoma recurrence did not vary signiﬁcantly between PA-LSLs and LSLs. All 7 patients with prior appen-
dicectomy achieved complete adenoma clearance. There were no cases of post-EMR appendicitis. Twenty of 22
PA-LSLs (91%) eligible for surveillance avoided surgery to longest follow-up.
Conclusions: EMR is a safe, effective, and durable treatment for PA-LSLs when speciﬁc criteria are fulﬁlled. If the
distal margin of the PA-LSL within the AO cannot be visualized or if more than 50% of the circumference of the
oriﬁce is involved, surgery should be considered. (Clinical trial registration number: NTC01368289.) (Gastrointest
Endosc 2018;87:1279-88.)(footnotes appear on last page of article)EMR of colonic laterally spreading lesions (LSLs) has
gained widespread acceptance because of cost1 and
morbidity2 advantages in comparison with surgery. Most
procedures are performed on an outpatient basis, and in
long-term follow-up >95% are cured.3 However,
endoscopic resection of lesions involving the appendiceal
oriﬁce (AO; periappendiceal LSLs [PA-LSLs]) is technically
more challenging, and such lesions are often managed sur-
gically. Reasons for this complexity are mainly anatomic;This video can be viewed directly
from the GIE website or by using
the QR code and your mobile de-
vice. Download a free QR code
scanner by searching “QR Scanner”
in your mobile device’s app store.
urnal.org Vthe appendix is a narrow blind-ended tube that cannot
be accessed endoscopically, and the colonic wall in the
cecum is the thinnest of the entire colon. In addition,
serrated and tubulovillous adenomas involving the appen-
dix may be more aggressive than their counterparts
throughout the rest of the colon.4
PA-LSLs are relatively uncommon, and technical data
regarding how to safely and effectively perform endoscopic
resection of such lesions are sparse. An expert multicenterUse your mobile device to scan this
QR code and watch the author in-
terview. Download a free QR code
scanner by searching “QR Scanner”
in your mobile device’s app store.
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Feasibility and safety of EMR for PA-LSLs Tate et alstudy from Japan5 described the successful endoscopic
submucosal dissection of 76 PA-LSLs. Only 40% of these
lesions actually involved the AO, however, and such expe-
rience with this technique is seldom available in Western
centers.
EMR is the current standard of care for the management
of LSLs; however, the medical literature regarding EMR for
PA-LSLs is limited to a report using “underwater” EMR.6 It
is currently unknown whether standard inject and resect
EMR for PA-LSLs is safe or effective or which lesion features
predict success or failure. The present study is a descrip-
tion of the technical aspects, outcomes, and safety for
PA-LSLs referred for EMR to 3 tertiary referral centers in
Australia over an 8-year period.METHODS
Data were collected and analyzed within a multicenter,
prospective, observational cohort study of patients
referred for EMR of LSLs performed at 3 academic, ter-
tiary referral centers in Australia from September 2008
until January 2017. Consecutive LSLs 20 mm and
PA-LSLs 10 mm were eligible for inclusion.
Demographic, lesion, and procedural data were
collected on all patients prospectively. Adverse events
were assessed at 2 weeks after the procedure by structured
telephone interview with the patient. Surveillance exami-
nations were scheduled at desired intervals of 4 to 6
months (ﬁrst surveillance) and 18 months (second surveil-
lance) after the index procedure.
Deﬁnitions
LSLs were deﬁned as PA-LSLs when they involved or
were located within 5 mm of the AO. Circumference of
involvement of the AO was recorded to the nearest 25%.
Deep extension into the AO was recorded if the distal
margin of the lesion within the AO could not be visualized.
An attempt at EMR was deﬁned by ﬁrst snare placement
and resection of tissue. Size of the LSL was described rela-
tive to an open snare of known diameter. Complete snare
excision described the resection of the LSL with no addi-
tional modality other than snare. Technical success was
deﬁned as complete clearance of visible adenoma.
Duration of the procedure was described as the time
from ﬁrst submucosal injection to completed EMR.
Intraprocedural bleeding was deﬁned as bleeding during
the procedure that required endoscopic control. Deep
injury to the colonic wall was recorded relative to the
Sydney Classiﬁcation of Deep Mural Injury.7 Delayed
bleeding was recorded if the patient required admission to
hospital or repeat intervention after they had left the
endoscopy room. Recurrence was deﬁned as endoscopic
evidence of residual or recurrent adenoma at the EMR
scar during surveillance colonoscopy. Histologic recurrence
was deﬁned as histologic evidence of recurrence at the1280 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 5 : 2018EMR scar. Late recurrence was recurrence after a
previously negative surveillance examination.Exclusions
Multiple lesions in the same patient were excluded
because of the possibility of correlated observations for a
single patient. Patients in the active arm of the Soft Coag-
ulation for the prevention of Adenoma Recurrence, or
SCAR, randomized trial (NCT01789749) were excluded
because of the potential that their outcomes differ signiﬁ-
cantly from standard inject and resect EMR. Similarly, pa-
tients who underwent snare tip soft coagulation to the
lesion margin outside the SCAR study and patients under-
going 2-stage EMR were excluded.EMR procedures
Senior endoscopists with extensive EMR experience or
senior endoscopy fellows under their direct supervision
performed all procedures. A microprocessor-controlled
electrosurgical generator (VIO 300D; Erbe Elektromedizin,
Tübingen, Germany)8 was used. The submucosal injectate
was composed of succinylated gelatin (Gelofusine; B.
Braun Australia Pty Ltd, Bella Vista, Australia)9 with indigo
carmine blue (80 mg/500 mL solution) and 1:10,000
epinephrine (1 mL/10-mL injection). Methylene blue was
substituted occasionally when indigo carmine blue was un-
available. Sedation was achieved with a combination of
midazolam, fentanyl, and propofol.
A standardized, previously described inject-and-resect tech-
nique10 was used for EMR of LSLs. Each lesion was carefully
assessed using high-deﬁnition white-light and narrow-band
imaging (Olympus, Tokyo, Japan) to evaluate morphology
and pit pattern. For PA-LSLs an attempt was made to assess
deep extension into the AO before endoscopic resection; if
this was detected, the patient was referred for surgery.
Once a decision had been made to attempt the lesion, a
careful, small-volume injection of chromogelofusine was
made so as not to occlude the AO and obscure visualiza-
tion of the distal aspect of the lesion. For resections
around the AO, a 10-mm thin-wire snare was used (eg,
Captivator II [Boston Scientiﬁc, Marlborough, Mass] or Tel-
eMed Hexagonal Snare [Telemed Systems, Hudson,
Mass]) to maximize tissue capture. Care was taken
throughout the resection to ensure deep extension into
the AO had not occurred after removal of surrounding ad-
enoma. Small areas of residual adenomatous tissue that
eluded snare capture were treated with argon plasma coag-
ulation (before 2012) or forceps avulsion with adjuvant
snare tip soft coagulation (Erbe Soft Coagulation, Effect 4,
80W) thereafter. Examples of the EMR of PA-LSLs are shown
in Figures 1, 2, and 3 and Video 1 (available online at www.
giejournal.org).
After EMR, patients were observed for 4 hours and dis-
charged home if well. A clear ﬂuid diet was recommended
until the next morning.www.giejournal.org
     
Figure 1. A, Half circumferential LSL at the base of the cecum extending to the AO. B, LSL seen to involve 50% of the AO. C and D, Sequential inject and
resect EMR used to isolate the periappendiceal component (E). F, Thin wire snare and cold forceps avulsion (white arrow) used to remove the portion of
the LSL involving the AO. G, Completed resection defect.H, Appearances of the endoscopic resection scar at second surveillance examination (18 months
after index) with no evidence of recurrence. LSL, Laterally spreading lesion; AO, appendiceal oriﬁce.
Tate et al Feasibility and safety of EMR for PA-LSLsAt ﬁrst and second surveillance the EMR scar was located
and was assessed under high-deﬁnition white-light and
narrow-band imaging according to our standardized scar
assessment protocol.11 If there was suspicion for recurrent
adenoma, this was removed with a snare or forceps
avulsion with adjuvant snare tip soft coagulation and the
margins of the resection site over the scar treated with
snare tip soft coagulation. If patients were referred for
surgery, details of the surgical outcomes and the resection
specimen were obtained from the relevant institution.
Statistical analysis
PA-LSLs were compared with LSLs. Statistical analysis
was performed using SPSS version 22 (IBM, Chicago, Ill)
with a 2-tailed t test used for normally distributed contin-
uous variables, Mann Whitney U test for skewed contin-
uous variables, and c2 test or the Fisher exact test for
categorical variables. Signiﬁcance was regarded at P < .05.RESULTS
A total of 2119patients (2376 LSLs)were recruited over the
study period (Fig. 4). After exclusions, 38 PA-LSLs and 1721
LSLs were included in the study. The mean age of patients
with PA-LSLs was 68.1 years (standard deviation, 11.8) versus
67.7 years (standard deviation, 11.8) for patients with LSLs
(PZ .82). Thirteenof 38patients (34.2%) in the PA-LSL group
were men versus 905 of 1721 patients (52.6%) in the LSL
group (P Z .025). Eight of 38 patients (21%) with PA-LSLs
had undergone prior appendicectomy.
Lesion assessment
Median size of PA-LSLs was 13 mm (interquartile range,
20-30) and was smaller than LSLs, median size 35 mmwww.giejournal.org V(interquartile range, 25-50; P < .001) (Table 1). Lesion
morphology and Kudo classiﬁcation were broadly similar
between PA-LSLs and LSLs. PA-LSLs were more commonly
Paris classiﬁcation 0-IIa (71.1%) than LSLs (48.4%; PZ .06).
Six of 38 PA-LSLs (22%) did not involve the AO but were
located within 5 mm thereof. A further 8 (21%) involved
25% of the AO circumference, 13 (34%) involved 50%, 2
(5%) involved 75%, and 9 (24%) involved 100%
(Supplementary Table 1, available online at www.
giejournal.org). Ten PA-LSLs (32%) extended deeply into
the appendiceal lumen; in 2 of these cases this was not re-
vealed until midway through the EMR procedure.
EMR procedures
EMR was attempted in 27 of 38 PA-LSLs (71.1%) versus
1634 of 1721 LSLs (94.9%; P < .001). Reasons for not
attempting PA-LSLs were deep extension into the AO in
10 of 11 (91%) and concern for submucosal invasive cancer
(SMIC) in 2 of 11 (18%). Reasons for not attempting LSLs
were concern for SMIC in 65 of 87 (75%) and technical rea-
sons in the remainder.
Submucosal ﬁbrosis within the EMR defect was more
common in PA-LSLs undergoing EMR (14/27, 51.9%) versus
LSL (405/1634, 24.8%; P < .001), and complete snare exci-
sion was lower in the PA-LSL group (18, 66.7%) versus the
LSL group (1287, 78.8%; PZ .13). Adjuvant modalities used
to assist resection in the PA-LSL group were argon plasma
coagulation in 6 of 27 cases (22.2%) and forceps biopsy
sampling with adjuvant snare tip soft coagulation in 3
(11.1%). Procedures were of similar median duration (23
vs 20 minutes, P Z .319). Technical success of EMR was
not different between the PA-LSL group (25/27, 92.6%)
and the LSL group (1595/1634, 97.6%; P Z .14). Lesions
achieving technical success in the PA-LSL group involved
a smaller percentage of the AO (P Z .038) and did notolume 87, No. 5 : 2018 GASTROINTESTINAL ENDOSCOPY 1281
     
Figure 2. A, Periappendiceal LSL involving 50% circumference of the AO. B, Snare resection with margin of normal tissue. C, Snare resection is
hampered by submucosal ﬁbrosis. D and E, Standard biopsy forceps used to avulse residual nonlifting adenoma. F, Snare tip soft coagulation is applied
to the avulsion bed. G, Completed resection with complete removal of visible adenoma. H, Surveillance colonoscopy with a well-formed scar at the AO 6
months after the index procedure. LSL, Laterally spreading lesion; AO, appendiceal oriﬁce.
Figure 3. EMR in patients with prior appendicectomy. A and B, Fully circumferential PA-LSL at the AO in a patient with a previous appendicectomy.
C, Sequential inject and resect has been performed to completely resect the lesion. D, At ﬁrst surveillance colonoscopy a central focus of recurrent ad-
enoma is seen overlying the EMR scar. E, Complete destruction of residual adenoma is achieved using a thin wire snare and coagulation current with snare
tip soft coagulation applied to the surrounding scar. F, 35-mm Paris 0-IIa LSL overlying the prior AO in another patient with prior appendicectomy. G and
H, Sequential inject and resect EMR used to completely remove the lesion, revealing underlying submucosal ﬁbrosis at the site of the prior AO. PA-LSL,
Periappendiceal laterally spreading lesion; LSL, laterally spreading lesion; AO, appendiceal oriﬁce.
Feasibility and safety of EMR for PA-LSLs Tate et aldeeply involve the AO (P < .001). All 7 patients with a prior
appendicectomy attempted for EMR achieved technical
success (Table 2).
The rates of intraprocedural bleeding (7 PA-LSL [25.9%]
vs 254 LSLs [15.5%], P Z .18) and occurrence of deep
injury to the colonic wall (PZ .61) did not differ between
the cohorts. Histologic type and dysplasia grade did not
vary between the cohorts. There was no SMIC in histologic
specimens after EMR of PA-LSLs versus 116 of 1634 (7.1%)
after EMR of LSLs (P Z .25).1282 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 5 : 2018Postprocedural adverse events
Three patients in the PA-LSL cohort were admitted
overnight after the procedure. One patient was admitted
directly for signiﬁcant pain with a normal CT scan, required
supportive measures only, and was discharged the next day.
The other 2 patients were admitted because of delayed
bleeding; this occurred at a similar rate in the PA-LSL cohort
(2/27, 7.4%) as the LSL cohort (93/1634, 7.1%; P Z .67).
There were no delayed perforations in the PA-LSL
cohort versus 4 (.2%) in the LSL cohort (P Z 1.000).www.giejournal.org
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Figure 4. Flow of patients through the study comparing the outcomes of PA-LSL and LSL. ER, Endoscopic resection; LSL, laterally spreading lesion;
PA-LSL, periappendiceal laterally spreading lesion; SMIC, submucosal invasive cancer; SC1, ﬁrst surveillance colonoscopy; SC2, second surveillance colo-
noscopy; AO, appendiceal oriﬁce; SCAR RCT, snare tip soft coagulation for the prevention of adenoma recurrence randomized controlled trial; duplicate,
smaller lesions in the same patient. Asterisk indicates percentage of patients undergoing SC1 who avoided surgery to this follow-up. Percentages rounded
to the nearest whole number.
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The outcomes of PA-LSLs are summarized in Figure 4.
All 22 PA-LSLs (100% due surveillance) underwent ﬁrst
follow-up (ﬁrst surveillance) at amedian of 5.7months. Recur-
rence was detected in 5 of 22 (22.7%) and was treated
endoscopically in 3 of 5 (60%) cases. Two of 5 recurrences
measured between 2 and 5 mm, 2 of 5 were between
5.1 and 10 mm, and 1 of 5 was >10 mm. Histologic conﬁrma-
tion of recurrence was available in 2 of 5 cases. Two patients
were referred for surgery because of an inability to resect
recurrence. One of these patients, having undergone a suc-
cessful EMR of a 30-mm PA lesion, underwent an attempted
hot snare excision of a 5-mm recurrence at the edge of the
EMR scar; this led to a full-thickness perforation that could
not be closedendoscopically. Thepatientwas referred for sur-
gery and underwent emergency right hemicolectomywith no
long-term adverse event. In comparison, LSL recurred with
similar frequency (186/1263, 14.7%, PZ .36). One hundred
sixty-nine (91%) were treated endoscopically and 17 (1.3%)
required surgery because of an inability to resect recurrence.www.giejournal.org VFourteen of 15 PA-LSLs (93% due surveillance) under-
went a second follow-up (second surveillance) at a median
of 18 months after index EMR. Recurrence was detected in
1 of 14 patients (7.1%). The previous surveillance proced-
ure had been clear. This recurrence was successfully
treated endoscopically. Of those PA-LSLs undergoing sur-
veillance colonoscopy 20 of 22 (91%) avoided surgery to
longest follow-up. In comparison, 52 of 751 patients
(6.9%) with LSLs experienced recurrence (P Z 1.0), of
which 29 (3.9%) were late recurrences (P Z 1.0). Forty-
nine of 52 patients (94%) were treated endoscopically,
and 3 of 52 required surgery. A total of 1243 of 1263
(98%) LSLs and 20 of 22 (91%) PA-LSLs undergoing surveil-
lance colonoscopy avoided surgery to longest follow-up.
Details of PA-LSL referred for surgery
Thirteen of 38 patients (34%) with PA-LSLs were
referred for surgery within 2 weeks of the index procedure,
11 without an attempt at EMR and 2 after technical
failure of EMR (Supplementary Table 2, available online atolume 87, No. 5 : 2018 GASTROINTESTINAL ENDOSCOPY 1283
          
TABLE 1. Characteristics of PA-LSLs vs LSLs
PA-LSLs (n [ 38) LSLs (n [ 1721) P value*
Patient
Age, y, mean (SD) 68.1 (11.8) 67.6 (11.8) .82
Sex, male 13 (34.2) 905 (52.6) .025
LSLs
Size, mm, IQR 25 (20-30) 35 (25-50) <.001
Previous attempt 3 (7.9) 215 (12.5) .62
Morphology
Granular 24 (63.2) 919 (53.4) .42
Nongranular 11 (28.9) 497 (28.9)
Mixed 2 (5.3) 124 (7.2)
Unable to classify 1 (2.6) 181 (10.5)
Paris
0-Is 5 (13.2) 321 (18.7) .06
0-IIa 27 (71.1) 833 (48.4)
0-IIa,Is 5 (13.2) 382 (22.2)
Other (IIb, IIaþc etc.) 1 (2.6) 185 (10.7)
Kudoy
II 2 (5.3) 193 (11.8) .340
III 10 (26.3) 500 (30.6)
IV 25 (65.8) 832 (50.9)
V 1 (2.6) 111 (6.8)
Attempted EMR 27 (71.1) 1634 (94.9) <.001
(n Z 27) (n Z 1634)
Procedure
Submucosal fibrosis 14 (51.9) 405 (24.8) <.001
Duration, min, IQR 23 (14-68) 20 (10-30) .319
Complete snare excision 18 (66.7) 1287 (78.8) .13
Adjuvant technique (of remainder)
APC 6 (22.2) 48 (2.9)
Forceps biopsy sampling and STSC 3 (11.1) 299 (18.3)
Technical success 25 (92.6) 1595 (97.6) .14
Intraprocedural bleeding 7 (25.9) 254 (15.5) .18
Deep injury
II 2 (7.4) 55 (3.4) .61
III 0 (0) 37 (2.3)
IV 0 (0) 9 (.6)
V 0 (0) 2 (.1)
Histology
TA 4 (14.8) 414 (25.3) .14
TVA 17 (63.0) 945 (57.8)
Serrated 5 (18.5) 267 (16.3)
Other 1 (3.7) 8 (.5)
(continued on the next page)
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TABLE 1. Continued
PA-LSLs (n [ 38) LSLs (n [ 1721) P value*
Dysplasia
None 4 (14.8) 186 (11.4) .23
LGD 19 (70.4) 1021 (62.5)
HGD 3 (11.1) 427 (26.1)
Cancer 0 (0) 116 (7.1) .25
Postprocedural AEs
Delayed bleeding 2 (7.4) 93 (5.7) .67
Delayed perforation 0 (0) 4 (.2) 1.000
Follow-up
Surgery by 2 wk 2 (7.4) 111 (6.8) .71
(n Z 22) (n Z 1263)
Time to first surveillance months, (IQR) 5.7 (4.9-6.8) 5.1 (4.0-6.9)
Recurrence at first surveillance 5 (22.7) 186 (14.7) .36
Histologic recurrence at first surveillance 2/14 (14.3) 129/574 (22.5) .75
Surgery at first surveillance 2 (9.1) 17 (1.3) .40
(n Z 14) (n Z 751)
Time to second surveillance months, (IQR) 18.0 (16.0-21.5) 18 (14.9-22.5)
Recurrence at second surveillance 1 (7.1) 52 (6.9) 1.0
Late recurrence at second surveillance 0 (0) 29 (3.9) 1.0
Surgery at second surveillance 0 (0) 3 (.4) 1.0
Values are n (%), unless otherwise defined. Recurrence denotes the endoscopic detection of recurrence at an EMR scar and histologic recurrence the histologic confirmation of
recurrence.
PA-LSL, Periappendiceal LSL; LSL, laterally spreading lesion; SD, standard deviation; IQR, interquartile range; APC, argon plasma coagulation; STSC, snare tip soft coagulation;
TA, tubular adenoma; TVA, tubulovillous adenoma; LGD, low-grade dysplasia; HGD, high-grade dysplasia; AEs, adverse events.
*Bold values indicate significance of P < 0.05.
yObservations available in 1539 cases.
TABLE 2. Specific characteristics of PA-LSLs
Not
attempted
(n [ 11)
Attempted but failed
(n [ 2)
Successful
EMR
(n [ 25)
Overall
(n [ 38) P value
Median size of LSLs, mm (range) 20 (15-20) 28 (25-28) 25 (20-30) 25 (20-30) .034
Percent involvement of AO
Within 5 mm 0 0 6 (24) 6 (22) .038
25% 1 (9) 0 7 (28) 8 (21)
50% 3 (28) 2 (100) 8 (32) 13 (34)
75% 2 (18) 0 0 2 (5)
100% 5 (46) 0 4 (16) 9 (24)
Deep extension into AO 10 (91) 2 (100) 0 12 (32) <.001
Prior appendicectomy 1 (9.1) 0 (0) 7 (28) 8 (21.1) .498
Appendicitis x 0 (0) 0 (0) 0 (0) 1
Values are n (%), unless otherwise defined.
PA-LSL, Periappendiceal LSL; LSL, laterally spreading lesion; AO, appendiceal orifice; x, not applicable.
Tate et al Feasibility and safety of EMR for PA-LSLswww.giejournal.org). Although this was higher than patients
with LSLs (237/1721, 13.8%), after EMRwas attempted rates of
surgery were similar between the cohorts (2/27 PA-LSLs
[7.4%] vs 111/1634 LSLs [6.8%], P Z .71). Figure 5 shows
examples of PA-LSLs referred directly for surgery.www.giejournal.org VTen patients with a PA-LSL underwent laparoscopic right
hemicolectomy, and 3 patients laparoscopic cecectomy. Two
of 11 patients (18.2%) with endoscopic evidence of deep
extension into the AO had evidence of invasive carcinoma in
the surgical specimen. No malignant histology was found inolume 87, No. 5 : 2018 GASTROINTESTINAL ENDOSCOPY 1285
          
Figure 5. Examples of PA-LSL that were referred directly for surgery without an attempt at EMR. A, Circumferential donut-shaped LSL fully encircling the
AO. B, A biopsy forceps is often useful to expose the oriﬁce if there is doubt about deep extension. C, Large LSL at the base of the cecum seen to
completely encircle the AO. D-F, Further views highlight deep extension into the appendiceal lumen beyond the limit of visualization. PA-LSL, Periappen-
diceal laterally spreading lesion; LSL, laterally spreading lesion; AO, appendiceal oriﬁce.
Feasibility and safety of EMR for PA-LSLs Tate et alpatients who achieved technical success at EMR. One patient
experienced signiﬁcant wound hematoma and malunion of
the abdominalwoundafter laparoscopic cecectomywith apro-
tracted inpatient stay. Other surgical outcomes were success-
ful and uneventful in terms of adverse events.DISCUSSION
EMR is the standard of care for colorectal LSLs without
evidence of SMIC. We present a prospective cohort study
of EMR of PA-LSLs in comparison with those in other
colonic locations. The results demonstrate that EMR is a
safe and effective technique for the management of
PA-LSLs. Meticulous case selection is required. If there is
no endoscopic imaging evidence of SMIC and provided the
distal margin of the lesion can be visualized within the AO,
91% of patients who underwent surveillance colonoscopy
avoided surgery at a median of 18 months.
Although there are few reports of standard EMR to
remove PA-LSLs, other techniques have been explored.
Binmoeller et al6 described the use of “underwater EMR”
to remove 27 PA-LSLs involving the AO. The distance
from the AO was not deﬁned, although 22 of 27 were
described as extending into the AO. Median lesion size
was 15 mm, signiﬁcantly smaller than this study. Technical
success was 89%, although the cohort from which these
patients originated was not described, and therefore no
comparator arm was provided. In addition, although 91%
of PA-LSLs underwent follow-up with residual adenoma
in 10%, median follow-up was only 29 weeks. One of the
resected specimens contained invasive cancer, and 2 of1286 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 5 : 201827 patients experienced postpolypectomy syndrome,
perhaps highlighting the difﬁculties of lesion and defect
assessment underwater and without a chromic dye.
An expert multicenter study from Japan5 described the
endoscopic submucosal dissection of 76 PA-LSLs. Although
over 60% of the lesions (median size, 49 mm) did not
involve the AO (deﬁnition included up to 12 mm from
AO), impressive rates of en bloc resection (94.7%) and
R0 resection (89.5%) were achieved. None of 63 patients
undergoing follow-up experienced recurrence. Such exper-
tise, although admirable, is not available in most Western
centers. In addition, the opportunity cost for this proced-
ure (mean duration of 91 minutes vs 20 minutes in this
study) is high for benign disease (2/76 lesions had SMIC
at histology; both had SM2 disease and underwent
surgery). Of note, appendicitis was experienced in 2 of
76 patients in this study.
A similar contemporary study that examined the feasi-
bility of endoscopic full-thickness resection for colorectal
LSLs12 also included 5 cases of PA-LSLs. Two of 5 cases could
not be successfully resected en bloc. One third that were re-
sected had a positive peripheral margin of the specimen for
adenoma. Appendicitis was not observed in the 3 successful
cases. A further study described the use of endoscopic full-
thickness resection to resect 4 PA-LSLs.13 Relationship to the
AO and PA-LSL–speciﬁc rates of complete/R0 resection were
not discussed. Appendicitis requiring laparoscopic
appendicectomy of the residual appendix was noted in 1
of the 4 cases. Despite these mediocre initial results and
despite technical drawbacks of the device, the technique
is conceptually appealing for this indication, and further
results are awaited.www.giejournal.org
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Figure 6. Suggested schema for the management of PA-LSL. High risk
features for SMIC include demarcated area of Kudo V pit pattern, NICE
III or Sano IIIb morphology, and Paris IIaþc morphology. PA-LSL, Periap-
pendiceal laterally spreading lesion; PA-LSL, Periappendiceal laterally
spreading lesion; SMIC, submucosal invasive cancer; AO, appendiceal
oriﬁce.
Tate et al Feasibility and safety of EMR for PA-LSLsNo other case series has addressed EMR of PA-LSLs
using standard inject and resect EMR techniques. This
is surprising because EMR is the standard of care for
LSLs among Western endoscopists for predicted benign
disease. The present study records 38 PA-LSLs, which
were assessed for EMR over an 8-year time period. These
lesions are uncommon (1% of our overall cohort). Once
an LSL involves the AO it is paramount to assess the
degree of extension into the appendiceal lumen. This
can often be performed with a biopsy forceps, manipu-
lating the LSL in an attempt to visualize the distal extent.
In this series we did not perform EMR if the lesion
extended beyond visualization within the AO. This
approach is borne out by the surgical specimens from
patients who had deep extension into the AO in which
2 of 12 specimens (17%) contained invasive cancer. In
2 cases of deep extension, it was not possible to assess
the degree of extension before resection, this only
becoming clear midway through the resection. These
resections were terminated when the degree of exten-
sion became clear. Neither of these specimens contained
invasive cancer.www.giejournal.org VPA-LSLs present the endoscopist with particular tech-
nical challenges. Access to the base of the cecum is often
difﬁcult. The colonic wall at the base of the cecum is
thin; this necessitates precise direction of submucosal
injection (tangential to the lesion) to prevent transmural
injection and its attendant risks. Submucosal ﬁbrosis is
common in this location (observed in over 50% of
PA-LSLs in this study) and may hamper tissue capture.
For this reason we prefer a stiff, thin-wire snare in this
location. Adjuvant techniques such as cold avulsion with
adjuvant snare tip soft coagulation were necessary in
over 30% of cases.
If the distal margin of the lesion within the AO can be
visualized, PA-LSL EMR outcomes are very good. Tech-
nical success of PA-LSLs (93%) was similar to LSLs
(98%). There was no difference in either intraprocedural
or postprocedural adverse events. No resection speci-
mens contained malignant histology. Recurrence and
surgery were not more common during surveillance
than LSLs. The lack of appendicitis is perhaps surprising
given that 14 of 20 attempted PA-LSLs (70%) in this study
without prior appendicectomy involved the AO. We
suggest that this reﬂects small-volume injection and care-
ful snare placement during the procedures. We also note
that we have completed resections of LSLs in patients
with previous appendicectomy where the LSL completely
encircles the prior AO. Intense submucosal ﬁbrosis is
experienced in this situation but is technically possible
(Fig. 3). Of the 2 patients in whom we have performed
this procedure, both had recurrence successfully treated
at surveillance.
Given the advances in laparoscopic surgery with tech-
niques to remove part of the cecum and spare the ileocecal
valve,14 the data from this study will inform a careful
discussion with the patient about which approach to take
to the initial lesion. In particular, the patient must
understand that surveillance colonoscopy and treatment
of recurrence is a necessary part of the endoscopic
treatment of their lesion. A suggested scheme for the
management of PA-LSLs is given in Figure 6. If the lesion
does not fulﬁll the stated criteria for endoscopic
resection, there is high likelihood that the lesion will
eventually require surgery. In this context it is hardly
ethical or cost-effective to attempt a resection that will
commit the patient to endoscopic surveillance procedures
if the risk of recurrence at those procedures or initial
incomplete resection is so high that surgery will eventually
be required.
Limitations of this study include the small sample size of
PA-LSLs. This is because of the rarity of these lesions.
PA-LSLs are often small, and we included lesions 10 mm,
whereas LSLs included were 20 mm; this may have pro-
vided an overstringent comparator arm and failed to high-
light differences between PA-LSLs and LSLs. There was
high compliance to follow-up for PA-LSLs and LSLs at ﬁrst
surveillance, but this was lower at second surveillance. Ifolume 87, No. 5 : 2018 GASTROINTESTINAL ENDOSCOPY 1287
     
Feasibility and safety of EMR for PA-LSLs Tate et alanything, this likely biases toward worse reported out-
comes at second surveillance because we routinely
followed-up patients with recurrence at the study center.
Despite these drawbacks the data were prospectively
collected from 3 tertiary endoscopy centers, and the LSL
cohort derives from the same centers, allowing valid com-
parison. The lack of men in the PA-LSL cohort is of interest
and deserves further attention; this was also the case in the
study of Jacob et al.5
In conclusion, EMR of PA-LSLs is a safe, effective, and
durable treatment but is technically challenging. PA-LSLs are
less likely to be suitable for EMR than LSLs throughout the
rest of the colon, and careful assessment of the lesion at the
index colonoscopy is essential. If the distal margin of the
LSL within the appendiceal lumen cannot be visualized, sur-
gery is the treatment modality of choice. If the distal margin
is visualized, EMR offers excellent outcomes that avoid the
risks of surgery and inmost cases offers a cure for the patient.REFERENCES
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SUPPLEMENTARY TABLE 1. Characteristics of PA-LSLs split by percentage involvement of the AO
Not involving AO (n [ 6) ≤50% AO involved (n [ 21) >50% AO involved (n [ 11)
Patient
Age, mean (SD) 73.7 (5.1) 67.9 (12.1) 65.4 (13.4)
Sex, male 3 (50.0) 8 (38.1) 2 (18.2)
LSLs
Size, mm, IQR 27.5 (20-30) 25 (15-32.5) 25 (20-35)
Previous attempt 0 (0) 2 (9.5) 1 (9.1)
Morphology
Granular 3 (50.0) 13 (61.9) 8 (72.7)
Nongranular 1 (16.7) 8 (38.1) 2 (18.2)
Mixed 2 (33.3) 0 (0) 0 (0)
Unable to classify 0 (0) 0 (0) 1 (9.1)
Paris classification
0-Is 3 (50.0) 1 (4.8) 1 (9.1)
0-IIa 3 (50.0) 16 (76.2) 8 (72.7)
0-IIa,Is 0 (0) 4 (19.0) 1 (9.1)
Other (IIb, IIaþc etc.) 0 (0) 0 (0) 1 (9.1)
Kudo*
II 0 (0) 1 (4.8) 1 (9.1)
III 2 (33.3) 6 (28.6) 2 (18.2)
IV 4 (66.7) 14 (66.7) 7 (63.6)
V 0 (0) 0 (0) 1 (9.1)
Attempted EMR 6 (100) 17 (81.0) 4 (36.4)
(n Z 6) (n Z 17) (n Z 4)
Procedure
Submucosal fibrosis 3 (50.0) 9 (52.9) 2 (50.0)
Complete snare excision 4 (66.7) 12 (70.6) 2 (50.0)
Technical success 6 (100) 15 (88.2) 4 (100)
Intraprocedural bleeding 1 (16.7) 4 (23.5) 2 (50.0)
Histology
TA 1 (16.7) 3 (17.6) 0 (0)
TVA 3 (50.0) 11 (64.7) 3 (75.0)
Serrated 2 (33.3) 2 (11.8) 1 (25.0)
Other 0 (0.0) 1 (5.9) 0 (0)
Dysplasia
None 2 (33.3) 3 (17.6) 0 (0)
LGD 4 (66.7) 11 (64.7) 4 (100)
HGD 0 (0) 3 (17.6) 0 (0)
Cancer 0 (0) 0 (0) 0 (0)
Postprocedural AEs
Delayed bleeding 0 (0) 1 (5.9) 1 (25.0)
Delayed perforation 0 (0) 0 (0) 0 (0)
(continued on the next page)
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SUPPLEMENTARY TABLE 1. Continued
Not involving AO (n [ 6) ≤50% AO involved (n [ 21) >50% AO involved (n [ 11)
Follow-up
Surgery by 2 wk 0 (0) 2 (11.8) 0 (0)
(n Z 6) (n Z 12) (n Z 4)
Recurrence at first surveillance 3 (50.0) 1 (8.3) 1 (25.0)
(n Z 3) (n Z 9) (n Z 2)
Recurrence at second surveillance 0 (0) 1 (11.1) 0 (0)
Values are n (%), unless otherwise defined.
PA-LSL, Periappendiceal LSL; AO, appendiceal orifice; SD, standard deviation; LSL, laterally spreading lesion; IQR, interquartile range; TA, tubular adenoma; TVA, tubulovillous
adenoma; LGD, low-grade dysplasia; HGD, high-grade dysplasia; AEs, adverse events.
SUPPLEMENTARY TABLE 2. Detailed characteristics of lesions that underwent surgery which were not attempted or failed at the index EMR
Patient PA-LSLs Surgery
Age
(y)
Prior
appendicectomy
PA-LSL size
(mm)
EMR
attempted?
Reason for
surgery
AO
involving
(%)
Paris
classification Morphology Type Histology
(Remnant)
dysplasia
(Remnant)
malignancy
46 No 60 No SMIC and
deep AO
100 0-Is G RH * * *
66 No 15 No SMIC 50 0-IIa G RH TVA HGD Yes
73 No 20 No Deep AO 100 0-IIa NG RH TVA LGD No
50 No 20 No Deep AO 100 0-IIa G C SSA None No
71 No 15 No Deep AO 75 0-IIa NG RH TVA HGD Yes
77 No 10 No Deep AO 25 0-IIa NG C SSA None No
65 No 10 No Deep AO 50 0-IIa NG RH TVA Yes
77 No 15 No Deep AO 50 0-IIa NG RH TVA LGD No
60 No 20 No Deep AO 100 0-IIa G RH SSA None No
49 Yes 20 No Deep AO 100 0-IIb NG RH Tubular LGD No
71 No 25 No Deep AO 75 0-IIa G RH SSA Focal HGD No
60 No 25 Yes Deep AO 50 0-IIa NG RH TVA LGD No
56 No 30 Yes Deep AO 50 0-IIa/Is G C Tubular LGD No
All described lesions involved the AO.
PA-LSL, Periappendiceal laterally spreading lesion; AO, appendiceal orifice; Remnant, presence of dysplasia or malignancy in the surgical specimen; SMIC, submucosal invasive
cancer; G, granular; RH, right hemicolectomy; TVA, tubulovillous adenoma; HGD, high-grade dysplasia; NG, nongranular; LGD, low-grade dysplasia; C, cecectomy; SSA, sessile
serrated adenoma; Deep AO, deep extension into the AO.
*In 1 case details of the surgical specimen are not available.
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Synopsis and Significance 
The results of this study demonstrate that if the distal margin of an LSL can be visualised within 
the AO and there is no endoscopic imaging evidence of submucosal invasive cancer that 91% 
of patients undergoing surveillance avoided surgery to a median of 18 months.  There was no 
incidence of appendicitis.  All patients with deep invasion of the AO required surgery.  In 
addition, a subset of patients with previous appendicectomy had successful EMR at the AO 
with LSL completely covering the prior orifice. 
This significance of this study is in patient selection for EMR at the AO.  In discussion with 
the patient if the LSL does not invade the AO deeply and involves less than 50% of the AO an 
attempt at EMR is warranted.  In addition, patients with previous appendicectomy should be 
offered EMR as a treatment option. 
 
 Page |  
 
51 
Theme 3 - MITIGATING RECURRENCE AFTER ENDOSCOPIC 
RESECTION OF LARGE COLONIC LATERALLY SPREADING 
LESIONS 
Introduction 
The introduction to Theme 3 is provided in the introductory comments to Chapter 10 . 
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Chapter 10 - Preventing adenoma recurrence after colonic endoscopic 
mucosal resection - A multi-center randomized control trial 
Introduction 
The commonest criticism of endoscopic mucosal resection (EMR) of LSL is the high rate of 
recurrence detected during follow up examinations in published series.  Depending on the 
publication this rate varies from 10 to 55%48, although the true rate is probably around 14% 46.  
Accumulated data suggests that these recurrences are often small33,45 and easily treated during 
follow up examinations.  However, such high rates of recurrence necessitate a structured 
programme of surveillance colonoscopy examinations which introduce compliance, cost and 
morbidity burdens for patients and healthcare systems.  Theme 3 contains 3 studies which aim 
to reduce the rates of recurrence after EMR. 
A small randomised study from 200249 using argon plasma coagulation (APC) to ablate the 
margin of the post endoscopic mucosal resection defect demonstrated a significant reduction 
in adenoma recurrence at 3 months in the active treatment arm.  Despite this the study has not 
been repeated since, and no follow up has been described.  In addition whilst APC is a well-
established non-contact endoscopic technique for superficial tissue destruction, it is 
unpredictable to apply and may result in an unpredictable depth of tissue destruction in certain 
cases 50,51.   
Due to the success of the above study we hypothesised that endoscopically invisible 
microscopic adenoma at the margin of the endoscopic resection defect was responsible for the 
majority of residual or recurrent adenoma at follow.  Due to the unpredictability of APC we 
designed a randomised control trial to test the ability of snare tip soft coagulation of the margin 
of an endoscopic resection defect to reduce adenoma recurrence at surveillance colonoscopy.  
The technique of snare tip soft coagulation has been described previously in Chapter 8. 
This study has been accepted for publication52 since the first draft of this thesis and appears 
below in journal proof form.  It was previously published as an abstract presented at the 
Digestive Diseases Week, San Diego in 201653.   
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Abstract: 
Background: Colorectal cancer (CRC) can be prevented by colonoscopy and polypectomy.  
Endoscopic mucosal resection (EMR) is a minimally invasive outpatient procedure to remove 
large laterally spreading colonic lesions (LSL) which are high-risk precursors of CRC.  
Endoscopically invisible micro-adenoma present at the margin of the post EMR mucosal defect, 
may account for adenoma recurrence, which is observed in 15%-30% during surveillance. We 
aimed to mitigate this risk by adjuvant thermal ablation. 
 
Methods: We conducted a randomized control trial at four tertiary referral centers.  Following 
complete excision by EMR, lesions were randomized 1:1 to either thermal ablation of the post 
EMR mucosal defect margin, or no additional treatment.  The primary end-point was 
endoscopic recurrence at first surveillance colonoscopy (SC1). This was performed at 6 months 
post EMR, with standardized photo documentation and biopsies of the scar.  
 
Results: We randomized 416 LSLs (null n=206, active n=210). Patient, procedure and lesion 
characteristics were similar between the groups. The rate of endoscopic recurrence at SC1 was 
significantly lower in the active arm compared to the null arm (10/192 [5.2%] versus 37/176 
[21.0 %], p<.001, relative risk (RR)=0.25 (95% confidence interval [CI] 0.13-0.48). Rates of 
adverse events were similar between the groups. 
 
Conclusion: Thermal ablation of the post EMR mucosal defect margin significantly reduces 
adenoma recurrence at SC1. Routine implementation of this simple and safe technique may 
enhance the utility of EMR, reduce surveillance burdens and contribute to reduced morbidity 
and mortality from CRC. (ClinicalTrials.gov NCT01789749). 
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Introduction: 
Colorectal cancer (CRC) is a major cause of cancer related morbidity and mortality worldwide. 
In western societies, approximately 5% of the population will develop CRC in their lifetime and 
up to 2.5% will die from the disease 1. The majority of CRC arise from pre-malignant polypoid 
lesions of the colon, through a gradual process of acquired genetic and epigenetic 
abnormalities 2. This sequence is effectively interrupted by colonoscopy and polypectomy 
resulting in a reduction in CRC mortality 3,4. Approximately 5% of colonic polyps encountered 
during colonoscopy are lateral spreading lesions (LSL) ≥10mm, which exhibit extensive growth 
along the bowel wall before developing an invasive component 5. Large (≥20 mm) LSL are 
considered high risk precursors of CRC. However, most are non-invasive and limited to the 
mucosa enabling them to be cured by endoscopic mucosal resection (EMR) even when very 
extensive.  
 
EMR is an outpatient day procedure that has emerged as a safe and effective alternative to 
surgery for non-invasive LSL 6. Prospective multicenter studies have outlined the therapeutic 
capabilities and limitations 6–10, highlighted mortality and cost reduction when compared to 
surgery 11,12, and demonstrated excellent long-term outcomes 13,14. 
The most often cited drawback of colonic EMR is the relatively high rate of adenoma 
recurrence (15%-30%) encountered during first surveillance colonoscopy (SC1) 13–15. 
Fortunately, recurrences are usually small, and easily treated at scheduled surveillance 
colonoscopy. However, such a structured surveillance program incurs compliance burdens, 
additional costs and potential patient morbidity. Reducing the risk of recurrence may enable a 
more flexible surveillance protocol with fewer procedures and extended intervals.  
 
Aim:  
To evaluate the efficacy of adjuvant thermal ablation of the EMR mucosal defect margin in 
reducing polyp recurrence rates following colonic EMR. 
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Methods: 
Study design: A prospective multicenter study with 1:1 randomization conducted at 4 
Australian tertiary referral centers. The scientific protocol, data collection sheets and patient 
consent form were reviewed and approved by the scientific advisory committee and 
registration was obtained (HREC2010/11/4.12[3155] AU RED; NCT01368731). The study was 
investigator-initiated and no external funding was sought. All the co-authors had access to the 
study data and reviewed and approved the final manuscript. 
 
Patients and lesions: Patients referred for EMR of colonic LSL ≥20 mm in size were enrolled in 
the study unless they declined. Written informed consent was obtained from each patient on 
the day of the procedure. Following successful complete snare excision, LSL from consenting 
patients were randomized 1:1 to the active arm or the null arm. Exclusions included: 
incomplete snare excision, previously attempted LSL, LSL located at the ileo-cecal valve (ICV), 
the appendiceal orifice and fully circumferential lesions. These lesions are all rare and 
significantly more challenging to remove endoscopically.  They have higher rates of incomplete 
resection and recurrence at surveillance endoscopy and do not represent the typical LSL 
amenable to EMR 16,17. 
 
Procedure: A study investigator or a senior endoscopy fellow under their direct supervision 
performed all procedures.  All 11 endoscopists had extensive EMR experience.  
A standardized previously described inject and resect EMR technique was used at all centers 
(figure 1) 18,19. High definition Olympus 180 or 190 series variable-stiffness colonoscopes 
(Q180/190 PCF/CF; Olympus, Tokyo, Japan) were used in all cases. For the submucosal 
injection solution, we used succinylated gelatin (Gelofusine; B. Braun, Bella Vista, Australia), 
which was technically superior to normal saline (NS) in a randomized trial 7. The colloid 
solution was combined with 0.4% indigo carmine and adrenaline diluted to 1:100,000. Snare 
excision was performed with a microprocessor-controlled generator (VIO 300D Endocut Q 
Effect 3; ERBE Electromedizin, Tübingen, Germany) in all cases. 
Prior to resection, all lesions underwent careful inspection with high definition white light 
(HDWL) and narrow band imaging (NBI) to exclude features consistent with deep submucosal 
invasion.  EMR was then typically composed of three steps which were performed repetitively:  
injection of the colloid solution into the sub-mucosal plane; 1-3 snare excisions and then 
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 7 
careful inspection of the resection defect including application of topical sub mucosal 
chromoendoscopy (TSC) where appropriate, to exclude residual adenoma and deep injury 20,21 .  
Intra-procedural bleeding was defined as that persisting for ≥30 seconds and requiring 
endoscopic control, which was achieved with STSC or coagulation graspers. Delayed bleeding 
was defined as bleeding occurring after the procedure and requiring presentation to the 
emergency department, hospitalization or medical intervention. Muscularis propria injury was 
suspected when a non-staining disrupted area was seen within the homogeneous blue EMR 
defect. Poorly staining areas were evaluated with TSC and if suspicious for deep injury were 
treated by clip closure. Complete snare excision was defined as complete resection of all visible 
adenoma using only a snare. No adjuvant techniques were allowed prior to commencement of 
the active treatment. The endoscopist performing the index procedure assessed the post EMR 
defect for completeness of resection to ensure no visible adenoma remained prior to 
randomization.  
Upon successful completion of the EMR, a non-procedural research assistant provided the 
study allocation. A computer-generated random number table created in blocks of 100, was 
used for the allocation sequence which was stored in a locked cupboard outside the procedure 
room. This method of allocation was replicated at each study centre. Patients were blinded to 
the treatment allocation. The endoscopists performing the index and surveillance procedures 
were not blinded to the treatment.  
Patients in the active arm were treated by thermal ablation of the entire margin of the mucosal 
defect (figure 2, supplementary video 1). No additional treatment was performed in patients in 
the null arm. Thermal ablation was performed with snare tip soft coagulation (STSC) 22. The 
technique requires the use of a microprocessor-controlled generator capable of delivering 
fixed low voltage output which is capped at 190 Volts to prevent deep tissue injury (SOFT 
COAG mode, 80W Effect 4, ERBE Electromedizin, Tubingen, Germany). The energy was applied 
systematically to the entire margin of the post EMR mucosal defect using a light touch with 1-2 
mm of exposed snare tip aiming to create a 2-3 mm rim of completely ablated tissue (complete 
whitening of the tissue) around the entire circumference of the resection defect. The STSC 
technique was taught by the chief investigator (MJB) to each of the other endoscopists by 
direct face-to-face instruction over 1-2 sessions. Particular aspects communicated included: 
Ablation can only be performed once all visible adenoma was removed by snare excision. 
Perform complete ablation of at least a 2-3 mm rim of normal appearing tissue around the 
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 8 
entire circumference of the resection defect to achieve complete whitening of the mucosa. 
Finally inspecting the defect margin and retreating any areas not adequately ablated.  
 
Standardized surveillance protocol: The post procedural recovery protocol and standardized 
surveillance protocol were identical in both arms and was utilized in all centers. Surveillance 
included a telephone interview 14 days after the procedure, first surveillance colonoscopy 
(SC1) at 5-6 months and second surveillance colonoscopy (SC2) at 18 months from the index 
procedure. In cases where invasive cancer was diagnosed in the EMR specimen, the patient 
was referred for surgery and excluded from further analysis in the study. At surveillance 
colonoscopy, the post EMR scar was carefully interrogated with HDWL and NBI. Meticulous 
photo-documentation was performed and biopsies were obtained. In the earlier phases of the 
study we realized that although imaging was highly accurate for excluding recurrence, 
additional strength would be added by obtaining routine biopsies and this was implemented 
with routine biopsies taken from all scars according to a standardized scar biopsy protocol.  
This included biopsies of the edge and centre of the scar in addition to any endoscopically 
suspicious areas. Recurrence identified during surveillance was primarily treated by snare 
excision, but if this was not feasible, then by cold forceps avulsion followed by snare tip soft 
coagulation of the avulsion bed (figure 3).  
During surveillance, endoscopists were not blinded to the original allocation (active treatment 
or no treatment), since active treatment was clearly documented in the endoscopic report from 
the index procedure. The pathologists who reviewed the biopsies obtained from scars during 
surveillance procedures were blinded to the original treatment allocation. 
 
Study end-points: The primary end-point was the presence of residual/recurrent polyp tissue 
at first endoscopic follow-up (SC1). Secondary end-points included histologic evidence of 
recurrence at the EMR scar, technical procedural data and frequency of adverse events such as 
bleeding, perforation, or readmission. 
 
Statistical analysis: The sample size calculation was based on a predicted reduction in the rate 
of recurrence at SC1 from 20% (expected to occur in the null arm) 6  to 10% when applying the 
active treatment. The sample size required to detect a difference in adenoma recurrence with 
80% power and an alpha of 0.05 was 199 lesions per group.  
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 9 
416 lesions in 390 patients were randomized in the study.  Randomization was conducted on a 
per lesion basis.  The initial cohort contained 368 patients with a single lesion, 19 patients with 
two lesions, 2 patients with 3 lesions and 1 patient with 4 lesions. IBM SPSS Statistics 24.0 
software (SPSS, IBM, New York, NY) was used for statistical analyses. Two-tailed tests with a 
significance level of 5% were used throughout. Secondary outcomes underwent a series of 
exploratory analyses in which no adjustment was made for multiple comparisons.  
Post hoc analyses of recurrence within certain high-risk subgroups were also performed. 
 
Categorical variables were described using frequencies. Continuous variables were 
summarized using mean and standard deviation (SD), or median and interquartile range (IQR) 
as appropriate.  Generalised estimating equations (GEEs) with patient identifier as the 
grouping variable, a binary response, logit link and robust covariance matrix with 
exchangeable correlation structure were used to test for imbalances in the distribution of 
potential risk factors between the active and control arms. This approach accounts for 
potential correlation between results obtained from lesions within the same patient. The 
relative risks and associated 95%CIs of dichotomous outcomes in the active versus control 
arms were estimated using the Zou modified Poisson regression approach 23 which utilizes 
GEEs with patient identifier as the grouping variable, a log link and robust covariance matrix 
with exchangeable correlation structure.  In cases where GEE’s failed to converge due to low 
numbers of observations in a category, Fisher’s exact test was used. 
 
 
 Results: 
 
Cohort characteristics: Over 34 months to May 2016, 829 patients with 922 lesions were 
referred to the four participating centers. 374 patients with 437 lesions declined participation 
(supplementary table 1) and 455 patients with 485 lesions were enrolled in the study. Prior to 
randomization 65 patients with 69 lesions were excluded in accordance with the study 
protocol. 390 patients with 416 lesions were included in the study.  Lesions were randomized 
to (null arm [n=206]; active arm [n=210], mean patient age 66.7 years, 49.0% male; median 
lesion size 30mm interquartile range [IQR 25-45]). A total of 48 lesions (11.5%) were lost to 
endoscopic follow-up (supplementary Table 2).  Results of SC1 were available for 368 lesions 
[null arm (n=176), active arm (n=192)]. The patient’s flow through the study is presented in 
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figure 4. Baseline patient, lesion and procedural characteristics such as lesion size, colonic 
location, histology, dysplasia grade, procedure duration, peri-procedural and delayed adverse 
events did not differ between the two study arms (table 1).  
 
 
Primary outcome: Median duration to SC1 was 5.9 months (IQR 5.1-7.3). Endoscopic 
recurrence at SC1 was encountered in 37/176 (21.0%) patients in the null arm versus 10/192 
(5.2%) in the active arm (relative risk (RR)=0.25, 95% confidence interval [CI] 0.13-0.48, 
p<.001) (table 2).  
A post hoc sensitivity analysis was performed to investigate the potential impact of missing 
data (n=48) on recurrence rates (table 2). Using the average recurrence rate of the entire 
cohort (12.8%), yielded 4 extra recurrences for the null arm (41/206 (19.9%)) and 2 extra 
recurrences for the active arm (12/210 (5.7%)), RR 0.29 (95% CI 0.16-0.53, p<.001). In a 
scenario where all the missing data was given the recurrence rate of the null arm (21.0%) 
independent of treatment status, the adjusted recurrence rate was 43/206 (20.9%) in the null 
arm and 14/210 (6.7%) in the active arm, RR = 0.32 (95% CI 0.18-0.56, p<.001). 
Characteristics of the patients who were lost to follow-up are presented in supplementary 
table 2. 
 
Secondary outcomes: Data on all secondary endpoints are presented in table 2 and 
supplementary table 3. 
 
Histological recurrence - Post EMR scar biopsies were available for 280/368 (76.1%) cases at 
SC1. Histological adenoma recurrence was detected in 30/131 (22.9%) in the null arm versus 
7/149 (4.7%) in the active arm (p<.001, RR=0.21 [95% CI 0.09-0.45]). Compared to the gold 
standard histopathology, endoscopic assessment had a sensitivity of 91.9% (95% CI 77.0-97.9), 
a specificity of 96.7% (95% CI 93.4-98.5) and a negative predictive value of 98.7% (95% CI 
96.1-99.7) for correctly identifying recurrence at the post EMR scar (Kappa coefficient 0.84). 
 
Adverse events - STSC was applied successfully to the margin of the post EMR mucosal defect 
in all cases in the active arm and no adverse events related to the additional ablative treatment 
were identified.  
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Post hoc analysis of risk factors for recurrence (figure 5):  
Piecemeal versus en bloc - En-bloc resection rate was similar between the study arms (table 1). 
For en-bloc resections, we observed no difference in the rate of endoscopic recurrence at SC1 
between the null arm and the active arm (0/23 (0%) versus 1/25 (4%) respectively, p=1.0). 
For LSL removed piecemeal, there was a significant difference in endoscopic recurrence at SC1 
between the null arm and the active arm (37/153 (24.2%) versus 9/167 (5.4%) respectively, 
p<.001)). Within the null arm, 0/23 (0%) lesions removed en-bloc and 37/153 (24.2%) lesions 
removed piecemeal had recurrence at SC1 (p=0.005). Within the active arm, 1/25 (4%) lesions 
removed en-bloc and 9/167 (5.4%) lesions removed piecemeal had recurrence at SC1 (p=1.0 
for this comparison).  
 
Lesion size - There were 151 LSL ≥40 mm (median size 50 mm, IQR 40-60 mm). Results of SC1 
were available in 126/151 (83.4%). Endoscopic recurrence at SC1 was detected in 24/66 
(36.4%) and 2/60 (3.3%) in the null and active arms respectively (p=.001). Within the null 
arm, recurrence in LSL ≥40mm and <40 mm was seen in 24/66 (36.4%) and 13/110 (11.8%) 
respectively (p<.001). Conversely, within the active arm, recurrence in LSL ≥40 mm and <40 
mm was seen in 2/60 (3.3%) and 8/132 (6.1%) respectively (p=0.73). 
 
 
Discussion: 
 
EMR is established as the preferred therapeutic modality for most non-invasive colonic LSL. 
The absence of lymphatics in the colonic mucosa, precludes lymph node metastasis and 
enables curative endoscopic resection of even very extensive mucosal lesions. EMR is a 
minimally invasive outpatient procedure with a sound safety profile and excellent long-term 
results 6,13,14.  Recurrence of neoplastic tissue following EMR, is the major limitation occurring 
in up to 30% in some series 14,15,24. A structured surveillance protocol is a proven effective 
long-term strategy for eradication of recurrence. However it is associated with additional 
patient discomfort, potential morbidity and consumption of health care resources 13,15.  
 
We report the results of a large interventional multi-center randomized control trial on 
prevention of post-EMR polyp recurrence. Previous studies in this field are predominantly 
retrospective and small comprising less than 200 patients 14. To date, this is the only large 
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randomized trial addressing this shortfall of EMR. We performed first surveillance 6 months 
after the index resection. This time frame is the accepted standard for first surveillance 
colonoscopy and is also the recommended interval in societal guidelines, since most 
recurrences (~ 96%) are discovered during this period 13,14,25. Treatment of recurrence at 
experienced tertiary centers during first surveillance is very effective making late recurrences 
uncommon 13, 24.  
 
Invisible, residual microscopic adenoma present at the resection margin may account for the 
majority of recurrence encountered following EMR.  The CARE study 27 clearly demonstrated 
that even for smaller lesions, incomplete resection with biopsy proven residual adenoma at the 
edges occurs frequently (10%) and that increasing lesion size correlates with higher 
incomplete resection rates of up to 23.3% for lesions 15-20mm. Even though the endoscopists 
in this study were aware that their results were being audited, they still frequently failed to 
detect and/or treat the adenoma at the resection margins. In the current study, we have  
demonstrated a 4-fold reduction in adenoma recurrence at first surveillance colonoscopy after 
systematic ablation of the post EMR mucosal defect margin using STSC. The STSC technique is 
readily learned, does not require additional consumables (the same snare is used for resection 
and STSC), is precise and can be performed with most modern electrosurgical generators. STSC 
did not significantly prolong procedure time and proved to be extremely safe with no adverse 
events related to the intervention. 
 
Post colonoscopy interval cancers, account for up to 6% of all CRC 28,29, a proportion of which 
are believed to be due to incomplete polyp excision/destruction 30. Taken together with the 
CARE study results, this indicates that conventional polypectomy for smaller lesions <20mm is 
an imperfect and highly operator dependent technique. It is conceivable that the 
implementation of this simple, readily learnt and inexpensive adjuvant technique after removal 
of smaller colonic polyps could significantly impact the effectiveness of conventional 
polypectomy and thereby interval cancer. Further prospective study with this technique in the 
field of conventional polypectomy is required.  
 
Risk factors for recurrence after EMR include lesion size ≥40mm, piecemeal resection and the 
presence of high-grade dysplasia (HGD) in the resected specimen 13,14,31–33. These allow 
stratification of risk, however currently no procedural modality has been shown to consistently 
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reduce the rate of recurrence. Extra wide field EMR involves wider excision at the edges of the 
lesion including at least 5mm of normal appearing tissue. In a large cohort study this technique 
was not effective in reducing recurrence. This most likely reflects the technical challenges of 
precisely excising an adequate margin around the entire lesion, thus risking residual, 
endoscopically invisible microscopic adenoma at the lesion margin particularly in the areas 
between sequential snare placements 34. Complete thermal ablation of the entire margin, does 
not entail such challenges. The technique results in a clearly defined approximate 3 mm rim of 
white non-viable tissue at the defect margin, which provides real time confirmation of 
adequate treatment for the endoscopist.  Areas that do not demonstrate this tissue effect can 
be revisited and treated again.  
 
In a previous small pilot study, Argon plasma coagulation (APC) was used to ablate the lesion 
margin after complete snare excision 35. Whilst this study was an important contribution to the 
field, when viewed with the perspective of contemporary imaging platforms and tissue 
resection techniques, its small size, and very high recurrence rates in the control group (63%) 
limit the interpretation of the data. Also, results from this small study, while generally positive, 
have not been duplicated since on larger cohorts. 
 
The tissue effect of APC relies in the variable arching of electrosurgical current from the 
catheter to the tissue. It is well documented that this is at times unpredictable, non-uniform 
(application distance is not controlled), highly operator dependent and unaccompanied by a 
direct visual correlate to confirm adequate tissue destruction. Complications such as deep 
injury with perforation and bleeding, or limited and inadequate tissue effect, at either end of 
the electrosurgical spectrum have all been reported 36,37. By contrast, STSC as a direct contact 
based technique, is inherently more precise, due to the standardized application distance and 
provides a more uniform tissue effect with a direct endoscopic endpoint – complete white 
blanching of the defect margin. Importantly, no adverse events have been reported in the 
literature. 
 
En-bloc EMR is associated with lower recurrence rates (3%) compared with piecemeal 
resection (20%) 14.  However, en bloc resection is only consistently safe and practicable in LSL 
less than 20-25mm in size. Larger LSL require piecemeal resection. In such cases, a large 
resection area, requires many more snare excisions, raising the potential for inaccurate 
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sequential snare placement. which may result in residual invisible adenoma at the margin. 
Similar to other published series, our recurrence rates within the null arm were significantly 
higher for piecemeal resection (24.2%) compared to en-bloc resection (0%). However, within 
the active arm, this difference was not observed. Thus, our treatment seems to have mitigated 
one of the biggest drawbacks of piecemeal EMR compared to en-bloc EMR.  
LSL size ≥40 mm is another consistent risk factor for recurrence following piecemeal EMR 33. 
Our cohort contained 126 such lesions amongst which a highly significant reduction in 
adenoma recurrence at SC1 from 36.4% in the null arm to 3.3% in the active arm was 
observed. Within the null arm recurrence was significantly higher in lesions ≥40 mm versus 
lesions <40 mm, however within the active arm no significant difference was observed.  So 
again, the active treatment appears to have negated the adverse effect of lesion size on 
recurrence risk.  
 
Limitations: 
In 88 cases, routine biopsies were not taken from a normal appearing post EMR scar at SC1.  
However, when comparing the accuracy of endoscopic diagnosis of recurrence to that of the 
gold standard of histopathology, we found endoscopic assessment for recurrence to be very 
accurate and in line with our separate independent study 38 and that of others 39 where 
endoscopic imaging for recurrence has a negative predictive value of  98.5-100%. In addition, 
the number of scars lacking histological correlate was identical in both study groups (n=38). 
Forty-eight lesions were lost to follow-up in this study (figure 4, supplementary table 2). Since 
the estimated effect size in the power calculation was 2x (relative risk of 0.5) and the observed 
effect was greater than 4x (relative risk 0.25) the study is adequately powered.  In addition, we 
conducted a sensitivity analysis which included these lesions in two scenarios: Using the 
average recurrence rate of the entire cohort (12.8%), and using the recurrence rate of the null 
arm (21.0%). In both circumstances, the reduction in rates of recurrence remained highly 
significant in favor of the active treatment.  
 
In conclusion, thermal ablation of the post EMR defect margin with STSC resulted in a 4-fold 
reduction in adenoma recurrence rates at SC1. This simple and safe technique overcomes the 
major limitation of piecemeal EMR and elevates it to a new level of efficacy, with recurrence 
rates similar to more complex and resource intensive techniques such as endoscopic sub-
mucosal dissection (ESD). Routine implementation of this technique is likely to consolidate the 
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position of EMR as the preferred technique for the removal of LSL and may result in 
recommendations for surveillance protocols with fewer procedures and extended intervals. 
Moreover, this inexpensive technique has the potential to be incorporated into conventional 
polypectomy to enhance its effectiveness, although further study is required. 
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Tables and figures: 
Table 1 – Patient, lesion and procedural characteristics of the two study arms 
Table 2 – Primary and Secondary study outcomes 
Figure 1 – Sequential steps in inject and resect EMR of a colonic LSL  
Figure 2 – Examples of post EMR scars with and without adenoma recurrence  
Figure 3 - Four examples of LSL of the colon with active treatment  
Figure 4 – Consort diagram of the patients flow through the study 
Figure 5 – Post hoc analysis of risk factors for recurrence 
 
Supplementary material: 
Supplementary table 1 – Characteristics of patients who refused enrollment in the study 
Supplementary table 2 – Characteristics of patients who were lost to follow-up 
Supplementary table 3 – Detailed breakdown of adverse events in the two study arms 
Supplementary video 1 – SCAR tutorial 
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 Null arm 
n = 206 
Active arm 
n = 210 
P value 
Patients 
Age (mean±STD) 67.0 ± 13.1 66.1 ± 11.6 .446 
Male sex 102 (49.5%) 101 (48.1%) .835 
Median time to SC1 – months (IQR) 5.7 (5.1-7.0) 6.0 (5.1-7.6) .200 
Procedure 
EMR duration (min) –median (IQR) 15 (10-30) 20 (10-30) .662 
No of snare resections required (median, 
IQR) 
4 (3-7) 4 (3-7) .629 
En-bloc 27 (13.1) 28 (13.3) .994 
Clear margins histologically 11/27 (40.7) 8/28 (28.6) .338 
Not reported/fragmented specimen 16/27 (59.3) 20/28 (71.4)  
SMF 48 (23.3) 56 (26.7) .464 
Lesion 
Size mm - median (IQR) 30(25-45) 30 (25-40) .165 
Location Right colon 109 (52.9%) 106 (50.5%) 
.578 
 Left colon 97 (47.1%) 104 (49.5%) 
Histology TA 35 (17.0%) 43 (20.5%) 
.575  TVA 124 (60.2%) 116 (55.2%) 
 SSP 47 (22.8%) 51 (24.3%) 
Dysplasia No dysplasia 32 (15.5%) 41 (19.5%) 
.595  Low Grade 127 (61.7%) 123 (58.6%) 
 High Grade 47 (22.8%) 46 (21.9%) 
Invasive cancer 9 (4.4%) 7 (3.3%) .576 
Pre-treatment procedural complications 
Intra-procedural bleeding 47 (22.8%) 49 (23.3%) .871 
Deep mural injury/perforation 3 (1.5%) 1 (0.5%) .328 
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Table 1 - Cohort characteristics: STD (standard deviation); IQR (interquartile range); EMR 
(endoscopic mucosal resection); SMF (sub mucosal fibrosis); IPB (intra-procedural bleeding); 
TA (tubular adenoma); TVA (tubulo-villous adenoma); SSP (sessile serrated polyp) 
 
 
 
 
Null arm Active arm RR (95% CI) P value 
Primary study outcome 
Endoscopic recurrence at SC1 37/176 (21.0%) 10/192 (5.2%) 0.25 (0.13-0.48) <.001 
Post-hoc sensitivity analyses for impact of missing data 
Average cohort recurrence 
rate (12.8%)  (Scenario  1) 
41/206 (19.9%) 12/210 (5.7%) 0.29 (0.16-0.53) <.001 
Null arm recurrence rate 
(21.0%) (Scenario 2) 
43/206 (22.5%) 14/210 (6.7%) 0.32 (0.18-0.57) <.001 
Secondary study outcomes 
Histologic recurrence (/280) 30/131 (22.9%)  7/149 (4.7%)   0.21 (0.09-0.45) <.001 
Delayed bleeding 12 (5.8%) 13 (6.2%) 1.06 (0.50-2.27) .872 
Repeat colonoscopy required 
for treatment of delayed 
bleeding 
8 (66.7%) 4 (30.8%)  .073 
Median size of largest defect 
vessel (mm) 
    
None 1 (12.5) 1 (25.0)  1.00 
1-2mm 5 (62.5) 3 (75.0)   
>2mm 2 (25.0) 0 (0)   
Location of bleeding vessel     
None seen 1 (12.5) 1 (25)  1.00 
Within defect 7 (87.5) 1 (25)   
Edge of defect 0 (0) 2 (50)   
Delayed perforation 1 (0.5%) 1 (0.5%)  .981 
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Table 2 – Primary and Secondary outcomes: SC1 (fist surveillance colonoscopy); HGD (high 
grade dysplasia), RR (relative risk), 95%CI (95 % confidence interval). Adverse outcomes 
stated using full cohort of lesions. 
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Figure 1 - Sequential steps in inject and resect piecemeal EMR. a+b) lesion
assessment; c+d) piecemeal EMR; e+f) the final mucosal defect before and after
Click here to download Figure figure1.tiff 
Figure 2 - Four examples of lesions with active treatment: Before resection (a); During
resection (b); The final mucosal defect with ablation of the entire margin (c )
Click here to download Figure figure2.tiff 
Figure 3 - Example of post EMR scars during surveillance. Two examples of normal
appearing scars without recurrence in high definition white light (a+c) and narrow band
Click here to download Figure figure3.tiff 
Figure 4 - Consort diagram of the patients flow through the study Click here to download Figure figure4.tiff 
Figure 5 - Post-hoc analysis of risk factors for recurrence. The active treatment
mitigated the adverse effect piecemeal resection, and large lesion size on the risk for
Click here to download Figure figure5.tiff 
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Supplementary data: 
 
Table of content: 
1. Supplementary table 1 – comparison between patients who were enrolled and those who 
refused (page 2) 
2. Supplementary table 2 – characteristics of patients who were lost to follow-up (page 2-3) 
3. Supplementary table 3 – Detailed breakdown of adverse events (page 4) 
4. Supplementary table 4 – Data on endoscopic recurrence per endoscopist (page 5) 
5. Supplementary table 5 – Data on histologic recurrence per endoscopist (page 5) 
6. Supplementary video 1 - SCAR ablation tutorial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary data Click here to download Supporting Document Supplementary
material SCAR.GASTROENTEROLOGY.docx
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 Did not consent 
n = 374 
Enrolled 
n = 455 
p value 
Patients 
Age (mean±STD) 68.0 (12.3) 67.1 (12.1) .302 
Male sex 209 (55.9%) 230 (50.5%) .126 
Lesion 
Size mm - median (IQR) 30 (25-45) 30 (25-50) .117 
Location Right colon 190 (50.8%) 239 (52.5%) 
.626 
 Left colon 184 (49.2%) 216 (47.5%) 
 
Supplementary Table 1 – Characteristics of lesions in 829 patients who underwent EMR.  Enrolled 
patients includes 390 patients with lesions randomized in the study and 63 patients with lesions 
which were excluded.  Comparison is presented between these patients and those who did consent. 
STD (standard deviation); IQR (interquartile range); EMR (endoscopic mucosal resection); SMF (sub 
mucosal fibrosis); IPB (intra-procedural bleeding); TA (tubular adenoma); TVA (tubulo-villous 
adenoma); SSP (sessile serrated polyp).  Multiple lesions in single patients removed with the largest 
retained for this analysis. 
 
 
 
 Null arm 
n = 30 
Active arm 
n = 18 
p value 
Patients 
Age (mean±STD) 68.0 ± 16.5 67.8 ± 13.4 .884 
Male sex 13 (43.3%) 7 (38.9%) .797 
Procedure 
EMR duration (min) –median (IQR) 15 (10-40) 20 (15-35) .518 
En-bloc 4 (13.3%) 3 (16.7%) .804 
SMF 8 (26.7%) 5 (27.8%) .960 
 3 
Lesion 
Size mm - median (IQR) 40.0 (30-50) 32.5 (25-50) .225 
Location Right colon 14 (46.7%) 12 (66.7%) 
.182 
 Left colon 16 (53.3%) 6 (33.3%) 
Histology TA 3 (10.0%) 5 (27.8%) 
.255  TVA 19 (63.3%) 9 (50.0%) 
 SSP 8 (26.7%) 4 (22.2%) 
Dysplasia No dysplasia 4 (13.3%) 4 (22.2%) 
.733  Low Grade 14 (46.7%) 8 (44.4%) 
 High Grade 12 (40.0%) 6 (33.3%) 
Invasive cancer 6 (20.0%) 5 (27.8%) .480 
Pre-treatment procedural complications 
Intra-procedural bleeding 3 (10.0%) 5 (27.8%) 0.125+ 
Deep mural injury/perforation 0 (0%) 0 (0%) n/a 
Post-treatment procedural complications 
Delayed bleeding 1 (3.3%) 3 (16.7%) .130 
Delayed perforation 1 (3.3%) 0 (0%) 1.000+ 
 
 
Supplementary Table 2 – Characteristics of the 48 lesions that were randomized but did not undergo 
first follow up colonoscopy (SC1):  STD (standard deviation); IQR (interquartile range); EMR 
(endoscopic mucosal resection); SMF (sub mucosal fibrosis); IPB (intra-procedural bleeding); TA 
(tubular adenoma); TVA (tubulo-villous adenoma); SSP (sessile serrated polyp). + result obtained 
using Fisher’s exact test 
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 Null arm 
n = 206 
Active arm 
n = 210 
p value 
Intra-procedural adverse events 
Intra-procedural bleeding  47 (22.8%) 49 (23.3%) .871 
Deep injury to the colonic wall *     
None 188 (91.3%) 192 (91.4%) .930+ 
Type I 7 (3.4%) 9 (4.3%)  
Type II 8 (3.9%) 8 (3.8%)  
Type III 2 (1.0%) 1 (0.5%)  
Type IV/V 1 (0.5%) 0 (0%)  
Deep injury to the colonic wall (any)*  18 (8.7%) 18 (8.6%) 1.000 
Intra-procedural perforation ** 3 (1.5%) 1 (0.5%) .368 
Post-procedural adverse events 
Delayed bleeding 12 (5.8%) 13 (6.2%) .861 
Delayed perforation 1 (0.5%) 1 (0.5%) .986 
Hospital admission for any reason 44 (21.4%) 32 (15.2%) .098 
Hospital admission for a procedural reason 22 (10.7%) 9 (4.3%) .015 
 
 
Supplementary Table 3 – Detailed breakdown of adverse events between the cohorts. 
* describes types I-V deep mural injury as per the Sydney Classification of Deep Mural Injury 35 
** describes target sign or actual hole in the colonic wall (types III-V deep mural injury as per the 
Sydney Classification of Deep Mural Injury). + result obtained using Fisher’s exact test 
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 Endoscopist 1 2 3 4 5 6 7 8 9 10 11 All P 
Null Recurrence 
N(%) 
15  
(30.6
) 
0  
(0) 
2 
(5.0) 
3 
(18.8
) 
2  
(33.3
) 
3 
(18.8
) 
7 
(41.2
) 
1 
(10.0
) 
0  
(0) 
0  
(0) 
4 
(30.8
) 
37 
(21.0
) 
.038 
 Total 49 2 40 16 6 16 17 10 5 2 13 176  
               
Active Recurrence 
N(%) 
1 
(2.4) 
0  
(0) 
2 
(4.4) 
3 
(21.4
) 
1 
(14.3
) 
1 
(5.3) 
0  
(0) 
1 
(5.9) 
0  
(0) 
0  
(0) 
1 
(6.3) 
10 
(5.2) 
.380 
 Total 42 4 45 14 7 19 11 17 9 8 16 192  
               
 
Supplementary Table 4 - Data for Endoscopic Recurrence at SC1.  n=368 patients who underwent 
SC1.  P values indicate comparison over all 11 endoscopists within treatment groups using Fisher’s 
exact test 
 
 
Endoscopis
t 
1 2 3 4 5 6 7 8 9 10 11 All P 
Null 
Recurrence 
N(%) 
13  
(31.7) 
0  
(0) 
4  
(19.0) 
2 
(33.3) 
1  
(25.0) 
2 
(14.3) 
4 
(26.7) 
1 
(11.1) 
0  
(0) 
0  
(0) 
3  
(23.1) 
30 
(22.9) 
.913 
 Total 41 2 21 6 4 14 15 9 4 2 13 131  
               
Active 
Recurrence 
N(%) 
1 (2.9) 
0  
(0) 
2 (7.7) 
3 
(33.3) 
1 
(25.0) 
0 
 (0) 
0 
 (0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
7 (4.7) .037 
 Total 35 4 26 9 4 15 11 15 9 7 14 149  
               
 
Supplementary Table 5 - Data for Histologic Recurrence at SC1 split by Endoscopist. n=280 patients 
who underwent SC1 and had a biopsy taken of the EMR scar.   P values indicate comparison over all 
11 endoscopists within treatment groups using Fisher’s exact test 
 
SCAR – FIGURE LEGEND 
 
 
• Figure 1 – Sequential steps in inject and resect piecemeal EMR. (a+b) lesion 
assessment; (c+d) piecemeal EMR; (e+f) the final mucosal defect before and 
after ablation of the entire margin. 
• Figure 2 – Four examples of lesions with active treatment: Before resection 
(a); During resection (b); The final mucosal defect with ablation of the entire 
margin (c)  
• Figure 3 – Example of post EMR scars during surveillance. Two examples of 
normal appearing scars without recurrence in high definition white light (a+c) 
and narrow band imaging (b+d); Scars with small recurrence (e+f); Treatment 
of recurrence with snare excision (g+h)  
• Figure 4 – Consort diagram of the patients flow through the study 
• Figure 5 – Post-hoc analysis of risk factors for recurrence. The active 
treatment mitigated the adverse effect piecemeal resection, and large lesion 
size on the risk for recurrence 
 
Figure legend Click here to download Supporting Document
renamed_db8ee.docx
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Synopsis and Significance 
The results of this study represent a step change in the efficacy of endoscopic mucosal 
resection.  The active treatment (thermal ablation of the post-EMR defect margin) reduced the 
risk of endoscopically detected recurrence 4-fold (relative risk [RR] 0.25 [95% CI 0.13-0.48], 
P < .001).  This result was consistent when histologic recurrence (structured biopsy protocol 
of the endoscopic resection scar) was used as the endpoint (RR 0.21 [95% CI 0.09-0.45], P < 
0.001).   
Size has been demonstrated to be the strongest risk factor for recurrence after LSL (Chapter 11 
).  Surprisingly the effect of the active treatment was greatest in the largest cohort of lesions 
(maximum dimension ≥ 40mm).  Thermal ablation of the post-EMR margin in these 126 
lesions reduced the risk of recurrence from 36.4% in the null arm to 3.3% in the active arm, P 
< 0.001.  A s a result of the active treatment there was no difference in the rates of recurrence 
between large LSL (3.3%) and smaller LSL (6.6%) in the active group. 
These results need to be validated outside of expert centres and long term follow up of this 
cohort must be obtained to ensure that the active treatment does not simply delay recurrence.  
If the technique is validated the implications for endoscopic resection of LSL are wide-
reaching.  The simple and inexpensive technique of thermal ablation of the post EMR margin 
overcomes the major limitation of piecemeal EMR and will likely result in a less intensive 
surveillance regimen for patients undergoing the technique.  It may also be applicable to 
polypectomy of small or intermediate sized colonic lesions enhancing its effectiveness. 
 Page |  
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Chapter 11 - Adenoma recurrence after piecemeal colonic EMR is 
predictable: the Sydney EMR recurrence tool. 
Introduction 
Recurrence after endoscopic mucosal resection is the Achilles heel of the technique.  The 
previous chapter discusses the role of a procedural technique at the index resection procedure 
which may reduce the risk of recurrence at follow up.  In this chapter a study8attempting to 
stratify the risk of recurrence during follow up is presented. 
Prior studies demonstrated that size, intraprocedural bleeding requiring endoscopic control and 
use of thermal techniques to ablate visible adenoma were risk factors for recurrence at first 
surveillance colonoscopy16.  En-bloc resection was known to also protect against recurrence 
from the low rates of recurrence after colonic ESD54 and other studies using EMR55.   
The Sydney EMR Recurrence Tool (SERT) was derived from a random half of a historical 
cohort of 1178 patients undergoing EMR and validated on the other half.  En bloc resections 
were excluded.  The aim was to create a clinically useful tool to enable to clinicians to advise 
their patients on the risk of recurrence after EMR of their particular polyp and to enable the 
future stratification of surveillance intervals. 
  
ORIGINAL ARTICLEwwwAdenoma recurrence after piecemeal colonic EMR is
predictable: the Sydney EMR recurrence tool.giejoDavid J. Tate, MA (Cantab), MBBS, MRCP,1,2 Lobke Desomer, MD,1 Amir Klein, MD,1
Gregor Brown, MBBS, PhD, FRACP,3,4 Luke F. Hourigan, MBBS, FRACP,5,6
Eric Y. T. Lee, MBBS (Hons), FRACP,1 Alan Moss, MBBS (Hons), FRACP,7,8
Donald Ormonde, MBBS, FRACP, PhD,9 Spiro Raftopoulos, MBBS, FRACP,9
Rajvinder Singh, MBBS, MRCP, MPhil, FRACP,10 Stephen J. Williams, MBBS, FRACP,1
Simon Zanati, MBBS, FRACP,3,7 Karen Byth, PhD,11 Michael J. Bourke, MBBS, FRACP1,2
Sydney, New South Wales City, Province, AustraliaBackground and Aims: EMR is the primary treatment of large laterally spreading lesions (LSLs) in the colon.
Residual or recurrent adenoma (RRA) is a major limitation. We aimed to identify a robust method to stratify
the risk of RRA.
Methods: Prospective multicenter data on consecutive LSLs 20 mm removed by piecemeal EMR from 8 Austra-
lian tertiary-care centers were included (September 2008 until May 2016). A logistic regression model for endo-
scopically determined recurrence (EDR) was created on a randomly selected half of the cohort to yield the Sydney
EMR recurrence tool (SERT), a 4-point score to stratify the incidence of RRA based on characteristics of the index
EMR. SERT was validated on the remainder of the cohort.
Results: Analysis was performed on 1178 lesions that underwent ﬁrst surveillance colonoscopy (SC1) (median 4.9
months, interquartile range [IQR] 4.9-6.2). EDR was detected in 228 of 1178 (19.4%) patients. LSL size 40 mm
(odds ratio [OR] 2.47; P < .001), bleeding during the procedure (OR 1.78; P Z .024), and high-grade dysplasia
(OR 1.72; PZ .029) were identiﬁed as independent predictors of EDR and allocated scores of 2, 1, and 1, respec-
tively to create SERT. Lesions with SERT scores of 0 (SERTZ 0) had a negative predictive value of 91.3% for RRA
at SC1, and SERT was shown to stratify RRA to speciﬁc follow-up intervals by using Kaplan Meier curves (log-rank
P < .001).
Conclusions: Guidelines recommendSC1within6monthsofEMR. SERTaccurately stratiﬁes the incidenceofRRAafter
EMR. SERTZ 0 lesions could safely undergo ﬁrst surveillance at 18months, whereas lesionswith SERT scores between 1
and4 (SERT1-4) require surveillanceat 6 and18months. (Clinical trial registrationnumber:NCT01368289.) (Gastrointest
Endosc 2017;-:1-10.)(footnotes appear on last page of article)Wide-ﬁeld EMR has become the primary treatment for
large laterally spreading lesions (LSLs) in the colon. As a
day case procedure, it has signiﬁcant cost1 and morbidity
beneﬁts over surgery, and modeling indicates that it is
also safer.2 However, residual or recurrent adenoma
(RRA) and the necessity for scheduled follow-up remain
signiﬁcant limitations.
Previously published data show RRA rates of 10% to
55%3 after EMR. In the largest prospective multicenter
series to date, a 16.0% recurrence rate was observed at
ﬁrst surveillance colonoscopy (SC1). Late recurrence was
observed in 4.0%. Lesion size 40 mm and bleeding
during the procedure requiring endoscopic control were
shown to be independent predictors of RRA at SC1.4 Inurnal.orgother series, piecemeal EMR has been an independent
risk factor for RRA at ﬁrst surveillance, with rates as low
as 3% quoted for en bloc resection.5
Current guidelines recommend ﬁrst follow-up colonos-
copy at 4 to 6 months6,7 and a second surveillance colonos-
copy (SC2) at a subsequent interval after piecemeal EMR. As
the technique of EMR has been steadily improved and rates
of recurrence have fallen, it now seems logical to move to
staged surveillance procedures depending on deﬁned risk
factors for individual patients. Because RRA is often diminu-
tive, without advanced histologic grade and being readily
amenable to endoscopic treatment,8 there may be a low-
risk population that does not beneﬁt from SC1 within 6
months of the initial EMR. This approach may reduce theVolume -, No. - : 2017 GASTROINTESTINAL ENDOSCOPY 1
Adenoma recurrence after piecemeal colonic EMR Tate et alburden of EMR on patients and health systems while simul-
taneously achieving cost savings.METHODS
Data collection
Data were collected and analyzed within a multicenter
prospective observational study of patients referred for
EMR of colon LSLs 20 mm performed at 8 Australian ac-
ademic tertiary-care referral centers from September 2008
until May 2016 (The Australian Colonic EMR Resection
Study, Clinicaltrials.gov NCT01368289). There were no
exclusions to enrollment. Institutional review board
approval was obtained at each center. This study involves
long-term follow-up of the original cohort of 479 patients9
as well as additional consecutively included patients until
May 2016.
Data collection at the initial EMR included patient,
lesion, and procedural characteristics. Postprocedural
data including delayed adverse events, and results of
follow-up were collected by structured telephone inter-
views at 14 days after the index procedure and at the
time of each surveillance colonoscopy. Delayed bleeding
was deﬁned as bleeding after the procedure that required
hospital admission or reintervention. All authors had
access to the study data and reviewed and approved the
ﬁnal manuscript.
EMR procedure
EMR procedures were performed by senior endoscop-
ists with extensive EMR experience or by a senior endos-
copy fellow under direct supervision by a senior
endoscopist. Written informed consent was obtained
from all patients. Split-dose bowel preparation was used.
Intravenous sedation was with a combination of fentanyl,
midazolam, and propofol. Insufﬂation of the colon was
initially with air, moving to carbon dioxide in August
2010.10
Colonoscopy was performed by using Olympus 180 or
190 series high-deﬁnition variable-stiffness colonoscopes
(180/190 PCF/CF; Olympus, Tokyo, Japan). Lesion assess-
ment was performed with high-deﬁnition white light and
narrow-band imaging. Size of lesions was determined
with reference to an open snare of known diameter. Pa-
tients were excluded if they were referred for surgery at
the time of the initial EMR, based on morphology or review
of histopathology. A standardized and previously described
inject-and-resect EMR technique11 was used. Figure 1
shows an example of the EMR of a near circumferential
LSL in the rectum. Most cases used a microprocessor-
controlled electrosurgical generator (Endocut effect 3,
VIO 300D; ERBE Elektromedizin, Tübingen, Germany)12
with fractionated current. The submucosal injectate was
made up of normal saline solution until 2010 when it was
replaced with succinylated gelatin (Gelofusine; B. Braun2 GASTROINTESTINAL ENDOSCOPY Volume -, No. - : 2017Australia Pty Ltd, Bella Vista, Australia).13 The ﬂuid was
dyed with indigo carmine blue (80 mg/500 mL solution),
and adrenaline was added to achieve a ﬁnal solution of
1:100,000. Lesions resected en bloc were excluded.
Bleeding during the procedure was treated with snare tip
soft coagulation (ERBE, effect 4, 80 W) and was recorded
as present if endoscopic control was required. Complete
snare excision was the goal in all cases. If this was not
possible, ablative thermal therapy was used. Before 2012,
argon plasma coagulation was used as a salvage ablative
therapy in cases of incomplete excision. Subsequently,
cold forceps avulsion followed by snare tip soft
coagulation to the avulsion bed has been used. Deep
injury was deﬁned as types II to V within the Sydney
Deep Mural Injury Classiﬁcation system.14 Pathologists
who were specialists in gastroenterology at the individual
centers reviewed all histologic specimens.
After EMR, patients were observed for 4 hours and dis-
charged home if well. A clear ﬂuid diet was advised until
the next morning.
Follow-up
Follow-up data were collected from patients eligible for
SC1 at a planned interval of 4 to 6 months. Time to
longest follow-up and any associated recurrence after
SC1 were recorded if available. SC2 was performed at a
planned interval of 12 months (ie, 18 months after the
original EMR) and SC3 at a planned interval of 18 months
(ie, 36 months after the original EMR). Later surveillance
was conducted in accordance with published interna-
tional surveillance guidelines for the particular patient.7
Analysis was performed on a per-patient basis, with only
the largest lesion from each patient included to avoid
the problem of potential bias associated with correlated
observations for a single patient. Patients with <3 months
of follow-up time (including lesions that underwent 2-
stage EMR) were excluded. Between May 2013 and
January 2016, patients enrolled and randomized to the
active arm of the SCAR study (snare tip soft coagulation
to prevent recurrence after colon EMR, NCT02000141)
were excluded. Patients with missing data were regarded
as lost to follow-up.
All EMR scars were evaluated endoscopically at SC1 and
at further follow-up if undertaken. The primary endpoint of
the study was endoscopically determined recurrence
(EDR), deﬁned as the presence of tissue suspicious for
adenoma under high-deﬁnition white light and/or
narrow-band imaging. When there was any doubt as to
the presence of EDR, biopsy specimens of the EMR scar
were taken to document the presence or absence of histo-
logic recurrence (histologically determined recurrence
[HDR]). Late recurrence was deﬁned as RRA that occurred
at a surveillance procedure 16 months after the index
EMR. Detected RRA, once sampled, was excised by snare
or, if this was not possible, removed by cold forceps avul-
sion followed by snare tip soft coagulation.www.giejournal.org
Figure 1. EMR. A, Near circumferential 100-mm laterally spreading lesion in the rectum. B, Sequential snare resection including a margin of normal tis-
sue. C, Submucosal ﬁbrosis associated with a prior biopsy site. D, Large herniated vessel in the foreground adjacent to an island of residual adenoma. E,
Large herniated blood vessel in the EMR defect, which did not require prophylactic treatment. F, Completed EMR defect without evidence of residual
adenoma.
Tate et al Adenoma recurrence after piecemeal colonic EMRStatistical analysis
Statistical analysis was performed by using SPSS version 22
(Armonk, New York) with 2-tailed t test used for normally
distributed continuous variables, Mann Whitney U test for
skewed continuous data, and chi-square test or the Fisher
exact test for categorical variables. P < .05 was regarded as
signiﬁcant.
Univariate analysis for EDR at SC1 was performed on a
randomly selected half of the enrolled patients (model
cohort, n Z 589). The independent predictors selected to
take forward to multivariate analysis were all signiﬁcant to
P < .10 in the initial univariate analysis, and modelling was
by stepwise backward binomial logistic regression. The rela-
tive weights of the signiﬁcant predictors were then used to
create a clinical score (the Sydney EMR recurrence tool
[SERT]) with the lowest possible whole number values.
Once the model was created, values for SERT for each case
within the validation cohort (the other half of the lesion pop-
ulation, nZ 589) were computed. Analysis to determine the
ability of individual SERT scores and a lesion with a binary
SERT score of 0 (SERTZ 0) versus lesions with SERT scores
between 1 and 4 (SERT 1-4) approach to accurately stratify
EDR at SC1 (whenever it was undertaken) was performed
by using cross-tabulation. The utility of this approach to strat-
ify EDR to speciﬁc time points in the validation cohort was
then tested by using Kaplan Meier survival curves. To ensure
the validity of the model, analysis of the agreement betweenwww.giejournal.orgEDR and HDR was included on the available data in all re-
ported outcomes. Only cases in which matched EDR and
HDR data were available were included in these analyses.RESULTS
Patient population
Over 8 years to May 2016, 2582 lesions in 2348 patients
were referred for EMR. Successful single session EMR was
accomplished in 2204 of 2348 (93.9%) lesions. Lesions re-
sected en bloc (nZ 291, 13.2%)were excludedbecause their
rate of recurrence is known to be very low; in our cohort the
recurrence rate was 7 of 291 (2.4%) at SC1. A total of 1178 of
2204 (53.4%) lesions were eligible for analysis at SC1.
Detailed recruitment and exclusions are shown in Figure 2.
The mean patient age in the cohort was 67.5 years (stan-
dard deviation [SD] 11.6 years) and 613 (52.0%) were male.
Median lesion size was 35 mm (interquartile range [IQR] 30-
45 mm). A total of 754 (64.0%) lesions were located prox-
imal to the splenic ﬂexure. A total of 574 (48.7%) lesions
were classiﬁed as Paris 0-IIa, and 782 (66.4%) were granular.
The majority of the lesions were conventional adenomas
(1008, 85.5%); the remaining lesions (170, 14.5%) were
sessile serrated adenomas and/or polyps.
Median time to SC1 was 4.9 months (IQR 4.9-6.2). EDR
at SC1 was detected in 228 of 1178 (19.4%) patients. In 577Volume -, No. - : 2017 GASTROINTESTINAL ENDOSCOPY 3
excluded
excluded
excluded
excluded
excluded
excluded
excluded
excluded
excluded
Referred for
EMR
2582 lesions
(2348 patients)
Lesions removed in
two-stage procedure
(n=50)
1.9%
Lesions referred for
surgery directly due to
suspicion of SMIC or
failed EMR
(n=94)
3.6%
Multiple lesions in
the same patient
(smallest lesion(s)
removed)
(n=234)
9.0%
Not yet due SC1 (<5
months since index
procedure)
(n=86)
3.9%
Referred for surgery due
to SMIC in
histopathology
(n=188)
8.5%
Randomized controlled
trial excluded (SCAR
active)
(n=167)
7.6%
EMR performed
en bloc
(n=291)
13.2%
Missing follow-
up data
(n=188)
8.5%
No follw-up due to
comorbidity (n=27),
deceased (n=6), declined
procedure (n=22) or
procedure due but not yet
performed (n=51)
(n=106)
4.8%
(n=950)
80.6%
Underwent long-term
follow-up (≥16 months)
median 22 months
(n=450)
47.4%
Underwent long-term
follow-up (≥16 months)
median 22 months
(n=116)
50.9%
No recurrence*
Late Recurrence
Adenoma free to
latest follow-up
Successful Single-
Session EMR
Underwent
SC1
(n=88)
75.9%
Early Recurrence
(n=22)
4.9%
(n=228)
19.4%
(median 5 months)
(n=1178)
53.4%
n=2204 lesions
2204 patients
Figure 2. Recruitment of patients to the study. Patients were recruited prospectively from September 2008 to May 2016. Exclusions were made for mul-
tiple lesions in the same patient and those referred for surgery. After successful single-session EMR, exclusions were made for various reasons in which the
patient was not followed-up at SC1. SMIC, submucosal invasive cancer; SC1, surveillance colonoscopy 1; SCAR, randomized trial using snare tip soft coag-
ulation to destroy the margin of the EMR defect; SC2, surveillance colonoscopy 2. *Denotes endoscopically determined recurrence.
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Adenoma recurrence after piecemeal colonic EMR Tate et al
Tate et al Adenoma recurrence after piecemeal colonic EMR(48.9%) cases, conﬁrmatory biopsy specimens of the post-
EMR scar were taken. For cases in which there was no ev-
idence of EDR, HDR was detected in 3 of 388 (0.8%) cases
(negative predictive value [NPV] 99.2% for endoscopic scar
assessment). Where EDR was detected, HDR was absent in
64 of 189 (33.9%) cases (positive predictive value [PPV]
66.1% for endoscopic scar assessment) (Supplemental
Table 1, available online at www.giejournal.org). RRA was
successfully managed endoscopically in 93.5% of cases.
Late EDR at a median of 22.0 months (IQR 18.3-34) was
detected in 22 of 450 (4.9%) lesions.Risk factors for EDR
Risk factors for EDR were analyzed within the model
cohort (Table 1), n Z 589 lesions. Corresponding data
for the validation cohort are shown in Supplemental
Table 2, available online at www.giejournal.org.
Independent predictors for EDR at SC1 were LSL
size 40 mm (OR 2.47; 95% CI, 1.59-3.83; P < .001),
bleeding during the procedure requiring endoscopic
control (OR 1.78; 95% CI, 1.08-2.94; P Z .024) and high-
grade dysplasia in the resection specimen (OR 1.72; 95%
CI, 1.06-2.79; P Z .029). These predictors were used to
create a clinical score, the SERT (Fig. 3) for RRA at SC1
as described in Methods.
SERT was tested by using the validation cohort (nZ 589
lesions). Values of SERT calculated for each lesion were
cross-tabulated with the known value of EDR and HDR at
SC1 to yield the incidence of recurrence for each integer
SERT value (0 to 4). SERT 0 to 4 lesions had an incidence
of EDR at SC1 of 8.7%, 17.5%, 26.0%, 27.4%, and 47.8%,
respectively. Values of HDR for SERT 0 to 4 were similar
(Supplemental Table 3, available online at www.giejournal.
org). Known values of EDR and HDR at SC1 were also
stratiﬁed in a binary SERT Z 0 versus SERT 1-4 fashion
(Fig. 4). SERT Z 0 lesions had an 8.7% incidence of EDR
at SC1 versus 25.9% for SERT 1-4 lesions. The incidence of
HDR was similar at 8.0% (SERTZ 0) and 30.6% (SERT 1-4)
(Table 2). The NPV of SERTZ 0 at SC1 was 91.3% for EDR
and 92.0% for HDR in the validation cohort. Speciﬁc
patient, lesion, and procedural factors did not differ
between the model and validation cohorts (Supplemental
Table 4, available online at www.giejournal.org).
Kaplan Meier survival curves were used to generate the
cumulative incidence of EDR to longest follow-up in the
validation cohort stratiﬁed by the presence of any multivar-
iate risk factor for EDR (ie, SERT Z 0 versus SERT 1-4 le-
sions) (Fig. 5). Two distinct populations of lesions were
identiﬁed. SERT Z 0 lesions had signiﬁcantly less
cumulative incidence of EDR over timed9.8%, 11.6%,
11.6%, and 16.6% cumulative incidence of EDR at 6, 12,
18, and 36 months, respectively. SERT 1-4 lesions had
23.0%, 34.9%, 36.3%, and 39.5% cumulative incidence
over the same intervals (log rank test; P < .001)
(Table 3). Kaplan Meier curves for EDR over the wholewww.giejournal.orgcohort (n Z 1178) are displayed in Supplemental
Figure 1, available online at www.giejournal.org).
Kaplan Meier curves also were generated for HDR for the
cases in which this was available and plotted alongside the
matching values of EDR in the validation cohort (nZ 280)
(Supplemental Fig. 2, available online at www.giejournal.
org). SERT Z 0 lesions had signiﬁcantly less cumulative
incidence of both HDR and EDR over time than SERT 1-4
lesions. In each case the cumulative incidence of HDR was
less than that of EDR (Supplemental Table 5, available
online at www.giejournal.org).Characteristics of lesions with RRA classiﬁed as
SERT [ 0
Twenty lesions in the validation cohort were classiﬁed
by SERT as low risk for recurrence (SERTZ 0) yet demon-
strated EDR at SC1. Detailed data on the endoscopic fea-
tures of the RRA were available in all cases. RRA was
diminutive (5 mm) in 15 of 20 (75%) cases and unifocal
in 17 of 20 cases (85%). The RRA was located within the
scar in 10 of 20 (50%) cases and at the scar margin in
the other 10 cases. If there was endoscopic suspicion of
RRA, endoscopic treatment was undertaken; all cases
were successfully managed endoscopically.
In 10 of 20 (50.0%) cases in which EDR was suspected,
no evidence of HDR was found. In a further 3 cases, there
was inadequate sample for histopathologic analysis. Of the
7 remaining cases, 7 of 7 showed low-grade dysplasia. Four
of 7 patients underwent SC2 at a median of 16.8 months
(IQR 13.9-20.9) with 3 of 4 showing recurrence (endo-
scopic and histologic), which was managed successfully
endoscopically in all cases.DISCUSSION
We have previously described risk factors for RRA after
EMR of colon LSLs 20 mm in a large prospective cohort.4
The current study focuses solely on piecemeal EMR and
expands on the previous study with 1178 lesions with
complete follow-up to SC1 across 8 Australian tertiary-
care referral centers. The analysis strengthens the evidence
that lesion size 40 mm and bleeding during the proced-
ure are signiﬁcant risk factors for RRA at SC1 and that
late recurrence after 16 months is uncommon. The
expanded cohort also enabled us to identify a new inde-
pendent risk factor (high-grade dysplasia) for early recur-
rence. Possible reasons for these factors leading to
increased rates of RRA include size of lesion increasing
the number of snare placements and the potential for re-
sidual tissue within, or at the margin of, the EMR defect,
bleeding during the procedure preventing careful attention
by the endoscopist at removing all visible residual ade-
noma and high-grade dysplasia, increasing the potential
for propagation of any remaining adenomatous tissue.Volume -, No. - : 2017 GASTROINTESTINAL ENDOSCOPY 5
TABLE 1. EDR at SC1 split by patient, lesion, and procedural factors
Endoscopic recurrence at SC1
P value
Multivariate
No.
n [ 474
Yes
n [ 115 OR 95% CI P value
Patient factors
Age, mean  SD, y 66.8  11.7 68.8  11.0 .094
Male sex, no. (%) 252 (53.2) 63 (54.8) .755
Lesion factors
Size 40 mm, no. (%) 199 (42.0) 77 (67.0) < .001 2.47 1.59-3.83 < .001
Paris classification, no. (%)
0-Is 80 (16.9) 18 (15.9) .001
0-IIa 267 (56.6) 32 (28.3)
0-IIa/Is 95 (20.1) 53 (46.9)
Other 30 (6.4) 10 (8.8)
Location, no. (%)
Right side of colon 219 (46.8) 43 (37.7) .043
Transverse colon* 93 (19.9) 21 (18.4)
Left side of colony 78 (16.7) 18 (15.8)
Rectum 78 (16.7) 32 (28.1)
Morphology, no. (%)
Granular 304 (67.6) 90 (79.6) .038
Nongranular 110 (24.4) 16 (14.2)
Serrated 36 (8.0) 7 (6.2)
Kudo classification, no. (%)
II 58 (12.7) 3 (2.6) .005
III 174 (37.9) 38 (33.3)
IV 223 (48.6) 71 (62.3)
V 4 (0.9) 2 (1.8)
Submucosal fibrosis, no. (%) 107 (22.6) 31 (27.0) .325
Histopathology, no. (%)
Tubular adenoma 135 (28.5) 25 (21.7) .001
Tubulovillous adenoma 261 (55.1) 84 (73.0)
SSA/P 78 (16.4) 6 (5.2)
Invasive cancer 0 (0) 0 (0)
High-grade dysplasia, no. (%) 78 (16.5) 35 (30.4) .001 1.72 1.06-2.79 .029
Procedural factors, no. (%)
En bloc resection, no. (%) 0 (0) 0 (0) 1
Adjunctive therapy used, no. (%)
Argon plasma coagulation 20 (4.2) 17 (14.8) < .001
Soft coagulation  biopsy forceps 98 (20.7) 22 (19.1) .712
Duration, median (IQR), min 23.9 (16) 30.0 (23) .001
IPB, no. (%) 70 (14.8) 31 (27.0) .002 1.86 1.08-2.94 .024
Deep injury, no. (%) 22 (6.3) 12 (17.1) .002
Delayed bleeding, no. (%) 38 (8.0) 9 (7.8) .672
Data taken from the model cohort, nZ 589. Variables significant to P < .10 were entered into stepwise backward binomial logistic regression analysis. Only those independent
predictors of recurrence remained in the multivariate model. Not all data points available for all lesions.
EDR, Endoscopically determined recurrence; SC1, first surveillance colonoscopy; OR, odds ratio; CI, confidence interval; SD, standard deviation; SSA/P, sessile serrated adenoma/
polyp; IQR, interquartile range; IPB, intraprocedural bleeding requiring endoscopic control.
*Including hepatic flexure.
yIncluding splenic flexure.
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Risk factor Score
2
1
1
4Total
High-grade dysplasia
IPB
LSL Size ≥ 40
Figure 3. The Sydney EMR recurrence toolda clinical tool to stratify the
incidence of recurrence after EMR. LSL, laterally spreading lesion; IPB, in-
traprocedural bleeding requiring endoscopic control.
Tate et al Adenoma recurrence after piecemeal colonic EMRTogether the independent risk factors for recurrence
make up SERT, a 4-point clinical score that may help physi-
cians triage timing of SC1 based on the individual procedural
and lesion characteristics of their patients. The strength of
SERT is its ability to predict the absence of RRA at SC1 in a
low-risk group of lesions. SERT Z 0 lesions, that is, those
with none of the identiﬁed risk factors for recurrence, had
only a 9.8% cumulative incidence of EDR at 6 months, climb-
ing to only 11.6% at 18 months. In addition, endoscopically
determined SERT Z 0 recurrences were commonly diminu-
tive and unifocal, with half lacking a histologic correlate and
no high-grade dysplasia within the remainder. Therefore, the
clinical signiﬁcance of RRA after EMR of a SERTZ 0 lesiond
and particularly the propagation of such RRA between follow-
up examinationsdis likely to be low.
The situation is different for high-risk (SERT 1-4) le-
sions. These demonstrated a 23.0% cumulative incidence
of RRA even at 6 months, which climbed to 36.3% at 18
months and reached 39.5% at 36 months. These lesions
are often complex to resect and require careful compliance
with scheduled high-quality endoscopic surveillance to
detect and successfully treat RRA.
Moving forward, SERT could be used to triage patients
to appropriate surveillance intervals depending on their
lesion characteristics. The cumulative incidence of EDR
for SERT 1-4 lesions incremented appreciably between
follow-up intervals at 6, 18, and 36 months. These lesions
therefore clearly require follow-up at these time points as
per international guidelines6 and our common practice.
However, because the cumulative incidence of EDR of
SERT Z 0 lesions did not increment appreciably
between 6 and 18 months and was still only 11.6% at 18
months, a strong argument can be made for delaying
SC1 of these lesions until 18 months. Indeed, this may
be useful in detecting RRA that may have been
microscopic if surveyed earlier and would then present at
future surveillance as late recurrence. It is important to
emphasize that because synchronous lesions in this
population are not infrequent,15 these should be
meticulously sought after and cleared during the referral
or EMR procedure.www.giejournal.orgThere are important cost-saving and patient factors that
drive the search for the optimal timing of SC1. Colonoscopy
should not be undertaken lightly because of its considerable
ﬁnancial costs, patient inconvenience, and potential for
morbidity. If SERT was applied to our entire cohort retro-
spectively, and patients were triaged to SC1 at 18 months
if they had no high-risk features (SERT Z 0), 473 of 1178
(40.2%) patients would have avoided 1 surveillance colonos-
copy. Colonoscopy (day stay, without adverse event) costs
AU $1459.69 (U.S. $1255) at the Westmead center, so the
Australian healthcare system would have been saved at
least AU $690,000 (U.S.$ 500,000) by this intervention
alone over 8 years (Supplemental Table 6, available online
at www.giejournal.org). Indeed, in centers performing
less-complexdparticularly smallerdresections, the cost
saving is likely to be much greater.
Combining recent improvements in EMR as a result of
better endoscopic imaging, electrosurgery, and EMR tech-
niques with the ability to triage patients’ risk of RRA de-
pending on their particular lesion characteristics is likely
to afﬁrm the position of EMR as the primary therapy for
large, noninvasive colon LSL. Given the signiﬁcantly
longer procedure time, restricted availability (particularly
in Western centers), steep learning curve, opportunity
cost, greater adverse event proﬁle, and mandation of a
multiple-day inpatient hospital stay,16,17 there would
seem to be little beneﬁt of endoscopic submucosal dissec-
tion over EMR with robust, triaged follow-up. This is partic-
ularly true for SERT Z 0 lesions.
This study has several strengths. The study population was
large, multi-institutional, well characterized, and prospec-
tively collected, with strong compliance to follow-up exami-
nations. In addition, en bloc lesions with their known low
rate of RRA were excluded from the study, allowing a focus
solely on RRA in lesions removed by piecemeal EMR; this
has not been previously studied in such a large cohort.
EDR was used as the main endpoint of the study because
of the large amount of such data available in our cohort. To
this point, the discussion has focused on the model’s ability
to predict actual outcomes of EDR in the validation cohort.
However, international expert opinion suggests that histolog-
ic determination should represent the criterion standard in
the assessment of the presence of RRA at an EMR scar.
The data suggest that assessment of an EMR scar with
high-deﬁnition white light and narrow-band imaging provides
an accurate prediction of HDR with an NPV of 98.9% and a
sensitivity of 97.0% in the validation cohort. We have recently
demonstrated this in a separate prospective series with an
NPV of 98.6%.18 The PPV of EMR scar assessment in
contrast is low (66.7%), indicating that EDR was often
without an HDR correlate. Endoscopic scar assessment,
with the latest generation of endoscopic imaging, can be
performed in real-time, and if there is any suspicion of RRA
the scar is treated endoscopically with proven safe and effec-
tive techniques. Overestimation of RRA by EDR is therefore
without signiﬁcant clinical consequence.Volume -, No. - : 2017 GASTROINTESTINAL ENDOSCOPY 7
TABLE 2. Rates of EDR and HDR at SC1 stratified by the presence of high-risk features* at the initial EMR in the model, validation, and combined
cohorts
EDR
Histologic data available
model n [ 297, validation n [ 280
EDR HDR
Model cohort n Z 589
SERT Z 0 22/243 (9.1%) 15/98 (15.3%) 12/98 (12.2%)
SERT 1-4 93/346 (26.9%) 78/199 (39.2%) 50/199 (25.1%)
Validation cohort n Z 589
SERT Z 0 20/230 (8.7%) 17/87 (6.1%) 7/87 (8.0%)
SERT 1-4 93/359 (25.9%) 79/193 (40.9%) 59/193 (30.6%)
Overall n Z 1178
SERT Z 0 42/473 (8.9%) 32/185 (17.3%) 19/185 (10.3%)
SERT 1-4 186/705 (26.4%) 157/392 (40.1%) 109/392 (27.8%)
EDR, Endoscopically determined recurrence; HDR, histologically determined recurrence; SC1, first surveillance colonoscopy; SERT, Sydney EMR recurrence tool.
*High-risk features are 1 or more of size 40 mm, intraprocedural bleeding requiring endoscopic control and high-grade dysplasia in the resection specimen.
Endoscopically
assessed EMR
scars
n=589
SERT 0
n=230
(39.0%)
SERT 0
n=87
(31.0%)
SERT 1-4
n=193
(68.9%)
SERT 1-4
n=359
(61.0%)
EDR
20 (8.7%)
EDR
17 (19.5%)
HDR
7 (8.0%)
HDR
59 (30.6%)
EDR
79 (40.9%)
Accuracy of EDR to
predict HDR
NPV 98.9%
PPV 66.7%
Specificity 85.0%
Sensitivity 97.0%
Histologic
correlate available
n=280
EDR
93 (25.9%)
Figure 4. Rates of recurrence at surveillance colonoscopy 1 (SC1) stratiﬁed by a binary Sydney EMR recurrence tool (SERT) SERTZ 0 versus SERT 1-4
approach. Endoscopically determined recurrence (EDR) was available for all 1178 patients. Histologically determined recurrence (HDR) was available for
297 patients in the model cohort and 280 patients in the validation cohort. SERT, the Sydney EMR recurrence tool; EDR, endoscopically determined recur-
rence; HDR, histologically determined recurrence; NPV, negative predictive value; PPV, positive predictive value.
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TABLE 3. Cumulative incidence of EDR among the validation cohort at specified intervals of follow-up as determined by the Kaplan-Meier curves
(Table 2)
Follow-up, mo
Cumulative incidence of EDR (%)
Log-rank test
SERT [ 0 lesion
n [ 230, 24 recurrences
(standard error)
SERT 1-4 lesions
n [ 359, 96 recurrences
(standard error)
6 9.8% (2.2%) 23.0% (2.5%) P < .001
12 11.6% (2.5%) 34.9% (3.1%)
18 11.6% (2.5%) 36.3% (3.2%)
36 16.6% (4.2%) 39.5% (3.5%)
This method uses the longest follow-up available for each lesion and includes 120 instances of EDR (120 lesions) by using survival tables generated by Kaplan-Meier curves.
Bold type indicates suggested follow-up intervals. Long-term follow-up (16 months) was available for 168 of 589 lesions in this cohort.
EDR, Endoscopically determined recurrence; SERT, Sydney EMR recurrence tool.
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Figure 5. Kaplan Meier plot of endoscopically determined recurrence (EDR) as stratiﬁed by the presence (Sydney EMR recurrence tool score [SERT] 1-4)
or absence (SERTZ 0) of high-risk features for recurrence at the initial EMR. Lesions displayed are from the validation cohort (nZ 589). Log-rank test;
P < .001. EDR, endoscopically determined recurrence; SERT, Sydney EMR recurrence tool.
Tate et al Adenoma recurrence after piecemeal colonic EMRThe ability of SERT, created by using EDR data, to predict
HDR is demonstrated throughout the study. Data on HDR
were available in approximately half of lesions because scar
biopsy was indicated only in the study protocol if the endo-
scopist suspected recurrence. SERT was able to accurately
predict both EDR and HDR outcomes to SC1 and to speciﬁc
follow-up intervals. Higher rates of recurrence (EDR in partic-
ular) in lesions with available HDR data are likely caused by
the bias introduced by scar biopsy only where the endoscop-
ist suspected RRA. Nevertheless, the important ﬁnding that
SERT can accurately identify and stratify 2 groups of lesions
at signiﬁcantly disparate risk of RRA to long-term follow-up
even when using HDR data provides strong validation for
the accuracy and utility of the model.www.giejournal.orgDrawbacks of the study included the derivation of the
study data from a tertiary-care referral cohort, potentially
limiting the applicability of the model for EMR practi-
tioners outside this context. However, expert opinion sug-
gests that EMR of large LSLs should preferably be carried
out in appropriately resourced and experienced tertiary-
care centers. In addition, SC1 was not always reliably per-
formed within the desirable range of 4 to 6 months after
initial EMR. In these cases, the data were still included as
SC1 with the associated time interval. This approach pro-
vided some insight into the temporal pattern of adenoma
recurrence, a phenomenon not well studied previously.
Our group has shown previously that the use of argon
plasma coagulation to treat visible residual adenoma19 isVolume -, No. - : 2017 GASTROINTESTINAL ENDOSCOPY 9
Adenoma recurrence after piecemeal colonic EMR Tate et ala multivariate risk factor for RRA at SC1.4 We have excluded
it from this study because it is no longer used at the study
centers. For visible residual adenoma, we prefer cold
forceps avulsion followed by thermal ablation of the
avulsed area.
In conclusion, this study demonstrates that adenoma
recurrence after piecemeal EMR of large LSLs of the colon
is predictable and stratiﬁable. Given that RRA can be treated
endoscopically in the vast majority of cases, practitioners
will beneﬁt greatly from knowing how adenoma recurrence
behaves after EMR and how to predict it. Based on SERT, we
believe that 1 approach would be to delay SC1 for low-risk
lesions (SERT Z 0) until 18 months, whereas high-risk le-
sions (SERT 1-4) would continue to undergo SC1 at 6 and
18 months. Prospective validation of this model must follow
to ensure its validity in clinical practice.REFERENCES
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Supplemental Figure 1. Kaplan-Meier plot of EDR of lesions as stratiﬁed by presence or absence of high-risk features for recurrence at the initial EMR
by the Sydney EMR recurrence tool (SERT)dSERT 1-4 indicating presence and SERTZ 0 indicating absence. Lesions displayed are from the entire cohort
(n Z 1178). Log-rank test; P < .001. EDR, endoscopically determined recurrence; SERT, Sydney EMR recurrence tool.
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Supplemental Figure 2. Kaplan-Meier plot of EDR of lesions as stratiﬁed by presence or absence of high-risk features for recurrence at the initial EMR
by the Sydney EMR recurrence tool (SERT)dSERT 1-4 indicating presence and SERT Z 0 indicating absence. Lesions displayed are from the validation
cohort in which matched endoscopically determined recurrence and histologically determined recurrence data were available (nZ 280). EDR, endoscop-
ically determined recurrence; HDR, histologically determined recurrence; SERT, Sydney EMR recurrence tool.
SUPPLEMENTAL TABLE 1. Comparison of EDR and HDR at the EMR scar at first surveillance colonoscopy after EMR for cases in which endoscopic
and histologic data were available
EDR
HDR
Negative Positive
Model Negative 203 (99.5%) 1 (0.5%)
n Z 297 Positive 32 (34.4%) 61 (65.6%)
Validation Negative 182 (98.9%) 2 (1.1%)
n Z 280 Positive 32 (33.3%) 64 (66.7%)
Overall cohort Negative 385 (99.2%) 3 (0.8%)
n Z 577 Positive 64 (33.9%) 125 (66.1%)
Bold text indicate the rates of agreement of EDR and HDR. The negative predictive value, positive predictive value, specificity, and sensitivity of EDR versus HDR in the validation
cohort were 98.9%, 66.7%, 85.0%, and 97.0%, respectively.
EDR, Endoscopically determined recurrence; HDR, histologically determined recurrence.
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SUPPLEMENTAL TABLE 2. EDR at SC1 in the validation cohort split by patient, lesion, and procedural factors
EDR
P value
Multivariate
No
n [ 476
Yes
n [ 113 OR 95% CI P value
Patient factors
Age, mean  SD, y 67.7  11.7 67.7  11.5 .993
Male sex, no. (%) 231 (48.7) 58 (51.3) .620
Lesion factors
Size  40 mm, no. (%) 198 (41.6) 75 (66.4) < .001 2.37 1.52-3.69 < .001
Paris classification, no. (%)
0-Is 80 (16.8) 30 (26.5) < .001
0-IIa 239 (50.3) 36 (31.9)
0-IIa/Is 114 (24.0) 41 (36.3)
Other 42 (8.8) 6 (5.3)
Location, no. (%)
Right side of colon 216 (45.7) 53 (47.3) .016
Transverse colon* 92 (19.5) 17 (15.2)
Left side of colony 77 (16.3) 9 (8.0)
Rectum 88 (18.6) 33 (29.5)
Morphology, no. (%)
Granular 298 (65.9) 90 (80.4) .005
Nongranular 116 (25.7) 13 (11.6)
Serrated 38 (8.4) 9 (8.0)
Kudo classification, no. (%)
II 52 (11.3) 1 (0.9) < .001
III 169 (36.7) 31 (27.7)
IV 227 (49.3) 77 (68.8)
V 2 (0.4) 3 (2.7)
Submucosal fibrosis (%) 120 (25.5) 39 (35.1) .040
Histopathology (%)
Tubular adenoma 120 (25.2) 16 (14.2) < .001
Tubulovillous adenoma 275 (57.8) 92 (81.4)
SSA/P 81 (17.0) 5 (4.4)
Invasive cancer 0 (0) 0 (0)
High-grade dysplasia 110 (23.1) 41 (36.3) .004 1.57 0.99-2.48 .053
Procedural factors
En bloc resection, no. (%) 0 (0) 0 (0) n/a
Duration, median (IQR), min 20 (18) 33 (35) < .001
Adjunctive therapy used, no. (%)
Argon plasma coagulation 24 (5.0) 15 (13.3) .002
Soft coagulation  biopsy forceps 103 (21.6) 31 (27.4) .187
IPB, no. (%) 61 (12.8) 32 (28.3) < .001 2.28 1.38-3.78 .024
Deep injury, no. (%) 26 (7.6) 7 (10.3) .461
Delayed bleeding, no. (%) 38 (8.1) 13 (11.6) .236
Data taken from the validation cohort, n Z 589. Not all data points were available for all lesions.
EDR, Endoscopically determined recurrence; SC1, first surveillance colonoscopy; OR, odds ratio; CI, confidence interval; SD, standard deviation; SSA/P, sessile serrated adenoma/
polyp; IQR, interquartile range; APC, argon plasma coagulation; IPB, intraprocedural bleeding requiring endoscopic control.
*Including hepatic flexure.
yIncluding splenic flexure.
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SUPPLEMENTAL TABLE 3. Cumulative incidence of recurrence at SC1 by values of SERT in the validation cohort (n [ 589)
SERT score EDR (n [ 589) 95% CI HDR (n [ 280) 95% CI
0 20/230 (8.7%) 5.7%-13.1% 7/87 (8.0%) 3.6%-16.4%
1 14/80 (17.5%) 10.2%-27.3% 7/36 (19.4%) 8.8%-36.6%
2 39/150 (26.0%) 19.6%-33.6% 23/83 (27.7%) 18.7%-38.8%
3 29/106 (27.4%) 19.8%-36.5% 22/60 (36.7%) 24.9%-50.2%
4 11/23 (47.8%) 27.4%-68.9% 7/14 (50.0%) 24.0%-76.0%
Data are presented for EDR and HDR (in 280 cases with EDR and HDR data available).
SC1, Surveillance colonoscopy 1; SERT, Sydney EMR recurrence tool; EDR, endoscopically determined recurrence; CI, confidence interval; HDR, histologically determined
recurrence.
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SUPPLEMENTAL TABLE 4. Characteristics of the modelling and validation cohorts
Model cohort
n [ 589
Validation cohort
n [ 589 P value
Patient factors
Age, mean  SD 67.14  11.64 67.72  11.68 .432
Male sex, no. (%) 315 (53.5) 298 (50.8) .352
Lesion factors
Size 40 mm, no. (%) 276 (46.9) 273 (46.3) .861
Paris classification, no. (%)
0-Is 98 (16.8) 110 (18.7) .462
0-IIa 299 (51.1) 275 (46.8)
0-IIa/Is 148 (25.3) 155 (26.4)
Others 40 (6.8) 48 (8.2)
Location, no. (%)
Proximal colon 262 (45.0) 269 (46.0) .736
Transverse colon* 114 (19.6) 109 (18.6)
Left colony 96 (16.5) 86 (14.7)
Rectum 110 (18.9) 121 (20.7)
Morphology, no. (%)
Granular 394 (70) 388 (68.8) .879
Nongranular 126 (22.4) 129 (22.9)
Serrated 43 (7.6) 47 (8.3)
Kudo classification, no. (%)
II 61 (10.7) 63 (11.0) .955
III 212 (37.0) 200 (35.0)
IV 294 (51.3) 304 (53.1)
V 6 (1.0) 5 (0.9)
Submucosal fibrosis, no. (%) 138 (23.5) 159 (27.3) .130
Histology, no. (%)
Tubular adenoma 160 (27.2) 136 (23.1) .310
Tubulovillous adenoma 345 (58.6) 367 (62.3)
Sessile serrated adenoma 81 (13.8) 95 (14.4)
Invasive cancer 0 0
High grade dysplasia, no. (%) 113 (19.2) 151 (25.6) .008
Procedural factors
En-bloc resection, no. (%) 0 (0) 0 (0) n/a
Duration, median (IQR), min 20 (15) 20 (16) .814
IPB, no. (%) 101 (17.1) 93 (15.8) .530
Deep injury, no. (%) 34 (8.1) 33 (8.1) .989
Delayed bleeding, no. (%) 47 (8.0) 44 (7.4) .894
Follow-up
Endoscopic recurrence at SC1, no. (%) 115 (19.5) 113 (19.2) .883
Histologic recurrence at SC1, no. (%) 62/297 (20.9) 66/280 (23.6) .436
Total follow-up available, median (IQR), mo 6.3 (13.85) 7 (13.60) .473
Not all data points were available for all lesions.
SD, Standard deviation; n/a, not applicable; IPB, intraprocedural bleeding requiring endoscopic control; SC1, first surveillance colonoscopy; IQR, interquartile range.
*Including hepatic flexure.
yIncluding splenic flexure.
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SUPPLEMENTAL TABLE 5. Cumulative incidence of EDR and HDR as determined by Kaplan-Meier curves with data restricted to cases in the
validation cohort in which matched EDR and HDR data were available (n [ 280)
Follow-up, mo Determination of recurrence
Cumulative incidence of recurrence (%)
SERT [ 0 lesion
n [ 101
(standard error)
SERT 1-4 lesions
n [ 211
(standard error)
6 EDR 17.7% (4.2%) 31.8% (3.5%)
HDR 7.0% (3.1%) 23.5% (3.3%)
12 EDR 22.0% (5.0%) 46.7% (4.1%)
HDR 11.8% (4.4%) 38.2% (4.3%)
18 EDR 22.0% (5.0%) 48.9% (4.2%)
HDR 11.8% (4.4%) 40.7% (4.5%)
36 EDR 30.3% (7.2%) 52.2% (4.5%)
HDR 17.7% (7.0%) 44.5% (4.9%)
EDR, Endoscopically determined recurrence; HDR, histologically determined recurrence; SERT, Sydney EMR recurrence tool.
SUPPLEMENTAL TABLE 6. Cost saving of a binary approach to lesion follow-up based on SERT in common currencies for the whole lesion cohort
(n [ 1178)
Non-SERT approach
n [ 1178
SERT approach
n [ 705
Saving
n [ 473
AUD 1,719,515 1,029,081 690,434
USD 1,478,390 884,775 593,615
EURO 1,361,756 814,973 546,783
GBP 1,173,140 702,091 471,048
JPY 157,707,253 94,383,373 63,323,880
Based on cost of a surveillance colonoscopy without complication of $1255 USD at the Westmead center; this cost likely varies between countries. Approximate conversion
provided based on exchange rate November 2016.
SERT, Sydney EMR recurrence tool; AUD, Australian dollar; USD, U-S dollar; GBP, British pound; JPY, Japanese yen.
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Synopsis and Significance 
The analysis of the historical cohort of patients undergoing EMR demonstrated important risk 
factors for recurrence at first surveillance were LSL size ≥ 40mm (odds ratio 2.47 [95% CI 
1.59-3.83], P< 0.001), intra-procedural bleeding requiring endoscopic control (odds ratio 1.86 
[95% CI 1.08-2.94]) and high grade dysplasia (odds ratio 1.72 [95% CI 1.06-2.79]).  These 
results were used to generate a clinical score to predict recurrence after EMR (SERT) (Table 
1). 
Clinical Criterion SERT score 
Size of LSL ≥ 40mm 2 
Intra-procedural bleeding requiring 
endoscopic control 
1 
High grade dysplasia in the resected 
specimen 
1 
Table 1 - Components of the Sydney EMR Recurrence Tool (SERT) 
Moreover, when actual times (months) of detected recurrence in patients within the validation 
cohort were plotted using Kaplan Meier curves it became clear that recurrence is a temporal 
phenomenon, occurring in the main within 6-12 months of the index EMR.  Late recurrence 
was confirmed to be a rare phenomenon.  Stratifying patients into binary SERT 0 versus SERT 
1-4 groups allowed a group of patients at high risk of recurrence during follow up to be 
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identified.
 
Figure 2 - Kaplan Meier plot of endoscopically determined recurrence (EDR) as stratified by the presence (Sydney EMR 
recurrence tool score [SERT] 1-4) or absence (SERT = 0) of high-risk features for recurrence at the initial EMR. Lesions 
displayed are from the validation cohort (n Z 589). Log-rank test; P < .001. EDR, endoscopically determined recurrence; 
SERT, Sydney EMR recurrence tool. 
These findings are significant since patients with SERT 0 resections can likely avoid initial 
surveillance and undergo a definitive surveillance procedure at 18 months.  SERT 1-4 patients 
continue to require surveillance at 4-6 months as is standard56.   
The significance of SERT in the context of the results presented in Chapter 10 is as yet unclear.  
Subgroup analysis of the data from this study indicated that the effect of size and high grade 
dysplasia as risk factors for recurrence were nullified by the active treatment.  Perhaps the role 
of SERT, outside of expert EMR centres, will be to identify a group of patients who may 
‘safely’ return for surveillance at an interval.  This is likely to be important as rates of 
recurrence, even at other academic centres57 are significantly higher than this series.  
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Theme 4 - FUTURE TOOLS AND METHODS FOR COLLABORATIVE 
RESEARCH IN CLINICAL ENDOSCOPIC PRACTICE 
Introduction 
Over the last decade clinical research in polypectomy has progressed immeasurably.  Vastly 
improved technology combined with novel techniques and a focus on evidence-based practice 
has driven the field forward.  However, the increasing proliferation of endoscopic techniques 
for polypectomy coupled with the widespread availability of equipment to perform them in 
many different contexts threatens this progress.   
Practitioners with little experience may be tempted to undertake resource intensive, overly 
complex techniques on patients inappropriately either due to a lack of understanding or due to 
unavailability of suitable cases.  Patients may have a varying understanding of the risks 
involved in such techniques and may simply accept treatment offered by their endoscopist. 
Whilst this approach to novel techniques or technology may be acceptable in the context of an 
absence of a safe, proven and effective alternative, such a technique is widely available in 
colorectal polypectomy.  For >90% of LSL endoscopic mucosal resection has a significant 
evidence base that it is safe and effective in the long term.  For the most part this is because the 
colorectal mucosa lacks lymphatic supply and so any neoplastic lesion limited to the mucosa 
cannot metastasise.   
Alternative techniques such as endoscopic submucosal dissection are not cost effective in the 
majority of cases58, subject patients to longer procedure times, rates of adverse events and risks 
of surgery 59 and should be avoided unless there is a strong indication.  Such indications are 
overt or high-risk covert evidence (see Chapter 6 ) for submucosal invasive cancer.  An 
important contemporary study shows that amongst a large population of LSL at a tertiary 
centre, these lesions are the minority 58.   
Therefore en-bloc or piecemeal endoscopic mucosal resection should be the treatment of choice 
for the majority of LSL.  There is a need for centres of excellence in endoscopic resection to 
pool data on safety and efficacy of all techniques in endoscopic resection, particularly novel 
techniques.  In addition, those centres must agree upon and publish evidence-based standards 
by which the practice of individual endoscopists performing endoscopic resection and their 
training / trainees should be judged.  To this end there is a need for a mechanism to allow 
standardised data collection around endoscopic resection in the colon.   
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Chapter 12 – Development and implementation of a collaborative research 
and data sharing platform for endoscopic research 
Adoption of new technology 
Over the past 5 years there has been an explosion in programming technologies allowing the 
creation of media rich internet-based tools available on many different platforms from desktop 
computers to mobile telephones.  These technologies include HTML (Hypertext Markup 
Language) 60 coupled with Javascript 61, PHP, CSS and upgraded, longstanding database 
technologies such as MySQL.  As a result, applications that could once only be run on large 
desktop computers can now be run simply using an internet browser on any device. 
This technology presents the opportunity to create a research specific application that can be 
shared amongst all collaborating parties in disparate locations.  Particular advantages include 
standardised data collection, 24-hour availability and instant sharing of data between 
institutions. 
The unmet need 
Prior to the creation of the data sharing platform data storage at our research centre was using 
Microsoft Excel (Microsoft, Seattle, Washington, USA), and later FileMaker Pro (Apple, 
Cupertino, California, USA).  These solutions provided secure data storage but did not allow 
for the standardised entry of data at each institution.  Data entry was not validated leading to 
multiple omissions which required later correction.  All data was communicated to the host 
study centre via fax machine for manual transcription into the database, potentially leading to 
errors at multiple stages of this pathway.  There was an increasing need to collaborate with 
expert centres abroad and standardise data collection which was not feasible using the 
contemporaneous method.  Despite an ability to deidentify the data there was no possibility to 
remotely update research records from the multiple locations used by investigators within even 
one single institution.  Deidentified images of endoscopic procedures could not be stored on 
this system, despite being increasingly recognised as vital to endoscopic research and training. 
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The beginnings of a data portal 
I commenced work on creating an online version to combine our multiple data collectors.  I 
took advice from professional information technology sources to ensure the security of the 
system, but all of the design, coding and implementation was performed by me. 
Several important requirements drove the design process: 
• The data needed to be stored online in a deidentified form, but each study centre had to 
have the ability to easily re-identify the data locally in a secure network environment 
for patient contacts and procedural planning. 
• The data needed to be validated on entry, such that particular fields were required, and 
particular combinations of data accepted whilst others were rejected. 
• The data needed to be accessible to investigators in different time zones around the 
clock and at an acceptable speed 
• The data needed to be able to be linked to deidentified endoscopic images and video 
for the purposes of increasing understanding regarding endoscopic imaging and its 
correlation with pathology. 
• The data needed to be presented in a user friendly way for busy investigators to arrange 
patient surveillance, collect patient outcomes from after the procedure and ensure the 
integrity of the entered data 
• The proffered data collection platform needed to be able to take a modular approach.  
Certain centres needed access to certain functionality whereas this needed to be 
withheld from others. 
• Data needed to be readily available to download from the system in deidentified form 
for use with data analysis programmes such as SPSS (IBM, Armonk, New York) and 
Microsoft Excel. 
Ethical approval 
Within the construct of our existing multicentre human research ethics approval for collection 
of data on all aspects of the resection of large laterally spreading lesions we applied to the 
Western Sydney Human Research Ethics Committee for additional approval to collect, store 
and share deidentified data with other study institutions using the online portal.  The approval 
for this is attached in Appendix 2.  
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The resultant research platform (iACE) 
The resulting platform was named iACE – international / interactive Australian Colonic 
Endoscopic Resection Study.  The following briefly describes the functions of the platform 
which will help take forward the next generation of research related to complex endoscopic 
resection of early neoplastic lesions in the colon. 
Security 
iACE is hosted on a server which uses a SSL certificate to provide secure, encrypted 
communication between the hosted data server and the client internet browser.  The database 
is accessible only via a private link and each user has a randomly generated password using a 
hash512 algorithm such that it is known to no other person including the chief investigator.  
The portal is only accessible to those named as investigators in the study. 
Data Entry 
As per the specification above iACE has modular functionality.  There is a standard data entry 
process for LST which is validated by a set of rules agreed by the investigators (Figure 3). 
 
Figure 3 - iACE portal screenshot illustrating standardised data collection form. 
The format of data entry varies between the stage of the lifetime of the LSL.  As can be inferred 
from reading the preceding chapters LSL undergo one or more initial endoscopic resections 
and then multiple subsequent follow up examinations.  These can all be recorded separately.   
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iACE does not only hold information on endoscopic mucosal resection.  The portal has the 
ability (through variations on the standard form through investigator agreed algorithms) to 
collect data on Endoscopic Submucosal Dissection, Piecemeal cold snare polypectomy and 
Full thickness resection procedures.  There is the potential for expansion and diversification as 
the field develops. 
Once a lesion (LSL) and its associated procedural and deidentified patient data have been 
entered there is the ability to upload deidentified images of the LSL and the progressant 
resection (Figure 4). 
 
Figure 4 - iACE portal screenshot illustrating ability to upload images for a specific lesion and stage of lesion resection 
Once images have been entered the user is shown the study screen for the LSL they have just 
entered.  Here the lesion / patient can be enrolled in specific studies depending on the institution 
and ethical/institutional review board agreements and patient consent.  The portal can be 
configured to allow any combination of studies for each patient depending on the above 
agreements for a certain centre or even study investigator (Figure 5). 
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Figure 5- iACE portal screenshot illustrating image capture and the modular nature of the study enrolment options such that 
any given LSL can be enrolled in multiple studies dependent on the type of resection, patient consent and agreements between 
study institutions. 
If an investigator wishes to enter a patient into one of the studies a series of questions leads 
them through a standardised and agreed set of inclusion criteria as per the relevant study 
protocol.  To be able to proceed the lesion data entered previously must match the enrolment 
criteria and the questions answered at this stage avoiding incorrect allocation of lesions and 
patients into studies (Figure 6).   
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Figure 6 – iACE portal demonstrating validation of lesion entry into a study due to inadequate data entry. 
Randomisations are also generated on the portal to remove this element of bias in randomised 
trials.  A computer algorithm generates the randomisation and once a randomisation is 
generated it cannot be altered for that lesion (Figure 7). 
 
 
Figure 7 – iACE portal screenshot demonstrating randomisation of a lesion into a study via a computer algorithm.  Once a 
randomisation is generated it cannot be changed for that lesion. 
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Data viewing 
iACE was designed by a clinician to work and present results in a format required by busy 
investigators. 
iACE can present lesion images from the centre the user is registered at in a format ideal for 
presentation in conference abstracts and meetings (Figure 8). 
 
Figure 8 – iACE screenshot illustrating the ability to display and download structured slides of images of LSL resection during 
initial endoscopic resection procedures and during follow up. 
iACE also has the ability to generate a table of stored lesion images with associated histology 
results and information on the presence or absence of submucosal invasive cancer.  This will 
be invaluable for data linkage and training a future generation of endoscopists in endoscopic 
imaging (Figure 9) . 
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Figure 9 – iACE portal screenshot illustrating the ability to display many lesion resections in an image table.  The user can 
hover over a row of images revealing the actual histology of this lesion and whether there was evidence of submucosal invasive 
cancer, in addition to zooming on a particular image. 
Various reports are available to the user.  Data can be viewed by patient or lesion level.  Tables 
can be filtered by any heading and stretched to reveal large amounts of data in comment fields.  
The majority of studies require study personnel to contact the patient at an interval after the 
procedure so that adverse event and other data can be obtained.  This is facilitated by iACE in 
terms of reports on those patients missing this check, those missing histology data and those 
missing surveillance data (Figure 10).   
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Figure 10 – iACE portal screenshot illustrating the ability to present data to the clinician/investigator in a user-friendly 
manner with missing data clearly highlighted. 
Since cross referencing of lists of identification tables and deidentified data can be difficult, 
time consuming and likely lead to data entry errors iACE includes the ability to identify the 
online deidentified information in the study centre on the secure intranet of the institution 
collecting the data.  The identified data is stored in a ‘key file’ (Microsoft Excel, comma 
separated values file) which has headings for patient identifiable information.  The user 
browser at the host institution can match the study identifiers in the key file with the online 
information and present a combined version to the user on the web page.  No identified data 
leaves the host institution or computer since it is stored in the local storage of the browser.  As 
soon as the user navigates away from the page the data is deleted. 
 
Maintaining data integrity 
Reports to the user regarding numbers of lesions missing certain aspects of important data such 
as surveillance checks are available.  From these screens missing data can easily be located and 
added.  Our understanding of the natural history of LSL after endoscopic resection is dependent 
on reliable long-term data which does not currently exist beyond around 18 months in the 
literature. 
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Output of data for analysis software 
iACE can output data for analysis in commonly used statistical packages such as SPSS 
Statistics (IBM, Armonk, NY, USA).  The data is stored using a set of numerical codes which 
can be identified using a predefined value list.  This is available to users as a separate download 
to add an extra layer of security to the data storage. 
 
Figure 11 – Sample of the output from the iACE portal.  The completeness of the data is evident visually.  This is due largely 
to data validation which was not available in our previous data entry methods.  The storage of the data as integers adds 
another layer of security since a key file is required to interpret even deidentified data.  Also present, although not appreciated 
graphically is a layer of validation that does not allow the entry of incompatible values e.g. Kudo I and NICE III etc. for LSL. 
Promoting a drive for practitioners of endoscopic resection to record and display key 
performance indicators of their practice 
iACE presents the user with a summary of the number of lesions recruited at their centre and 
those missing important data on the introductory page. 
Importantly a set of investigators proffered key performance indicators for endoscopic 
resection of LSL using EMR are presented on an iACE metrics page (Figure 12). 
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Figure 12  iACE portal screenshot illustrating the key performance indicators calculated from the entered data for individual 
endoscopists and centres 
  Whilst in the early phases of development this data can be stratified by SMSA score (Chapter 
4) since the outcomes of different complexity of lesions should not be considered together.  
The portal also allows the user to see the proportion of different SMSA score lesions they have 
recruited/performed as versus the overall centre rate. 
 
Figure 13 – iACE portal screenshot illustrating the ability to stratify outcomes for a centre or endoscopist by SMSA score – 
beta demonstration only 
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This data will likely become extremely important in the future for informed patient consent 
and identification of practitioners who should receive a future certification to perform 
endoscopic resection. 
 
Summary 
The iACE data portal will be important going forward to improve collaboration between 
centres undertaking endoscopic resection, quality of data captured, correlation of endoscopic 
imaging, histologic and procedural data and the co-ordination of high quality observational and 
randomised studies. 
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Chapter 13 – Conclusions and Future Directions 
Over the last decade the technology available for polypectomy and the evidence base 
underpinning its practice has progressed immeasurably.  In this thesis I have been lucky enough 
to have the opportunity to co-ordinate research that has advanced the field in four major areas, 
representing the 4 themes of this thesis.  In this final chapter a detailed discussion of the main 
conclusions reached and future research directions is provided.   
Quality and safety of polypectomy are paramount if the larger goal of reducing rates of 
colorectal cancer is to be achieved.  Chapter 2’s study1 demonstrates how is possible to reliably 
characterise an important precursor of colorectal cancer (the sessile serrated polyp with 
dysplasia [SSP-D]) using endoscopic imaging.  This knowledge requires widespread 
dissemination by endoscopy societies such that these important high-risk lesions are not 
mistaken for adenomas and incompletely resected.  The optimal technique to remove SSP-D 
endoscopically is unclear and requires further elucidation in high quality prospective studies; 
for example, is cold snare resection appropriate as has been suggested for SSP without 
dysplasia [Chapter 3]2?   
Our patients have a right to expect their physicians to avoid harm where at all possible.  The 
study in chapter 5 provides a snapshot of current practice indicating benign appearing disease 
is still often referred for surgery.  Since it has been demonstrated that surgery for benign 
colorectal polyps has significantly higher morbidity and mortality34-36 when compared to 
endoscopic resection this argues for a system whereby polyps are discussed with a tertiary 
endoscopist, perhaps present in a multi-disciplinary setting prior to referral for surgery.  This 
study also demonstrates that endoscopists do not always recognise submucosal invasive cancer 
within colorectal polyps; this may also cause harm to patients due to unnecessary procedures 
and potential adverse events due to failed or incomplete resection and even perforation.  
Addressing these issues will require focussed efforts on training in endoscopic imaging and the 
merits and possibilities of endoscopic resection by international organisations.  In addition, the 
fast-advancing field of artificial intelligence is likely to make a significant impact in this area; 
this should not be at the expense of education or human excellence in these techniques. 
When performing polypectomy, physicians should choose a technique with a solid and 
contemporary evidence base.  If the polyp is large, with perhaps greater risks of adverse events 
from the proposed management, the physician should discuss the proposed intervention and its 
alternatives with the patient.  One theme which has emerged as a key safety parameter in 
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polypectomy is the avoidance of diathermy where at all possible.  Chapter 3’s study2 provides 
evidence that for large sessile serrated polyps (>9mm) using cold snare polypectomy resulted 
in no episodes of bleeding after the procedure requiring readmission to hospital or further 
colonoscopy and therapy.  This finding will need to be borne out in larger high-quality 
prospective studies and efficacy should be confirmed in controlled trials where cold snare 
polypectomy is randomised with the standard of care (endoscopic mucosal resection).  The 
upper polyp size limit (if indeed one exists) to which this technique can be applied should be 
defined.  The differences between the appearances of scars at surveillance versus those formed 
by techniques using diathermy should be defined along with the rate of adenoma recurrence at 
surveillance.  Chapter 5’s study provides evidence of the current situation that cold snare 
polypectomy is underutilised in routine practice for diminutive polyps <10mm in size.  Further 
data should be obtained from large randomised studies as to the optimal technique here 
emphasising both safety and efficacy.  In particular the long-term consequences of incomplete 
resection of polyps < 10mm in size should be explored.  There remains controversy about the 
safest and most effective technique for polyps between 10 and 20mm in size; this needs further 
exploration in randomised studies.   
Particularly relevant to patient consent are data to inform practitioners and patients about the 
risk and resource usage of a specific polypectomy prior to the procedure (Chapter 4’s study3).  
A previously published clinical score (the size, morphology, site and access score [SMSA]38) 
was shown to predicts the likelihood of EMR success, likelihood of adverse events including 
delayed bleeding, adenoma recurrence and requirement for surgery at 2 weeks (SMSA 3 versus 
4) for polyps ≥20mm in size.  Upfront knowledge of these risks prior to the procedure allows 
patient and polyp specific consent.  It may also allow for accurate resource allocation and unit 
planning for a tertiary endoscopy service.  In addition, it may allow trainees to be allocated to 
lesions which are suitable for their level of competence.  All of these uses of the SMSA score 
should be examined in prospective studies.  The SMSA score is not particularly well adapted 
to more complex lesions such as those that have been previously attempted, those at difficult 
colonic locations such as the anorectal junction or ileo-caecal valve; the score should be 
expanded to take account of factors which expert endoscopists judge to increase difficulty and 
this tested against datasets including the endpoints above. 
Endoscopic mucosal resection has emerged as the preferred technique for the resection of large 
sessile colonic polyps (LSL).  This thesis contains multiple studies that may elevate the 
technique to a new level of effectiveness and allow patients to avoid the potential morbidity 
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and mortality of colorectal surgery.  Non-lifting adenoma previously resulted in failed 
endoscopic resection and the common referral of patients for surgical resection.  Chapter 8’s 
study6 demonstrates that non-lifting adenoma can be reliably, simply and safely treated using 
a cost-effective technique (CAST) in a single session.  If this approach fails, the study in 
Chapter 75 demonstrates that a second attempt at a 2-3 month interval is safe and effective to 
avoid surgery.  The study in Chapter 97 demonstrates that laterally spreading lesions (LSL) 
around the appendiceal orifice can be treated with endoscopic resection provided they meet 
certain evidence-based criteria.  Further research is required to compare CAST to other 
techniques described for treating non-lifting adenoma (such as endoscopic submucosal 
dissection, hot avulsion, underwater EMR and endoscopic full thickness resection) preferably 
in a randomised setting.  These studies should use the endpoint of long-term avoidance of 
surgery but also contain a comparison of the cost effectiveness of the included techniques. 
The high rate of recurrence after piecemeal endoscopic mucosal resection has long necessitated 
close follow up and a structured programme of surveillance colonoscopy which imposes cost 
and morbidity burdens on patients and healthcare systems.  The technique of thermal ablation 
of the post EMR margin (Chapter 10) 52 reduces rates of recurrence 4-fold and, if validated in 
non-expert centres, promises a new era of endoscopic resection without the need for such 
regular surveillance.  In addition, those LSL which will recur may be identified by our work 
on risk factors resulting in a simple clinical score to predict recurrence (Chapter 11)16.  Finally, 
if recurrence does occur contemporary evidence indicates that is usually small and can be easily 
and successfully treated using readily available endoscopic techniques30.  Recurrence after 
endoscopic mucosal resection should therefore not be a reason for LSL to undergo more 
cumbersome or resource intensive techniques such as surgery.  
Further research in this area should focus on the specific morphologies of recurrence and the 
best methods to treat it.  No techniques have been subject to rigorous systematic review to date.  
The technique of thermal ablation should be validated in large, international, multicentre 
studies.  Reduction of the remaining approximately 4% of recurrence should be investigated 
by interpretation of images of the centre of the post-EMR defect to identify possible targets for 
intervention.  In this manner it is likely that the reduction of the rate of recurrence after 
piecemeal EMR may be reduced to a similar rate to that observed after en-bloc resection62.  
Since en-bloc resection of LSL > 25mm requires advanced techniques such as endoscopic 
submucosal dissection, is time-consuming and risks a higher rate of adverse events and hospital 
admission as versus piecemeal resection63 this may have extensive benefits for patients. 
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Finally, there is currently a proliferation of new technology and techniques in endoscopic 
resection.  It is vital that in studying such techniques the principles of STROBE64 and or 
CONSORT65 (depending on trial type) guidance are rigorously applied so that we can 
understand the place of each technique in daily practice.  It is essential that practitioners of 
endoscopic resection record their key performance outcomes (particularly rates of successful 
resection and adverse events) and make these available to their patients and the wider 
endoscopic community.  This data should be shared between institutions to allow the creation 
of standards against which future practitioners may be certified during their training.  A 
comprehensive data sharing platform for techniques within endoscopic resection (such as that 
described in Chapter 12) will be at the heart of this endeavour. 
The future of the management of early neoplastic colonic lesions is minimally invasive via 
endoscopy.  Only by the deployment of multicentre, international observational and 
randomised studies and incorporating the evidence they provide will we be able to provide an 
effective patient and lesion centric approach to every colonic polyp. 
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Appendix 2 - Ethical and institutional review board approval for the included studies 
Ethical approval for the studies contained in this thesis is included below. 
The study in Chapter 2 (SERRESH) was covered by the following Western Sydney Human 
Research Ethics Committee and institutional review board approval. 
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The studies in Chapter 3, Chapter 4, Chapter 7, Chapter 8, Chapter 9 and Chapter 11 were 
performed under the ethical and institutional review board approval for the Australian Colonic 
Advanced Mucosal Neoplasia and Endoscopic Resection Study. Two iterations of the  Human 
Research Ethics approval,  Clinicaltrials.gov entries and most recent study protocol are 
included below.  The approval for the online data collector is also included. 
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Email: WSLHD-ResearchOffice@health.nsw.gov.au 
WESTERN SYDNEY LOCAL HEALTH DISTRICT 
ABN  48 702 394 764 
 WSLHD Office, Westmead Hospital  
Cnr Hawkesbury & Darcy Roads, Westmead  NSW  2145 
PO Box 533, Wentworthville  NSW  2145 
Telephone  02 8890 5555   
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Laywoman 
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Dr Christopher Ryan 
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Mr John Shaw 
Layman 
 
Dr Geoff Shead 
Medical Graduate – Surgeon 
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Dental Graduate 
 
Dr Howard Smith 
Medical Graduate – Endocrinologist 
 
Ms Shane Waterton 
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 Research Office File No: (4831) 
 
HREC Ref: HREC/16/WMEAD/342 
SSA Ref: SSA/16/WMEAD/383 
 
16 August 2017 
 
Professor Michael Bourke 
Gastroenterology Department 
Westmead Hospital  
 
Dear Professor Bourke 
 
Research Proposal:  The Australian Colonic Large Sessile Lesion Endoscopic 
Resection Study  
  
We acknowledge your request for amendment dated 1 August 2017 and 
attached documentation in relation to the above study which was discussed by 
the HREC Sub-Committee at its meeting held on 15 August 2017.   
 
The HREC Sub Committee is constituted and operates in accordance with the 
National Health and Medical Research Council’s National Statement on Ethical 
Conduct in Human Research and the CPMP/ICH Note for Guidance on Good 
Clinical Practice. 
 
I am pleased to advise that the HREC Sub Committee has granted ethical 
approval of the Request for Amendment / Modification for this multicentre 
research project being conducted at: 
 
 Westmead Hospital – Coordinating Chief Investigator Prof Michael 
Bourke  
 Blacktown Hospital (NSW) – Chief Investigator Dr Farzan F Bahin  
 Westmead Private Hospital (NSW) – Prof Michael Bourke  
 Princess Alexandra Hospital (QLD) – Chief Investigator Dr Luke 
Hourigan  
 Queen Elizabeth II Hospital (QLD) – Chief Investigator Dr Nicholas  
Tutticci  
 Lyell McEwin Hospital (SA) – Chief Investigator Professor Rajvinder 
Singh  
 The Alfred Hospital (VIC) – Chief Investigator Professor Gregor Brown  
 Western Health Footscray Hospital (VIC) – Chief Investigator  
A/Professor Alan Moss  
 Western Health Sunshine Hospital (VIC) – Chief Investigator A/Professor 
Alan Moss  
 Monash Health Clayton (VIC) – Chief Investigator Dr Michael Swan 
andenong Hospital (VIC) – Chief Investigator Dr Michael Swain 
 University Hospital Geelong (VIC) – Chief Investigator Dr Sina Alexander 
 St John of God Hospital, Geelong (VIC) – Chief Investigator Dr Sina 
Alexander 
 
 
 
   
T:\RESEARCH OFFICE\ETHICS\COMMITTEES\SUB\CORRESPONDENCE\2017\1708\170816 - 4831 Bourke 
Outcome.docx 
 
The following documentation has been reviewed and approved by the HREC Sub 
Committee: 
 
 Protocol – version 3, dated 1 August 2017 
 Participant information sheet and Consent Form Version 3 dated 1 August 2017 
 
The Committee resolved to approve the above documentation and request the 
following matter be addressed; 
 Provide information of the provider of the database service 
 Provide information of location and storage of the database 
 
This amendment has also been reviewed  by the Research Governance Officer for 
Western Sydney Local Health District. The Research Governance Officer has advised 
contracts are required for all the institutions and the internet company. The WSLHD 
Information Technology Department are required to be informed of the de-identified 
data being sent to an external organisation  -  
(email: WSLHD-ITS-CustomerEngagement@health.nsw.gov.au)       
 
HREC approval is valid for 12 months from the date of the original approval and continuation 
of the HREC approval beyond the initial 12 month approval period is contingent upon 
submission of an annual report each year.  A copy of the Annual / Final Research Report 
Form can be obtained electronically from the Research Office on request. 
 
We appreciate your keeping us informed and look forward to receiving your next annual 
report.   
 
 
Yours sincerely 
 
Mrs Pat Fa 
Secretary 
WSLHD Human Research Ethics Committee 
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STUDY PROTOCOL 
 
Project Title:  The Australian Colonic LSL Endoscopic Resection Study. (ACE) 
 
Co-ordinating Principal Investigator:  Prof. Michael Bourkea,b,  
 
Investigators:   Dr Nicholas Burgessa 
    Dr Stephen Williamsa 
Dr David Tatea 
Dr Luke Houriganc,d  
    Assoc. Prof. Rajvinder Singhe 
Assoc. Prof. Gregor Brownf 
    Dr Simon Zanatif,g 
    Assoc. Prof. Alan Mossg 
Dr Spiro Raftopoulosh,i 
Dr Michael Swanj,k,l 
Dr Sina Alexanderm,n 
Dr Nicholas Tutticcio 
Dr David Hewetto 
Dr Farzan Bahinp 
     
 
Sites:  Departments of Gastroenterology and Hepatology, Endoscopy Units:  
aWestmead Hospital, Sydney, NSW.  
bWestmead Private Hospital, Sydney, NSW 
cPrincess Alexandra Hospital, Brisbane, QLD  
dGreenslopes Private Hospital, Brisbane, QLD 
eLyall McEwin Hospital, Adelaide, SA 
   fThe Alfred Hospital, Melbourne, VIC 
gWestern Hospital, Melbourne, VIC 
hSir Charles Gairdner Hospital, Perth, WA 
iHollywood Private Hospital, Perth, WA 
jMonash Health Clayton, Melbourne, VIC 
kDandenong Hospital, Melbourne, VIC 
lJessie MacPherson Hospital, Melbourne, VIC 
mUniversity Hospital Geelong, Barwon Health, Geelong, VIC 
nSt John of God Hospital Geelong, Geelong, VIC 
oQueen Elizabeth II Jubilee Hospital, Coopers Plains, QLD 
pBlacktown District Hospital, Blacktown, Sydney, NSW 
    
 
Protocol Version:  1.0 
 
 
 
Background: 
Colonoscopic polypectomy is well established as an effective way of reducing colorectal cancer mortality1.  The 
majority of polyps detected and removed at colonoscopy are adenomas <10mm in size without advanced 
histology.  These lesions have a low risk of progression to malignancy and are relatively easily removed by 
standard snare polypectomy with low complication rates2.  Polyps that are sessile or flat and greater than 20mm 
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in size are found in approximately 1% of all colonoscopies3 and are more difficult to manage.  These lesions, 
known as large sessile lesions (LSL), have a high rate of advanced histology4.  Traditionally they have been 
managed by referral for open or laparoscopic surgery, which is definitive, but invasive, costly and associated 
with a significant mortality risk in patients with advanced age or comorbidities5. Endoscopic Mucosal Resection 
(EMR) has emerged in recent years as an alternative to surgery that is now becoming the standard of care.  It is 
an outpatient procedure which is effective, safe and less costly than surgery when delivered at a tertiary referral 
centre6.  
The Australian Colonic Endoscopic Mucosal Resection study (ACE), comprises two multicentre prospective 
observational studies which examined EMR of colonic LSL (Ethics approval No.s HREC JH/TG 
2008/9/6.1(2858) and HREC/13/WMEAD/233 (3778)).  The project now has an extensive dataset from leading 
colonic endoscopic resection centres in Australia on more than 2000 lesions resected over 4 years since 
September 2008.    
These studies have been successful in addressing several aspects of the resection of LSL, resulting in several 
high profile papers in internationally recognised journals.  The collection of this data has produced robust 
information on the efficacy of the procedure4, recurrence rates7, bleeding complications8,9 and mortality and 
costs when compared to surgery10,11.  Single centre analysis of the ACE dataset at Westmead has also allowed 
insights into how to refine the procedure to improve outcomes. The target sign is now a recognised indication 
for the placement of clips to prevent perforation12, CO2 insufflation for EMR has been shown to be superior to 
air insufflation13 and succinylated gelatin (Gelofusine®) has been shown to be superior to normal saline as a 
submucosal lifting agent14.  Assessment and management strategies for bleeding and deep mural injury or 
perforation have been derived from analysis of the data9,15.  Snare tip soft coagulation of the resection margin 
post-EMR has been shown to reduce recurrence in a randomised controlled trial16.  Several ACE study papers 
have been incorporated into review papers and international guidelines for the safe and effective performance of 
EMR17,18.  
There remain a number of unanswered questions regarding the endoscopic resection of large sessile lesions and 
a new study incorporating a greater number of endoscopy units around Australia will allow these to be 
addressed as well as answer questions on the clinical effectiveness of the technique.   Enhancing the prediction 
of submucosal invasive cancer, advanced lesion classification, validation of the assessment of deep injury, 
treatment of lesion margins post resection to reduce recurrence, prevention and prophylaxis of bleeding, and 
subtype analyses of the different histological groups of colonic lesions will be examined.     
 
Literature Review: 
 
The ACE study was initially designed to assess the efficacy of and complications related to EMR of large sessile 
lesions.  These lesions are uncommon, but are an important subgroup of bowel lesions as they contain a high 
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proportion of incipient and inevitable bowel cancers. Few centres internationally have published studies on the 
resection of LSL and there are only 3 prospective studies which have accrued more than 200 patients19–21.  The 
focus of these studies was generally on technical efficacy, and data on complications or lesion subtypes was 
limited.  Through its unique dataset and collection of rare but clinically important lesions, the data generated 
through the ACE studies has provided an insight into the technical aspects of resection, and valuable data to 
examine other aspects of colon LSL.  
 
Since its inception in 2008, the ACE studies have gathered data on over 2000 patients through a now well 
established tertiary referral service for the resection of LSL at 8 Australian major centres. The high throughput 
of cases and established research infrastructure means it has generated multiple internationally relevant studies 
and has adequate power to look at specific patient, lesion, technique and outcome subgroups.  Due to these 
positive results, the data has now created several questions that could be addressed by maintaining the same 
structure, but incorporating other study centres and broadening the data collection.   Technological advances in 
endoscopy have meant that real time prediction of lesion histology is becoming more accurate22, and the ACE 
study is well placed to expand lesion assessment data to provide robust evidence on the appearance of large 
colonic lesions and prediction of submucosal invasive cancer.  The endoscopic appearance of sessile serrated 
polyps (SSPs) is also poorly described23 and data will be collected on the prospective assessment of these 
lesions in the ACE study.  Expanding the centres and endoscopists involved in the study means that the 
outcomes more closely reflect “real-world” outcomes and have increased applicability in terms of affecting 
clinical practice internationally.  New aspects of resection will also be assessed in this prospective cohort.  
Validation of the Sydney Deep Mural Injury Classification grading system for will be added to the study and 
assessed to examine the effect of pro-active management of deep injury.  Treatment of the margins of defects 
with snare tip soft coagulation to reduce recurrence will be assessed for clinical effectiveness.  Kudo24 and 
Sano25,26 grades will be prospectively assessed for their prediction of sub mucosal invasive cancer.  Clip closure 
of defects and endoscopic ultrasound of EMR defects to assess bleeding risk may also be examined.  
Incremental improvement in refining the technique of EMR by scrutinizing outcomes means that the 
acceptability and availability of the procedure is improved internationally, and it is seen as a safe, efficacious 
and cost effective technique.   
 
The ACE study has been valuable as a way of providing a base population for interventional studies.  Several 
studies will tie in to the expanded ACE data.  These studies will be independently submitted for HREC approval 
and review.  
 
 
Aims: 
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To enhance understanding of the risk factors for LSL, improve lesion assessment and prediction of submucosal 
invasive cancer, improve endoscopic resection efficacy, reduce complications of EMR and improve the 
understanding of the progression of large lesions to cancer.   
 
Methodology: 
 
Project Design: 
Prospective, observational multi-centre study which aims to enrol all cases of LSL ≥20mm presenting to  
one of 14 academic endoscopy units across Australia.   
 
Inclusion Criteria: 
• Patients referred for endoscopic resection of a large sessile colonic polyp or laterally spreading 
tumour ≥20mm in size. 
• Age > 18 years 
• Able to give informed consent to involvement in the clinical study 
 
Exclusion Criteria: 
• Unable to provide informed consent for involvement 
 
Method of Screening: 
Patients referred to a study centre for colonic EMR of a known sessile colonic polyp or laterally 
spreading lesion (LSL) ≥20mm in size 
 
Sequence of Procedures: (for flowsheet see Appendix 1.) 
1. Patient is referred to one of 14 academic tertiary referral endoscopy units for removal of a large 
sessile colonic polyp or LST ≥20mm in size.  
2. All patients referred to this service are routinely mailed an information pack about the EMR 
procedure. If the referral information indicates that the patient is potentially eligible for the trial, 
written information about the study is included in this pack for the patient to read in advance of 
their arrival for the procedure. 
3. The patient reads the supplied information and consent form. 
4. Once checked into the endoscopy suite on the day of the procedure, the patient is met by one of 
the investigators to discuss the risks and benefits of the procedure and the study.  An interpreter 
is used to assist with the discussion if required.  
5. If the patient agrees to participate, the informed consent form is signed and witnessed with the 
help of an interpreter if required.  
6. If the patient decides not to participate, the colonoscopy and EMR proceed as per usual.  
7. Patient enters the endoscopy room and the procedure commences.  
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8. During the EMR procedure, data is recorded by the gastroenterology registrar or clinical 
research nurse regarding the technical aspects of the procedure.  Still images of the colon are 
taken routinely during the procedure as part of the normal medical record in a standardized 
manner of the lesion, the resection procedure and the completed defect.  De-identified video 
images may be collected of the procedure. 
9. The patient is moved to recovery for observation.  They are observed for 2 hours in first stage 
recovery and at this stage are nil by mouth.  They are then observed in second stage recovery 
while consuming clear fluids for 4 hours.  They are examined by the proceduralist prior to 
discharge and provided with written post procedure information including a phone number to 
call in the event of any problems.  
10. Overnight they remain on a clear fluid diet and resume a normal diet the following day. 
11. Any adverse event is recorded prospectively on the data sheet as per the unit’s standard 
practice.  Adverse events include immediate or delayed bleeding, deep mural injury or 
perforation, persistent pain indicative of a serositis (inflammation of the outer layer of the 
bowel wall) or an unscheduled admission or readmission.  
12. Patients are contacted by the research nurse by telephone 14 days following their procedure to 
assess ongoing symptoms and advise of any adverse events including admissions.   
13. The formal histology results of the resected specimens are recorded on the follow-up data sheet.  
The slides are also reviewed as per usual endoscopy unit practice in the monthly 
gastroenterology unit histopathology meeting.  
14. All patients return for a follow up procedure (scheduled colonoscopy) to check whether the 
lesion has been completely resected and to remove any recurrent or residual polyp.  For the 
majority of patients this is at 5 months at the centre that performed the initial resection.  A few 
patients will have lesions which are a low risk for recurrence and were resected “en-bloc”, these 
patients may be booked for a 12 month follow up procedure, which may be performed by the 
referring institution.  
15. Patients who have no, or low risk recurrence which is completely treated, are then followed up 
at 12 months, 3 years and 5 years at the referring institution. Endoscopy reports and histology 
are forwarded to the initial study centre for inclusion in the study.  Patients with high risk or 
incompletely treated recurrence are managed by further endoscopic resection, or referral for 
surgery.  This is based on the endoscopists assessment of the lesion and histology findings.  
16. In the event that follow up information is not provided by the referring physician at the 
proscribed time points, a reminder letter will be sent to the referrer to ask them to review 
whether a follow up examination has been performed and to provide further information.  
17. Patients who have significant adverse events may have their records for this event reviewed to 
create a more detailed picture of the complication. 
18. The study outcomes will then be documented in manuscript form and submitted to a major 
internationally recognized peer reviewed journal for publication.  
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19. All participants will be mailed a letter outlining the results of the trial, and thanking them for 
their involvement.  
20. All records of patients who participate in the trial will be marked so they are not destroyed by 
medical records for at least 15 years.  
 
 
Data Security: 
De-identified raw data will be entered onto data sheets by the the study investigator/ 
gastroenterology registrar/ endoscopy research nurse. This will then be transferred to a password secured 
Filemaker database at Westmead Hospital accessible only via password protected access to the local WSLHD 
network. Patients are assigned a study code on this database.  Access to this is restricted to principal study 
investigators and the Clinical Research Nurse. The file has encrypted source code so data cannot be viewed by 
examining the raw file data. This database is held on a Westmead Hospital internal virtual drive and is regularly 
backed up to an external hard drive which is stored in a locked office in the endoscopy suite.  The paper 
datasheets are stored in a locked office at Westmead Hospital.  Scanned images of de-identified paper datasheets 
and reports are stored in the database.  The study codes and associated patient details (name, date of birth, 
medical record number) are maintained on a separate, password secured, encrypted database for re-identification 
when required. For centres outside Westmead, a local study code is assigned and reidentification data is 
maintained locally on a password protected spreadsheet by the principal site investigator.  Paper datasheets are 
stored locally in a locked office and faxed to a dedicated fax machine used only for ACE study datasheets in the 
research nurse office at Westmead Hospital.  The Clinical Research Nurse is the custodian of both electronic 
and paper data storage.  Images of the colon collected at the time of the study are routinely stored on the hospital 
endoscopy reporting system database as part of the medical record.  De-identified images are also stored in the 
study database, linked to the patients study ID.  Videos of procedures are de-identified and referenced according 
to the patients study ID.  
 
Participant Withdrawal From the Study: 
In accordance with the Declaration of Helsinki and the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Practice 
Guidelines, a participant is free to withdraw from the study at any time for any reason without prejudice to their 
future medical care by the physician or the institution.  The Investigator may also withdraw the participant at 
any time in the interests of patient safety. Should a participant decide to withdraw, all efforts will be made to 
complete and report the observations as thoroughly as possible.  Participants may be removed from the study if 
one or more of the following events occur: 
• Withdrawal of consent 
• Decision made by the investigators that removal from the study is in the patients best 
medical interest. 
• Study stopped by ethics/regulatory authorities 
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The primary reason and additional reasons for withdrawal will be recorded in the participants 
medical record. 
 
Statistics: 
The ACE study aims to enrol patients for 10 years. This will result in 4000-5000 patients in the 
study.  Comparison of quantitative variables will be performed by Students t-test and for qualitative variables by 
Pearson’s χ2 -test. A p value of < 0.05 will be considered significant. Statistical analyses will be performed with 
SPSS statistical software (IBM Corp. 2012. IBM SPSS Statistics, Version 22.0. Armonk, NY) with the help of 
an independent statistician.   
 
Analyses and Outcome Measures: 
The study will examine key outcome measures including procedural success, requirement for 
surgery, recurrence at scheduled surveillance colonoscopies, and clinical success (participants free from surgery 
or recurrence at surveillance colonoscopy).   The study will also examine prediction of submucosal invasive 
cancer and prediction of LSL histology type.  The study will report on key adverse events: bleeding (immediate 
and delayed), deep mural injury and perforation, pain, and surgery for adverse events and will examine 
demographic, clinical and technical predictors of these outcomes.  Univariable analysis and multiple logistic 
regression of potential risk factors will primarily be used to examine outcomes. Enhancing the prediction of 
submucosal invasive cancer, advanced lesion classification, validation of the assessment of deep injury, 
treatment of lesion margins post resection to reduce recurrence, prevention and prophylaxis of bleeding, and 
subtype analyses of the different histological groups of colonic lesions are all areas where results from a large, 
prospective, multicentre cohort will influence international practice. 
 
Ethical Issues: 
All patients will be managed according to established best practice according to international 
research and consensus on EMR.  Treatment does not differ according to whether or not the patient 
chooses to participate in the study. 
 The key ethical issues are: 
1. Dependent Relationships 
• Most eligible participants will not be the regular patients of the investigators or the 
colonoscopists involved in the study.  This is because the majority of the patients 
are referred from other medical specialists (Gastroenterologists or surgeons) to the 
tertiary referral service operated by the study centre Endoscopy Unit.  Follow up 
after confirmed curative EMR is with the referring specialist. Vigilance in 
explaining the voluntary nature of participation will be exercised for all patients.  It 
will be emphasized that a decision not to enroll in the study will have no 
ramifications whatsoever for the patients care and ongoing relationship with the 
treating medical team. 
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2. Conflict of Interest 
• None of the investigators have financial conflicts of interest. 
 
Potential Significance of the Study: 
The ACE study has already produced substantial internationally significant research output and 
the unique dataset is of considerable interest due to its potential to answer further questions about colon 
LSL and EMR.  The areas of research will cover epidemiological factors associated with LSL, advanced 
lesion classification, refinement of the assessment of deep injury and subtype analyses of the different 
histological groups comprising LSL.  The research has the potential to influence advice on screening 
and surveillance of colorectal polyps and in particular large lesions, to improve the ability of 
endoscopists to identify and resect LSL safely and to improve the worldwide acceptance of endoscopic 
resection of LSL as an alternative to surgery, reducing costs for healthcare systems.   
 
Budget: 
The cost of investigator time is free.  
 
Funding for the project at is through the Westmead Hospital Endoscopy Research Fund. 
 
Budget: 
 Ethics Committee Application Fee  $50.00 
  
 ______________________________________ 
 Total:     $50.00 
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Appendix 1. 
Study Flowchart: 
 																			
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NB: *=cumulative time from study entry to typical follow up for patients without recurrence.   Follow up times are variable and are decided by the 
clinician at each procedure based on evidence of recurrence and histopathological findings. If recurrence occurs then typical subsequent follow 
up is 5 months, lesions without recurrence are followed up at 12 month, 3 year and then 5 year intervals. 
Patients may be referred for surgery at any time point based on endoscopic findings or histology.  
Patient	referred	for	resection	of	flat	or	sessile	colon	polyp	20mm	or	greater	in	size	
Patients	receive	study	information	in	mail	along	with	procedure	information	pack		
Patient	presents	to	study	centre	endoscopy	unit	for	procedure	
Study	investigator	meets	with	patient,	explains	study,	answers	patient	questions.	Consent	form	signed	by	patient.	
Data	collection	Point	2	
Telephone	follow	up	(14	days)		 Performed	by	Study	Research	Nurse	or	Investigator	Adverse	Events		 Histopathology	data	recorded		 	
Data	collection	Point	1	
Index	Procedure	 	 												Patient,	procedure	and	polyp	resection	data	Recovery		 Observation		 Monitoring	for	adverse	events		 Any	admission	details		
Data	collection	Point	3	
Scheduled	Colonoscopy	1	(5	months)*		 Procedure	performed	at	study	institution	Recurrence	and	any	treatment		 Surgery	details	(if	any)		 	
Data	collection	Point	4	
Scheduled	Colonoscopy	2			(17	months)*			 Procedure	performed	at	study	institution	or	referral	centre.	1	year	following	Scheduled	Colonoscopy	1	Recurrence	and	any	treatment		 Surgery	details	(if	any)		 	
Data	collection	Point	5		
Scheduled	Colonoscopy	3				(53	months)*			 Procedure	performed	at	study	institution	or	referral	centre.	3	years	following	Scheduled	Colonoscopy	2	Recurrence	and	any	treatment		 Surgery	details	(if	any)		 	
Data	collection	Point	6	
Scheduled	Colonoscopy	4			(113	months)*		 Procedure	performed	at	study	institution	or	referral	centre.	5	years	following	Scheduled	Colonoscopy	3	Recurrence	and	any	treatment		 Surgery	details	(if	any)		 	
b
b
b
Contacts and Locations
The Australian Colonic Advanced Mucosal Neoplasia and Endoscopic Resection
Study (ACER/AMN)
Study Description
Brief Summary:
To enhance understanding of the risk factors for AMN, improve lesion assessment and prediction of
submucosal invasive cancer, improve endoscopic resection efﬁcacy, reduce complications of WF-EMR and
improve the understanding of the progression of large lesions to cancer
Condition or disease b Intervention/treatment b
Colonic Polyps Procedure: Endoscopic Mucosal Resection
Detailed Description:
Study Design
b
b
b
b
b
Groups and Cohorts
Group/Cohort b Intervention/treatment b
Endoscopic Mucosal Resection Procedure: Endoscopic Mucosal
Resection 
Outcome Measures
Primary Outcome Measures b:
Secondary Outcome Measures b:
Eligibility Criteria
Study Population
Criteria
Contacts and Locations
Contacts
Locations
Australia, New South Wales
Recruiting
Sponsors and Collaborators
Investigators
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identiﬁer (NCT Number):
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The study in Chapter 5 (INCEPT) was covered by the following Western Sydney Human 
Research Ethics Committee and institutional review board approval. 
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The randomised control study in Chapter 10  was approved by the Western Sydney Human 
Research Ethics Committee and the institutional review boards of the individual participating 
centres.  The Human Research Ethics approval and Clinicaltrials.gov entry are included below. 
 
 
  


b
b
b
Soft Coagulation for the Prevention of Adenoma Recurrence (SCAR)
Study Description
Brief Summary:
Recurrence after endoscopic mucosal resection of laterally spreading lesions (LSL) >= 20mm in size occurs
in approximately 20% of cases at surveillance colonoscopy. We aim to evaluate the efﬁcacy of prophylactic
adjuvant thermal ablation of the EMR mucosal defect margin in reducing adenoma recurrence following
colonic EMR.
Condition or disease b Intervention/treatment b Phase b
Colonic Adenomas Other: Snare Tip Soft Coagulation
Other: No Snare Tip Soft Coagulation
Not Applicable
Study Design
b
bb
b
b
Arms and Interventions
Arm b Intervention/treatment b
Active Comparator: No Coagulation Arm Other: No Snare Tip Soft
Coagulation 
Experimental: Coagulation Arm Other: Snare Tip Soft
Coagulation 
Outcome Measures
Primary Outcome Measures b:
Secondary Outcome Measures b:
Eligibility Criteria
Criteria
Contacts and Locations
Locations
Australia, New South Wales
Australia, Queensland
Australia, South Australia
Australia, VA
Sponsors and Collaborators
More Information
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Appendix 3 - Other papers authored throughout the candidacy not included in this 
thesis 
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patients without serrated polyposis syndrome. Endoscopy. 2018 May. 41 
 
Klein A, Ahlenstiel G, Tate DJ, Burgess N, Richardson A, Pang T, et al. Endoscopic resection 
of large duodenal and papillary lateral spreading lesions is clinically and economically 
advantageous compared with surgery. Endoscopy. 2017 Jul;49(7):659–67. 66 
 
Heitman SJ, Tate DJ, Bourke MJ. Optimizing Resection of Large Colorectal Polyps. Curr Treat 
Options Gastro. 2017 Mar;15(1):213–29. 67 
 
Tate DJ, Burgess NG, Bourke MJ. Endoscopic detection of large and advanced colonic lesions: 
Are we missing the forest for the trees? Gastrointest Endosc. 2017 Jan;85(1):234–6. 68 
 
1. Desomer L, Tutticci N, Tate DJ, Williams SJ, McLeod D, Bourke MJ. A standardized 
imaging protocol is accurate in detecting recurrence after EMR. Gastrointest Endosc. 2017 
Mar;85(3):518–26. 44 
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Appendix 4 - Statistical Methods 
Statistical methods used throughout this thesis are described in the individual chapters.   
Where not stated study data was exported and analysed using SPSS version 23 (IBM, Armonk, 
New York).   
Categorical variables were correlated using the chi square test. Continuous variables were 
analysed using either student t test (two tailed) for normally distributed variables or Mann 
Whitney U test for skewed variables.  
2x2 tables were described using negative predictive value, specificity and accuracy. 
P values are stated to be significant where P < .05. 
Odds ratio and relative risk were used where appropriate to describe the effect size of an 
intervention or risk factor. 
Binary logistic regression was used to derive predictors of a desired outcome from a randomly 
selected half of an historical cohort and the derived predictors tested against the other half of 
the cohort. 
Kaplan Meier curves and the Log Rank test were used to describe recurrence of LSL during 
follow up. 
Grateful thanks are offered to Ms Karen Byth for her assistance with statistical methods and 
understanding where stated. 
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